0000012208-18-000014.txt : 20180416 0000012208-18-000014.hdr.sgml : 20180416 20180413175043 ACCESSION NUMBER: 0000012208-18-000014 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180416 DATE AS OF CHANGE: 20180413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO RAD LABORATORIES INC CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 18755186 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 10-K 1 a10k123117.htm 10-K 2017 Document
0.07false--12-31FY20172017-12-3110-K0000012208247014075103283YesLarge Accelerated Filer4795291430BIO RAD LABORATORIES INCNoNo23367000255490000.00010.00010.00010.000180000000200000008000000020000000244540485123883246791275107674244539265122966246785455106757.101P9YP1YP8YP1YP12YP3YP9YP1YP9YP2YP0YP0YP8YP4YP8YP1YP7YP1YP12YP1YP12YP1YP8YP1YP0YP0YP6YP1Y18100000170000000.00010.0001750000075000000000P12YP3Y120100000P5YP5Y00122917582917 0000012208 2017-01-01 2017-12-31 0000012208 2017-06-30 0000012208 us-gaap:CommonClassBMember 2018-04-10 0000012208 us-gaap:CommonClassAMember 2018-04-10 0000012208 2016-12-31 0000012208 2017-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 2016-01-01 2016-12-31 0000012208 2015-01-01 2015-12-31 0000012208 2015-12-31 0000012208 2014-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000012208 us-gaap:TreasuryStockMember 2014-12-31 0000012208 us-gaap:CommonStockMember 2014-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2014-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2015-01-01 2015-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 0000012208 us-gaap:ScenarioAdjustmentMember 2015-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2015-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:FirstTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-12-31 0000012208 us-gaap:DeferredRevenueArrangementTypeDomain bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:DiscountrateMember 2017-01-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:CostofdebtMember 2017-01-01 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-01-01 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-01-01 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 bio:CellsorterMember 2017-01-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-01-01 2017-12-31 0000012208 bio:CellsorterMember 2012-09-30 2017-02-01 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:ScenarioForecastMember 2017-12-30 2020-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2017-12-31 0000012208 bio:CellsorterMember 2017-12-31 0000012208 bio:CellsorterMember 2012-09-30 2016-12-31 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-07-01 2017-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2017-12-31 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:TradeNamesMember 2017-02-15 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-03-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:LicensingAgreementsMember 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-03-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 bio:LifeScienceMember 2015-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2017-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2017-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2016-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-12-31 0000012208 bio:QuantalifeMember us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2017-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2017-12-31 0000012208 bio:NetofprepaidtaxesMember 2017-12-31 0000012208 us-gaap:ForeignCountryMember 2017-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 bio:TaxCutsandJobsActMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 us-gaap:CommonClassAMember 2014-12-31 0000012208 us-gaap:CommonClassAMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2014-12-31 0000012208 bio:TreasuryClassBMember 2012-04-01 2012-06-30 0000012208 bio:TreasuryClassAMember 2017-01-01 2017-12-31 0000012208 bio:TreasuryClassAMember 2012-04-01 2012-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:ParentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ParentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:ParentMember 2015-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2017-12-31 0000012208 bio:StockAwardPlansMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2017-01-01 2017-12-31 0000012208 country:US 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-12-31 0000012208 bio:LifeScienceMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:AmericasMember 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2015-01-01 2015-12-31 0000012208 country:US 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 us-gaap:AmericasMember 2017-01-01 2017-12-31 0000012208 us-gaap:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 us-gaap:EuropeMember 2016-12-31 0000012208 us-gaap:AmericasMember 2016-12-31 0000012208 us-gaap:AmericasMember 2017-12-31 0000012208 country:US 2017-12-31 0000012208 us-gaap:AsiaPacificMember 2016-12-31 0000012208 us-gaap:EuropeMember 2017-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2015-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2015-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2016-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:EmployeeSeveranceMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:OtherOperatingIncomeExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:ResearchAndDevelopmentExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2017-01-01 2017-03-31 0000012208 us-gaap:ScenarioAdjustmentMember 2017-07-01 2017-09-30 0000012208 us-gaap:ScenarioAdjustmentMember 2016-07-01 2016-09-30 0000012208 us-gaap:ScenarioAdjustmentMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:ScenarioAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ScenarioAdjustmentMember 2016-01-01 2016-03-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-10-01 2016-12-31 0000012208 2017-10-01 2017-12-31 0000012208 2016-04-01 2016-06-30 0000012208 2017-07-01 2017-09-30 0000012208 2016-10-01 2016-12-31 0000012208 2017-01-01 2017-03-31 0000012208 2016-07-01 2016-09-30 0000012208 2017-04-01 2017-06-30 0000012208 2016-01-01 2016-03-31 0000012208 us-gaap:InventoriesMember 2017-07-01 2017-09-30 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:ScenarioAdjustmentMember 2017-10-01 2017-12-31 0000012208 bio:EmployeeBenefitExpenseMisstatementMember 2017-10-01 2017-12-31 0000012208 bio:TaxMisstatementMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-04-01 2016-06-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-07-01 2016-09-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-03-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-10-01 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-07-01 2017-09-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-01-01 2017-03-31 0000012208 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2018-04-13 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-01-01 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 10-K
(Mark One)
 
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the year ended December 31, 2017
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from ___________________________ to _________________________________
 
Commission file number 1-7928
 
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
1000 Alfred Nobel Drive, Hercules, California
 
94547
(Address of principal executive offices)
 
(Zip Code)
 
 
Registrant's telephone number, including area code
 
   (510) 724-7000 
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of Each Class
 
Name of Each Exchange on Which Registered
Class A Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
Class B Common Stock Par Value $0.0001 per share
 
New York Stock Exchange
 
Securities registered pursuant to Section 12(g) of the Act:  NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
  ¨ Yes
 
 ý No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
 
 ¨ Yes
 
   ý  No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
 ý Yes
 
¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).
    ý Yes
 
¨ No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ý
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
 
 
 
 
 
 
Large accelerated filer
ý
 
 
Accelerated filer
¨
Non-accelerated file
¨
(Do not check if a smaller reporting company)
 
Smaller reporting company
¨
 
 
 
 
Emerging growth company
¨
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No
As of June 30, 2017, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A Common Stock held by non-affiliates was approximately $4,732,091,180 and the aggregate market value of the registrant's Class B Common Stock held by non-affiliates was approximately $63,200,250.
 
As of April 10, 2018, there were 24,701,407 shares of Class A Common Stock and 5,103,283 shares of Class B Common Stock outstanding.
Documents Incorporated by Reference
 
 
 
 
 
 
 
 
 
Document
 
 
Form 10-K Parts 
(1)
Definitive Proxy Statement to be mailed to stockholders in connection with the
 
 
 
 
registrant's 2018 Annual Meeting of Stockholders (specified portions)
 
 III



BIO-RAD LABORATORIES, INC.

FORM 10-K DECEMBER 31, 2017

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this Annual Report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including but not limited to those identified under “Item 1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PART I.

ITEM 1.  BUSINESS

General

Founded in 1952 and incorporated in 1957, Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications.  We entered the field of clinical diagnostics with the development of our first test kit based on separation techniques and materials developed for life science research.  Through internal research and development efforts and acquisitions we have expanded into various markets.  Today, Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

As we broadened our product lines, we also expanded our geographical market.  We have direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts are supplemented by distributors and agents.

Description of Business

Business Segments

Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics.  Both segments operate worldwide.  Our Life Science segment and our Clinical Diagnostics segment generated 36% and 63%, respectively, of our net sales for the year ended December 31, 2017. We generated approximately 37% of our consolidated net sales for the year ended December 31, 2017 from U.S. sales and approximately 63% from sales in our remaining worldwide markets.

For a description of business and financial information on industry and geographic segments, see Note 14 of Item 8 of Part II of this report.

3



Life Science Segment

Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions.  We are a leader in the life sciences market and develop, manufacture and market approximately 6,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting.  We focus on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cellular biology and food safety.  We estimate that the worldwide market that our portfolios can address for products in these selected segments of our addressable markets is approximately $9 billion. Our principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories.

Clinical Diagnostics Segment

Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.  Our products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the higher margin, higher growth segments of this market.
We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. We estimate that the worldwide sales for products in the markets we serve were approximately $12 billion. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed system.  Our principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories.

Raw Materials and Components

We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, computing and peripheral devices.  Most of these materials and components are available from numerous sources, and generally we have not experienced difficulty in securing adequate supplies. However, in certain instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials.

Patents, Trademarks and Licenses

We own numerous U.S. and international patents and trademarks.  We also pay royalties on the sales of certain products under several patent license agreements.  We view these patents, trademarks and license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing positions.

Seasonal Operations and Backlog

Our business is not inherently seasonal.  However, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income.


4


For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. Management has concluded that backlog information is not material to our business as a whole.

Sales and Marketing

We conduct our worldwide operations through an extensive direct sales force, employing approximately 970 direct sales and sales management personnel around the world. Our sales force typically consists of experienced industry practitioners with scientific training, and we maintain a separate specialist sales force for each of our segments. We believe that this direct sales approach allows us to sell a broader range of our products and have more direct contact with our customers.

We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs that require compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a transparent sale to our customers.

Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and research institutions; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries.  In 2017, no single customer accounted for more than two percent of our total net sales.  Our sales are affected by a number of external factors.  For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding.  A significant reduction of government funding has in the past and could in the future have a detrimental effect on the results of this segment.

Most of our international sales are generated by our wholly-owned subsidiaries and their branch offices.  Certain of these subsidiaries also have manufacturing facilities.  Bio-Rad’s international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations.  

Competition

The markets served by our product groups are highly competitive.  Our competitors range in size from start-ups to large multinational corporations with significant resources and reach.  We seek to compete primarily in market segments where our products and technology offer customers specific advantages over the competition.

Because of the breadth of its product lines, our Life Science segment does not face the same competitors for all of its products.  Major competitors in this market include Becton Dickinson, GE Biosciences, Merck Millipore and Thermo Fisher Scientific. We compete primarily based on meeting performance specifications and offering complete solutions.
Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin. We compete in our customer segments by providing high quality products, broad product portfolios and outstanding customer support.
Research and Development

We conduct extensive research and development activities in all areas of our business, employing approximately 820 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry. We spent approximately $250.3 million, $205.9 million and $193.0 million on research and development activities in 2017, 2016 and 2015, respectively.

5



Regulatory Matters

The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities.  FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and market surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters, initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal sanctions, among other things.

We are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls and restrictions on reimbursement. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures.

As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Union and other jurisdictions.  

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations could also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties.

These regulatory requirements vary widely among countries.

6



Employees

At December 31, 2017, Bio-Rad had approximately 8,150 employees.  Approximately seven percent of our approximately 3,270 U.S. employees are covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of our non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.  We consider our employee relations to be generally good.

Available Information

Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended.  The public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549.  The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  Also, the SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC.  The public can obtain any documents that we file with the SEC at http://www.sec.gov.

Bio-Rad’s website address is www.bio-rad.com.  We make available, free of charge through our website, our Form 10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC. The information on our website is not part of this Annual Report on Form 10-K.

ITEM 1A. RISK FACTORS

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this Annual Report.  We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock.  We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock.

Our settlement with government agencies in connection with violations by us of the U.S. Foreign Corrupt Practices Act could have a material adverse effect on our business, results of operations and financial condition.

As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the U.S. Foreign Corrupt Practices Act (FCPA). Under the terms of the NPA and the SEC Order, we agreed to pay a financial penalty and certain amounts in disgorgement and interest as well as to compliance, reporting and cooperation obligations to be performed for two years. On October 28, 2016, the DOJ and SEC informed Bio-Rad that they did not intend to extend the NPA after it expired November 2, 2016.

Whether by virtue of disclosure of the NPA and the SEC Order or otherwise, we may be subject to investigations by foreign governments or further claims by third parties arising from conduct subject to the investigation or our other international operations. For additional information regarding further claims by third parties, see Note 13, “Legal Proceedings” in the Notes to Condensed Consolidated Financial Statements of Part II, Item 8 of this Annual Report on Form 10-K. Many of our customers in our significant international operations are government agencies or state-owned or state-controlled universities, hospitals and laboratories. The disclosure of the NPA and the SEC Order and any further violations of the FCPA could harm our reputation with these customers, which could materially adversely affect our business, results of operations and financial condition. Any further violations of the FCPA also could result in more punitive actions by the SEC and DOJ, which also could materially adversely affect our business, results of operations and financial condition.

7



Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and in 2017 our foreign subsidiaries generated 63% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including with respect to the invalidation of the U.S.-European Union safe harbor by the European Court of Justice in October 2015, compliance with the EU-U.S. Privacy Shield adopted by the European Commission in July 2016, and the requirements for compliance with the EU General Data Protection Regulation, which takes effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, export requirements, U.S. laws such as the FCPA and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers.

Given the high level of complexity of these laws, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factor regarding government regulations below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do and are less leveraged than we are, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition. 

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results

8


of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.
 
We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies, such as the Swiss Franc, Brazilian Real and Russian Ruble, may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. We launched our third deployment in Western Europe in April 2017. We have experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product availability and shipments. We also have experienced lower productivity levels related to the April 2017 go-live of the ERP in Western Europe, which adversely impacted our sales during the second and third quarters of 2017. The third deployment was more complex than our prior deployments due to its scope. While we invested significant resources in planning, project management and training, additional and significant implementation issues may arise. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure in 2014, 2015 and 2016, and we continued to make significant organizational changes in 2017. In 2014 and 2015, we functionalized our manufacturing and selling organizations globally and separated them from our marketing and research and development organizations. Specifically, we combined our international selling organization with our North American selling divisions into one global selling group and consolidated our manufacturing, procurement and logistics operations into one global supply chain group. We also created new management positions to head each of these groups. In addition, we appointed new executives to head each of our Life Science and Clinical Diagnostics segments, and we appointed a Chief Operating Officer. We also restructured our Life Science segment based on functional groups rather than product line divisions. In 2016, we began implementing the reorganization of the structure of our European organization. We continued to implement the reorganization of our European organization in 2017. These changes may have unintended consequences, such as distraction of our management and employees, business disruption,

9


attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our consolidated financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
 
Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements.  During the third quarter of 2017, we identified two items that were recorded in the three-month period ended September 30, 2017 that should have been recorded in the three-month period ended June 30, 2017.  In each case, the misrecorded item was due to errors as a result of data migration and system configuration arising from our new European business structure during our ERP system conversion in Europe in April 2017.  Our review controls and our user acceptance testing controls were not sufficiently designed to identify these items on a timely basis. Though there was no impact on the financial statements for the nine-month period ended September 30, 2017, we concluded that our disclosure controls and procedures were ineffective as of September 30, 2017 and that this deficiency constituted a material weakness.  Our management believes that our enhanced post-conversion management review control activities and augmented user acceptance testing of system changes, which were designed to remediate the material weakness over financial reporting disclosed as of September 30, 2017, were sufficiently implemented as of December 31, 2017.

In connection with our assessment of the effectiveness of internal control over financial reporting as of December 31, 2017, we determined that we did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization that the Company undertook in April 2017, including the implementation of reporting lines, appropriate authorities and responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries. We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting. As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers. These control deficiencies resulted in immaterial misstatements to inventory, revenue and cost of goods sold, certain of which were corrected in the consolidated financial statements as of December 31, 2017, prior to issuance.

Because the deficiencies create a reasonable possibility of material misstatement in the annual or interim consolidated financial statements that will not be prevented or detected on a timely basis, they represent a material weakness in internal control over financial reporting and accordingly, our management concluded that our internal control over financial reporting was not effective as of December 31, 2017.  KPMG, LLP, an independent registered public accounting firm, has audited the consolidated financial statements included in this Annual Report on Form 10-K and, as part of the audit, has issued an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017.

In response to this evaluation and assessment, our management is enhancing its control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and using our new ERP system, (ii) implementing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations, and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements. Our management is also enhancing its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to similar ERP system conversions and reorganizations that may occur in the future. In addition, our management also is in the process of designing additional control activities over financial

10


statement amounts reported by entities impacted by the European reorganization. However, we cannot assure you that these efforts will be effective in timely remediating the material weakness or that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.

Such material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002.  Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations.  This could cause us to lose public confidence, and could cause the trading price of our common stock to decline.  For further information regarding our controls and procedures, see Part II, Item 9A of this Annual Report on Form 10-K.

Breaches of our information systems could have material adverse effect on our business and results of operations.

Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our Web site. We also acquire and retain information about suppliers and employees in the normal course of business. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Computer hackers may attempt to penetrate our or our vendors’ information systems and, if successful, misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our ERP implementation above and our information technology systems below.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products.  However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us.  For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future.  Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages to an infringed party.  Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

11



Global economic conditions could continue to adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. A deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. As of December 31, 2017, we had accounts receivable, net of allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $41.0 million. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that have been affected by the decline in oil prices, could adversely affect our business, results of operations or financial condition. We also are monitoring developments following the United Kingdom's decision to leave the European Union to determine if there will be any potential impact on our business.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Clinicians may decide not to order clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced

12


the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

•
The PPACA has also imposed a 2.3% excise tax on the sales of certain medical devices in the U.S., which we are required to pay on most of our United States Clinical Diagnostic sales. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two year moratorium on the medical device excise tax. On January 22, 2018, the moratorium on the medical device excise tax was further extended until January 1, 2020.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes to its regulations regarding in vitro diagnostic devices and medical devices, including stricter product labeling requirements, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Due to these evolving and diverse requirements, we face

13


uncertain product approval timelines, additional time and effort to comply, reduced sales and potential fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

14



Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition.

A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our ERP implementation and data security above and events beyond our control below.


15


Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of tax liability is always subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

The results from various tax examinations, audits and litigation may differ from the liabilities recorded in our financial statements and could materially and adversely affect our financial results and cash flows in the period or periods for which that determination is made.

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act made a number of substantial changes, including, among other changes, the imposition of a one-time mandatory deemed repatriation tax on previously unrepatriated earnings accumulated offshore since 1986, establishment of a global minimum income tax and base erosion tax provisions related to offshore activities and affiliated party payments, and reduction of the corporate tax rate from 35% to 21% for US taxable income, resulting in a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. These changes to U.S. tax laws will significantly impact how U.S. multinational corporations are taxed on foreign earnings.

To determine the transition tax, the Tax Act requires complex computations not previously provided in U.S. tax law, including calculating and supporting with primary evidence U.S. tax attributes such as accumulated foreign earnings and profits, foreign taxes paid, and other tax components involved in foreign tax credit calculations since

16


1986. The application of accounting guidance for such items is currently uncertain, and compliance with the Tax Act and the accounting for such provisions require collection of information not previously required, regularly produced or within our control. As a result, these provisional tax amounts recorded are based on our reasonable estimate and we will need additional information to complete our assessment. As additional regulatory guidance is issued by the applicable taxing authorities, as accounting treatment is clarified, as we perform additional analysis on the application of the Tax Act, and as we refine estimates in calculating the effect, our final analysis, which will be recorded in the period completed, may be materially different from our current provisional amounts, which could materially affect our tax obligations and effective tax rate.

We are still evaluating the tax provisions related to two new U.S. tax base erosion provisions, the base-erosion and anti-abuse tax (BEAT) provisions and the global intangible low-taxed income (GILTI) provisions. The BEAT provisions in the Tax Reform Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. We are not yet able to reasonably estimate the effect of the BEAT and GILTI provisions of the Tax Act.

Our global operations subject us to income and other taxes in the U.S. and in numerous foreign jurisdictions, each with different tax schemes and tax rates. In addition to the changes in tax laws, the interpretation of tax laws and tax rates in these jurisdictions, the jurisdictional mix of our earnings in countries with differing statutory tax rates can have a significant impact on our effective tax rate from period to period.

The liability for the transition tax, changes to the provisional tax amounts, and other ongoing effects of the Tax Act, including the effect of our investment in Sartorius, and the jurisdictional mix of our earnings could materially affect our financial results and cash flow.

In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in particular country.

Our reported financial results may be materially affected by changes in accounting principles generally accepted in the United States.
Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or FASB, the U.S. Securities and Exchange Commission, or SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.
For example, in January 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), such as our investment in the preferred shares of Sartorius AG, will generally be measured at fair value through earnings. Entities may elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We expect that the impact of adoption of ASU 2016-01 will materially impact our consolidated statement of income due to our ownership of preferred shares of Sartorius AG. In future periods after adoption, changes in the market value of the preferred shares of Sartorius AG along with our other equity investments may materially impact our consolidated statement of income.


17


Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of December 31, 2017, we had approximately $435.0 million of outstanding indebtedness. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.5 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.

Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other

18


indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare fraud and abuse regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are quite volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell

19


these instruments without significant losses due to current debtor financial conditions or other market considerations.

Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2016 with the SEC on May 10, 2017.

Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.


ITEM 1B.  UNRESOLVED STAFF COMMENTS
None.


20



 
ITEM 2.  PROPERTIES

We own our corporate headquarters located in Hercules, California.  The principal manufacturing and research locations for each segment are as follows:

 
 
 
Segment
Location
Owned/Leased
 
 
 
Life Science
Greater San Francisco Bay Area, California
Owned/Leased
 
Singapore, Singapore
Leased
 
Oxford, England
Leased
 
 
 
Clinical
 
 
Diagnostics
Greater San Francisco Bay Area, California

Owned/Leased
 
Irvine, California
Leased
 
Greater Seattle Area, Washington
Leased
 
Lille, France
Owned
 
Greater Paris Area, France
Leased
 
Nazareth-Eke, Belgium
Leased
 
Cressier, Switzerland
Owned/Leased
 
Dreieich, Germany
Owned/Leased

Most manufacturing and research facilities also house administration, sales and distribution activities.  In addition, we lease office and warehouse facilities in a variety of locations around the world.  The facilities are used principally for sales, service, distribution and administration for both segments.

 
ITEM 3.  LEGAL PROCEEDINGS  

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s

21


litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleged that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. In January 2018, we entered into a settlement agreement with the District pursuant to which we paid the District $990,000 to settle all claims and/or potential claims arising out of our use of the three power generation units. This settlement amount was accrued for as of December 31, 2017.
  

22



We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

 
ITEM 4.  MINE SAFETY DISCLOSURES  

Not applicable.

PART II.


ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Information Concerning Common Stock

Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the symbols BIO and BIO.B, respectively.  The following sets forth, for the periods indicated, the high and low intraday sales prices for our Class A and Class B Common Stock.

 
 
Class A
 
Class B
 
 
High
 
Low
 
High
 
Low
2017
 
 
 
 
 
 
 
 
Fourth Quarter
 
$
273.87


$
214.44


$
273.50


$
218.15

Third Quarter
 
242.79


208.95


243.50


210.71

Second Quarter
 
230.40


198.25


232.35


199.05

First Quarter
 
209.50


181.87


211.55


182.40

2016
 
 
 
 
 
 
 
 
Fourth Quarter
 
$
184.89


$
154.89


$
194.15


$
154.05

Third Quarter
 
164.45


140.53


171.12


140.69

Second Quarter
 
150.00


135.02


150.04


134.86

First Quarter
 
139.63


122.03


146.41


123.43


On April 10, 2018, we had 260 holders of record of Class A Common Stock and 115 holders of record of Class B Common Stock.  Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans.

23



Stock Performance Graph

The following graph compares the cumulative stockholder returns over the past five years for our Class A Common Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2012, and reinvestment of dividends if paid:             
    
    chart-6b100d05c0505debbd8.jpg        
(1)  The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher Scientific, Meridian Bioscience and PerkinElmer. Companies in our peer group reflect our participation in two different markets: life science research products and clinical diagnostics. No single public or private company has a comparable mix of products which serve the same markets. In many cases, only one division of a peer-group company competes in the same market as we do. Collectively, however, our peer group reflects products and markets similar to those of Bio-Rad.

This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these Acts.


24



ITEM 6.  SELECTED FINANCIAL DATA

BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
Selected Financial Data
 
 
 
 
 
 
(in thousands, except per share data)
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
2014
 
2013
 
 
 
 
 
 
 
 
 
 
 
Net sales
 
$
2,160,153

 
$
2,068,172

 
$
2,019,441

 
$
2,175,044

 
$
2,132,694

Cost of goods sold
 
972,754

 
930,085

 
897,771

 
996,527

 
954,216

Gross profit
 
1,187,399

 
1,138,087

 
1,121,670

 
1,178,517

 
1,178,478

Selling, general and administrative expense
 
808,942

 
816,724

 
761,990

 
808,200

 
798,070

Research and development expense
 
250,301

 
205,864

 
192,972

 
220,333

 
210,952

Impairment losses on goodwill and long-lived assets
 
11,506

 
62,305

 
—

 
—

 
—

Interest expense
 
21,914

 
21,942

 
21,692

 
22,131

 
61,271

Foreign exchange losses, net
 
9,128

 
4,542

 
10,249

 
9,305

 
8,566

Other (income) expense, net
 
(12,197
)
 
(14,850
)
 
(11,080
)
 
(13,009
)
 
(12,766
)
Income before income taxes
 
97,805

 
41,560

 
145,847

 
131,557

 
112,385

Benefit from (provision for) income taxes
 
24,444

 
(15,560
)
 
(36,608
)
 
(42,712
)
 
(34,574
)
Net income attributable to noncontrolling interests
 
—

 
—

 
—

 
—

 
(21
)
Net income attributable to Bio-Rad
 
$
122,249

 
$
26,000

 
$
109,239

 
$
88,845

 
$
77,790

 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share
 
$
4.12

 
$
0.88

 
$
3.74

 
$
3.08

 
$
2.72

Diluted earnings per share
 
$
4.07

 
$
0.88

 
$
3.71

 
$
3.05

 
$
2.69

Cash dividends paid per common share
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Total assets
 
$
4,273,012

 
$
3,850,504

 
$
3,709,718

 
$
3,341,278

 
$
3,388,790

Long-term debt, net of current maturities
 
$
434,581

 
$
434,186

 
$
433,883

 
$
435,710

 
$
435,615



ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion should be read in conjunction with the information contained in our consolidated financial statements and the accompanying notes which are an integral part of the statements.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized products needed for biological research and clinical diagnostics.  

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits

25


opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union, and a change in the U.S. executive branch of government. Approximately 37% of our 2017 consolidated net sales are derived from the United States and approximately 63% are derived from international locations, with Europe being our largest international region.  The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

Upon our implementation of our global single instance enterprise resource planning ("ERP") platform in Europe during the second quarter of 2017, $10.5 million of assets in France were misclassified as Equipment that should have been reported as Buildings and leasehold improvements in periods prior to 2017. The reclassification on the 2016 balance conforms to the correct balance sheet presentation as of December 31, 2017, and there was no impact on the Consolidated Statements of Income or Cash Flows.

During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. As a consequence, Deferred income taxes in 2016 were understated by $2.4 million and the Provision for income taxes was understated by $2.4 million in 2015.

The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. As a consequence, Retained earnings were overstated by $1.4 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $4.6 million in 2016 and the Provision for income taxes was understated by $1.9 million and $1.3 million in 2016 and 2015, respectively.

The third misstatement was related to a design deficiency associated with transfer pricing. As a consequence, our Retained earnings were overstated by $0.2 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $0.6 million in 2016 and the Provision for income taxes was understated by $0.2 million in both 2016 and 2015.

Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.

During the fourth quarter of 2017, we identified errors in the unaudited interim condensed consolidated financial statements for the three months ended September 30, 2017. We identified an error in the recording of deferred revenue acquired in our acquisition of RainDance (see Note 2, "Acquisitions"). This resulted in an overstatement of revenue recorded in the third quarter of 2017 of $0.9 million that was corrected in the fourth quarter of 2017. In addition, we identified an error in an estimated employee benefit expense that resulted in an understatement of expenses reported in Cost of goods sold, Selling, general and administrative expense and Research and development expense, net, in the third quarter of 2017 of $3.8 million that was corrected in the fourth quarter of 2017. Finally, we identified an error during our reconciliation of various inventory accounts which resulted in an understatement of Cost of goods sold in the third quarter of 2017 of $3.5 million that was corrected in the fourth quarter of 2017. The impact of these errors resulted in an overstatement of our Provision for income taxes reported in the third quarter of 2017 of $2.9 million that was corrected in the fourth quarter of 2017.


26



Management evaluated the materiality of all the errors described in the previous paragraph from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of SAB 108. Accordingly, we are correcting these errors in the financial statements for the quarter ended September 30, 2017 included in this Form 10-K.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations. See Note 4 to the consolidated financial statements.
 
In December 2017, we announced the termination of an infectious disease research and development project, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded restructuring charges related to severance and employee benefits of $11.0 million, and asset write-offs and exit costs of $10.1 million for the year ended December 31, 2017. The amounts recorded were reflected in Cost of goods sold of $2.3 million, in Selling, general and administrative expense of $3.3 million, and Research and development expense of $15.5 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability of $14.1 million as of December 31, 2017 consisted of $11.1 million recorded in Accrued payroll and employee benefits and $3.0 million recorded in Other current liabilities in the Consolidated Balance Sheets. See Note 15 to the consolidated financial statements.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It is included in our Clinical Diagnostics segment’s results of operations as a division, and is primarily based in Massachusetts. In September 2017, we announced that we are closing the GnuBIO research program facilities in Massachusetts. As a result, we recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and is recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. We expect the remainder to be paid in early 2018. See Note 15 to the consolidated financial statements.

In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.

The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses. The final allocation of the payments reflect the effects of correcting an error that were recorded in the fourth quarter of 2017. These corrections reduced goodwill, deferred revenue and deferred tax assets by $1.9 million, $3.3 million and $1.4 million, respectively, and had no significant impact on our Consolidated Statements of Income. See Note 2 to the consolidated financial statements.

27


During the fourth quarter of 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. During the second quarter of 2016, we impaired an intellectual property license associated with a research and development project for $2.4 million. See Note 4 to the consolidated financial statements.

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, are expected to be incurred through 2019. As a result, we recorded approximately $0.5 million and $12.5 million in restructuring charges related to severance and other employee benefits for the years ended December 31, 2017 and 2016, respectively. The liability of $6.3 million as of December 31, 2017 consisted of $6.2 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2017 and 2016, respectively. See Note 15 to the consolidated financial statements.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination and is included in our Life Science segment's results of operations from the acquisition date. The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $16.7 million as of December 31, 2017. See Notes 2 & 3 to the consolidated financial statements.

Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP).  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.  We evaluate our estimates on an on-going basis.  We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Annual Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial condition and results of operations.

Accounting for Income Taxes.  Management is required to make estimates related to our income tax provision in each of the jurisdictions in which we operate.  This process involves estimating our current tax exposures, as well as making judgments regarding the recoverability of deferred tax assets in each jurisdiction. Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Management assesses the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent management believes that recovery is not likely, a valuation allowance must be established.  To the extent

28


management establishes a valuation allowance or increases this allowance in a period, an increase to expense within the Provision for income taxes in the Consolidated Statements of Income may result.

We have recorded a valuation allowance of $66.4 million as of December 31, 2017 and 2016 due to uncertainties related to our ability to utilize some of the deferred tax assets, primarily consisting of certain foreign net operating losses carried forward and certain state research and development credits.  The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.  In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, an additional valuation allowance may need to be established, which would increase the tax provision, lowering income and impacting our financial position.  Should realization of these deferred tax assets for which a valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting Bio-Rad’s financial position.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense. Our overall effective tax rate is subject to fluctuations because of changes in the geographic mix of earnings, changes to statutory tax rates and tax laws, and because of the impact of various tax audits and assessments, as well as generation of tax credits.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available.

Valuation of Business Acquisitions, Goodwill and Long-lived Assets.  Upon the consummation of a business combination, we use multiple analyses to determine the fair market value of the consideration of assets acquired and liabilities assumed. Once the fair market value of the acquired business is determined, any residual value between fair market value and the consideration is defined as goodwill.

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses, which could include contingent consideration. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interest to the former owners of an acquiree as part of the exchange

29


for control of the acquiree if specified future events occur or conditions are met. Contingent consideration is reported at fair value each reporting period until the contingency is resolved. Any changes in fair value are recognized in earnings, which could become volatile over time depending on the facts and circumstances.

Goodwill amounts are assigned to reporting units at the time of acquisition and are adjusted for any subsequent significant transfers of business between reporting units. We assess the impairment of goodwill annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We perform the impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. On January 1, 2017, we adopted Accounting Standards Update 2017-04, "Simplifying the Test for Goodwill Impairment," in which a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.

We use a projected discounted cash flow model to determine the fair value of a reporting unit. This discounted cash flow method for determining goodwill may be different from the fair value that would result from an actual transaction between a willing buyer and a willing seller. Projections such as discounted cash flow models are inherently uncertain and accordingly, actual future cash flows may differ materially from projected cash flows. Management judgment is required in developing the assumptions for the discounted cash flow model. These assumptions include revenue growth rates, profit margins, future capital expenditures, working capital needs, expected foreign currency rates, discount rates and terminal values. We estimate future cash flows using current and longer-term financial forecasts. These forecasts take into account the current economic environment. The discount rates used are compiled using independent sources, current trends in similar businesses and other observable market data. Changes to these rates might result in material changes in the valuation and determination of the recoverability of goodwill. For example, an increase in the discount rate used to discount cash flows will decrease the computed fair value.

Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions that could result in impairment losses. Our forecasts utilized in our 2017 impairment test assumed, among other things, sales growth from executing our sales and marketing programs, new product introductions, successful product development and timely registration of our products when required, while controlling costs. In addition, external factors, such as currency, inflation rates, cost of capital, and forecasted tax rates could affect the determination of fair value of our reporting units. Aside from our Pasteur Sanofi Diagnostics S.A. and AbD Serotec reporting units, which reflected a carrying value that exceeded its fair value, our impairment tests resulted in excessive fair value over book value ranging from 8% to more than 400% for our various reporting units. One reporting unit, which consists mainly of our 2010 acquisition of Biotest AG, and our 2007 through 2009 acquisitions of DiaMed Holding AG, had excess fair value over book value of only 8% at December 31, 2017. Goodwill in the amount of $263.6 million is allocated to this reporting unit at December 31, 2017. If the initiatives mentioned above do not achieve the desired results, or external factors change detrimentally, future impairment losses may occur.

To validate the reasonableness of the reporting unit fair values, we reconcile the aggregate fair values of the reporting units to the enterprise market capitalization. In performing the reconciliation we may, depending on the volatility of the market value of our stock price, use either the stock price on the valuation date or the average stock price over a range of dates around the valuation date.

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangibles) whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that we consider important that could trigger an impairment review include:

•
significant reporting unit under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;

30


•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. Also in 2016, we impaired intellectual property in the amount of $2.4 million associated with the termination of a research and development project. There were no impairment losses recorded in 2015.

Valuation of Inventories.   We value inventory at the lower of the actual cost to purchase and/or manufacture the inventory, or the current estimated net realizable value of the inventory.  We review inventory quantities on hand and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product demand, production requirements and the quality, efficacy and potency of raw materials.  This review is done on a quarterly basis or, if warranted by the circumstances, more frequently.  In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand.  Our estimates of future product demand may prove to be inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is determined to be overvalued, we would be required to write down the value of inventory to market and recognize such costs in our cost of goods sold at the time of such determination.  Therefore, although we make efforts to ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall inventory quality, any significant unanticipated changes in demand, technological developments, regulations, storage conditions, or other economic or environmental factors affecting biological materials, could have a significant impact on the value of our inventory and reported results of operations.

We adopted ASU 2015-11, "Simplifying the Measurement of Inventory," on January 1, 2017, which requires inventory measurement at the lower of cost and net realizable value. See Note 1 to the consolidated financial statements.

Valuation of Investments.   We regularly review our investments for factors that may indicate that a decline in the fair value of an investment below its carrying value is other-than-temporary.  Some factors considered in evaluating whether or not a decline in fair value is other-than-temporary include our ability and intent to retain the investment for a period of time sufficient to allow for a recovery in value, the duration and extent to which the fair value has been less than cost and the financial condition and prospects of the issuer.  Such reviews are inherently uncertain in that the value of the investment may not fully recover or may decline further in future periods resulting in realized losses.

Allowance for Doubtful Accounts.   We maintain an allowance for doubtful accounts for estimated losses resulting from the collectability of our customer accounts.  The amount of the allowance is determined by analyzing known uncollectible accounts, the age of our receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ general credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.  Uncertainty in the current economic

31


environment, if prolonged, could result in greater amounts becoming uncollectible in the future.  Should the estimates of losses be higher than the actual uncollectible accounts, we would report lower profitability when the estimates are made and higher profitability when the receivable is collected.


Results of Operations - Sales, Gross Margins and Expenses

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
Net sales
100.0
%
 
100.0
%
 
100.0
%
 
Cost of goods sold
45.0

 
45.0

 
44.5

 
Gross profit
55.0

 
55.0

 
55.5

 
Selling, general and administrative expense
37.4

 
39.5

 
37.7

 
Research and development expense
11.6

 
10.0

 
9.6

 
Net income
5.7

 
1.3

 
5.4

 

Net sales

Net sales (sales) in 2017 were $2.16 billion, an increase of 4.4% compared to $2.07 billion in 2016. Excluding the impact of foreign currency exchange rate fluctuations, 2017 sales increased by approximately 3.5% compared to 2016. Currency neutral sales growth was reflected in most regions.

The Life Science segment sales in 2017 were $785.2 million, an increase of 7.5% compared to 2016.  On a currency neutral basis, sales increased 6.8% compared to 2016. The currency neutral sales increase was primarily driven by growth in our Droplet Digital™ PCR and gene expression product lines, in addition to sales from our acquisition of RainDance in 2017. The currency neutral sales increase was primarily reflected in all regions except Latin America mostly due to government imposed spend control.

The Clinical Diagnostics segment sales in 2017 were $1.36 billion, an increase of 2.8% compared to 2016. On a currency neutral basis, sales increased 1.6% compared to 2016. The currency neutral sales increase was primarily attributable to growth across quality control, immunohematology, diabetes and immunology, partially offset by lower sales in infectious disease. On a geographic view, the currency neutral sales increases for 2017 were primarily reflected in Asia Pacific, excluding Japan, and Latin America, partially offset by lower sales in North America and Japan.

Net sales (sales) in 2016 were $2.07 billion, an increase of 2.4% compared to $2.02 billion in 2015. Excluding the impact of foreign currency, 2016 sales increased by approximately 4.0% compared to 2015. Currency neutral sales growth was primarily reflected in all regions except Europe.

The Life Science segment sales in 2016 were $730.7 million, an increase of 5.1% compared to 2015.  On a currency neutral basis, sales increased 6.5% compared to 2015. The currency neutral sales increase was primarily in our Droplet Digital™ PCR and process media products. The currency neutral sales increase was in all regions.

The Clinical Diagnostics segment sales in 2016 were $1.32 billion, an increase of 1.0% compared to 2015. On a currency neutral basis, sales increased 2.6% compared to 2015. The currency neutral sales increase was primarily attributable to growth in quality control, immunology, blood typing and diabetes product lines. On a geographic view, currency neutral sales in 2016 increased most notably in the Americas and Asia, while sales declined in Europe.

32



Gross margin

Consolidated gross margins were 55.0% in 2017 compared to 55.0% in 2016. Life Science segment gross margins in 2017 increased from 2016 by approximately 1.2 percentage points primarily due to higher margins in gene expression and digital biology businesses largely due to a decline in royalty expense for license agreements relating to amplification reagents. In addition, gross margins were impacted by legal matters that reduced cost of goods sold by approximately $10.4 million. These gross margin improvements were partially offset by $10.0 million for a preexisting condition and higher acquisition intangible amortization, both associated with the RainDance acquisition. Clinical Diagnostics segment gross margins in 2017 decreased by approximately 0.8 percentage points compared to 2016 primarily due to lower margin sales and the termination of an infectious disease research and development project that effected cost of goods sold at a cost of $2.3 million in 2017, partially offset by lower amortization of intangibles, licenses fees and favorable manufacturing variances as compared to 2016.

Beginning in 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA), among other initiatives, provided for a 2.3% annual excise tax on the sales of certain medical devices in the U.S. Bio-Rad had been paying this excise tax on most of our U.S. Clinical Diagnostic sales, which we accounted for as a period cost in Cost of goods sold. However, the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), signed into law on December 18, 2015, included a two year moratorium on the medical device excise tax. On January 22, 2018, the moratorium on the medical device excise tax was further extended until January 1, 2020.

Consolidated gross margins were 55.0% in 2016 compared to 55.5% in 2015. Life Science segment gross margins in 2016 decreased from 2015 by approximately 0.7 percentage points, primarily due to lower margins in protein quantification and cell biology, higher service costs, higher acquisition intangible amortization, and $0.7 million of restructuring costs, partially offset by higher margins in Droplet Digital™ PCR, process media products and antibody products. Clinical Diagnostics segment gross margins in 2016 decreased from 2015 by approximately
0.5 percentage points. The decrease compared to 2015 was primarily driven by sales mix and pricing pressures, along with higher period expenses, and $1.4 million of restructuring costs, partially offset by the suspension of the medical device tax.

Selling, general and administrative expense

Consolidated selling, general and administrative expenses (SG&A) decreased to $808.9 million or 37.4% of sales in 2017 compared to $816.7 million or 39.5% of sales in 2016.  Decreases to SG&A were primarily due to $21.0 million for various legal matters in 2016 that did not occur in 2017, including the Wadler judgment as discussed further in Note 13 to the consolidated financial statements compared to a few legal matters in 2017 that reduced SG&A by approximately $0.7 million, $10.4 million of restructuring costs associated with the European reorganization announced in June 2016 (see Note 15) that did not occur in 2017 compared to the other restructuring costs in 2017 of approximately $8.5 million that are also in Note 15 in addition to a few other reduction in force activities, lower contingent consideration of $19.7 million, lower third party commissions of $2.5 million and other numerous net costs of $12.1 million. Increases to SG&A primarily included employee-related expenses (excluding restructuring costs) of $17.0 million, facilities of $12.2 million, software of $7.7 million, bad debt expense of $5.4 million, advertising of $3.5 million, other taxes of $3.3 million, travel of $3.0 million and purchase accounting amortization of $1.0 million. Some of these increased costs were associated with the transition that took place to a new European operating model supported by the European ERP implementation, the inclusion of RainDance, closure costs for the GnuBIO research program facilities, and the termination of an infectious disease research and development project that all occurred in 2017.

33



Consolidated SG&A increased to $816.7 million or 39.5% of sales in 2016 compared to $762.0 million or 37.7% of sales in 2015.  Increases to SG&A primarily included employee-related expenses, our largest cost, which also included $10.4 million of restructuring costs, $21.0 million for various legal matters, including the Wadler judgment, professional fees, software, the revaluation of contingent consideration primarily associated with the cell sorting system and to a lesser extent the analytical flow cytometer platform, travel, facilities and recruitment/relocation. Decreases to SG&A in 2016 primarily included bad debt expense and a one-time distributor cost in 2015.

Research and development expense

Research and development expense increased to $250.3 million or 11.6% of sales in 2017 compared to $205.9 million or 10.0% of sales in 2016.  Life Science segment research and development expense increased in 2017 from 2016 primarily due to higher milestone expenses of $5.5 million associated with the 2016 Propel platform acquisition, and increased project activities, which included our recent RainDance acquisition. Clinical Diagnostics segment research and development expense increased in 2017 from 2016 primarily driven by a termination of an infectious disease research and development project of $15.5 million (see Note 15 to the consolidated financial statements), an asset purchase for an early stage diagnostic device for $7.5 million, and closure costs of $7.6 million that included severance and the impairment of equipment and leasehold improvements for the GnuBIO research program, which all occurred in 2017, partially offset by lower spending due to the timing of projects.

Research and development expense increased to $205.9 million or 10.0% of sales in 2016 compared to $193.0 million or 9.6% of sales in 2015.  Life Science segment research and development expense increased in 2016 from 2015 primarily due to increased project activities in Droplet Digital™ PCR, protein quantification and cell biology. Clinical Diagnostics segment research and development expense increased in 2016 from 2015 primarily from increased spending associated with the GnuBIO business.

Impairment losses on goodwill and long-lived assets

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

During the fourth quarter of 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. During the second quarter of 2016, we impaired an intellectual property license associated with a research and development project for $2.4 million.

Results of Operations – Non-operating

Interest expense

Interest expense in 2017 was unchanged from $21.9 million in 2016, and increased slightly in 2016 compared to $21.7 million in 2015.
  
Foreign currency exchange gains and losses

Foreign currency exchange gains and losses consist of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Net foreign currency exchange losses for 2017, 2016 and 2015 were $9.1 million, $4.5 million and $10.2 million, respectively.  The 2017, 2016 and 2015 net foreign currency exchange losses were attributable to market volatility, costs to hedge and the result of the estimating process

34


inherent in the timing of shipments and payments of intercompany debt, the intercompany movement of assets and capital for the new European operating model in 2017, and our decision to reclassify a large percentage of our intercompany receivable from Brazil to long-term in 2015. All years are affected by the economic hedging program we employ to hedge our intercompany receivables and payables.

Other income and expense, net

Other income and expense, net includes investment and dividend income, generally interest income on our cash and cash equivalents, short-term investments and long term marketable securities.  Other (income) expense, net in 2017 decreased to $12.2 million of income compared to $14.9 million of income in 2016. The decrease was primarily due to $6.4 million of higher other-than-temporary impairment losses on investments in 2017 than in 2016 in light of continuing declines in the investment market prices and investees' financial conditions at that time, partially offset by $1.2 million of higher dividend income in 2017 than in 2016 on the ordinary and preferred shares of our investment in Sartorius AG, and higher investment income.

Other (income) expense, net in 2016 increased to $14.9 million income compared to $11.1 million income in 2015. The increase was primarily due to higher dividend income in 2016 on the ordinary and preferred shares of our investment in Sartorius AG, and higher investment income.

Effective tax rate

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including, among other changes, the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities.

Our effective tax rate was (25)%, 37% and 25% in 2017, 2016 and 2015, respectively. Prior year effective tax rates have been revised (see note 1 to the consolidated financial statements). As a result of the Tax Act, we recognized a provisional estimate for the Transition Tax and the remeasurement of our deferred taxes assets and liabilities, which decreased our provision for income taxes in 2017 by approximately $70 million. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of December 31, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.3 million. Substantially all such amounts will impact our effective income tax rate.


35


 

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our domestic $200.0 million unsecured Credit Agreement, and to a lesser extent international lines of credit.  Borrowings under the 2014 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2017, however, $0.5 million was utilized for domestic standby letters of credit that reduced our borrowing availability.  The Credit Agreement matures in June 2019. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $208.4 million available for borrowing and usage as of December 31, 2017, which was reduced by approximately $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital.
 
At December 31, 2017, we had available $755.0 million in cash, cash equivalents and short-term investments, of which approximately 23% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Act, which also repeals U.S. taxation on the subsequent repatriation of those earnings.  It is generally our intention to repatriate those foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs.  While we currently estimate that the repatriation of those earnings would not trigger material costs, these estimates are provisional, and we are still evaluating the full impact of these potential repatriations in accordance with SAB 118.

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity. As of December 31, 2017 and December 31, 2016, we had accounts receivable, net of an allowance for doubtful accounts, in Spain, Italy, Greece and Portugal of $41.0 million and $32.7 million, respectively. While economic growth is improving in some geographical locations, instability still exists in some of the developed nations, such as a less dependable rate of growth in the Chinese economy and in emerging markets, especially those oil producing countries that have been affected by a decline in oil prices, which may adversely affect our future cash flows.


36




Cash Flows from Operations

Net cash provided by operations was $103.9 million, $216.4 million and $186.2 million in 2017, 2016, and 2015, respectively.  The net decrease between 2017 and 2016 of $112.5 million primarily resulted from:

•
more cash paid to suppliers primarily related to increased inventory, higher employee related costs primarily for merit increases, an asset purchase for an early stage diagnostic device for $7.5 million, $10.0 million for the RainDance preexisting condition, and higher value added taxes in part due to the European reorganization,
•
higher net payments in 2017 compared to 2016 for forward foreign exchange contracts primarily associated with the timing of product shipments, intercompany debt payments, and the intercompany movement of assets and capital for the new European operating model, and
•
lower income tax refunds in 2017 compared to 2016, partially offset by
•
higher cash received from customers in 2017 primarily due to higher sales, partially offset by higher accounts receivable balances due in part to implementation matters associated with the European ERP system, and
•
higher investment income received.

The net increase between 2016 and 2015 of $30.2 million primarily resulted from:

•
higher cash received from customers in 2016 primarily due to lower U.S. collections in the second half of 2015 from delays associated with the second phase of an ERP implementation, and
•
higher investment income received, partially offset by
•
more cash paid to suppliers and employees primarily related to higher payments to inventory suppliers as payments were delayed in the latter part of 2015 mostly associated with the second deployment of the ERP system, higher annual performance-based compensation payments in 2016, and higher legal and other professional fees,
•
higher net income tax payments than in 2015, and
•
net payments in 2016 compared to net cash received in 2015 for forward foreign exchange contracts.

We regularly review past due receivables to assess the allowance for doubtful accounts and believe net accounts receivable are fully realizable. We also routinely review inventory for the impact of obsolescence and changes in market prices caused by the introduction of new products, technologies and in government reimbursement policies. Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth quarter sales commissions to third parties and annual employee bonuses, and we expect this pattern to recur in the first quarter of 2018.

Cash Flows from Investing Activities

Net cash used in investing activities was $175.6 million, $213.9 million and $166.9 million for 2017, 2016 and 2015, respectively. Proceeds from sales and maturities, net of purchases of marketable securities and investments combined, were $17.1 million in 2017 compared to net purchases in 2016 of 58.2 million. Purchases, net of sales and maturities of marketable securities and investments combined, had an overall decrease of $13.2 million in 2016 compared to 2015 primarily due to a decrease in maturities and securities sales, partially offset by a decrease in purchases.

Short-term restricted investments of $5.6 million, $4.6 million and $4.2 million for 2017, 2016 and 2015, respectively, represent a money market fund for collateral that secures worker's compensation and general liability insurance. Investment income accrues to us and is recorded in Investment proceeds and miscellaneous receipts, net in the Consolidated Statements of Cash Flows.


37


Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

Purchases of intangible assets in 2017 were primarily due to a $3.8 million payment for an acquired technology and know-how to expand our product offerings, and in 2016 and 2015 were primarily due to purchases of licenses. Payments for acquisitions, net of cash received, and long-term investments in 2017 and 2016 were primarily due to the following:

•
in February 2017, we acquired all the issued and outstanding stock of RainDance for approximately $72.7 million including certain assumed net liabilities. Cash payments at closing were $72.9 million.
•
in January 2016, we acquired a high performance analytical flow cytometer platform from Propel for total consideration of $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.

We continue to review possible acquisitions to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of the subject companies.  We are currently in discussion and assessing a few possible acquisitions in which we expect our current reported cash and cash equivalents to be sufficient for any cash consideration for these possible acquisitions. However, it is not certain at this time that any of these discussions involving material or significant acquisitions will advance to completion.

Capital expenditures in 2017 totaled $111.3 million, compared to $141.4 million and $112.0 million in 2016 and 2015, respectively. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. As we implement the remaining smaller phases of the ERP platform, we expect capital expenditures to decline over the next couple of years. Capital expenditures were lower in 2017 than in 2016 as implementation costs were higher in 2016 for the third phase of the ERP platform, which was implemented in April 2017. Capital expenditures were lower in 2015 compared to 2016 as the second phase of the ERP system was implemented in July 2015 and the third phase ramped up in 2016. The current estimated future project cost for global implementation for the single instance ERP platform is projected to be $140 million, and is estimated to take approximately the next 3 to 4 years to fully implement.

Cash Flows from Financing Activities

Net cash provided by financing activities was $0.3 million, $9.0 million and $8.6 million in 2017, 2016 and 2015, respectively, and was primarily sourced from proceeds from issuance of our common stock. In 2017, 2016 and 2015, there were payments of $3.7 million, $3.5 million and $3.0 million, respectively, to Propel Labs' shareholders in contingent consideration for sales milestones that were associated with the valuations as of the 2016 and 2012 acquisition dates. In addition, we repurchased our common stock under our repurchase program as described below.

We have outstanding Senior Notes of $425.0 million, which are not due until 2020. We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.

On November 28, 2017, we announced that the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250 million of outstanding shares of our common stock. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock. During the second and third quarters of 2017, we made open market purchases of 13,200 shares of our Class A common stock. In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our

38


foreign entities. The Credit Agreement may limit our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. We had no other repurchases of our stock during 2017, 2016 or 2015.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future material effect on our financial condition, results of operations or liquidity.

Contractual Obligations

The following summarizes certain of our contractual obligations as of December 31, 2017 and the effect such obligations are expected to have on our cash flows in future periods (in millions):

 
 
Payments Due by Period
 
 
 
 
Less
Than
 
1-3
 
3-5
 
More
than
Contractual Obligations
 
Total
 
One Year
 
Years
 
Years
 
5 Years
Long-term debt, including current portion (1)
 
$
436.9

 
$
0.4

 
$
425.6

 
$
0.6

 
$
10.3

Interest payments (1)
 
60.9

 
20.7

 
40.2

 
—

 
—

Operating lease obligations (2)
 
144.9

 
39.3

 
60.3

 
30.0

 
15.3

Purchase obligations (3)
 
24.5

 
3.7

 
7.5

 
7.5

 
5.8

Long-term liabilities (4)
 
131.3

 
10.4

 
24.9

 
9.5

 
86.5

 
 
 
 
 
 
 
 
 
 
 
(1) These amounts represent expected cash payments, including capital lease obligations, which are included in our December 31, 2017 Consolidated Balance Sheet. Our debt is fixed and primarily consists of the 4.875% Notes. See Note 5 of the Consolidated Financial Statements for additional information about our debt.
 
 
 
(2) Operating lease obligations are described in Note 12 of the Consolidated Financial Statements.
 
 
 
(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms.  Purchase obligations exclude agreements that are cancelable without penalty.
 
 
 
(4) Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $53.2 million.  We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table above.  See Note 6 of the Consolidated Financial Statements for additional information about our income taxes.
 
 
 

Recent Accounting Standards Updates

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the

39


consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc.

In February 2018, the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by $120.1 million.

In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements.

40



In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately $17 million.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements.

41



In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP.

42


Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard.


ITEM 7A.  QUANTITIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Financial Risk Management

The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows arising from unexpected foreign exchange rate and interest rate changes.  Financial exposures are managed through operational means and by using various financial instruments, including cash and liquid resources, borrowings, and forward and spot foreign exchange contracts.  No derivative financial instruments are entered into for the purpose of trading or speculation.  Company policy requires that all derivative positions are undertaken to manage the risks arising from underlying business activities.  These derivative transactions do not qualify for hedge accounting treatment.  Derivative instruments used in these transactions are valued at fair value and changes in fair value are included in reported earnings.

Foreign Exchange Risk.  We operate and conduct business in many countries and are exposed to movements in foreign currency exchange rates.  We face transactional currency exposures that arise when we enter into transactions denominated in currencies other than U.S. dollars.  Additionally, our consolidated net equity is impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S. dollar.

Foreign currency exposures are managed on a centralized basis.  This allows for the netting of natural offsets and lowers transaction costs and net exposures.  Where possible, we seek to manage our foreign exchange risk in part through operational means, including matching same-currency revenues to same-currency costs, and same-currency assets to same-currency liabilities.  Moreover, weakening in one currency can often be offset by strengthening in another currency.  Foreign exchange risk is also managed through the use of forward foreign exchange contracts. Positions are primarily in Euro, Swiss Franc, British Sterling, Singapore Dollar, Brazilian Real and Japanese Yen. The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income along with the change in fair market value of the forward exchange contract used as an economic hedge of those assets or liabilities.

Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign currency exchange rates.  All other variables were held constant.  Market risk associated with derivative holdings is the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange rates.  A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of $37 million on our derivative position as of December 31, 2017.  This impact of a change in exchange rates excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect significantly.

Interest Rate Risk of Debt Instruments.  Bio-Rad centrally manages the short-term cash surpluses and shortfalls of its subsidiaries.  Our holdings of variable rate debt instruments at year-end were analyzed to determine their sensitivity to movements in interest rates.  Due to the relatively small amount of short-term variable rate debt we have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely by 10%.  Our long-term debt consists primarily of fixed-rate instruments, and is thus insulated from interest rate changes.  As of December 31, 2017, the overall interest rate risk associated with our debt was not significant.

43






ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
 
 
Index to Consolidated Financial Statements
 
 
Page
 
 
 
Reports of Independent Registered Public Accounting Firm
 
45-47

Consolidated Balance Sheets at December 31, 2017 and 2016
 
48-49
Consolidated Statements of Income for each of the three years in the period ended
 
 
December 31, 2017
 
50
Consolidated Statements of Comprehensive Income for each of the three years in the period
 
 
December 31, 2017
 
51
Consolidated Statements of Cash Flows for each of the three years in the period ended
 
 
December 31, 2017
 
52
Consolidated Statements of Changes in Stockholders’ Equity for each of the three years
 
 
in the period ended December 31, 2017
 
53
Notes to Consolidated Financial Statements
 
54-99
 
 
 



44


Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors

Bio-Rad Laboratories, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2017 and 2016, and the related consolidated statements of income, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2017, and the related notes and financial statement schedule (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated April 13, 2018 expressed an adverse opinion on the effectiveness of the Company's internal control over financial reporting.
 
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
                                                                                                   /s/ KPMG LLP
 We have served as the Company's auditor since 2013.
 
San Francisco, California
April 13, 2018
 

45



To the Stockholders and Board of Directors

Bio‑Rad Laboratories, Inc.:

Opinion on Internal Control Over Financial Reporting
        We have audited Bio-Rad Laboratories, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
        We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2017 and 2016, the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes and financial statement schedule (collectively, the consolidated financial statements) and our report dated April 13, 2018 expressed an unqualified opinion on those consolidated financial statements and financial statement schedule.
        A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness related to the control environment, risk assessment and control activities of certain European entities has been identified and included in management’s assessment. The material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2017 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.
Basis for Opinion
        The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
        We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
        A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable

46


assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
        Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 
San Francisco, California
April 13, 2018

47




BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands, except share data)
 
December 31,
 
2017
 
2016
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
383,824

 
$
456,264

Short-term investments
371,154

 
383,176

Restricted investments
5,560

 
4,560

Accounts receivable, less allowance for doubtful accounts of $25,549 at 2017 and $23,367 at 2016
464,847

 
372,348

 
 
 
 
Inventories:
 
 
 
Raw materials
113,925

 
116,540

Work in process
142,589

 
125,982

Finished goods
338,290

 
282,439

Total inventories
594,804

 
524,961

 
 
 
 
Prepaid expenses
146,135

 
91,014

Other current assets
10,325

 
12,201

Total current assets
1,976,649

 
1,844,524

 
 
 
 
Property, plant and equipment:
 
 
 
   Land and improvements
18,026

 
17,895

   Buildings and leasehold improvements
315,984

 
300,834

   Equipment
971,140

 
908,659

     Total property, plant and equipment
1,305,150

 
1,227,388

Less: accumulated depreciation and amortization
(811,654
)
 
(738,774
)
Property, plant and equipment, net
493,496

 
488,614

 
 
 
 
Goodwill, net
506,069

 
477,115

Purchased intangibles, net
174,113

 
161,609

Other investments
1,027,736

 
830,790

Other assets
94,949

 
47,852

Total assets
$
4,273,012

 
$
3,850,504

 
 
 
 

The accompanying notes are an integral part of these consolidated financial statements.

 48



BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)

 
December 31,
 
2017
 
2016
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
  Accounts payable
$
135,182

 
$
133,109

  Accrued payroll and employee benefits
171,632

 
163,364

  Notes payable and current maturities of long-term debt
420

 
334

  Income and other taxes payable
39,941

 
28,124

  Deferred revenue
28,233

 
31,003

  Other current liabilities
127,288

 
115,388

Total current liabilities
502,696

 
471,322

 
 
 
 
Long-term debt, net of current maturities
434,581

 
434,186

Deferred income taxes
222,209

 
225,299

Other long-term liabilities
183,276

 
140,537

Total liabilities
1,342,762

 
1,271,344

 
 
 
 
Commitments and contingent liabilities


 


 
 
 
 
Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
—

 
—

  Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 24,679,127 and 24,454,048 at 2017 and 2016, respectively; shares outstanding - 24,678,545 and 24,453,926 at 2017 and 2016, respectively
2

 
2

  Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued - 5,107,674 and 5,123,883 at 2017 and 2016, respectively; shares outstanding - 5,106,757 and 5,122,966 at 2017 and 2016, respectively
1

 
1

Additional paid-in capital
361,231

 
332,911

  Class A treasury stock at cost, 582 shares at 2017 and 122 shares at 2016
(128
)
 
(12
)
  Class B treasury stock at cost, 917 shares at 2017 and 2016
(89
)
 
(89
)
Retained earnings
1,830,439

 
1,828,581

Accumulated other comprehensive income
738,794

 
417,766

Total stockholders’ equity
2,930,250

 
2,579,160

Total liabilities and stockholders’ equity
$
4,273,012

 
$
3,850,504

 
 
 
 



The accompanying notes are an integral part of these consolidated financial statements.

 49



BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income
(In thousands, except per share data)


 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
 
 
 
 
 
 
 
Net sales
$
2,160,153

 
$
2,068,172

 
$
2,019,441

 
Cost of goods sold
972,754

 
930,085

 
897,771

 
Gross profit
1,187,399

 
1,138,087

 
1,121,670

 
Selling, general and administrative expense
808,942

 
816,724

 
761,990

 
Research and development expense
250,301

 
205,864

 
192,972

 
Impairment losses on goodwill and long-lived assets
11,506

 
62,305

 
—

 
Income from operations
116,650

 
53,194

 
166,708

 
Interest expense
21,914

 
21,942

 
21,692

 
Foreign exchange losses, net
9,128

 
4,542

 
10,249

 
Other (income) expense, net
(12,197
)
 
(14,850
)
 
(11,080
)
 
Income before income taxes
97,805

 
41,560

 
145,847

 
Benefit from (provision for) income taxes
24,444

 
(15,560
)
 
(36,608
)
 
Net income
$
122,249

 
$
26,000

 
$
109,239

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
Net income per basic share
$
4.12

 
$
0.88

 
$
3.74

 
Weighted average common shares - basic
29,655

 
29,440

 
29,186

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
Net income per diluted share
$
4.07

 
$
0.88

 
$
3.71

 
Weighted average common shares - diluted
30,034

 
29,646

 
29,409

 

The accompanying notes are an integral part of these consolidated financial statements. 


50


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income
(In thousands)


 
Year Ended December 31,
 
2017
 
2016
 
2015
Net income
$
122,249

 
$
26,000

 
$
109,239

Other comprehensive income (loss):
 
 
 
 
 
Foreign currency translation adjustments
76,050

 
(32,394
)
 
(37,536
)
Foreign other post-employment benefits adjustments, net of income taxes
(3,767
)
 
2,086

 
(4,403
)
Net unrealized holding gains on available-for-sale (AFS) investments, net of income taxes and effect of adoption of ASU 2018-02*
248,745

 
65,936

 
205,132

Other comprehensive income, net of income taxes
321,028

 
35,628

 
163,193

Comprehensive income
$
443,277

 
$
61,628

 
$
272,432


*See Note 1, "Significant Accounting Policies" under "Recent Accounting Standards Update"
Reclassification adjustments are calculated using the specific identification method.
The accompanying notes are an integral part of these consolidated financial statements.



51


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)
 
Year Ended December 31,
 
2017
 
2016
 
2015
Cash flows from operating activities:
 
 
 
 
 
Cash received from customers
$
2,093,948

 
$
2,074,024

 
$
1,956,084

Cash paid to suppliers and employees
(1,918,971
)
 
(1,810,844
)
 
(1,730,062
)
Interest paid, net
(21,124
)
 
(21,318
)
 
(20,793
)
Income tax payments, net
(52,136
)
 
(38,442
)
 
(31,715
)
Investment proceeds and miscellaneous receipts, net
19,892

 
15,683

 
11,953

Excess tax benefits from share-based compensation
—

 
(1,506
)
 
(3,610
)
(Payments for) proceeds from forward foreign exchange contracts, net
(17,724
)
 
(1,164
)
 
4,353

Net cash provided by operating activities
103,885

 
216,433

 
186,210

Cash flows from investing activities:
 
 
 
 
 
Capital expenditures
(111,332
)
 
(141,436
)
 
(112,000
)
Proceeds from dispositions of property, plant and equipment
86

 
398

 
79

Payments for acquisitions and long-term investment
(76,645
)
 
(14,165
)
 
(4,356
)
Payments for purchases of intangible assets
(3,795
)
 
(135
)
 
(1,372
)
Payments for purchases of restricted investment
(1,000
)
 
(350
)
 
(4,210
)
Payments for purchases of marketable securities and investments
(282,656
)
 
(278,071
)
 
(294,497
)
Proceeds from sales of marketable securities and investments
97,523

 
76,859

 
78,664

Proceeds from maturities of marketable securities and investments
202,247

 
143,020

 
170,823

Net cash used in investing activities
(175,572
)
 
(213,880
)
 
(166,869
)
Cash flows from financing activities:
 
 
 
 
 
Net (payments) borrowings on line-of-credit arrangements and notes payable
(36
)
 
37

 
—

Payments on long-term borrowings
(316
)
 
(303
)
 
(282
)
Proceeds from issuances of common stock for share-based compensation
7,294

 
11,280

 
8,236

Payments for purchases of treasury stock
(2,920
)
 
—

 
—

Payments of contingent consideration
(3,681
)
 
(3,500
)
 
(2,983
)
Excess tax benefits from share-based compensation
—

 
1,506

 
3,610

Net cash provided by financing activities
341

 
9,020

 
8,581

Effect of foreign exchange rate changes on cash
(1,094
)
 
(12,858
)
 
16,376

Net (decrease) increase in cash and cash equivalents
(72,440
)
 
(1,285
)
 
44,298

Cash and cash equivalents at beginning of year
456,264

 
457,549

 
413,251

Cash and cash equivalents at end of year
$
383,824

 
$
456,264

 
$
457,549


The accompanying notes are an integral part of these consolidated financial statements.

52


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
 
 
Common
Stock
 
Additional Paid-in Capital
 
Treasury Stock
 
Retained
Earnings
 
Accumulated Other Comprehensive Income
 
Total Stockholders' Equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2014
 
$
3

 
$
271,346

 
$
(101
)
 
$
1,693,342

 
$
218,945

 
$
2,183,535

Net income
 
—

 
—

 
—

 
109,239

 
—

 
109,239

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
163,193

 
163,193

Issuance of common stock
 
—

 
8,236

 
—

 
—

 
—

 
8,236

Stock compensation expense
 
—

 
16,983

 
—

 
—

 
—

 
16,983

Tax benefit-exercise stock options
 
—

 
3,843

 
—

 
—

 
—

 
3,843

Balance at December 31, 2015
 
3

 
300,408

 
(101
)
 
1,802,581

 
382,138

 
2,485,029

Net income
 
—

 
—

 
—

 
26,000

 
—

 
26,000

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
35,628

 
35,628

Issuance of common stock
 
—

 
11,280

 
—

 
—

 
—

 
11,280

Stock compensation expense
 
—

 
19,730

 
—

 
—

 
—

 
19,730

Tax benefit-exercise stock options
 
—

 
1,493

 
—

 
—

 
—

 
1,493

Balance at December 31, 2016
 
3

 
332,911

 
(101
)
 
1,828,581

 
417,766

 
2,579,160

Effect of adoption of ASU 2016-09*
 
—

 
391

 
—

 
(256
)
 
—

 
135

Net income
 
—

 
—

 
—

 
122,249

 
—

 
122,249

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
200,893

 
200,893

Effect of adoption of ASU 2018-02*
 
—

 
—

 
—

 
(120,135
)
 
120,135

 
—

Issuance of common stock
 
—

 
4,490

 
—

 
—

 
—

 
4,490

Stock compensation expense
 
—

 
23,439

 
—

 
—

 
—

 
23,439

Purchase of treasury stock
 
—

 
—

 
(2,920
)
 
—

 
—

 
(2,920
)
Issuance of treasury stock
 
—

 
—

 
2,804

 
 
 
 
 
2,804

Balance at December 31, 2017
 
$
3

 
$
361,231

 
$
(217
)
 
$
1,830,439

 
$
738,794

 
$
2,930,250


*See Note 1, "Significant Accounting Policies" under "Recent Accounting Standards Update"

The accompanying notes are an integral part of these consolidated financial statements.

53


 
BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements


1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million and $4.6 million at December 31, 2017 and 2016, respectively, represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

54



Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating

55


segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.


56


We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available. We expect to complete the relevant analysis no later than December 31, 2018.

Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent

57


agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) cost per test conducted and reported. Revenue on a cost per reported basis is estimated in the current period, and billed at actual in the month reported by our customer.

Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.

Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2017
 
2016
January 1
 
$
17.6

 
$
17.4

Provision for warranty
 
29.9

 
33.4

Actual warranty costs
 
(28.8
)
 
(33.2
)
December 31
 
$
18.7

 
$
17.6



Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

58



Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Basic weighted average shares outstanding
 
29,655

 
29,440

 
29,186

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
379

 
206

 
223

Diluted weighted average common shares
 
30,034

 
29,646

 
29,409

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
13

 
113

 
109



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

59



RECLASSIFICATION OF CERTAIN AMOUNTS, AND CORRECTION OF IMMATERIAL ERRORS

2016 Reclassification of Buildings and leasehold improvements, and Equipment

Upon our implementation of our global single instance enterprise resource planning ("ERP") platform in Europe during the second quarter of 2017, $10.5 million of assets in France were misclassified as Equipment that should have been reported as Buildings and leasehold improvements in periods prior to 2017. The reclassification on the 2016 balance conforms to the correct balance sheet presentation as of December 31, 2017, and there was no impact on the Consolidated Statements of Income or Cash Flows. Please see the table below for the corrected amounts for Buildings and leasehold improvements, and Equipment.

2016 and 2015 Misstatement of Income Taxes

During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. As a consequence, Deferred income taxes in 2016 were understated by $2.4 million and the Provision for income taxes was understated by $2.4 million in 2015.

The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. As a consequence, Retained earnings were overstated by $1.4 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $4.6 million in 2016 and the Provision for income taxes was understated by $1.9 million and $1.3 million in 2016 and 2015, respectively.

The third misstatement was related to a design deficiency associated with transfer pricing. As a consequence, our Retained earnings were overstated by $0.2 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $0.6 million in 2016 and the Provision for income taxes was understated by $0.2 million in both 2016 and 2015.

The impact of the reclassification, and the immaterial error corrections, both described above on our Consolidated Balance Sheet and Consolidated Statements of Income for the periods presented is as follows (in thousands, except per share data):
 
 
December 31, 2016
 
 
As reported
 
Adjustment
 
As revised
Buildings and leasehold improvements
 
$
290,367

 
$
10,467

 
$
300,834

Equipment
 
919,126

 
(10,467
)
 
908,659

Deferred income taxes
 
222,919

 
2,380

 
225,299

Other long-term liabilities
 
135,318

 
5,219

 
140,537

Total liabilities
 
1,263,745

 
7,599

 
1,271,344

Retained earnings
 
1,836,180

 
(7,599
)
 
1,828,581

Total stockholders' equity
 
$
2,586,759

 
$
(7,599
)
 
$
2,579,160




60


 
Year ended December 31,
 
2016
 
2015
 
As reported
Adjustment
As revised
 
As reported
Adjustment
As revised
Provision for income taxes
$
(13,435
)
$
(2,125
)
$
(15,560
)
 
$
(32,754
)
$
(3,854
)
$
(36,608
)
Net income
$
28,125

$
(2,125
)
$
26,000

 
$
113,093

$
(3,854
)
$
109,239

Net income per basic share
$
0.96

$
(0.08
)
$
0.88

 
$
3.87

$
(0.13
)
$
3.74

Net income per diluted share
$
0.95

$
(0.07
)
$
0.88

 
$
3.85

$
(0.14
)
$
3.71



Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.

Recent Accounting Standards Updates

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc.

In February 2018, the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by $120.1 million.

In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.


61


In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately $17 million.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.

62



In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition, we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.

63



In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP. Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard.


2.    ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses. The final allocation of the payments reflect the effects of correcting an error that were recorded in the fourth

64


quarter of 2017. These corrections reduced goodwill, deferred revenue and deferred tax assets by $1.9 million, $3.3 million and $1.4 million, respectively, and had no significant impact on our Consolidated Statements of Income.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.

Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $16.7 million as of December 31, 2017 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. The goodwill related to this acquisition is deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving manufacturing, engineering and marketing support from Propel on which payments are made upon the successful completion of all contracted services. As a result, these services were not included in the total purchase consideration and have been and will be expensed.


3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)


65


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (c)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.6

 
$
—

 
$
1.6

     Contingent consideration (e)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):


66


 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
$
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
—

 
$
1.3

 Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
Short-term investments
$
371.2

 
$
383.2

Other investments
930.2

 
732.4

Total
$
1,301.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):

67


 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5




In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. The current contingent consideration is built on a sales forecast of $78 million through December 31, 2020. In the third quarter of 2017, we paid $0.6 million upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by $6.0 million. The contingent consideration was accrued at its estimated fair value of $16.7 million as of December 31, 2017.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2017 (in millions):

 
2017
 
 
January 1
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(8.1
)
Payment of sales milestone
$
(0.6
)
December 31
$
16.7




The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.

68


 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.8
%
 
 
Cost of debt
4.2
%



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of December 31, 2016 in the amount of $10.0 million and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc.

To estimate the fair value of Level 2 debt securities as of December 31, 2017 and 2016, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is Securities Evaluations as the primary pricing source and then our custodian as the secondary pricing source. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of December 31, 2017 and 2016, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.

Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):


69


 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4


 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
$
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):


70


 
December 31,
2017
 
December 31, 2016
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
43.9

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
168.7

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.7

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2017 or at December 31, 2016.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2017 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2017
Contracts maturing in January through March 2018 to sell foreign currency:
 
Notional value
$
52.0

Unrealized loss
$
0.1

Contracts maturing in January through March 2018 to purchase foreign currency:
 
Notional value
$
413.2

Unrealized loss
$
1.0



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
126.3

 
$
126.1

Mature in one to five years
157.9

 
157.2

Mature in more than five years
45.0

 
44.7

Total
$
329.2

 
$
328.0




71


The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
91.8

 
$
1,249.4

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases
and current maturities
$
423.1

 
$
449.8

 
2
 
$
422.5

 
$
454.2

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2017.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is too thinly traded and the fair value is not readily determinable in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.


72



4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2017
 
 
2016
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.1

 
$
311.7

 
$
518.8

 
 
$
207.2

 
$
316.9

 
$
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
179.9

 
297.2

 
477.1

 
 
180.0

 
315.9

 
495.9

Acquisitions
 
26.2

 
—

 
26.2

 
 
0.1

 
—

 
0.1

Impairment
 
(8.7
)
 
(2.8
)
 
(11.5
)
 
 
—

 
(13.5
)
 
(13.5
)
Currency fluctuations
 
1.4

 
12.9

 
14.3

 
 
(0.2
)
 
(5.2
)
 
(5.4
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.7

 
324.6

 
559.3

 
 
207.1

 
311.7

 
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
$
198.8

 
$
307.3

 
$
506.1

 
 
$
179.9

 
$
297.2

 
$
477.1



In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded $26.2 million of goodwill and $37.6 million of definite-lived intangible assets: $36.4 million of licenses, $1.0 million of developed product technology and $0.2 million of tradenames.

In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations. In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc., which is included in our Clinical Diagnostics segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1


73



 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6




Amortization expense related to purchased intangible assets for the years ended December 31, 2017, 2016 and 2015 was $30.8 million, $35.2 million and $36.5 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2018, 2019, 2020, 2021, 2022 and thereafter is $28.4 million, $25.0 million, $22.9 million, $22.1 million, $18.0 million, and $57.7 million, respectively.


5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $208.4 million available for borrowing and usage as of December 31, 2017, which was reduced by $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.9
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
423.1

 
422.5

Capital leases and other debt
11.9

 
12.0

 
435.0

 
434.5

Less current maturities
(0.4
)
 
(0.3
)
Long-term debt
$
434.6

 
$
434.2



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including

74


limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2017. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2017 or 2016, however, $0.5 million and $0.8 million were utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2017 and 2016, respectively. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.94% at December 31, 2017.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2017.

Maturities of long-term debt at December 31, 2017 are as follows: 2018 - $0.4 million; 2019 - $0.3 million; 2020 - $425.3 million; 2021 - $0.3 million; 2022 - $0.3 million; thereafter - $10.3 million.


6. INCOME TAXES

On December 22, 2017, comprehensive tax legislation (the “Tax Act”) was enacted into law. The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including, but not limited to, (1) a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings (“Transition Tax”) that is payable over eight years; (2) bonus depreciation that allows for full expensing of qualified property; and (3) a reduction in the U.S. federal corporate tax rate from 35% to 21% effective in 2018, which requires us to remeasure our deferred tax assets and liabilities as of December 31, 2017. The Tax Act also includes provisions that may affect our 2018 financial statements, including, but not limited to, (1) the elimination of the corporate alternative minimum tax; (2) the creation of the base erosion anti-abuse tax, a new minimum tax; (3) a change from a worldwide tax system to a modified territorial system; (4) a new provision designed to tax global intangible low-taxed income, which allows for the possibility of using foreign tax credits and a deduction of up to 50 percent to offset the income tax liability (subject to some limitations); (5) a new limitation on deductible interest expense; (6) the repeal of the domestic production activity deduction; (7) limitations on the deductibility of certain executive compensation; (8) limitations on the use of foreign tax credits to reduce the U.S. income tax liability; and (9) limitations on net operating losses generated after December 31, 2017 to 80 percent of taxable income. We are currently reviewing and evaluating the Tax Act and its impacts to our financial statements.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable

75


estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available.

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U.S.
 
$
72.8

 
$
(38.5
)
 
$
48.4

International
 
25.0

 
80.1

 
97.4

Income before taxes
 
$
97.8

 
$
41.6

 
$
145.8



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
6.7

 
$
16.1

 
$
8.7

State
 
3.4

 
3.1

 
1.7

International
 
32.0

 
30.4

 
34.1

Current tax expense
 
42.1

 
49.6

 
44.5

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(69.8
)
 
(42.4
)
 
2.0

State
 
4.3

 
(2.8
)
 
1.4

International
 
(19.3
)
 
(6.0
)
 
(7.1
)
Deferred tax benefit
 
(84.8
)
 
(51.2
)
 
(3.7
)
Non-current tax expense (benefit)
 
18.3

 
17.2

 
(4.2
)
(Benefit from) provision for income taxes
 
$
(24.4
)
 
$
15.6

 
$
36.6



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:


76


 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U. S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
7

 
(15
)
 
(4
)
Foreign dividends, net
 
—

 
(40
)
 
(4
)
Research tax credits
 
(4
)
 
(9
)
 
(2
)
Nontaxable subsidies
 
(2
)
 
(4
)
 
(1
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
47

 
(3
)
Goodwill impairment
 
—

 
11

 
—

Domestic manufacturing deduction
 
—

 
(4
)
 
(2
)
Stock-based compensation
 
(5
)
 
3

 
1

Nondeductible executive compensation
 
2

 
3

 
1

Fines and penalties
 
—

 
2

 
—

Prior period adjustments
 
—

 
4

 
3

U.S. taxation of foreign income
 
3

 
2

 
—

Acquisition-related
 
10

 
—

 
—

U.S. tax reform
 
(71
)
 
—

 
—

State taxes
 
3

 
1

 
1

Other
 
(3
)
 
1

 
—

(Benefit from) provision for income taxes
 
(25
)%
 
37
 %
 
25
 %


Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Our effective income tax rate was (25)%, 37% and 25% in 2017, 2016 and 2015, respectively. The lower effective tax rate in 2017 is primarily due to an estimated provisional tax benefit from the Tax Act of approximately $70 million. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions.
  
In accordance with SAB 118, our accounting for the following elements of the Tax Act is incomplete. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:

–
Our deferred tax assets and liabilities are measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled. In connection with the Tax Act, we have provisionally recorded a deferred income tax benefit of $125 million for the statutory corporate tax rate reduction as our U.S. federal deferred tax liabilities exceed our deferred tax assets. This deferred tax benefit is primarily related to the remeasurement of the deferred tax liability for our investment in the preferred shares of Sartorius AG.

–
The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. We recorded a provisional income tax expense of $55 million for Transition Tax. As additional information and guidance become available, the determination of the Transition Tax will be completed within the measurement period in accordance with SAB 118.

Our accounting for certain other elements of the Tax Act is incomplete, and we are not yet able to make reasonable estimates of those effects. For example, we have not made a determination as to our accounting policy with respect to the new Global Intangible Low Tax Income ("GILTI"). Therefore, no provisional adjustments were recorded.


77


Many jurisdictions in which we operate have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2017
 
2016
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.6

 
$
25.8

Other post-employment benefits, vacation and other reserves
 
24.0

 
26.3

Tax credit and net operating loss carryforwards
 
73.3

 
96.4

Other
 
19.7

 
35.7

    Total gross deferred tax assets
 
145.6

 
184.2

Valuation allowance
 
(66.4
)
 
(66.4
)
       Total deferred tax assets
 
79.2

 
117.8

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
33.5

 
22.2

Investments and intangible assets
 
219.1

 
287.8

        Total deferred tax liabilities
 
252.6

 
310.0

Net deferred tax liabilities
 
$
(173.4
)
 
$
(192.2
)


Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

At December 31, 2017, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of $207.2 million.  Of these loss carryforwards, $150.6 million have no expiration date.  We believe that it is more likely than not that the benefit from approximately half of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of $27.8 million relating to these net operating loss carryforwards.

At December 31, 2017, Bio-Rad had approximately $53 million of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At December 31, 2017, Bio-Rad had a deferred tax asset of $29.6 million relating to California research tax credit carryforwards, including $2.0 million from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.

Although we believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future, if or when recognized, the tax benefits relating to any reversal of the valuation allowance will be recognized as a reduction of income tax expense.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions an

78


d allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2017
 
2016
 
2015
Unrecognized tax benefits – January 1
 
$
21.1

 
$
11.9

 
$
15.8

Additions to tax positions related to prior years
 
1.3

 
10.4

 
0.7

Reductions to tax positions related to prior years
 
(1.0
)
 
—

 
(0.2
)
Additions to tax positions related to the current year
 
34.8

 
3.4

 
2.9

Settlements
 
(0.2
)
 
(2.4
)
 
(0.5
)
Lapse of statute of limitations
 
(3.4
)
 
(2.3
)
 
(6.3
)
Currency translation
 
2.3

 
0.1

 
(0.5
)
Unrecognized tax benefits – December 31
 
$
54.9

 
$
21.1

 
$
11.9



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2017, 2016 and 2015, respectively was $10.9 million, $11.8 million and $3.1 million. Bio-Rad accrued interest and penalties of $(0.9) million, $8.7 million, and $(0.7) million in 2017, 2016, and 2015, respectively. The total unrecognized tax benefits and interest and penalties of $65.8 million in 2017 was partially offset by deferred tax assets of $2.8 million and prepaid taxes of $14.5 million, for a net amount of $48.5 million.

As of December 31, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.3 million. Substantially all such amounts will impact our effective income tax rate if recognized.

Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Act, which also repeals U.S. taxation on the subsequent repatriation of those earnings. It is generally our intention to repatriate those foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. While we currently estimate that the repatriation of those earnings would not trigger material costs, these estimates are provisional, and we are still evaluating the full impact of these potential repatriations in accordance with SAB 118.


79



7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2015
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108


Treasury Shares

On November 28, 2017, we announced that the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock. During the second and third quarters of 2017, we made open market purchases of 13,200 shares of our Class A common stock. In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. We had no other repurchases of our stock during 2017 or 2016.


80




8.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2016
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02**
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8


**See Note 1, "Significant Accounting Policies" under "Recent Accounting Standards Update"

The increases in 2017 and 2016 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2017
2016
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.1
)
$
(2.5
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.1

$
0.8

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.

81





9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.

In April 2017, our stockholders approved the 2017 Plan. The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 1,999,714 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2017, there were 1,771,794 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2017, 2016 and 2015, we recognized share-based compensation expense of $23.4 million, $19.7 million and $17.0 million, respectively.  The income tax benefit related to share-based compensation expense was $5.8 million, $5.1 million and $4.3 million for 2017, 2016 and 2015, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2017, 2016 and 2015 was $6.3 million, $1.5 million, and $3.6 million, respectively. The actual tax benefit realized for the tax deductions from share-based

82


compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled $6.0 million and $9.3 million in 2016 and 2015, respectively.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
 
 
 
Granted
 
44,000

 
$
215.98

 
 
 
 
Exercised
 
(78,890
)
 
$
89.41

 
 
 
 
Forfeited/expired
 
(7,200
)
 
$
177.99

 
 
 
 
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
5.09
 
$
48.2

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2017
 
125,720

 
$
164.84

 
8.29
 
$
9.3

Exercisable, December 31, 2017
 
281,760

 
$
100.56

 
3.66
 
$
38.9




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2017, 2016 and 2015 was approximately $10 million, $1 million and $13 million, respectively. The total fair value of options vested during 2017, 2016 and 2015 was $4.2 million, $2.1 million and $1.6 million, respectively.

Cash received from stock options exercised during 2017, 2016 and 2015 was $1.6 million, $1.2 million and $2.9 million, respectively.  

As of December 31, 2017, there was $5.5 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Expected volatility
 
20
%
 
21
%
 
23
%
Risk-free interest rate
 
1.87
%
 
1.35
%
 
1.90
%
Expected life (in years)
 
7.2

 
7.4

 
7.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
58.65

 
$
42.40

 
$
42.74



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

83



Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and in 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
 
 
 
Granted
 
192,860

 
$
215.98

 
 
 
 
Vested
 
(127,189
)
 
$
133.54

 
 
 
 
Forfeited
 
(41,263
)

$
151.36

 
 
 
 
Outstanding, December 31, 2017
 
473,230

 
$
172.75

 
2.14
 
$
112.9



The total fair value of restricted stock units vested in 2017, 2016 and 2015 was $27.7 million, $18.7 million and $15.8 million, respectively. As of December 31, 2017, there was approximately $74.7 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2017
 
 
 
2016
 
 
 
2015
Expected volatility
19
%
 
 
 
20
%
 
 
 
18
%
Risk-free interest rate
0.83
%
 
 
 
0.26
%
 
 
 
0.02
%
Expected life (in years)
0.24

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
38.86

 
 
 
$
27.36

 
 
 
$
25.08



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 74,409 shares for $13.0 million, 93,605 shares for $11.5 million and 96,634 shares for $10.8 million under the 2011 ESPP to employees in 2017, 2016 and 2015, respectively.  At December 31, 2017, 721,712 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.


84




10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
 
 
 
 
 
 
Interest and investment income
 
$
(19.1
)
 
$
(14.7
)
 
$
(10.1
)
Net realized gains on investments
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Other (income) expense, net
 
$
(12.2
)
 
$
(14.9
)
 
$
(11.1
)


Other-than-temporary impairment losses on investments were recorded in 2017, 2016 and 2015 in light of continuing declines in the investment market prices and investees' financial conditions at that time.



85


11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Net income
 
$
122.2

 
$
26.0

 
$
109.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
148.7

 
142.9

 
131.8

Share-based compensation
 
23.4

 
19.7

 
17.0

Gains on dispositions of securities
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Losses on dispositions of fixed assets
 
8.1

 
0.6

 
0.3

Excess tax benefits from share-based compensation
 
—

 
(1.5
)
 
(3.6
)
Changes in fair value of contingent consideration
 
(18.1
)
 
(0.4
)
 
(5.6
)
(Increase) decrease in accounts receivable, net
 
(64.1
)
 
12.5

 
(39.0
)
Increase in inventories, net
 
(47.7
)
 
(57.1
)
 
(54.2
)
(Increase) decrease in other current assets
 
(36.1
)
 
(6.6
)
 
0.1

Increase in accounts payable
 


 


 


and other current liabilities
 
7.8

 
30.1

 
28.6

(Decrease) increase in income taxes payable
 
(22.4
)
 
10.7

 
12.7

Decrease in deferred income taxes
 
(82.0
)
 
(51.4
)
 
(4.0
)
Decrease in other long term assets
 
2.4

 
12.7

 
0.3

Increase (decrease) in other long term liabilities
 
38.1

 
10.4

 
(10.7
)
Impairment losses on goodwill and long-lived assets
 
11.5

 
62.3

 
—

Other
 
5.2

 
5.7

 
4.3

Net cash provided by operating activities
 
$
103.9

 
$
216.4

 
$
186.2

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
—

 
7.2

 
—

   Purchased marketable securities and investments
 
$
2.8

 
$
0.6

 
$
2.2





86


12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $43.6 million, $44.4 million and $45.0 million in 2017, 2016 and 2015, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.

Annual future minimum lease payments at December 31, 2017 under operating leases are as follows: 2018 - $39.3 million; 2019 - $33.2 million; 2020 - $27.1 million; 2021 - $17.8 million; and 2022 and beyond - $27.5 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $16.0 million, $15.1 million and $14.7 million in 2017, 2016 and 2015, respectively.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2017 and 2016 of $74.9 million and $63.9 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):


87


Change in benefit obligation:
2017
2016
Benefit obligation at beginning of year
$122.7
$120.8
Service cost
6.5

6.1

Interest cost
1.1

1.4

Plan participants' contributions
2.8

2.6

Actuarial (gain) loss
3.3

—

Gross benefits paid
(3.2
)
(3.3
)
Plan amendments
1.1

—

Special termination benefits
(2.0
)
—

Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
9.4

(2.4
)
 
 
 
Benefit obligation at end of year
136.6

122.7

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
58.8

56.7

Actual return on plan assets
0.5

1.3

Employer contributions
4.0

4.7

Plan participants' contributions
2.8

2.6

Gross benefits paid
(2.3
)
(2.9
)
Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
3.0

(1.1
)
 
 
 
Fair value of plan assets at end of year
61.7

58.8

 
 
 
Under funded status of plans
$(74.9)
$(63.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(0.5)
Noncurrent liabilities (Other long-term liabilities)
(73.8
)
(63.4
)
 
 
 
Net liability, end of fiscal year
$(74.9)
$(63.9)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2017
2016
2015
Service costs
$6.5
$6.1
$5.3
Interest costs
1.1

1.4

1.4

Expected returns on plan assets
(1.1
)
(1.0
)
(1.2
)
Amortization of actuarial losses
1.4

1.7

0.8

Amortization of prior service costs
—

—

0.4

Settlements
1.2

0.4

—

 
 
 
 
Net periodic benefit costs
$9.1
$8.6
$6.7
 
 
 
 


88



Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2017
2016
Discount rate
0.8
%
0.9
%
Compensation rate increase
1.8
%
1.6
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2017
2016
2015
Discount rate
0.9
%
1.1
%
1.3
%
Expected long-term rate of return on plan assets
1.9
%
1.6
%
2.3
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2017 and 2016 was $3.7 million and $3.5 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Purchase Obligations

As of December 31, 2017, we had obligations that have been recognized on our balance sheet of $131.2 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2017 are as follows: 2018 - $10.3 million, 2019 - $14.3 million, 2020 - $10.6 million, 2021 - $6.9 million, 2022 - $2.6 million and after 2022 - $86.5 million.

As of December 31, 2017, we had purchase obligations that have not been recognized on our balance sheet of $24.5 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2017 are as follows: 2018 - $3.7 million, 2019 - $3.8 million, 2020 - $3.7 million, 2021 - $3.8 million, 2022 - $3.7 million and after 2022 - $5.8 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.2 million of standby letters of credit/guarantees with financial institutions as of December 31, 2017.

89



Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. The current contingent consideration is built on a sales forecast of $78 million through December 31, 2020. In the third quarter of 2017, we paid $0.6 million upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by $6.0 million. The contingent consideration was accrued at its estimated fair value of $16.7 million as of December 31, 2017.

In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of December 31, 2016 in the amount of $10.0 million and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc.

In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2017, approximately seven percent of Bio-Rad's approximately 3,270 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.


13.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption

90


was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleged that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. In January 2018, we entered into a settlement agreement with the District pursuant to which we paid the District $990,000 to settle all claims and/or potential claims arising out of our use of the three power generation units. This settlement amount was accrued for as of December 31, 2017.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any

91


assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2017, 2016, and 2015 and for the years then ended is as follows (in millions):


92


 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2017
 
$
785.2

 
$
1,360.8

 
$
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
 
 
 
 
 
 
 
Allocated interest expense
2017
 
$
7.0

 
$
14.9

 
$
—

 
2016
 
6.4

 
15.5

 
—

 
2015
 
6.1

 
15.4

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2017
 
$
36.2

 
$
80.2

 
$
—

 
2016
 
31.7

 
80.5

 
—

 
2015
 
30.7

 
77.8

 
0.1

 
 
 
 
 
 
 
 
Segment (loss) profit
2017
 
$
(10.1
)
 
$
112.5

 
$
1.4

 
2016
 
(19.2
)
 
57.0

 
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
 
 
 
 
 
 
 
Segment assets
2017
 
$
453.0

 
$
1,038.4

 
$
4.8

 
2016
 
380.8

 
909.1

 
4.9

 
 
 
 
 
 
 
 
Capital expenditures
2017
 
$
12.6

 
$
59.0

 
$
—

 
2016
 
14.3

 
67.1

 
—

Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Total segment profit
$
103.8

 
$
38.7

 
$
152.4

Foreign exchange losses
(9.1
)
 
(4.5
)
 
(10.2
)
Net corporate operating, interest and other expense, net not allocated to segments
(9.1
)
 
(7.5
)
 
(7.5
)
Other income (expense), net
12.2

 
14.9

 
11.1

Consolidated income before taxes
$
97.8

 
$
41.6

 
$
145.8




The following reconciles total segment assets to consolidated total assets (in millions):


93


 
 
December 31,
 
 
2017
 
2016
Total segment assets
 
$
1,496.2

 
$
1,294.8

Cash and other current assets
 
965.8

 
980.3

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
57.0

 
91.1

Goodwill, net
 
506.1

 
477.1

Other long-term assets
 
1,247.9

 
1,007.2

Total assets
 
$
4,273.0

 
$
3,850.5



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Europe
 
$
758.5

 
$
742.2

 
$
763.7

Pacific Rim
 
461.3

 
427.1

 
392.2

United States
 
800.2

 
770.6

 
735.0

Other (primarily Canada and Latin America)
 
140.2

 
128.3

 
128.5

Total net sales
 
$
2,160.2

 
$
2,068.2

 
$
2,019.4


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2017
 
2016
Europe
 
$
230.6

 
$
221.1

Pacific Rim
 
18.4

 
16.1

United States  
 
1,305.2

 
1,084.7

Other (primarily Canada and Latin America)
 
13.1

 
12.3

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,567.3

 
$
1,334.2




94



15.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately $0.5 million and $12.5 million in restructuring charges related to severance and other employee benefits for the years ended December 31, 2017 and 2016, respectively. The liability of $6.3 million as of December 31, 2017 consisted of $6.2 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2017 and 2016, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2017
 
2016
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
3.2

 
$
5.8

 
$
9.0

 
$
—

 
$
—

 
$
—

Charged to expense
 
—

 
—

 
—

 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.2

 
0.3

 
0.5

 
0.3

 
0.5

 
0.8

Cash payments
 
(1.5
)
 
(2.7
)
 
(4.2
)
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation losses (gains)
 
0.3

 
0.7

 
1.0

 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance as of December 31
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0




Restructuring Costs for GnuBIO, Inc.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It is included in our Clinical Diagnostics segment’s results of operations as a division, and is primarily based in Massachusetts. In September 2017, we announced that we are closing the GnuBIO research program facilities in Massachusetts. As a result, we recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and is recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. We expect the remainder to be paid in early 2018.

Restructuring Costs for Termination of an Infectious Disease Research and Development Project

In December 2017, we announced the termination of an infectious disease research and development project, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded restructuring charges related to severance and employee benefits of $11.0 million, and asset write-offs and exit costs of $10.1 million for the year ended December 31, 2017. The amounts recorded were reflected in Cost of goods sold of $2.3 million, in Selling, general and administrative expense of $3.3 million, and in Research and development expense

95


of $15.5 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability of $14.1 million as of December 31, 2017 consisted of $11.1 million recorded in Accrued payroll and employee benefits and $3.0 million recorded in Other current liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the infectious disease research and development project restructuring reserves for severance and exit costs (in millions):

 
 
2017
Balance as of January 1
 
$
—

Charged to expense
 
14.0

Cash payments
 
—

Foreign currency translation losses

 
0.1

Balance as of December 31
 
$
14.1




16. QUARTERLY FINANCIAL DATA (UNAUDITED)

During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. The third misstatement was related to a design deficiency associated with transfer pricing.

Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.

During the fourth quarter of 2017, we identified errors in the unaudited interim condensed consolidated financial statements for the three months ended September 30, 2017. We identified an error in the recording of deferred revenue acquired in our acquisition of RainDance (see Note 2, "Acquisitions"). This resulted in an overstatement of revenue recorded in the third quarter of 2017 of $0.9 million that was corrected in the fourth quarter of 2017. In addition, we identified an error in an estimated employee benefit expense that resulted in an understatement of expenses reported in Cost of goods sold, Selling, general and administrative expense and Research and development expense, net, in the third quarter of 2017 of $3.8 million that was corrected in the fourth quarter of 2017. Finally, we identified an error during our reconciliation of various inventory accounts which resulted in an understatement of Cost of goods sold in the third quarter of 2017 of $3.5 million that was corrected in the fourth quarter of 2017. The impact of these errors resulted in an overstatement of our Provision for income taxes reported in the third quarter of 2017 of $2.9 million that was corrected in the fourth quarter of 2017.

Management evaluated the materiality of all the errors described in the previous paragraph from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of SAB 108. Accordingly, we are correcting these errors in the financial statements for the quarter ended September 30, 2017 included in this Form 10-K.



96


The impact of the immaterial error corrections described above are presented on a as reported, adjustment and as revised basis in the following summarized quarterly financial data for 2017 and 2016 (in millions, except per share data):

As reported:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
535.0

 
$
620.4

Cost of goods sold
 
230.1

 
231.4

 
230.5

 
280.8

Gross profit
 
270.0

 
273.3

 
304.5

 
339.6

Selling, general and administrative expense
 
194.9

 
213.0

 
196.8

 
204.2

Research and development expense
 
49.5

 
62.6

 
61.4

 
76.8

Income before income taxes
 
20.1

 
1.1

 
38.9

 
37.7

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(11.5
)
 
32.2

Net income
 
12.4

 
5.0

 
27.4

 
69.9

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.92

 
$
2.35

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.91

 
$
2.32

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(7.9
)
 
(8.9
)
 
(4.3
)
 
7.6

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)



97


Adjustments:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
(0.9
)
 
$
0.9

Cost of goods sold
 
—

 
—

 
4.7

 
(4.7
)
Gross profit
 
—

 
—

 
(5.6
)
 
5.6

Selling, general and administrative expense
 
—

 
—

 
1.9

 
(1.9
)
Research and development expense
 
—

 
—

 
0.7

 
(0.7
)
Income before income taxes
 
—

 
—

 
(8.2
)
 
8.2

(Provision for) benefit from income taxes
 
—

 
—

 
2.9

 
4.6

Net income
 
—

 
—

 
(5.3
)
 
12.8

Basic earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

Diluted earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
—

 
$
—

Cost of goods sold
 
—

 
—

 
—

 
—

Gross profit
 
—

 
—

 
—

 
—

Selling, general and administrative expense
 
—

 
—

 
—

 
—

Research and development expense
 
—

 
—

 
—

 
—

Income (loss) before income taxes
 
—

 
—

 
—

 
—

(Provision for) benefit from income taxes
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Net income (loss)
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Basic earnings (loss) per share
 
$
(0.04
)
 
$
(0.05
)
 
$
(0.05
)
 
$
0.07

Diluted earnings (loss) per share
 
$
(0.05
)
 
$
(0.05
)
 
$
(0.04
)
 
$
0.07



98


As revised:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Cost of goods sold
 
230.1

 
231.4

 
235.2

 
276.1

Gross profit
 
270.0

 
273.3

 
298.9

 
345.2

Selling, general and administrative expense
 
194.9

 
213.0

 
198.7

 
202.3

Research and development expense
 
49.5

 
62.6

 
62.1

 
76.1

Income before income taxes
 
20.1

 
1.1

 
30.7

 
45.9

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(8.6
)
 
36.8

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(9.2
)
 
(10.3
)
 
(5.6
)
 
9.5

Net income (loss)
 
11.0

 
16.6

 
17.1

 
(18.7
)
Basic earnings (loss) per share
 
$
0.38

 
$
0.56

 
$
0.58

 
$
(0.63
)
Diluted earnings (loss) per share
 
$
0.37

 
$
0.56

 
$
0.58

 
$
(0.63
)



Note: As a result of the net loss for the three months ended December 31, 2016,
all potentially issuable common shares have been excluded from the diluted shares
used in the computation of earnings per share as their effect was anti-dilutive.


17. SUBSEQUENT EVENT

Subsequent to December 31, 2017, the Company obtained an extension of time to provide its annual audited financial statements for its 2017 fiscal year and related compliance certificate and other deliveries as currently required by the Credit Agreement discussed in Note 5. This extension provides that the Company may provide its annual audited financial statements for its 2017 fiscal year within 120 days after the end of its 2017 fiscal year and its compliance certificate in respect of its 2017 fiscal year within 130 days after the end of its 2017 fiscal year. No amounts were outstanding under this Credit Agreement at December 31, 2017 and no amounts have been borrowed since. 


ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.


99




ITEM 9A.  CONTROLS AND PROCEDURES

(a)
Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting at December 31, 2017, which we view as an integral part of our disclosure controls and procedures, discussed in further detail below.

(b) Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) or 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017 using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on our evaluation, our management identified the internal control deficiencies described below.

We did not maintain a sufficient complement of personnel in certain European countries with appropriate training and expertise in accounting and reporting in the new ERP system following the system conversion and European reorganization including the implementation of reporting lines, appropriate authorities and

100


responsibilities within and between our accounting and reporting function, information technology and the business operations in these European countries.

We did not conduct continuous risk assessment over changes in our European business operations, IT systems and personnel to identify and assess necessary changes in internal control over financial reporting.

As a result, we did not design effective control activities over the accounting for financial statement amounts, including inventory and revenue, reported by entities impacted by the European reorganization, including management review controls with sufficient precision to identify and investigate potential outliers.
    
These control deficiencies resulted in immaterial misstatements to inventory, revenue, and cost of goods sold, certain of which were corrected in the consolidated financial statements as of December 31, 2017, prior to issuance.

Because the deficiencies create a reasonable possibility of material misstatement in the annual or interim consolidated financial statements that will not be prevented or detected on a timely basis, they represent a material weakness in internal control over financial reporting and accordingly, management concluded that our internal control over financial reporting was not effective as of December 31, 2017.

KPMG, LLP, an independent registered public accounting firm, has audited the consolidated financial statements included in this Annual Report on Form 10-K and, as part of the audit, has issued an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017, which is included in Part II, Item 8 of this Form 10-K.

(c) Changes in Internal Control Over Financial Reporting

Our management believes that our enhanced post-conversion management review control activities and augmented user acceptance testing of system changes, which were designed to remediate the material weakness over financial reporting disclosed as of September 30, 2017, were sufficiently implemented as of December 31, 2017. Other than the changes in internal control described above and the material weakness described in Management’s Report on Internal Control Over Financial Reporting, there were no changes in our internal controls over financial reporting (as defined in Rules 13a - 15(f) and 15(d) - 15(f) under the Exchange Act) that occurred during fiscal 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(d) Inherent Limitations on Effectiveness of Internal Controls

Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

(e) Planned Remediation Actions to Address the Material Weakness

Our management has discussed the results of the evaluation and assessment with our Audit Committee.

Management is enhancing its control environment in the entities impacted by the ERP system conversion and European reorganization by (i) increasing resources with sufficient accounting and reporting expertise within our reorganized business and using our new ERP system, (ii) implementing and monitoring reporting lines and appropriate authorities and responsibilities within the accounting and reporting function, information technology and the business operations and (iii) providing training to our control owners to effectively perform controls in the new environment including training on reconciliation review controls and certain ERP system enhancements.


101


Management is also enhancing its risk assessment process to continuously assess the potential impact on internal control over financial reporting of changes to business operations, including changes relating to similar ERP systems conversions and reorganizations that may occur in the future.

Management is also in the process of designing additional control activities over financial statement amounts reported by entities impacted by the European reorganization.

These remediation efforts began in the three-month period ended December 31, 2017 and are expected to be completed during the year ended December 31, 2018.

However, we cannot assure you that these efforts will be effective in timely remediating the material weakness or that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations, which in turn could cause the trading price of our common stock to decline.


ITEM 9B.  OTHER INFORMATION

None.


PART III.

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2018 annual meeting of stockholders (the “2018 Proxy Statement”) under “Election of Directors,” “Committees of the Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.”

Bio-Rad’s Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K.  Each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual.

We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, controller and all other employees and is available through the Corporate Governance section of our website (www.bio-rad.com).  We will also provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA  94547.” We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com).


102



ITEM 11.  EXECUTIVE COMPENSATION

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2018 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested Table,” “Pension Benefits,” “Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or Change in Control,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and "Pay Ratio Disclosure.”  In addition, the information from a portion of the 2018 Proxy Statement under “Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.



ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2018 Proxy Statement under “Principal and Management Stockholders.”

Equity Compensation Plan Information as of December 31, 2017
Plan category
 
Number of securities
to be issued
upon exercise of outstanding options,
warrants and rights
 
Weighted-average exercise price of
outstanding options,
warrants and rights
 
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
 
 
(a)
 
(b)(3)
 
(c)
Equity compensation plans approved by
 
 
 
 
 
 
 
 
security holders (1)
 
880,710

 
$
120.39

 
2,493,506

 
(2)
Equity compensation plans not approved by
 
 
 
 
 
 
 
 
security holders
 
—

 
—

 
—

 
 
Total
 
880,710

 
$
120.39

 
2,493,506

 
 

(1)
Consists of the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan, the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(2)
Consists of 1,771,794 shares available under the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan and 721,712 shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(3)
Excludes Restricted Stock Units.


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2018 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.”


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required to be furnished by this item is incorporated by reference from a portion of the 2018 Proxy Statement under “Report of the Audit Committee of the Board of Directors.”


103



PART IV.

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
 
 
(a)1
Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and
 
Supplementary Data" on page 44 for a list of financial statements.
 
 
 
2
Schedule II Valuation and Qualifying Accounts
 
 
 
 
All other financial statement schedules are omitted because they are not required or the required information is included in the consolidated financial statements or the notes thereto.
 

BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2017, 2016, and 2015
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 
Additions
Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549

2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367

2015
 
$
27,973

 
$
8,783

 
$
(12,338
)
 
$
24,418



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356

2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403

2015
 
$
58,615

 
$
(338
)
 
$
—

 
$
58,277



 
 
 
3.
Index to Exhibits
 
 
 
 
The exhibits listed below in the accompanying Index to Exhibits are filed or incorporated by reference as part of this report.
 
 
 



104



 
BIO-RAD LABORATORIES, INC.
INDEX TO EXHIBITS ITEM 15(a)3
 
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.”
 
Exhibit No.
 
 
 
3.1

 
 
3.1.1

 
 
3.2

 
 
4.1

 
 
 
10.1

 
 
10.2

 
 
10.2.1


 
 
10.3

 
 
10.4

 
 
10.4.1

 
 
10.4.2




105


 
 
10.7

 
 
10.8

 
 
10.9

 
 
 
10.10

 
 
 
 
Exhibit No.
 
 
 
21.1

 
 
23.1

 
 
31.1

 
 
31.2

 
 
32.1

 
 
 
32.2

 
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
(1
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended
 
December 31, 2010.
 
 
(2
)
Incorporated by reference to Exhibit 3.1 to Bio-Rad’s Form 8-K filing, dated October 27, 2017.

 
 
(3
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 8-K filing, dated December 9, 2010.
 
 
(4
)
Incorporated by reference to the Exhibits to Bio-Rad’s 8-K filing, dated June 26, 2014.
 
 
(5
)
Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011.
 
 
(6
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017


106


 
 
(7
)
Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated
 
November 13, 1997.
 
 
(8
)
Incorporated by reference to Exhibit 10.7 to Bio-Rad’s March 31, 2003 Form 10-Q filing, dated
 
May 13, 2003.
 
 
(9
)
Incorporated by reference to Exhibit 10.7.1 to Bio-Rad’s March 31, 2007 Form 10-Q filing, dated May 4, 2007.
 
 
(10
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s June 30, 2012 Form 10-Q filing, dated August 9, 2012.
 
 
(11
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007.
 
 
(12
)
Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated November 4, 2009.
 
 
(13
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014.
 
 
(14
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017

 
 
(15
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017

 
 
(16
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017

 
 
(17
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated August 7, 2017.
 
 
(18
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 7, 2014.
 
 
(19
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended December 31, 2014.


Item 16. FORM 10-K SUMMARY

Not applicable.




107



SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.
 
 
By:
/s/ Christine A. Tsingos
 
Christine A. Tsingos
 
Executive Vice President, Chief Financial Officer
 
 
Date:
April 13, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
 
 
Principal Executive Officer:
Chairman of the Board, President
 
/s/ Norman Schwartz
and Chief Executive Officer
April 13, 2018
(Norman Schwartz)
 
 
 
 
 
Principal Financial Officer:
 
 
/s/ Christine A. Tsingos
Executive Vice President,
 
(Christine A. Tsingos)
Chief Financial Officer
April 13, 2018
 
 
 
Principal Accounting Officer:
 
 
/s/ James R. Stark
Vice President, Corporate Controller
April 13, 2018
(James R. Stark)
 
 
 
 
 
Other Directors:
 
 
/s/ Jeffrey L. Edwards
Director
April 13, 2018
(Jeffrey L. Edwards)
 
 
 
 
 
/s/ Gregory K. Hinckley
Director
April 13, 2018
(Gregory K. Hinckley)
 
 
 
 
 
/s/ Melinda Litherland
Director
April 13, 2018
(Melinda Litherland)
 
 
 
 
 
/s/ Arnold A. Pinkston
Director
April 13, 2018
(Arnold A. Pinkston)
 
 
 
 
 
/s/ Alice N. Schwartz
Director
April 13, 2018
(Alice N. Schwartz)
 
 


108
 EX-21.1 2 ex211123117.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
LISTING OF SUBSIDIARIES
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories Pty Ltd
 
Australia
Bio-Rad Laboratories Ges.m.b.H.
 
Austria
DiaMed Österreich GmbH
 
Austria
Bio-Rad Laboratories NV
 
Belgium
Research Specialties for Laboratories NV
 
Belgium
DiaMed Benelux NV
 
Belgium
Bio-Rad Laboratórios Brasil Ltda.
 
Brazil
DiaMed Latino-América S.A.
 
Brazil
Bio-Metrics Properties Limited
 
California, USA
Bio-Rad Laboratories (Israel), Inc.
 
California, USA
Bio-Rad Pacific Limited
 
California, USA
Bio-Rad Laboratories (Canada) Limited
 
Canada
Bio-Rad Laboratories (Shanghai) Co., Ltd.
 
China
Bio-Rad (Shanghai) Life Science Research & Development Co., Ltd.
 
China
Wuxi BioCanal Nano Technology Co. Ltd.
 
China
BIO-RAD spol. s r.o.
 
Czech Republic
Bio-Rad Export LLC
 
Delaware, USA
Bio-Rad Holdings, LLC
 
Delaware, USA
Bio-Metrics, Limited
 
Delaware, USA
Bio-Rad QL, Inc.
 
Delaware, USA
GnuBIO Inc.
 
Delaware, USA
Raindance Techologies, Inc.
 
Delaware, USA
Bio-Rad Denmark ApS
 
Denmark
DiaMed Fennica Oy
 
Finland
Bio-Rad France Holding
 
France
Bio-Rad Innovations
 
France
Bio-Rad Laboratories SAS
 
France
Bio-Rad France
 
France
Bio-Rad
 
France
Bio-Rad Services France
 
France
DiaMed France SA
 
France
Bio-Rad 1
 
France
Bio-Rad Laboratories GmbH
 
Germany
Bio-Rad Germany Holding GmbH
 
Germany
DiaMed Diagnostika Deutschland GmbH
 
Germany
Bio-Rad Medical Diagnostics GmbH
 
Germany
Bio-Rad AbD Serotec GmbH
 
Germany
Bio-Rad Laboratories Logistik GmbH
 
Germany
 
 
 

1


LISTING OF SUBSIDIARIES- continued
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories M.EPE
 
Greece
Bio-Rad China Ltd.
 
Hong Kong
Bio-Rad Hungary Trading LLC
 
Hungary
IMV Medical Information Division, Inc.
 
Illinois, USA
Bio-Rad Laboratories (India) Private Limited
 
India
Bio-Rad Haifa Ltd.
 
Israel
Bio-Rad Laboratories S.r.l.
 
Italy
Bio-Rad Laboratories K.K.
 
Japan
Bio-Rad Korea Ltd.
 
Korea
Bio-Rad Luxembourg S.à r.l.
 
Luxembourg
International Marketing Ventures, Ltd.
 
Maryland, USA
Bio-Rad, S.A.
 
Mexico
Bridger Technologies, Inc.
 
Montana, USA
Bio-Rad Laboratories B.V.
 
The Netherlands
Bio-Rad Norway AS
 
Norway
Bio-Rad Polska Sp. z o.o.
 
Poland
Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios, Lda
 
Portugal
Bio-Rad Laboratorii OOO
 
Russia
Bio-Rad Laboratories (Singapore) Pte Ltd
 
Singapore
Bio-Rad Laboratories (Pty) Ltd
 
South Africa
Bio-Rad Laboratories, S.A.
 
Spain
Distribudora de Analítica para la Medicina Ibérica, S.A.U.
 
Spain
Bio-Rad Laboratories AB
 
Sweden
Bio-Rad Europe GmbH
 
Switzerland
Bio-Rad IHC Europe GmbH
 
Switzerland
DiaMed Holding GmbH
 
Switzerland
DiaMed (Schweiz) GmbH
 
Switzerland
DiaMed GmbH
 
Switzerland
Bio-Rad Laboratories AG
 
Switzerland
Bio-Rad Laboratories Ltd.
 
Thailand
DiaMed S.E.A. Limited
 
Thailand
Bio-Rad Middle East FZ-LLC
 
United Arab Emirates
Bio-Rad Laboratories Limited
 
United Kingdom
DiaMed (G.B.) Ltd
 
United Kingdom
Bio-Rad AbD Serotec Ltd
 
United Kingdom
Bio-Rad Services UK Limited
 
United Kingdom
Bio-Metrics (U.K.) Limited
 
United Kingdom
Raindance Technologies Limited
 
United Kingdom
Respiratory Diagnostics, Inc.
 
Washington, USA


2
 EX-23.1 3 ex231123117.htm EXHIBIT 23.1 Exhibit


Exhibit 23.1



Consent of Independent Registered Public Accounting Firm




The Board of Directors
Bio-Rad Laboratories, Inc.:

        We consent to the incorporation by reference in the registration statement on Form S-3 (No. 333‑170981) and on Forms S-8 (Nos. 333-220219, 333-144962, 333-133507, 333-124187, 333-53335, 333-53337, 333-179876, 333-197979 and 333-206885) of Bio-Rad Laboratories, Inc. of our reports dated April 13, 2018, with respect to the consolidated balance sheets of Bio-Rad Laboratories, Inc. as of December 31, 2017 and 2016, and the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes and financial statement schedule (collectively, the "consolidated financial statements"), and the effectiveness of internal control over financial reporting as of December 31, 2017, which reports appear in the December 31, 2017 annual report on Form 10‑K of Bio-Rad Laboratories, Inc.

        Our report dated April 13, 2018, on the effectiveness of internal control over financial reporting as of December 31, 2017, expresses our opinion that Bio-Rad Laboratories, Inc. did not maintain effective internal control over financial reporting as of December 31, 2017 because of the effect of a material weakness on the achievement of the objectives of the control criteria and contains an explanatory paragraph that states that a material weakness related to the control environment, risk assessment and control activities at certain European countries has been identified and included in management’s assessment.

/s/ KPMG LLP

San Francisco, California
April 13, 2018



EX-31.1 4 ex311123117.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
April 13, 2018
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer



 EX-31.2 5 ex312123117.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine A. Tsingos, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
April 13, 2018
 
/s/ Christine A.Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer


 EX-32.1 6 ex321123117.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Saran's-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
April 13, 2018
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.


 EX-32.2 7 ex322123117.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
April 13, 2018
 
/s/ Christine A. Tsingos
 
 
 
Christine A. Tsingos, Executive Vice President,
 
 
 
   Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.



 EX-101.SCH 8 bio-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - 10. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - 10. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - 10. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - 11. Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - 12. Commitments & Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - 13. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - 14. Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - 14. Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - 14. Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - 15. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - 15. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - 15. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - 16. Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - 16. Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - 17. Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - 17. Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - 17. Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - 1. Significant Accounting Policies Details (Details) link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301303 - Disclosure - 1. Significant Accounting Policies Prior Year Misstatements (Tables) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - 1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - 2. Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - 2. Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 3. Fair Value Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 3. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 3. Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 3. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - 6. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - 6. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - 7. Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 9. Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 9. Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 9. Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Schedule II - Valuation and Qualifying Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bio-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 bio-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 bio-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] RainDance Technologies, Inc. [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Future Amortization Expense, Year One Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Future Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Future Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Future Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Future Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Impairment losses on goodwill and long-lived assets Asset Impairment Charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) Share-based Compensation [Abstract] Stock Options Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Stock Options Outstanding Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Stock Options Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Resticted Stock Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Quarterly Financial Data [Abstract] Quarterly Financial Data [Text Block] Quarterly Financial Information [Text Block] Restructuring Costs [Abstract] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract] Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Domain] Retirement Plan Funding Status [Domain] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Defined Benefit Plan, Asset Categories [Axis] Defined Benefit Plan, Asset Categories [Axis] Plan Asset Categories [Domain] Plan Asset Categories [Domain] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Equity Securities by Entity Size [Axis] Equity Securities by Entity Size [Axis] Equity Securities, Entity Size [Domain] Equity Securities, Entity Size [Domain] Equity Securities by Investment Objective [Axis] Equity Securities by Investment Objective [Axis] Equity Securities, Investment Objective [Domain] Equity Securities, Investment Objective [Domain] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Schedule of Assumptions Used [Table Text Block] Schedule of Assumptions Used [Table Text Block] Income Statement [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Net sales Revenue, Net Cost of goods sold Cost of Goods Sold Gross profit Gross Profit Selling, general and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Income from operations Operating Income (Loss) Interest expense Interest Expense Foreign exchange losses, net Foreign Currency Transaction Gain (Loss), before Tax Other (income) expense, net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Basic earnings per share: Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic Earnings Per Share, Basic Weighted average common shares - basic Weighted Average Number of Shares Outstanding, Basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Earnings Per Share, Diluted Earnings Per Share, Diluted Weighted average common shares - diluted Weighted Average Number of Shares Outstanding, Diluted Debt Disclosure [Abstract] Notes Payable and Long-term Debt Long-term Debt [Text Block] Reclassification and Correction of Immaterial Errors [Abstract] Reclassification and Correction of Immaterial Errors [Abstract] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block] Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block] Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Scenario [Axis] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Treasury Class-A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Preferred stock par value Preferred Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Common stock par value Common Stock, Par or Stated Value Per Share Common stock authorized Common Stock, Shares Authorized Common stock issued Common Stock, Shares, Issued Common stock outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] European Reorganization [Member] European Reorganization [Member] European Reorganization [Member] Termination of an Infectious Disease Research and Development Project [Member] Termination of an Infectious Disease Research and Development Project [Member] Termination of an Infectious Disease Research and Development Project [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] GnuBIO [Member] GnuBIO [Member] GnuBIO [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Life Science [Member] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Other Operating Income (Expense) [Member] Other Operating Income (Expense) [Member] Cost of Goods, Total [Member] Cost of Goods, Total [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Research and Development Expense [Member] Research and Development Expense [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Restructuring Reserve Restructuring Reserve Restructuring Charges Restructuring Charges Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Payments for Restructuring Payments for Restructuring Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Foreign Currency Translation Gain (Loss) Restructuring Reserve, Current Restructuring Reserve, Current Restructuring Reserve, Noncurrent Restructuring Reserve, Noncurrent Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Business Combinations [Abstract] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Fair Value Disclosures [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Short-term Investments [Member] Other Long-term Investments [Member] Other Long-term Investments [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Interest-bearing Deposits [Member] Interest-bearing Deposits [Member] Domestic Time Deposit [Member] Certificates of Deposit [Member] Municipal Obligations [Member] Municipal Bonds [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Marketable Equity Securities [Member] Equity Securities [Member] Available-for-sale Securities [Member] Available-for-sale Securities [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Foreign Government Obligations [Member] Foreign Government Debt Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Available-for-sale Securities Statement of Financial Position [Abstract] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Deferred Revenue [Domain] Deferred Revenue [Domain] Common Class A [Member] Common Class B [Member] ASSETS: Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Restricted investments Restricted Investments, Current Accounts receivable, less allowance for doubtful accounts Accounts Receivable, Net, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment: Property, Plant and Equipment, Gross [Abstract] Land and improvements Land Buildings and leasehold improvements Buildings and Improvements, Gross Equipment Machinery and Equipment, Gross Total property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill, net Goodwill Purchased intangibles, net Other investments Long-term Investments Long-term deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Notes payable and current maturities of long-term debt Notes and Loans Payable, Current Income and other taxes payable Taxes Payable, Current Accrued royalties Accrued Royalties, Current Deferred revenue Deferred Revenue, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current maturities Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingent liabilities Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Segment Reporting Information, Profit (Loss) [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Operating Segments [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Income before income taxes Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Valuation Technique [Axis] Valuation Technique [Axis] Valuation Technique [Domain] Valuation Technique [Domain] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of investments with gross unrealized losses and the associated fair value Schedule of Unrealized Loss on Investments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets by Major-Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Statement of Comprehensive Income [Abstract] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Net Income (Loss) Attributable to Parent Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other post-employment benefits adjustments, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Net unrealized holding gains on available-for-sale investments, net of tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Comprehensive income attributable to Bio-Rad Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Domain] Fines and penalties [Domain] [Domain] for Fines and penalties [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Domain] Net of prepaid taxes [Domain] [Domain] for Net of prepaid taxes [Axis] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Dividends [Axis] Dividends [Axis] Dividends [Domain] Dividends [Domain] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Acquisition-related Costs [Member] Acquisition-related Costs [Member] QuantaLife [Member] QuantaLife [Member] QuantaLife [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Limitations On Use Limitations On Use [Member] Limitations On Use [Member] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Income Taxes [Line Items] Income Tax Contingency [Line Items] Prepaid Taxes Prepaid Taxes U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic International Income (Loss) from Continuing Operations before Income Taxes, Foreign U.S. Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) International Current Foreign Tax Expense (Benefit) Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) U.S. Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) International Deferred Foreign Income Tax Expense (Benefit) Deferred tax benefit Deferred Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisonal Income Tax Benefit Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisional Income Tax Benefit Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisional Income Tax Benefit Non-current tax expense (benefit) Non Current Income Tax Expense Non Current Income Tax Expense Provision for income taxes U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Impact of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Foreign dividends, net Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Nontaxable subsidies Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Tax settlements and changes to unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Domestic manufacturing deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Fines and penalties Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Prior period adjustments Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Other reconciling items Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent U.S. tax reform Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Provision for income taxes Effective Income Tax Rate Reconciliation, Percent Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Bad debt, inventory and warranty accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves Legal reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other post-employment benefits, vacation and other reserves Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Tax credit and net operating loss carryforwards Deferred Tax Assets, Tax Credit Carryforwards Other Deferred Tax Assets, Other Total gross deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Investments and intangible assets Deferred Tax Liabilities, Other Finite-Lived Assets Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax liabilities Deferred Tax Liabilities, Net Unrecognized tax benefits period start Unrecognized Tax Benefits Additions to tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions to tax positions related to prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Additions to tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Unrecognized tax benefits period end Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Operating Loss Carryforwards, Expiration Dates Operating Loss Carryforwards, Expiration Date Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Tax Credit Carryforward, Amount Tax Credit Carryforward, Amount Tax Credit Carryforward, Limitations on Use Tax Credit Carryforward, Limitations on Use Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Credit Carryforwards, Research Operating Loss Carryforward, Valuation Allowance Operating Loss Carryforwards, Valuation Allowance Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforwards Operating Loss Carryforwards Other Tax Expense (Benefit) Other Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Segment Reporting [Abstract] Information regarding industry segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Net sales and assets to external customers by geographic area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Net Periodic Benefit Cost [Abstract] Net Periodic Benefit Cost [Abstract] Schedule of Net Benefit Costs [Table Text Block] Schedule of Net Benefit Costs [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Scenario, Forecast [Member] Scenario, Forecast [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Discount rate [Member] Discount rate [Member] Discount rate [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Cost of debt [Member] Cost of debt [Member] Cost of debt [Member] CellSorter [Member] CellSorter [Member] CellSorter [Member] [Member] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Other Income and Expenses [Abstract] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Accounting Changes and Error Corrections [Abstract] Nature of Error [Axis] Nature of Error [Axis] Nature of Error [Domain] Nature of Error [Domain] Scenario, Previously Reported [Member] Scenario, Previously Reported [Member] Scenario, Adjustment [Member] Scenario, Adjustment [Member] First Tax Misstatement [Member] First Tax Misstatement [Member] First Tax Misstatement [Member] Second Tax Misstatement [Member] Second Tax Misstatement [Member] Second Tax Misstatement [Member] Third Tax Misstatement [Member] Third Tax Misstatement [Member] Third Tax Misstatement [Member] Income Tax Expense (Benefit) Machinery and Equipment, Gross Liabilities Stockholders' Equity Attributable to Parent Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] All Other Segments [Member] Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Number Of Products And Services Number Of Products And Services Number Of Products And Services Depreciation and amortization Depreciation, Depletion and Amortization Segment profit Total assets Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other Investments Other Investments Total long-term debt, excluding leases and current maturities Long-term Debt, Fair Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Range of Exercise Prices, Group One [Member] Range of Exercise Prices, Group One [Member] Range of Exercise Prices, Group Two [Member] Range of Exercise Prices, Group Two [Member] Range of Exercise Prices, Group Three [Member] Range of Exercise Prices, Group Three [Member] Range of Exercise Prices, Group Four [Member] Range of Exercise Prices, Group Four [Member] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Equity Award [Domain] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] Stock Options [Member] Employee Stock Option [Member] Employee Stock [Member] Employee Stock [Member] Stock Options [Member] Employee Stock [Member] Stock Award Plans [Member] Stock Award Plans [Member] Stock Award Plans [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted Average Remaining Contractual Term (in years) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in millions) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options - Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options Granted Term Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Options Forfeitured/expired - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options - Shares Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options Vested and Expected to Vest - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted Average Exercise Price - Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) - Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options Exercisable Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Cash Received from Exercise of Stock Options Proceeds from Stock Options Exercised Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options Total unrecognized compensation cost from stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Options Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Employee Contribution Rate - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Employee Purchase Price Discount from Market Price Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Share-based Compensation Expense Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Weighted average fair value of options granted, period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Weighted average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options - Shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options - Shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options - Shares Forfeitures/expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding end of period Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Supplemental Cash Flow Information [Abstract] Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Schedule of Quarterly Financial Data [Table Text Block] Quarterly Financial Information [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid Interest Paid Income tax payments Income Taxes Paid, Net Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities (Payments for) proceeds from forward foreign exchange contracts, net Proceeds from derivative instruments, operating activities Proceeds from derivative instruments, operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Payments for acquisitions, net of cash received, and long-term investments Payments to Acquire Assets, Investing Activities Payments for purchases of intangible assets Payments to Acquire Intangible Assets Payments for purchases of restricted investment Payments to Acquire Restricted Investments Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net (payments) borrowings on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Payment for Contingent Consideration Liability, Financing Activities Payment for Contingent Consideration Liability, Financing Activities Excess tax benefits from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Stock by Class [Table Text Block] Schedule of Stock by Class [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit [Member] Line of Credit [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Long-term Line of Credit Long-term Line of Credit Business Combination, Consideration Transferred Business Combination, Consideration Transferred Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Accounting Policies [Abstract] Basic weighted average shares outstanding Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Anti-dilutive shares excluded from the computation of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Inventories [Member] Inventories [Member] Tax Misstatement [Member] Tax Misstatement [Member] Tax Misstatement [Member] Employee Benefit Expense Misstatement [Member] Employee Benefit Expense Misstatement [Member] Employee Benefit Expense Misstatement [Member] Quantifying Misstatement in Current Year Financial Statements [Line Items] Quantifying Misstatement in Current Year Financial Statements [Line Items] Operating Income (Loss) Gross profit Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-term Commitment [Table] Employee Location [Axis] Employee Location [Axis] Employee Location [Axis] Employee Location [Domain] Employee Location [Domain] [Domain] for Employee Location [Axis] UNITED STATES UNITED STATES Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment, Excluding Long-term Commitment [Line Items] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating leases, due next twelve months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating leases, due in two years Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Operating leases, due in four years Operating Leases, Future Minimum Payments, Due in Four Years Operating leases, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Post-Employment Benefits Liability Postemployment Benefits Liability Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation, Due in Twelve Months Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Letters of Credit Outstanding Amount Letters of Credit Outstanding, Amount Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees covered by collective bargaining agreements, percentage Entity Number of Employees Entity Number of Employees Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign currency translation adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other Postretirement Benefit Plan [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Net Unrealized Investment Gain (Loss) [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Parent [Member] Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Other assets Additional Paid in Capital Deferred Tax Assets, Gross Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Valuation Allowance of Deferred Tax Assets [Member] Allowance for Doubtful Accounts [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation Allowances and Reserves, Period Increase (Decrease) Valuation Allowances and Reserves, Period Increase (Decrease) Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Movement in Valuation Allowances and Reserves [Roll Forward] Valuation Allowances and Reserves, Balance Period Start Valuation Allowances and Reserves, Balance Deductions Valuation Allowances and Reserves, Deductions Other Valuation Allowances and Reserves, Reserves of Businesses Acquired Valuation Allowances and Reserves, Balance Period End Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Business Combination, Consideration Transferred, Liabilities Incurred Business Combination, Consideration Transferred, Liabilities Incurred U.S. and international components of income before taxes [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Provision for income taxes [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of deferred tax assets and liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax years currently under audit or open to examinations [Table Text Block] Summary of Income Tax Examinations [Table Text Block] Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Letters of Credit Outstanding, Amount Operating Leases, Rent Expense, Net Operating Leases, Rent Expense, Net Contribution expense Deferred Compensation Arrangement with Individual, Contributions by Employer Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Unsecured Debt [Member] Capital Lease Obligations [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Performance Guarantee [Member] Performance Guarantee [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Long-term debt Long-term Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Long-term Debt and Capital Lease Obligations, Including Current Maturities Long-term Debt and Capital Lease Obligations, Including Current Maturities Debt and Capital Lease Obligations Debt and Capital Lease Obligations Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year Long-term Debt and Capital Lease Obligations Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Face amount of debt sold Debt Instrument, Face Amount Maturities of Long-term Debt [Abstract] Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Interest and investment income Investment Income, Interest and Dividend Net realized (gains) losses on investments Realized Investment Gains (Losses) Other-than-temporary impairment losses on investments Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Other (income) expense, net Income Taxes [Text Block] Income Tax Disclosure [Text Block] Document and Entity Information -- None. No documentation exists for this element. -- Entities [Table] Entities [Table] Entity Registrant Name Entity Registrant Name Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Fiscal Period Focus Document Fiscal Period Focus Entity Public Float Entity Public Float Other Significant Noncash Transactions [Table] Other Significant Noncash Transactions [Table] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transactions [Line Items] Other Significant Noncash Transactions [Line Items] Share-based compensation Share-based Compensation Loss (gain) on disposition of securities Gain (Loss) on Sale of Securities, Net Other than Temporary Impairment Losses, Investments Other than Temporary Impairment Losses, Investments Loss on disposition of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Changes in fair value of contingent consideration (Increase) decrease in accounts receivable, net Increase (Decrease) in Accounts Receivable Increase in inventories, net Increase (Decrease) in Inventories (Increase) decrease in Other Current Assets Increase (Decrease) in Other Current Assets Increase in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities (Decrease) increase in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Decrease in deferred income taxes Increase (Decrease) in Deferred Income Taxes Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Decrease in other long term assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Other Long Term Liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash Purchased Marketable Securities and Investments Noncash or Part Noncash Acquisition, Investments Acquired Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Obligations and Funded Status [Abstract] Obligations and Funded Status [Abstract] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Shares, Issued Shares, Issued Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Common Stock, Voting Rights Common Stock, Voting Rights Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Statement of Stockholders' Equity [Abstract] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Bio Rad [Member] Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Net income Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock Stock compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Tax benefit-exercise stock options Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Balance Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative, Notional Amount Derivative, Notional Amount Loss on foreign currency derivative instruments not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Other Current Assets [Member] Other Current Assets [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment Goodwill [Member] Goodwill [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Fair Value Hierarchy [Domain] Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Gross unrealized losses for investments in a loss position 12 months or more Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss Gross unrealized losses for investments in a loss position less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss Cost Method Investment, Percentage Owned Cost Method Investment, Percentage Owned Cost Method Investments, Percentage Owned Segments, Geographical Areas [Abstract] Geographical [Axis] Geographical [Domain] Europe [Member] Europe [Member] Pacific Rim [Member] Asia Pacific [Member] Other (primarily Canada and Latin America) [Member] Americas [Member] Other assets and property, plant and equipment, net Long-Lived Assets Equity [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Selling, general and administrative expense Realized Investment Gains (Losses) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total unrecognized compensation cost from restricted stock Nonvested shares - Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Units Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units - Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted Average Grant Date Fair Value - Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Disclosure of Compensation Related Costs, Share-based Payments Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] First Tax Misstatement [Member] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software [Member] Computer Software, Intangible Asset [Member] Building and Building Improvements [Member] Building and Building Improvements [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Equipment [Member] Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Long-term Debt and Capital Lease Obligations Other Investments [Member] Other Investments [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Foreign Time Deposits [Member] Bank Time Deposits [Member] Money Market Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Cash Equivalents [Member] Cash Equivalents [Member] Money Market Funds [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted Investments, at Fair Value Restricted Investments, at Fair Value Available-for-sale investments Forward foreign exchange contracts, Asset Foreign Currency Contract, Asset, Fair Value Disclosure Financial Assets Carried at Fair Value Assets, Fair Value Disclosure Forward foreign exchange contracts, Liability Foreign Currency Contracts, Liability, Fair Value Disclosure Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Class of Treasury Stock [Table] Class of Treasury Stock [Table] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Stock Issued During Period, Shares, Treasury Stock Reissued Stock Issued During Period, Shares, Treasury Stock Reissued Movement in Standard Product Warranty Accrual [Roll Forward] Warranty accrual, beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accrual, end of period Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Retirement Benefits [Abstract] Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Fair Value of Plan Assets Defined Benefit Plan, Fair Value of Plan Assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan Liability, Defined Benefit Plan Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill period start Goodwill, Gross Accumulated impairment loss period start Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net period start Goodwill, Impairment Loss Goodwill, Impairment Loss Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Goodwill period end Accumulated impairment loss period end Goodwill, net period end Principal components of long-term debt [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Litigation Settlement Interest Litigation Settlement Interest Loss Contingency, Damages Paid, Value Loss Contingency, Damages Sought, Value Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis Total Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Mature in less than one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Mature in one to five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Mature in more than five years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value Estimated Fair Value Available-for-sale Securities, Debt Securities Segment Information Segment Reporting Disclosure [Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Available-for-sale Investments Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Shipping and Handling Shipping and Handling Cost, Policy [Policy Text Block] Warranty Standard Product Warranty, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Forward Foreign Exchange Contracts Derivatives, Policy [Policy Text Block] Share-based Compensation Plans Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] EX-101.PRE 12 bio-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 chart-6b100d05c0505debbd8.jpg STOCK PERFORMANCE GRAPH begin 644 chart-6b100d05c0505debbd8.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" $* E@# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **Y/QUXK;P1X2UWQ4GAOQ5XQFT:R M:YMO"O@C2HM:\6>(+MI(X+32="TZYO=,LI;Z\N)8XEGU/4]+TBRC,E]J^J:; MIEM=7T'RQX)_;J^$WCSX:_#WQWI/AGXHZ?XH^)OQ?\;_ \-?!+Q'X3LO#_ M ,8_^%T?#&^\<6GQ*\ ZCHFH:^GA2RN/ EK\-O'&M^(/%8\:3_#\>'] FUG3 M/%NI6E]I1OP#[3HKX:N_^"AG[.B^%[+Q=HVI^)_%.DP_";QM\=/'">'_ ZT MNJ?"GX3_ T\77G@#XB>+OB/H^HWVF:CH[^#?'&C^)_"NJ^%=*M]=\;76K^" M_'":)X;U>V\'Z]65]97<*7%I M>6=W;O)!%-3U31_!7BKXA7L;65M_P (MX*U'PUI?B>\M=0O M[:POKS2KWQ;XI\%Z+%+HUE&?V(?BW M\*O%'[-GQ4TG6/B)\3M#_9M_;!_:5^+'@;X.^,?B.OB[XB>&_P!G_P#:3^#G MC/X/XA>.?$ES%XX\3^ ?B!XINO'^AV_C3QQJ-U9^"==U;P3:^-=0OM# MTI=1_96B@#^?CPC_ ,$_OVF?A5H_Q_UW3=$T'QEX[_;#_9*_:-^$'B/2K#Q7 MIT'A?X*?%GXS_M5?M3?M'^$KC5Y=:N=._MCX MZB2"YU2W\%^&-*\,PZC<0(\B0SWT>EK=RQ+(ZQR3,@9@N3Z-10!S'C'PAH?C MSPYJ'A7Q)#?3Z-JGV87D6FZUKGAV\?[)=P7T'DZQX;U/1]9M,7%M$S_8]1M_ M.C#V\_F6\LL4GXD_'FUU+X _\%A_^"1OPR^$_C+XF>%OAS\MO!\>FIK#^*KC6]+@\-II$B)(FJ-KTMVFDC37C M='6_-X+1D96$Q4@GSK]H2]^!FF?"/Q;J/[26H?#_ $WX+V4>ES^-9OBGJ.B: M=\/IX%UG3QI.G^*/^$EN;7P]J-CJ>O'2["#1-9:;3]RTN>TO/M2VTGY. M>#/V?OV7/%O['GQ(^%WP\_:N^#'P>^'?Q9_:I^(7Q2T'0?AEKW[-OQ3^ ?@/ MQ-JEM'XQL_V<9_A[X_L?'/P;\6>#-/TRPT[XM?%/X3^';;1S<>,;_P 2>)O# M.I^&M,N+35W /VEL?&W@[4]+T'6].\5>&[_1O%4T%MX9U:QUW2KO3/$-Q#0M0M[R6SUB><6\Y@ATV:ZEF$,IC1A%(5Z>OYE?$^I>*[WPM\2IOCQ\./" M'PJT*R_X(H>)+3X!>!OA[X>N?!OP_M/CGI7Q0^,FC_%75_V=_"$I\OPIK_BV MRT_]DKQ?\-O#6FS7'CWPW8^)O!>B6-]>ZA:SWUU_0Q\#O^$]_P"%,?"7_A:? MF?\ "S?^%9^ ?^%B>=Y(E_X3O_A$=&_X3#S1;XMQ)_PD?]I^9Y(\KS-WE_)M MH ]2K\,?VW/^4X'_ 0Y_P"R;_\ !5+_ -4C\&:_:KQ;!XNN?#]_!X%U3P[H MOBA_LW]F:EXLT'5/$V@VQ6[@:[^WZ+HWB3PEJ5[YMD+B&W%MX@L/(NI(;F4W M,,4EK-^"'[3MC\6++_@M_P#\$3?^%H>)_AYXD,GPV_X*B_V)_P (%X%\3>"A M9;/@G\)?[1&J#Q'\1OB =3^T!K'[$;0Z2;0PW7GB]%Q!]E /Z$Z*** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ***"0.I R<#/<^GUH **X/Q_\ %/X:?"G2#X@^)WQ \%_# MS0\NHU;QOXGT7PMI[R(I8Q0W6MWME'/,P&$A@,DSG"HC,0#\TK^VOX5\8D0? M +X2_'3]H>:<,EIK?@?X>W?@_P"&\DP!*2'XL_&"X^'7@*]L2,%KOPWJWB-] MA#P6UP2JGNP^68_%P=6AA:TJ"?++$RC[+"4W_P!/<75<,-2]:E6*\SS<7G&6 M8*HJ&(QM".)DE*&#A+V^.JIVLZ."H*IBZVZ=J5&;:V1[WXT^//P-^'&LKX=^ M(?QG^$_@+Q UE;ZDNA>-/B+X0\+:RVG7Z$!@ MFDMITCD9H9 O2^"/B-\/?B;I5QKOPW\=^#?B#HEK?RZ5=:QX(\3Z)XKTJVU. M""WN9M-N-0T&^O[2&_AMKNUN);.29;B."YMY7C$*/V<_$>C7\_P:\ 6=MI7PYM?%WQITNPT^VU?QG+#;ZSXTT+X?:/HH\3 MB>YNGU31-)CU"PTNW;3V@UG4Q=M,/V;_ .""'@WQ7X)_9$^(>E^+_"/B;P9J M5Q^T-XLOX=,\5>&=9\*ZA/92^ _AO!'?0Z?KFGZ==S60RPN6X5YA['-*L<;0KU8X10=)U,+B"O#'B:X\!?%OQMXF^)WQYOOV*_&6L?$?QSXC\&>#]'\!>'-2\7Z MCJ5OIK:II%[8W]Q^.\ MWQ>_X)L?!W]K7XE?&;XD>*/CSX2\6? C1_BI\/\ X6>//C1X0^,:_LS>%/$/ MBSQ7I=I\?/AW^P]+K?A.7P1\0OC9X@\:RZ1X6\2>#?AK;>./B/K\]C=_#?X7 M:?J'A;0_$WAFP_33]D)]1N?V?O!&JZIX(^+'P\O/$5UXT\4CPQ\=;S3;OXQQ MV7B?Q]XIU_2M9^)<6E7%Q:Z-XQ\4Z3J-CXHUCPH[0WW@N76$\'ZG9Z?J6A7> MGVH![KXH\(^%O&^CS^'O&7AO0/%F@W4EO-G:C+H]_'JFE2W]C:WDFF:G%')%%J.GR7,4KV5_'%--''>VK172)+( MBRA78'4HHH *_#']MS_E.!_P0Y_[)O\ \%4O_5(_!FOW.K\,?VW/^4X'_!#G M_LF__!5+_P!4C\&: /W.HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HI"0,9(&>!D]3Z"O._B+\7_A5\(=+76_ MBI\1_ _PYTF3>(;_ ,;^*=$\,6]RZ DPV9UB]LVO9V(VI;V:3SR.0D<;,0#I M2I5:U2-*C3J5:LW:%.E"52I-]HP@G*3\DFS*M7HX>G.MB*U*A1IKFJ5:U2-. MG".GO3G-QC%:J[DTE=:GHM%?%H_;.TWQF@C_ &?/@A\=OC\UQ$[6/B/1/ [_ M Q^&,DJC(=OB;\;+GX>Z#J5C@@M=^#[?Q/X9_#72+TJ4SAD&Q7 MND!9_1_L?$T]<;4PN6I?$L=75/$0[IY']OX.KIEU+&9 MO)J\)9;AI5,+477DS3$2PV42:NKQ_M!25TN4^T6=$5G9E5$#%V)PJ!1EB[=% M"@98L0 .2:^6O&'[:?[-?A+6I?"D'Q*LO'_CJ/S4_P"%>?!S2==^-/CU;F/> M!:W?A3X6Z9XLU32979"HDUR/2[6,D-/<0QGS!S _8?\ AKXHD%U\=O&OQ@_: M5NS.EV]C\8_B#J$W@-;@%7D\GX/> X/ _P (?L[.H"0WO@G4'6)5C>>4 D_4 M?@[P)X)^'FC0>'/ /A#POX(\/6IS;:#X0T#2?#6C6YQC]SIFBVEC9(< D0Y M/.+Q%:%].6>"PDVOM1OH<_$&)_AT8XV"NO=E9GRO_ ,+O_:E^(?[OX1_L MJ7'@;2[J'=:>-?VH?B!HO@")" Q-Q#\,OAK'\4/'MU@JICT_Q%-X$N9%=1/- M9,)!&X_L^_M#_$'?)\:/VL_%>E:=(_&VB6VMM((X_#5C/)KOBNX<@D+:^%- BU3Q'5TG7E')\EH*2B\3B'3G+G=N1K%9M5Q/L:VET\(\-=W<8I:+*KE5!053.,WQ MV+A>UL1C89;A$Y+WJ;HY='+Z5>E+5*GC7BVXVBY2LV_._ '['_[-WPVUD>*? M#_PH\.ZEXV\U)W^(GCI]2^)WQ*DN%W%IV^(?Q'O_ !5XQ5W=FD98=9AB#ME8 MU 4+])D*.3C@YRQS@GT)Z?08%> _\+6^(GB8^7\._@IXGDMG+QIXB^*>HVOP MOT,%MXCGCT>:W\0>/[B, "0QR^$--+J0HFC9MRI_P@'QG\5@-XW^,">%;*92 M)O#_ ,'?#EKH;A58[89O&WC$^*-?GR-HDNM(TWPQ.V&,8AW"OG,1Q37S.:J8 M;#9WGM7EY5B)TYT,.H>[R3AC\YJX*CB<.^9>]E\\8U%2E&G*R3Z,(\#@Z?L, MHRMQI-N?+@\'2P.&>TK+"TJJD[-SH>WDTKI2LD_'?VIOVT]"_9SU_1O M!]GX1NO&OBO4]+CUV]MO[9&@Z7H^D3W5Q:63W%ZMCJ<]S?7\MG>&"S@LU2&" M W%SZ!I][HS+J-YHFMZ'J$T=UGI;RW M%H+R)4BOK62VN[2\LKV..$7%M?%:;2=5TSQAXQ M\+^)[.)[;5?$6KZGJOQ%N_$ELS^;'_;$GBO6GO\ [5:2-*+*:QU*TM8(9Y;< MV#QB$0_2OP&^"/A?]G_X>V7@'PO<7VH1+>W>L:OK.IF(7^M:WJ"PI=ZA/%;J MEM:H(;:UM+2SME$5K9VL$6Z:42SS?"9$O%.7'N;5,^664N!Y8.3R[#X:M@Z_ MLZ[6&]A&A6CA\/FM3$1?M_KD\=3AA)-S^JQ<50:\_ +BEY]BY8]86.2.B_JU M.E*C4<:EJ?(H35.GBI5%[_MI5XJDW=4DTJ;7LU%%%?J9]2%%%% !1110 4$9 M_,'\CFBB@#\0_P!HO]F?X+? "QTCXB?M$?\ !5#]I?X&Z!IWQG^(/Q6^$OA. M3Q!^R/IVA^'OB!X^UKQ_'4Q_9S27_V#[+^@O[#.NP^)OV9/ FN6WC+X[_$*UO\ 6_BBUGXS_::\ M$'X;_'7Q#9P_%KQS;6>H?$3P,W@OX"IX_#L>C2W'A7 M0IY9-.@\U\:?\$^/@])\3?%GQ\^&VFZ/X5^-OC3QYX#^(?B[QQXNT*7XI:KK M5W\/O&GA;QQ8>'-%\1>*=0N?B#\-?"6HWG@_3M.N/!OPO\6^'? -O%=:AJ<' M@*YUN[FNYOJOX*>.]5^)/P[TOQAK+>!6OM0UCQE8EOAOXNG\<^$3:^'_ !KX MA\.:?]B\276DZ#>7&I"QTFW'B33;[1=*O_#OB<:SX;O;**ZTB;< ;WQ'T7QC MXC\&ZQH?@/QHWP[\3:I';6EEXVAT'2/$U_X;@DO+?^T-1T;0_$,5QX>O==73 MQ=0Z(WB"RU/0K/4YK6_U;1=*O#;_#VP\4:3X1L_!GB;P+I=Q\2O#G@G3KK7]/AT[]1_C9\,+WXR?#; MQ%\.;'XH?$OX.R>)$L8)O'OPBO/".G^/=+M+74+6^N[31KWQQX.\>>';:+68 M+9](U5[KPS>SR:3>7MO9RV=Q,MU%X;H?[&VEV?A3P=I7B_X[?'OXJ^._AK\4 M)OBQ\,/C5\0-4^%B?$OX=:Y<>#=1^'D^B^%[7P)\)O _PS3P?<^"M>\4>'-0 M\-ZK\.M4M=7L/$^JMJ\E]=0Z+%;+P;HFG>*O"FBW'PD\:_ CQX/#_ (C,6H_%KX2_$KQ= MJ'C_ .(7A'XD:OJ5AJ>IZM+XP\<:[XL\4ZIXKT>YT#QK;:KXX\='1O$6E6OB M_6K:Y^X;"PL=*L;/3-,L[33M.T^UM[&PT^PMH;.RL;*TA2WM+.SM+=(X+:UM M;>*."WMX42*&&-(HU5$4 P_&/B=/!WAS4/$%];\6V'@JPG\/>&M3\4WKZ[J.EZQK%M%)I^E(] MQ#;-9:'?L]VX$,*?B=\-_ ZL_C M3Q_X)\(HJEW?Q1XL\/\ A]40*CEV.KZC9A5"RQL2> LB$X#J3X=J?[;_ .R9 MIUP;2W^/?P[\27@(7[#X$U>3XC7Y(CO>AAJU56TUO3A+35:G9B,URS"/EQ>8X'"R_EQ&+H4 M'K;I5J1?7^K,^JJ*^2YOVPO!=\D;^"?A7^TQ\0UFV>3/X<_9R^*NC:=.7 *" M+7/B-H'@/02C[X2MPVJ+:^7,EP9A:K-/"V;X^?'/5HXY/!O[&OQ:,9XJ^,OQ#\?ZA%N,H#RZ1X5^$?A'3W90 M8F>&+Q0R$HZ+=$2B2!9? O[9FOPC^U?V@O@MX)ZAH/ '[/.NZO>J"TN"FL?$ M#XS:O9/(J^4=[>&%0_,OD@@22']FJ'\?,+^;>6T<:K>=P_M>53 M7"Y5F^*5D[_5:> T=OLYM7RZ3>KT2Z?=]:$A1DD >I( _6@L,9Y(_P!D%O;^ M$&ODQOV/]+T%E&R M'Y3I6&>"&9]UPAF8^K9=#^+F;J:_\P.!K5M._P#MD\N_+IZ!]K_ R:-%6 MO_PI9C0P[OII_P )]/-EWLVUZ::_3&N>)O#GAFT-_P"(]>T;0+( DW>MZK8: M1;#:45LSZC<6T0P98PU#5M4=VWJ$1+-G]Z%X6\,^&+9;+PW MX>T/P]9HA1+70])T_1[=$)4E5ATZVMHU7*)PJ@?*IQE1@_X1Z?\ T,L7K_U" MY?I_YD]0_P"%^K_T*,#I_P!1F:ZZ>63V6_5[[['\Y_\ P51_X*E?%KX5>(?@ MFO['OQ1U#0/#_B'0O'EQXQN]<^"UPMAK-_IVI>%8M!FT/4OBSX"M(]4AM;2] MU,7O?V7#(+2\UWPM::4FD!5U< M/J;(OZU_M:?L)_LR_M=W/A#Q#^T'HNMZBWPYT_7;'0;W3O'OB'P7:V%EXCNM M*NM4^W/I&HV-O<^;<:18&*:]9FMPCQQ,HF<-?_9*_8C_ &?\ R-8UW4JYE0G@\;52PG[J+6'A M!N,<-4C4H<_/^7QX2\0ZOB&\XQ/%+HU*6*Y%2JG]G+X[>/6DD^-?[6_Q ;3[ATGD\$_LZ^'=% M_9_\+(68F2T?Q4L_COXT7$ C/DF:S^)NAR2A1*8H79E'HWPY_9(_9Q^%>K'Q M)X0^$GA5?&+3?:)?B!XF@N_'OQ)N)B2S2W7Q&\>7?B7QO.[NQD;?KVW=@A1M M&/3?&7Q4^'/P]5/^$T\:>'?#L\JAK;3]1U.V35[[<,A-.T6)Y=7U&5@"4AL; M&XE<\*A)KS\_&GQ%XA)7X9_!WQ]XIA+)Y?B#Q;;P_"GPG)%(#MF2Y\9)'XNN MX>C>;I?@F_C=""CL>#^6X[C2C1E4P$\UA"K91K93DU#FQ$HM)\U;*,DH.O52 M27-5JX6=E\4[O7]&6 X?PE>,YTH8S'T6G">*GB<[S.CV=)XB>.QM&"WM2Y*< M='961[]A1R>V3DG)&>N"G:19SZCJM_9Z;I]K&9;F^U"Z@LK M*",) .2TDB@#J:\-_X17X_>*\'Q-\2?#/PXL'9UDTCX5^&UUS7 M%@DSF-_'/Q!CN[0RJA">?8> -/D5LR0R*RJ1>T_]G7X71WD&J^)=(O\ XDZ[ M!RFM_%+6M3^(%W&X+%9+*R\17%WH.CE2Q*)HFC:;%&2!'&H5<>+_ &EG&*TP M&1SHP?\ S$9UBZ6!A*#2Y:E'#8..98V4E>\J&-HY;.R<>:,GIZ?UC%U-,/@7 M"/\ S\QE6%"+3M9PI45B:S:ZPK0PSTM=,@N?VC/AY=3367@9?$OQ9U*"7R7M MOA;X/=2B5CAX)5R&]X@MK> MU@BMK:"&WMH(UBAMX(DA@BC081(H8U6*-%'"JB*H& *GZ=:?]F9IB?^1C MGE90>DL-DV&AE="I"Z=JE>K4S#,XS5DO:X/,,%=7M"/,T'U7%5?]XQTTGHZ6 M#IQPM-K>TJDY8C%*73GI8BC=;13V\ _X43+XA&[XH_$[XB_$(21M'<:)#K7_ M K[P:RG=B+_ (1OX?+H,U];D-AH?$.LZ\74*LKR#<#ZAX3^'_@?P):M9>"_ M"/AOPK;2*HFC\/Z-8:2;DKR)+J6S@BGNY222TMS+-*Y)9W9B2>N#*7$-I;0J6EN+J1+:"-00"SS3F.-5!(^9F Y'/-=.$R/*L M%56(H8*D\7;E>/Q'/C,QE%ZT:F(DE=I)+0UI8+"4)^TIT(>U MM9UZEZV(DNTL16_D<,>4CMF8 ,2 %8CB(?VT?@1J@D'A&^^(OQ&D7:$' MPS^"'QI\>VTI;! CU7PYX O=$SLW/\^IH"L<@!+IM/JG4?5I('6BOYL_^"MW M_!2#Q/I7A3P-\$?A-H7Q9^#_ (ZU3Q)X:^)_B'6_''AY?!6LQ^%O!^M#5?!] MOINE#6;W61:ZSXZT2*YU6'6+'2?MNE>&9K)8;[3=9>0_M9^QM^TCH?[6'[.G MPX^-6D_9;?4/$.D"Q\9:-;2!_P#A'/'NBD:=XOT)TWR2116VKQ2W6F^<1)<: M+>Z9>8*7*,0#Z@HHHH **** "BBB@ H.>WJ/RSS^E%!SV]1^6>?TH _-*_G_ M ."MD.L>)O[!T[]@6Y\*Q^+/&#>$)?&6M?M$P>,Y/ X\4:PW@L>)[7P=X=O/ M#2^)AX2_L9-:BT*>XL'U07'V4L&V#W[]B9?&)_9V\.WOQ"USX6^(O&^N>.OC MAXH\4ZK\%M6U76OAC)K7BSXZ_$GQ+>V7A6^U\)X@6WTB753HVI6'B&&VU[2- M,-9MOAY@FT:\ MUQ+J#3I9'S&/TM_9.\)?%;P7\$=%TGXWGP"WQ3U'QE\7O&?B]_A;6.) M7.-#^'_P> MMM5U+2[3_A"?'(\+:)8_%GQ3XI_X1SQK?>!]-L](\):-XCL? WB.2;Q%I,\O MANW\0?>7AGQ)H7C+PYH/BWPQJ=MK7AOQ1HNE>(O#^L69=K35=$US3[?5=(U* MU:1(W:WO].N[:[@+HC&*9=RJV0 #ZO;F"TMHMOF7%S-%;P1[V"+OEF9(TW.RJNYAEF"C)(!_"K]L_5 M-,U/_@N!_P $/?[.U&QO_)^&W_!4\R_8KRWN_*$GP2^#@0R?9Y9-@HZC=VUAI]A; M7%[?7UY/%;6EG9VL3SW5U=7,S)#;V]O!')-/-*Z1Q1(\DC*BDCYT@_;-_9!N MI((;;]J7]G>XENI((;:.#XS?#N5[B6Y=([:.!$\1,TLEQ))''"D89I7=%0,S M*#T4,)B\2I2PV%Q&(4+*;H4:E50UU?<^E:**:64=648ZY(&/UKG.L=13? M,0]'0_\ A_C2@@C(((]N?Y4 +13=X]&_P"^'_\ B:-X/9O^^''\UH =16=> M:QI.G02W5_J>GV5M!M\Z>[O;6UABW.L:B66XECCC)D94 =ER[!!EB >+U/XO M?"G17ABUCXE_#_2I;A&E@CU+QKX8L'FC1@CR1)=ZK"TB(Y",Z!E5OE)!XK2% M&M4=J=*I4>ND(2D]%=Z13V6K\C&IB*%+6K6I4EIK4J0AN[)^\UI?2^U]#T6B MO!;W]JC]F336N4U#]HGX%V+V3.EY'=_%SX?026KQG$B7$?MK_LAV7EA_VE_@A%M3U*;Q#HEC>07-WID6E:7>)!IE[?NR0^)+4PW<*1RN)4>W;\>OV8_\ M@M_^UQ\3?VA?A'\/O'?A+X:ZSX,\6^,[?1?$6E_#7X7>+=0\?:AILNGZE.;? MPG9KX\U+S]6:XM[=U5K"Y1+5+J:2-8XWDC^GRO@#B7-LMQ>:4,+"A0P3KJI3 MQLJF%Q$U0P\,3.5&E4I+VD7":C"7,HRJ*4;KE;/CO2KVIRC4A*52'+*4:;C*SYDC^LZBOD8_M#_& M+6[:.;P3^QS\;;I7 (O?B#XH^"?PRL2"JLK&UO/B3XC\4Q!@6 6;PM'*CE%D M1 9&B63Q#^V[XA2)M,^&?[-WPVBPM[J,[%+"+5_BI\1OB9#(P M<,OFOX>C#(2WDQLZK Y_V5]3UB9;CQM^T]^U1XN8\S6UG\2]%^%NGOEB65+; MX)^#/AO<1QLC/'M^W.RAMR2+(D+POZE@H6=7-\))=8X;#X^K53TT4:^%PM%[ M[JO;31L/[0S&;:I9%C8.ZM/%XK+*-%IVNV\/C<9B(V71X9ONE9H^L'ECB5GD M<1HBEGDD^2-% )+-(V$50!DDL *\5\5?M+?L[^!GEA\9?'7X0>%[B'?OL]<^ M)/@W3KXL@R8X]/N-92^EE.,+#%;O*S854+$ ^=Q_L._LOS72WOB+X8Q_$.\! MW-<_%OQ=X]^,$LLAQNDD7XG>*O%<#,[ .V(57>-P5>,>T>$/@S\(?A\V[P'\ M+/AQX).<@^$? WA;PT088C-H>J5-+RW/DC_A M,_VTO$-O_P 2?X&? OP!G)%SX^^/'BCQ3?HA",N_0? /PB6P>558K(B>,1'Y MJR+'.\2Q37"OX$_;,\0P)_;/[07P:\"9P)+;X<_L_:SK-]&N7R8==^(WQ=UF MQ>8 H5EE\("+J#:MC=)];T4O[2Y/]WP&6X?6[7U18S_U9SQS2]&@_L=5/]ZS M/-\4TM_KKP';7_A'AEJ>WVE)[:Z'X8_\%.OV!_VH?V@O@/X1\.?#SXL_$7]H M3QOIWQ3T37+_ ,*>.-2^!_PT\$Z9H5OX8\66-UK^FV7A_P #^"#)K%I?7]E8 M6D=[XAU:066IWC"UF>+[5#\2_P#!-O\ X)(_M _#+]HJY\2?M9_!GPY_PJA_ MAMXLTM8E^)7AS7X;CQ7>:IX7ET2&\TGPCX@^WWEHUI::N[QWD%Q"Q">(I86>&Q=+ZQ;G="6$KX?#4G& MWN-89VUYN9GQF.\*>&,QXFPG%.*J9K5QN$>%<<+7QE/&8"O]4NJ:Q,,?AL7B MJT9IVJ1EBTFM(J"/ ?#O[*?[,GA)H9/#7[/?P5T6Y@9'COK'X8>"X]1WQE2C MOJ3Z+)?R2*RAQ*]RT@<;]V\EC[E9:=8:;;1V>G6=M86D(58K6Q@BL[>-418U M5(+5(HD541$550 *JJ %4 7**^,K8G$XE\V(Q%>O+O6JU*K^^2#Q+XY\.Z?>QD Z4FH1ZAK;$YP(M#T ML7VL3,<':D5B[,1@#-?.WBW]NGX-^'?,CM+VT=R0+>]\9^,/ 'PDTF3Y0^]O M^%F^*?#OB:2/:R$'3O">I32"1!!!*[(K>/6X@R:C5GA_K]&OBJ>D\%@N?,,? M'UP& AB<:[;-J@TGHVG9')/'X.$G3]O"I5CO1H-8C-<_"/\ ;6^)'F+L>#Q- MXI^$'[,_@J>$Y&V71M$\>^%O&XMG*J98=2TS4[KR2^^-W'E2Y?VMC:^F R/, M*JEI#$9A*AE6%O\ ]/:=>I4S>CNM\GD_+0CZW7GIA\#B)I_#5Q#IX6E_V]&I M*6+BO7"-^7;[[\4_$'P+X'A%QXR\8^&/"L31M)&WB'7=,T=IE7.?(CO[J"6= MCC"I!'([-A54L0#YG_PT)X7U7:/ 7A7XE?$PN=BW'A#P-JT&AM(3A57Q;XO_ M .$5\)NAX8RP:U/&J98GC!^?O"W@7X\Z2$OO /[+W[*_PGOF(9M=\8_$WQ1\ M0O%_1-CWC>&/A183W4R%3O5OB!,"YWI<'86E],E^'7[6_B$0OKO[2/P\\'(< M&6T^%W[/\)N83@$B+6OBC\2/'\$KC+)YK^&8E8!7\A"60+V/$>)UJXO*\LIR MTE1P>&Q&98F"T]ZEF&+J8+#J6^E7)JL5LT]Q\*-*IB:BVUAB M*LJ%.^_Q8.2\F?#/_!16^^-?B+P#X1\2^)_!;^ ?A;H&LW46OV,WC;1M<7(]E<7-DUUI_\ !/+X6>*/ M&OPOU_6/%/BSX@:7\(]0UV*;P-HOA;QM?>&]!\2S1+>6/BS4A>^'9[?6O['6 M]MK335BTS6M-TN]U*UU=IK>ZN(7G7XB_X*V_!W]KSQA)X$^#'PRM_P!KG]I; MPS<6J^.OB1KL_A3PS2VG@[PWI6C_ X^'7@G2'U723;ZCX@U62XF MU46;76A(NVY:4PQ_\$DOV:?&,%]XY^$/[87[(WC]/#UE90^,/A3XH^+G@WQ4 MW@S2)5O(K;Q9X%&EZK:&(_!Q\)*@ MJ]6K43G2EX7^J="6>RSROCL5BI2H^SGAJT:2A4:HJBE4=&-*$J"C%3^KJC&, MJJ4YRDKQ?[E6WB+]D?X"RNC>+?@5\,=1=72ZO]:\8>"=#\17VY@)&U'6=;U= M/$&I2LS#S);Z]N969LNY)K-7]MC]FFZN#:^'OB#=>/9QA53X7>!/B3\5=YP& M"K/\._!WB:W9MI9L?:,[4F;_ )8R[?5O"OP)^"?@5TD\$_"#X7^$)$V%9?#' MP_\ "6A3;HP KF;3=(MIF< >8TC.<9+$Y)]36-5 "@JJ@*J@D*%48 "@A0 M. !QZ"OU+"X3"X*C'#X+#8?"8>%^2AAJ-.A1A??EI4HPA&]M>6*/J*5*E0 M@J=&E3HTUM"E"-."](P2BODCY53]J.^U29H?"/[-7[4GBP%?W5S-\,-+^'%H M[%"XS+\9/&'PYG5?E<%S:%2R@)O,UL)VI\4_VJ-8F>/0OV5M#\/1$$1W'Q2_ M:"\*:-*C%'*O+8_#+PE\6@5#J,*FH!G#IEH\R-#]6[5SG:N?7 S^>*=70:'R M@EG^VWK,L@N->_9@^'EO('55L?#/Q8^+E[ &5@KQW=]XE^#UE+(N49?,TOR@ MZG>DBL4HB^"W[1&JRR'Q3^U[XHL+>4,KVGPM^#OPD\%Q;7)W+%=^-M*^+FJP M@(Q2)X[\7$96.3SFD1FD^KZ* /E*+]DW0KYY&\9_&G]IWQZDV?.M]5^/7C/P MC83*S!Y$ETKX2R?#?3&BD)D5H/LGDK'(8HT2..W2"Q8?L4?LKVES]LOO@IX. M\6WF\/\ ;?B-'JGQ0OBP97WM>_$?4_%5RSLZEY':3,DCRN^YIIB_U+10!P_A M7X9?#GP*@B\$^ ?!7@^(;<1>%O"F@>'HU"A0H":1IUFH"JJJO&0%4 C KMMH M&>6YS_$QZ^F2FVNDZ7I>D:9!IK0:;I6G6%G%#:V<3,JLT\\CR7%Q/+)[_^ MR;^Q7\'_ -C'2?&6@_!JZ\>)H?CC5-,UO5])\7>,+KQ58P:QIEE+IJZEI,5W M9VYTRZOK!K:TU-X'*W\.G:;YR;[*)Z^NJ* "BBB@ HHHH **** "D;D''/3C MCD Y(YP.1D,\@CC.>01ZT ?B]J'Q<_93_ &=?$'Q, M^&_[1W[)?QN\0_&;QUXX\;:MK_C'PI^P%\:OVG](_:8C\1:QJE]X<\0:7\4_ M@_\ "+XJ^%]61_"=YHGA%/ /Q \3>&M6^'%OI4/@M] TOP=I>AZA>_HE^R7X M;U/PI\!O!>D7_@C5?A?8^;XFU+PG\*=%OL0\*:)>W>DZ'9W,OX@>-?'/_!)OXP_$ MOXM^-?VR_P!N/Q'%\?\ 3?C'\5_"6C^'$_;)^//P'?\ 9ITOX<^/O$/P\\+> M"/AIX$^"OQ'\"^%_"FLZ/:>%+/Q/KOC+4-*U7QIXP\8:OJ.MZ]K%QHSZ+H&D M_LY^PW\2[+XM_LO?#+QII?Q5/QTTC/C7PCHWQGD&G&Y^*^B_#;XB^+_AOH_Q M%U"72(;72;G5O&.E^$[37M8O-,L=-T^^U:]O;ZSTO3;>YCL+< ^J+^6[@L;R M>PM$O[Z&UN);.QDN5LX[RZCB=K>UDO&CF6U2XF"1/_P_P#A#XW\;_#SX>>#/A7\5M,U;XK>(M$\&KI7ASPI M+H-[KOA378/@_P")[SQ9;7U]:6'F^']>\)^%C/HFH:@SWGVZQAL-1^[:* /Q MI?\ X)G>+_AMX=\0Z!\#_%?A*)?B?^P5J'[!_BR;Q*NJ:58_#7P_:^.OBQXW M^'OC/XOB=X9T/X6W\VC1CP_IGPZTJU\4V-GI6K&3]8 M/AKX#T7X6_#SP)\-/#ANF\/?#WP;X6\#:$U]*L]ZVC>$=!T_P[I37DRI&LUT MUAIMN;B58T5YB[*J@@#MJ* ,+Q-X6\->,]%O?#?B_P /:'XJ\/:CY']H:%XD MTC3M=T:^^RW,-Y;?;-+U6VN["Z^SW=O!=0>?;R>3<0Q3Q[98T=?P5_:H^&'P MV^&__!;_ /X(E#X>?#_P1X$&L?#?_@J/_:P\&^$_#_A8:I]@^"7PB-B=1&A: M=8"^^Q_;+O[+]I$HM_M-QY(0SS%_Z!Z_#']MS_E.!_P0Y_[)O_P52_\ 5(_! MF@#]SJ*** "BBD) &20!ZDX'YF@!:*S-7UK2- T^ZU?7-4T_1M*L8C->ZGJU M[;:;IUI"H):6YOKZ6WM((U RSRS*H')(%?*&K?MU_LX+J5UX?\!>+=7^.OBF MV1BWAS]GCP=XJ^-]VCHVQX;[5_A]I>L>$=#=&(61O$/B72(8LYFEC4$CKPV! MQN,YOJF$Q&(4/CE1HU*D*:TUJ3C%PIQ5TW*D7%R##=?#7]C?P?X2M==CF0 MD/9-J]])^T+\5YBK9C:[T:W\)WLLAQ#';2%%'5_9:I_[YF&787JHK$?7JC75 M&]-N]9\0ZOIFA:18QF:]U76;^TTK3+2(9S+"?%_QOG\T'#07 M6M?#[1]9\(:0ZGB237?$VE6\1SYTT8!(^6='\ ?LT7VLV^L:+^QW^TY^U)XH MCC5K/QS\?O"OBKQ'YMUCD6:"WL8OB!\7;[6KNRM%)6.*/P5\)? %UH$1 MC4$M;6_C](5RJ1SGYB#_ (1:.RS''R[MX?+*<6NG*O[2J5H/OS86;3^RT+_C M(L0]\HRR/6RQ><59Q?52?]CTL/42>B<,9!23OS1M?S;XJ_%G]JCXD?#/XCZ? M\/\ ]DZX\$Z'J?P^\8Q)KOQ[^)_AW0?$,UO<>&=5BE71_AE\([+XOZY?ZI/& M[1:=I>MZ[X6FEO'MXK@V^]@O\+_@;X0?%*Y^(WASP%8_#+XBKXYTK4/"E[?^ M$XOA[XDG\::#80WV@W)UC4_"G]B2ZM8VVGVEW9:E/<7^G)81P36\URXL[A'? M^[OXIZ5^U1X6^'?C+XB>)OCP2/"/A35]>3X??LS_ +/>FR>+/$=YIUC+/9^' M=!OOB7K'QKO[[4=6O1!80W,'A6U2))'NYH;:.*62+^27P;9_M4:%\;M&_:BU MT>,?%WC[5_&=KXE\=:5X1\>Z]X;^*GC/3/$-W:V7BCPK:7W@"X\.ZU97>OZ) M*V@VNE^%[^RFMMNGVMKIL-O;+8I[>4^,>3>','@\91R'+GQ!BJ%#!0Q>:UL% M4Q6(H*4.2G]:^LTU)T_94J+*VI?M@?M4W$ESO^UFSU'X):!#(K\.EO%HGP+LFTM#'B-9-,FM9X>9H)XKC M]Z*>D_LD? ?Q5HNG:WJ.G?&C4TUW3=/U)[7Q[\>/VCY=7%K>VD%S!I?B+1-> M^)HEMY[2)TM-0T+5+3=:3QSV-Y;ATECJ^G[#O[*AWF[^#'A?6'W8LS/;6\D5O([-))&SDL?!_M7%IWBL%!Z:T\LRVF] M/.GA(M:ZV6E];7U/U'^Q,#9*4LPJ)=*N<9Q67W57I=;-HYJ]_9M\+:<8 M7\3?M2_M-O!*9$LXM0_:/OO#,9F&PR-%/X.D9"&&YNKNWB5_-%NDS M+,.)OO 7[(^C13GQ5^U9\03*MS):75[X@_;W^*.D.)OFB^P2Q6/Q@T6QB>,1 M21B%;.*X)64S-)*&8>_VG[(7[*5@S/;?LU_ :-G01DM\)? DI**00H^T:'* M,@$[0"<#).!7:Z5\"_@EH4D4NA_"+X6Z-);P&VMWTKX?>#M.>"V950V\+V>C M0O' 454,2,(RJJI4@"AYQF?V<;6I_P#7F2H]M/W2A9;.RW=F[NP+(,G7Q9?A MZO\ U_B\0WMJW7=1MZ63>R;BK)V/A'5-&_X)C0))%J_QQ\$ZPEHR%M,U7]LG MXE^+8S.0L:,FB7'QGUB.ZO(UE_=/#9S7, =WC:/,AKF?LW_!*%);C$/PU\6S M8B::^1/B9\29H\1MY%E%JJ#Q-)%($!>+28+Q)!)*LB6@EN5>7]4K#0]"TF*& MWTS2=)TV"W+&WAL=/L;** NS.YACMH(DB+.[LQC"DLS,268DZA\L]7_*5A_) MA0LZS=*RS;,K=OK^)MNFM/:V>MG]PGP]D#=_[#RBZZ_V;@[]O^?/;3TTV9^8 M6FVW_!-<20G1OV9-%UF6S1&9M,_88^+7B&2V 4Q)+?D_!*\82R_/MEO-\\\B MRR%FE5GKH;75?V3K!6'A;]A3QQ.;IUD=-)_86O?#J7$$:N8KR6X\2^"?#-FZ MA6 AADN!?XF^6SPL_E?HZ-G9L_\ R?_ &8T$(>"%/UP?YUG+,\RJ?'F&.FG M_-BZ\KZWZU'UU]=3:&3Y13:=/*\NIM:IPP6&@UI;3EI*VFFG30^&='^(OAJT M%A#X2_8,^-<<=K(BZ-Y'PG^!G@NWA$$C.DT"^)/B9X=FT1(G5Y8A?VVFS%PI MAB+30L_:CXR?&-#/)X=_8K^*ENKH(HY=9\?_ +.'AJ228#(^UQZ?\5M=GBL( MY'YN(DO9]BRO%82.J1R_605.RK^ ']!3L =!BN6=6K4UJ5*DW_?G*7GU;ZZO MN]=SMIT*-)6I4J=-::0A&"T22TBDM$K+LC\E_P!NCQK\1/&'[)/QVTCX\?L[ M3>"?@W)X-2?QSK>G?M*>!].\7K:Z=K6EZKIUGX1CM?AKX[TJYU;5M9L-+T:R MM]3@MY+Z\U**QMH=\XNX/YC/^"9EAH=M^V?\)+X:!)K?C2PU^?6OA5I6J?$J MV^'/A^\\:Z;I^JSV_A[Q!K,WPZ\>'5I-;T:6_P!/T6PAMO#8N]?AM ^MP+ MRZ'JFDW%Q#82R-=QV]SUMY8OAOX9_L%_\$NM4\76VH?"CX:_ M"S4O&G@75M.\16=QX/\ B5XOOM:\/ZIH>I6]YINL0"P\=331'3]4M[:2*\C6 M2W2Y2.-W)8(W=A>+5I/# MPA&JJ5W&FDVEHSY_->&>%\US3 9GF^6X#%9MA?91R[$XF36(I_5:\L525"/M M(J;HUYRJJT)-2E>6EK?2/_"R_P!K&&(LO[+O@*18TW>7;_M,6)GE5!G9")_@ M]:V[3.H(B$]Q;0M(5$L\$9:5(S\8OVG "1^R+=M@$A1\?/A9O;'(4 VX3>W0 M N$W$ N%RP^M 5Z @\GOGGJ>_P"G:C<,XY_[Y;'YXQ^M>:?2GRO_ ,+M^/>! M_P 8;?%$' X/Q5_9RX..F1\4SP#W /KCM5A/C[\4-J";]CO]HE9@JB58M>_9 MJGB64 "013?\+_C\Z(/N$DM-4>6G]I?Q9&6CG_9+_ &IHIXV9)HX_#WPA MO421"5=8[NR^-,UI=)D$I/:RRP2J0\;LI!J ?M5W"%X[O]FK]JVRN8Y'CEMC M\(+;4MC(V 5OM#\7:KI-U'(N'22RU"YCVMM=EE62-/1(OVA/A1=L%TS5->U] MF.$_X1KX>_$/Q(DF07_=S:+X3O8'/E@SD+*3]G*7 S%)&[,/QI@N'"Z5\)_C M3J^0"&7X<7.@H>&8GS/&-_X:7"QA7Z_.76*,O<"2%./_ %CR*23I9K@L4V[* M."KPQU1O33V>$=:I?7;EN^BN8_VC@7;DQ="K?94)JO)^D://+\->APL7[66A M %;[X*?M4:=TG6M+D616R%BU"2:(ADN(H9!LJ MS%^UQ\.5#+J?@K]HS1;A6&+74?V5_P!HEYGB(!6=&TOX;ZE;&)FWH ;A95>- M@\2C87[23XC?$F< Z3\ /&$:$*5?Q#XP^&.B*,J7;?'8>*_$5RG!18_]'):4 MNDH@$9OGP$W,/L^B_#,QX9F5%8WNY2D MA:-E,9)_;V";:CA\YF^EN'\]C&7I4GET*5GWVH?7Z.RIXQOI;+\9PDW[9/P0M'$>IM\7-&D=/,BCUO]F_]HS29+B,,4:2W6\^%2&>. M-QLD:/(C&UN0I <6C:]\/] M.6\:(LOG+:F9H \;2A!(A;T&&R_:*NS_ *1X@^#6A+R#]F\*^.O$\F0@.0]S MXQ\*QX=SC!A)C5-P:4RE(@^!OC/=-_IWQT6S0CE?#/PO\+Z=@A,+L?Q'J'B] MAN8L\I96W;8UB\@+)YI_:V*DDZ7#^=58O[5\GH6]88S-\+5_\I^J0?6ZKUC@ M,;)=_P#9*?\ Y+6Q=.?_ )*>2>(/V\_V:M*\/^(=4TKX@V&O:SI.@:SJ^D>% MDL=?T/5/%FHZ7837EKX;T&;Q%H>F6-SK.K31QVEK;BX+H)'NY56TMKB:/Y>_ M8T_X*$WOBOX0+:?M-:=XAMOCII.N^*&OM&^&_P /?%_Q%BU[PI-J?]I>'-U\&WTNM7&F!M3T9;V:0KJL4K>H_M6?LJ?'7XN:#X=T7 MPA\9;CQ'HFFW&KZYXD\/?$<:19-KFK6=A#;^$+?P_/X+\(:%IVD&UEN-9EU* M\UI=0CNFN;*-(8# UW'\Y?LY?L&?'#PG\1O"7C/Q_9_"F/PAIVL7EIXT\ >* MXF\<3^)_#5UI%[#%<:8=.CF\/Z7K&EZX^EZMID^IF_#K8W-K)#:"[,P^ S/B MGQ&I<<9/DV6<%TY\-8S">TQF9XZI43H57[?VM2KF>7U\9@,#]7Y*+C@ZF&Q> M(Q:DXTIQE7@Z'@8K-.(H9Y@\%ALEC++*U+FK8JO*5Z)P\ZU"A[/E@ MU1E3JU*MVH-.<7#ZMAS%;Z;H_A?P?I<\TF M5(66SUKQQ!KMEE6!/VS0H&C8A)EB8.(]W0/C;^VIX^$;:#^R%X<^&5A,Q$>J M_&3XUVB7D:9<*UQX5\%>$]2U"-]H1S$-1)^9UW@HI?[;TG1=(T*RAT[1=+T[ M1]/@ $-CI-C;:;90@ #;%:V<4$"* , +&, "M/ '08[_ (^M?>?4L]Q'^\YU M1P<=U')\MHTZL;VO"IB,VJ9O2K16JYZ>"PDI:22IO1>][''5/XF,A16Z6#PT M(R6WNRJ8N6,C-;KFC0HM[I19\WVOA;]I_7[#9XF^*WPU\"7;=4^&OPWO]>N( M250?NM9^(7B2]LY0I#_,WA52VY>FS#PJ MREAX-]?9T8+LD?%_AK_@GM^Q_P"%RK6OP9TK69"[2S/XS\1>-?'GVJ5I#(TE MW%XQ\2ZU:W+,S.&$MLRLKR(5*22!_H7PC\&/A#\/RA\"?"SX<^"V1516\*>" M/#'AYPJAE'[S2=+M)2<._P S.6.]R22[$^ET5[%&C1PU*%##TJ5"A35J=&C3 MC2I02V4*<%&$5Y121V0A"G!4Z<(TX1TC"$5&$5V48I)?)#=H]S]68C\B2/TI M0JK]U0/H /Y4M%:E!1110 F >H!_"C '0 ?A2T4 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% %*QTW3],MEL].L[:PM$DN)5M;*% M+6W62ZN)KNYD6& 1QA[BZN)[B9@NZ6>:65RSNS%]G8V6GQ206%I;V<,MU>WT ML5M#'!')>ZE=S7^H7;I$JJUS>WUS<7EW,P,EQ*UM+.TM8GGN;JZN9WC@M[:W@C>:>>9TBAB1Y)'5% M9AYU-\:?A+#\/?#WQ87XC>#;KX:^+K/0-0\(^.-/U_3]3\->+K/Q6D,GA:?P MIJNG375OXF3Q-'<02>'ET)M0DUJ.:*334ND=6/H>H7=C86%[?:G/;VNFV5I< MW6H7-VZ1VEO96\+RW4]S)*1&EO% CO,\A"+&K%OE!K\&O@QHWB6U_9]_X(5? M%226\B^"OP'L43XY6)T2_DM_!NL>(_V-_B=\)_A_XM\5:<]JEUX>T_P1\0=; M;PCJM]?6,'_"*ZAXQM+S4_[,L;6\O+8 _9K6_CI\&_#FF>#M:UOXG^!=-T?X M@VBZCX*U:Y\3:2-,\3:4RZ:W]M:/?I=/:7>A1G6M$2?7DF&C6TNM:-!<7\4V MK:?'<^K YZ?Y_P ]Z_EL\#?!SXN_#SPG^T[JGQ)^&7C1O#/[27[ 7[8WPZ_9 M?^',OA75+K5]/\2?$_\ ;7_;)^*OA/X'I96\%SJ7AGQC\1OA-\CW-MIOA#4K"ZC@M?AAJQT;^D'X'^'/%_A#X,_"7PI\0-2.L^._#/PS\ > M'O&FKFZ>^.J^+=$\(Z-I?B34C>R_O+S[=K5I?77VI_GN?-\]N9#0!ZE_G\^E M?S]_M#OCWXTL_$=A- MHWPP\1^//A=X!\+^&M+\4W2.8]/N+WQ'X/UW0I(Y&\RVU6U%G,BR-Q^Z?C^U MO;OPAK<=AXWO?AQ/#;+?2>-;"R\-W]SH%GILT6H:C=BV\7:5K?AYH386MS#= M2ZCIEREO;2S7$/E7,4,T?\;U]^T;\(];OO%'B"#Q@\$<_B?QEJ%K!K&CS:3X MCUN&?Q#JM\NMV?A^PTVVANW\2Q7":Z8M%M([.*35##+;V 5H8OA/$'B?B+A7 M*,%CN'.#\QXNQ.)S?"8'$4)=)\7KJ]C'X;U# MP_JUG%J&F:S:ZU//%I\NFWUE/#=VMV)Q#-;RI*K%&!KXO^)?_!4#]ASX97UQ MHEW\?/"GC7Q1"&$?A3X4"]^*6N3RI@/;X\%V^JZ59RJ2JM_:>K6,:,0))$KY MB_9N_8._8R_:F_9\^"OQ@\6Z)XX^*%IXI\ :%=QZ+XY^)7CC5] \*7]O8)I6 ML>$]&\*7NHQZ9X9M/"NM6-]I-OHMC:00:1)9&TMMUK'&'^WO!G[!7[(?P]C$ M?@WX&>#]" (;=:_VOOW*"%.YM4)RFY_+/6+S9ECVK*ZG[58RK%'\5.K?W M\+F6>X3*IX::?O4JE3+A6AA\CRV M%6C1J7J5\=CZM55:<9N4:?U? QP/KVPE4BU\5?%"W\2:;9H%0R/=)H'PX\+^.K6>!(@TS1:UX[\)8B4F:Y MM\,5\^U3XQ_M;^/YI(/%OQ5TWX;V=T@6;0?!WCS]FK]GJV5"1^YFU[5]?_;+ M^,[2 ,HE;2_#'@S6 9 (;6VD(5/UCM?@9\&K/88OA;X"D=#E)KOPKHVH3H0Z MNI6?4+2ZF78R(8\2?NPB+'M554=[I?AW0-$C$6CZ)I&E1*H58],TRQT]%56= MU54LX(5 5Y'90 &=F&"S$O^U>(6_P#9,NX6R;O/V&,XAJ-I+E?-F?U65.:? MV\-+#VM=13:9K_8V/Q#OCLRQ5?JH/'5Z-*+>\?99-2R%5J;U7)BY8EN.DI,_ M$?2?@3H?BO5FUCQ1J/P:\6:V%2.VUWQA\.?VK/\ @H)XMAE!.+S2-?\ B]K6 M@^ -*NY522:"71/AG:6,4,)EL;+RAN7ZBTKP!KU[I^GZ5J_Q!_;B\5:980B* M#P]\._!/@?\ 9H\'PVPW/]EL+7PQX;^&7B2TM/*V+'&WB^XG1)0D RJEAJE5JWO5)RKU_:3=KN MK;>K_/"V_9R^&IOEU.3]BV_\=ZID%=8_:#^*6@?$N^$FWF0S^//'/Q;NX6\Y MBV8( -BRW"+YXC@E^A="TSXNZ%ID>E^"_A+\#?AWID8*0V-IXOUI[>W1=L46 MW2?"OPTT&QQ&J&00QWR+)&8H?,MV#,OT717+_96,E?VG$.^88QK^51P,%\G#!1FO_ .^N^QXBFC_ +05^I^U>-?A M-X?W!<#2_AYXK\07,8+EBJ7>J_$#2(79%54$CZ:%D\R1C!"R)DA^'GQ5N&SJ MOQZU^%2V6C\+^ ?AYHR=&8B-M:0_9T$4A>5FN6]NHH_L'". MSJ8K.:DEO)Y_G5-2=[^]2P^/HT/DJ2CTL'U&B[6T]I<1/XW@T**2*X@DMW!@\(Z'X=B8!9I7, M;AXI6<1W*3PQQ1Q_F)X;_P""8GQ"L_B/81:WXT\*2?#73=:MKR35]-FU:'Q5 MJ6BV5XEQ#8PZ,-/BMM)U:[@BCM9[Q-:FMM/=Y+VQ:XDCMX#^V5%?+\1>%W!O M%%7+:^;Y?6JU,LKSK4IPQN*C+$1J.E*KAL9.=6I4Q&'J2H4VXN<:D;25.I!5 M:JGY>8\+Y-FD\-/%X>_P#FUKV6BOJ5P[D"5EDN5)=EE^%27HE221ZO]GX!;8+"KR6' MI)=]E!+?7UU/%V^!OAQ#_H?B_P",-@A WQV_QF^)4J2."<2,;_Q)?.K;2%(B M>-" "4+#<6_\*/TC_H?OC1_X>'QW_P#+:O:J*'P]D?3*L%%=H48PBO2,.6*^ M277NP_L[ _\ 0+17DH)+Y)62VV2[]V>(-\$8%8_9/BA\;+.,@%HA\3-7OU+C M(WB36H-4N$RN 8XIXX/E#B(2%W=/^%*2?]%;^-G_ (7R_P#REKW"BI_U=R:^ MF"45_+"MB(06VD80JQC%:;)):ON+^SL'TH)>2G426VR4TELMD>))\'-2AW+: M_&KXU6T;$,8F\2>&-1^? !83ZSX*U&[4, ,Q+<"!2"T<2,\A9_\ PJ'6_P#H MN/QH_P#!IX"_^=W7M5%-*BND89EF4(K;11CBU&*TVBDE=V0?V?A5M M"JET2Q.)27HE626RV1XPGPL\60 I:_'KXMQQ$[@EQ;_"O4) Q #$7%[\,99] MIV@B,N40EB@7<13_ /A6/C3_ *+[\5/_ 4_"#_YUU>R452R+ )64\S26B4< M\SN*2[*,H6-CI'B#1_AYIT&K221H\NCWVO:!X0T74+*TU6..6P-Q M;/;- MUBXEDMO.#?F+^RI^RA^T'9_&WP[K.L>'?&GPDT;PM)JE?"\0>$O#_$7$.0\18K'9[2Q&15*4Z>'AFN)Q%+$+#XI8RA!UL;/$XO" MJ-=-S>"Q%!S@[1Y*BA5CX>8<)Y?F.88#,:M?'1J8"4'&"Q56I&HJ=7VT(N=: M52K22G>[HU(-Q=ERR2DO$HO@?82,&UCXC_&?7.5+II1R!I6,[HT9C:XQ<;!,JN/;J*^X_UTRC+\0U]O%X6EBZCVWJXF-6H M]NLN_=GM_P!G8#[6#P]1KK5I1K2_\"JJ_T_1=(TE!%I>EZ=IL8" )86-K M9(!&GE( MK#$H"1_NU &%3Y%PO%:=%=V'R[+\'_NF!P>%_[!\-1H?^FH1-Z> M'P]'^#0HTO\ KW2A#_TF*$ ]?Q)/\R:-JYSM&?7 S^=+178;!1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %-VC 7G Z'@I: $90RLK ,K JRD @ M@C!!!!!!!P0001P17X7?MM11I_P6]_X(=QHB+')\-O\ @JBKHJ*J.!\$O@V0 M'55"L!O? 8$#GT44 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !7RK^V3\-?C5\6_@EJG@7X&>(/"> MA^)=6UG1WUVS\7^+?C#\-K+Q9X0LI+B[U7P58?%GX":]H/Q7^$>I>)+V+2;3 M_A8WA!M9U'P_IJZD@\.:W'>O:'ZJKS3XE?"+P+\6[;P_:>.=.U2^B\+ZY_PD M6C-I'BSQCX0N(-2;3-0T:9;F[\&>(/#UWJ>FWFEZI?66H:'JL]]H>HP3[;_3 M;AHX6C /P[\/?'3Q%\2Y_#7PXT:X^,?[/7PJ^'/_ 2H^+7[1&@P:_\ &#QE MXR\:^&?V@O#?Q8U3X8:U?^*OB[K/BC5/$WQG'P$N/!=S>:-KGBS6=6\,^.++ MQ_9^*O$.DWZ7VB6VD_LG^RI\0_%?Q=_9A_9S^*_CRQBTOQQ\3?@1\'_B%XRT MN"TDL(=,\5^-?AWX;\3>(M/BL9?WME'9ZQJE[!':2@26T:+ P!C-:WCC]GKX M+_$;3O#FD>,/AYX>U32_"6@:OX1T'3XH;C2;.S\$^(;32[#Q'X"FMM$N=-BU M'X>^)K+0]$M/$_@#4UO/!OB.WT72(M;T._33+$0>QQ11P1QPPQI%%$BQQ11J MJ1QQHH5$1$ 5$10%1% 55 50 * .:\9ZIXET;PWJ.I>$/#$7C'Q#;_9?L'A MV;7[/PQ'J'FWEO#<[M;O[2^M++[-:23W8\VUD\\P"V39),CK_/M^W=X?_;L\ M:?\ !1S_ ()??&[X)_ 7X'1^/?@AX)_;ZL['P5\9/VA=6T+PSXKM/B+\./@_ MH6I7)\4_#WX3>-K_ $B?0K1%NK2"30[A=4NG6VEFTV!&OS_1C7E?B?X0^&?% M?Q2^&'Q=6/[4W_!:3 M4/BWXG^"\'[&'_!/@>+O"7PW\"?%+5)I/VV_CFNBOX<^(?BKXB^#]"@M+X?L MH-<3:K%JGPP\12ZC;264-M;6:6/PK\.Z?\8/%/QL@N M=6;Q9XN^&W@+X6ZG9R7-JVA1>'OAWXI^)'B[0[FSM%LEO8M6GU/XH^(8M2N) M=0GM9[.WTF*WL[66WNI[P _,7_A:_P#P7(_Z,U_X)R?^)S?'C_Z$>C_A:_\ MP7(_Z,U_X)R?^)S?'C_Z$>OV%HH _'K_ (6O_P %R/\ HS7_ ()R?^)S?'C_ M .A'H_X6O_P7(_Z,U_X)R?\ BO^%K_ /!/_H1Z/^%K_P#!/_H1Z_86B@#\>O\ A:__ 7( M_P"C-?\ @G)_XG-\>/\ Z$>C_A:__!01ZUYKX!^%GAWXRM)+72?[ ^&N@W!M[R6_N MO[4N-4N/MGV:XMK2T /S$_X6O_P7(_Z,U_X)R?\ B/_H1Z_86B@#\>O^%K_P#!/_H1Z/\ MA:__ 7(_P"C-?\ @G)_XG-\>/\ Z$>OV%HH _'K_A:__!O^ M%K_\%R/^C-?^"/_ *$>C_A:_P#P7(_Z,U_X)R?^)S?'C_Z$>OV% MHH _'M?BM_P7'+(I_8W_ ."<:!W1-[?MR_'HJN]PFY@G[(KN54G+!$=\ [58 MX!\Q^#_[5_\ P6?^-WP_T?XD^#?V,?\ @GS#H&M7_BO3;:'6_P!MGXYV&IQ7 M/@[QGXC\"ZJ+BV@_91O;=4DU?PQ?SV4D-W.)M/EM)I?L]S)/:6_[HD!A@^JG M\58,/U'/M7EOP8^$7AGX&?#W2OAMX0NM9O-!T?4O%FJ6MQK]U:7FJ/<>,?&7 MB'QQJBS7%E8Z=;O#%J_B6_ALE2TC>*PCM89GGGCEN9@#\S?^%K_\%R/^C-?^ M"/_ *$>C_A:_P#P7(_Z,U_X)R?^)S?'C_Z$>OV%HH _'K_A:_\ MP7(_Z,U_X)R?^)S?'C_Z$>C_ (6O_P %R/\ HS7_ ()R?^)S?'C_ .A'K]A: M* /QZ_X6O_P7(_Z,U_X)R?\ B/ M_H1Z_86B@#\>O^%K_P#!/_H1Z/\ A:__ 7(_P"C-?\ M@G)_XG-\>/\ Z$>OV%HH _'K_A:__! O''Q&\1_L9_\$\6 M\/\ @#P;XJ\<:W'IO[;WQVN]1ETCPAH&H^(]2AT^U?\ 9,MX[B_GLM,GAL89 MKBVMY+IX4N+JU@:2XCT_#'QX_P""W'BWPUX=\5:3^QI_P3K&E^)] T7Q%IRW M7[/_ *$>OV%HH _' MK_A:_P#P7(_Z,U_X)R?^)S?'C_Z$>C_A:_\ P7(_Z,U_X)R?^)S?'C_Z$>OV M%HH _'K_ (6O_P %R/\ HS7_ ()R?^)S?'C_ .A'H_X6O_P7(_Z,U_X)R?\ MBO^%K_ /!/_H1Z/^%K_P#!/_H1Z_86B@#\>O\ A:__ 7(_P"C-?\ @G)_XG-\>/\ Z$>C M_A:__! -0U/PEX:UO]F+P MSHFN:WI2^*DU.UTO5_$6AV%Z+.2WEU*W9XP_[3J=PS[L/^^6*_KC->6_&?X1 M>&?CG\/=5^&WB^ZUFST'6-2\)ZI=7&@75I9ZHEQX.\9>'O'&EK#<7MCJ-ND, MNK^&K"&]5[21Y;"2ZAA>">2*YA]2 "C ]6//JS%C^IX]J %HHHH **** "BB MB@ HHHH **** "BBB@ HHIDBEHW59&B9E95D0(SQL00KHLB21ET)#*'C=2P M9&7*D 4.ISU&.I964?4%@ 1[C(]^:7<"">>.HP<^O3&3[8'/:OP*_:H^%/CG M]E3X9_M^?M+_ +'7B'XA^&;./]CWQ;I%]8W?Q+\:>+E^(OQUT[Q1/K7C+]I# M0[7Q?KOB0:;XV^"WPV.NVM_X\T**Q'C'5=0GTW6(KJT^&>@RVOH/CZ:7PI^) MGCKX>:@_Q?\ $'PXT?\ X1[QU'KG@KQ%X?U+3_$'@_4TCUV#QU>W%Y+\/].C MUO7]-C@OIY6N_NKX2Z#K_A7X7?#GPOXK\;7/Q*\5>&? OA'P[XG^(=ZMO'>^ M.O$>A>'].TC7O&%[': 6L5YXFU>RO=:NX;=4BBN;V6-$4)M !Z%1110 4444 M %%%% !1THK"\4:5:Z[X0!_>5E/_?+ $YZ M# Y/ R:7<,9YQG'0YSG'3&?TX'/3FOP%^)OPF\5?LR^#_&/_ I#5O&GA#]F M']HW]N7]@/P#<> +GXC>,=0A\!_!7Q9\6/!_P^_:%^*/AC4_$FNZOXB\ >%_ MVB=K:5IVL:?IM[I0N/B!:_P!G:_\ $+5[F?1^)'B?Q3!^S=_P47\+ MZ+XE\467@7X)_P#!17X*>$/@9>:+K>L:#)X>\+3^(/V)O'7CCP'X?O\ 1;K3 MKJ;P)X7^+/C_ .*7@^'PTLLGANRT5M0^'C63^']&72+4 _>@L 0#G)]%8@?4 M@$+_ ,"(IU?EG_P4\\!6MM\/_A[^T98^ /B)XT\2_L__ !=^$'C2[USX6_&K MQ)\-?B7\/OAQHGQ9\,:G\1-4^%_A..*\\$?$[Q'XGT!;KPIXJ^'/B>+23\0_ M >HZUX9M=9N]37P_H-]^I2].,_>8!/B#\./$7A;XFSZ@G@#4(8#XJL[#7-; M\/C6=*M[F.=]#O[WPW>:=KMSI6K3)!9ZCHFG7T#^([>1M N([ZSU*YTZ\ /4 MMZX!YYZ##;OIMQN!'<$<4N1QWSP, G\\=.G4X&>.M?A)X3^%GQ&^$/Q*_8&_ M9:\4ZGXPU/\ 9K^*GQZ_;B\:W_PZ\9^+-8\4R^!?#NC?#[6?B'^RU^S-XH\2 MZSJ&J^(/$^A>%O"6K^+/']EX/U[7]4MM"U/P3I6A6,FI^'/A_H4D%_X">/?B M%X[^!/\ P25\;>,/%_C;5];N_P!M+XR>!;7Q!?Z[X@L[KXB?"#0/A5^WAX<^ M%NL^.+6&\MK/QU_PDWP\\!?#+QBFL>)[/4Y+_6([/Q?;R1:G=?;7 /W-ST]_ M_P!?/H/<\9P.I%%?BI^T?^TD=0_;L_82\,W5O^T1X6TOPW^VIXV^%EMX /',5W^Q[^TQ:ZAXUU/QA;_#Z/X<^/=&/C&7PXOA(6'B#7='\+^$]# M\0_%/4IK'3'OM5\+_M4O0?04 +1110 4444 %%%% !2,P49.?P5F/Y*"?QQ2 MU\P?M7?!_P"%7QC^&TF@_%WPUXC\?Z%;27DVA_#;P_XY\8>!YO&_C&XL)H?# MNG0WG@O7O#FI2:U;3)-<:!J-SJ2V'@^\,WC>0V5QX>M]9TH ^G2RCG/OP">/ M4X' ]SBG9YQSTST./SZ9]LY_(U_.Q\2K;XN_#JS^*?P;^.'QD\6^+KK]E+_@ MB?8_$[X?_%H^*KU];U7]IWPYKWQ<\.?%CXT6.JPPV6I>(?B1\-9_AE\&[/2_ M%NI"^U^T3QAJ']I(EW\1O$%MK'WO\-?$'C_Q!^UW^R#X@\?RZ]HOC'QS_P $ MT?BGXA^)GA#^TM;T_P -VOC^V^*'['M]?RR>"VOCX?L->T75/%_BW2XM2735 MUJWL+R;29;Y[&**WC /TNW#=MYR.^UMO_?6-I/MG/Y4ZORE^&GP@\3_"#_@H M[X@\9?$#0/AQ\8-1_:/^'7Q?\0^"?CQX7\*>,O!WQ7^$N@>!/%G@!8?@O\2= M*O?B#XS\ >+_ (>2>%/$?A/1/A_\3/"VC_#S7;;5O!EQH'BGPOKU]XG?Q,GZ MM4 %%%% !1110 4444 %(6 (!SSZ*Q ^I (4>[$#KSQ2U^>?[?/[,NB?M#^# MXK#0]5\;:-^T&MA%I_[/GC?PO\3/'/@E_@5XM36;2[O/CK86GA?7=-TL/X(B MEM]4\0W&MZ=JD/B_3-.T[X83Q76F^+;K1M4 /T+W#.,\\=C@9Z GH">P)R+/@O\9O^"M?Q0\.VNN>.K[X3?L]?!/XO>$/A]J6M>(] M7T;4O$_A7X"_&G7(_#_A[1S>W,6AP>++KP;HEIJ5CX7MK :C?O+J-OV3O@G M^UQ-^TUHGB"\\0VWQ)O/BG?ZAX?\::'KUC=Z;9V/@BST_P 7:;+J_P (]!\( M7X^&MZNDZ)HGA^Y\%Z@^M?J50 4444 %%%% !1110 4W<-VWG/\ NMM_ M%L;0?8G/3CD4ZOSG_: _9FT/QS^TG\#_ (N^ /$'C7PM\9_ WQ7\$>,?'WQ) ML_B+XOL]$T#X"Z%IVHV/B/X-ZIX0&O)X&U+PS\9)C;>'(/!MWX<=GU74-8^+ M"W"^)?".EZG0!^B^X9QWY['''7!Q@D=P#D<^AH+ GG S_"Q/'' R?; .>H MXK\!?V:?B1\4]0\2_L&_$;Q+JVN6?QY^//[;W_!1CX9?M.^&Y-5NM11OA=\, M8_VLQI'AG7K&A_!#6_@[\ /#_@&)[>S3PX-7GL]/C%S\1_$+Z]]A_LP M_#+PK\=?@M^UW\(?BY%KOCOX?ZW^VY^UGX>U/1/$7BSQ=>27OAFR^,\VK6?A MA]:_MR+Q!'X6M9TCM(-!M-6MM*@T*)/#D%O'X?!TT@'Z;*P89 8=OF5E/Y, M3]1Q3J^!O^"=_P %OAG\)O@YXMU_X2>$+?P+X"^-7Q:\:_%7P?X9M)]6N+*Q M\"2_V;X&^&]_9-K.JZQ=11>+/ 7@K0/'MS$ET(/[3\8:A(D:M(Y;[YH **** M "BBB@ HHHH **** "BBB@ J&YMX;NWGM;A!)!(O$WARZ\'^(-:\ M!_#KPWX=U+6O"U]>VVHWWA[4[JQL8Y+S1KV^LK2[O-.G+VMW<6T,MS%*T:$> MI6WP'^#5E\/?%'PHL?AEX+L?AOXVL=0TSQ?X)LM L;+PYXGTS5M,AT/4M.U[ M3;6*&'5;"]T"VMO#UQ97OG6S^'K:VT'RAH]O!8Q^M44 ?*_Q5_8@_9$^.>B^ M /#OQE_9R^$/Q2T+X5:)<^&_AMI7C[P7I7BJQ\#:#>0:;:76D^%K?6(KM-&L M;BTT;2+.:"R$2R6FEZ=:MFWLK>./Z+\+^&/#O@GPUX>\&^$-$TOPSX4\)Z'I M7AKPSXIV4TUG?V4ZO!=VLTMO.CQ2.C=/ M10!\P_"K]BO]DCX&^'?'?A'X/_LW_!?X;>%_B?!IUK\1/#_@[X>>&]$TCQM: MZ/#>V^E6WB>PM+%;?6;?38=2U!+"&]26*S^V7+6ZQO*['T#7_@%\%_%'PW'P M?\0?#+P;JWPN-_9:K)X"N]$M7\+7&J:?KT?BNTU.[TA%2VO-1A\50P^*!?7: MSWYNM4TI[EIIM-U"ZNKRRE@N+F>23T2B MB@ HHHH **** "BBB@ KRWXQ?!'X1?M!^"+OX:_&_P"''@_XJ_#_ %#4-*U6 M_P#!GCO0[/Q'X:OM1T.]CU+1KR\T?4(Y;*YGTO488=0L'GB?[+?007<(2X@A MD3U*B@#YV\&_LC_LQ?#OX9K\&O GP$^%'A#X5IXEN?&()?O;[K5IS;.\+=YX@^#/PK\4R?#677O /A? M46^#>LVGB+X4K+I-O%%\.]=L-&NO#ECJ_@V"U%O;^'K^R\.WVH>'[2YTR*WD MMM"U'4=&@,>FW]Y:S^FT4 OV&>[A19WLWEM?, M$$TR2>]T4 >)67[-GP T[PE\._ =A\&OAI:>"_A+8QZ9\,_"T'@W0H]!\#:7 M$]G(NF>&M,%D;72]->;3=-N9M/@C%EF:;>7,$MUI]G-!UMY\*_AYJ'Q(T M7XOWOA#0[KXG>'/#&J^"]"\F6,UOZ!10!YG\/?@S\)OA/)KTOPR^&_@GP#+XGU2 M^UGQ!)X2\-Z5H+ZOJ6I:A=ZK>W-ZVGVT#3&?4[^_U%XB1;B^OKV[2%)[NXDD M],HHH **** "BBB@ HHHH *^6_CC^Q'^R)^TOXGTOQI^T%^S?\&_C-XKT30D M\,:/X@^)/@/0_%VJ:7X=CU"ZU8:'I]WK%M'M+;6])L=/BOX--M M[#4#:_:+9-+M]6UBWTIHW$FEV^LZQ;Z<]K#JVHQW3]"^%?P[\,^.?&WQ,T#P MAHFD^/\ XD6V@6?CWQ=96GDZ[XOM/"EM<67A>V\0WV\R:I#X;LKN\L]!CN=Z M:1:7EY;:>+>"ZN(Y/0** //? 'PF^&7PJM]0M/AMX!\(^!+75'MWO[;PIH&F MZ%!<)9FY-A;M%IUO BV.FB]O%TS3HPFGZ8EW=)IUK:I)I6,VOZM/NOM7G/G7\T\H#CT> MB@#-T?1]*\/:3I>@Z%IMCH^B:)IUCI&CZ3IEK#8Z=I>EZ9:Q66G:=86=ND<% MI96-G!#:VEM"B0V]O%'#$BHBJ-*BB@ HHHH **** "BBB@ HHHH **** "BB MB@ HH) Y)P/4T @\@Y'J* "BBB@ HI"0HRQ 'J2 /S- 96^ZP;Z$'^5 "T44 MC,JC+,%'JQ 'YF@!:*0$,,@@CU!!'YBEH ** 01D'(/((Z$>M% !1110 444 M4 %%%% !1102 ,D@ =2> /QH **:)$)P'0D] &!)_#-.H **** "BFAT8D!E M)&<@,"1CKD YX[TZ@ HHI"0!DD >I.!Z?SH 6BD!!Z$'MP<\^E+0 4444 %% M%&1Z]>1[CUH **** "BBB@ HHHR!CW_S_GWP.I% !1110 444A('4@=>I Z= M>OIWH 6BD) &20 >A)&#^-!95&68 '@$D $GH,GUH 6BD!!&001UR",8]<]* M 01D$$'D$$$$>N1Q0 M%("& *D$'H000?H1Q1D<\CCKST^OI0 M%(&4]&!XS MP0>/7CM[TM !1129')R,#J"/[ M(_L+X6>._B7_ &E]N^U?\(5)X2C_ +&^R?9?).I?\)1XE\/9^W_:)!:?8?M> M/LEQ]H\C]SYOF?\ POGX@?\ 1K7QU_\ CX3_P#SR:^F2 >H!^M)@>@_(5X> M,RS,\1B:E;#\1YC@*,^3DPE#!Y-5I4N6$(RY*F+RVOB)<\HRJ2]I5G:4Y*/+ M!*"XJV&Q-2I*=/,<10@[6I4Z."G"-E%.TJV&J5'S-.3YINSD[6227Y4_M@?M M;?&GP=X3\-6'A3X=>//@K=^)-5OK>Y\5>,+;P3?WEQ;Z?9QS_P!E^&SHNO\ MBJSM;V& M[S26L_$GA*W\%V.J:=#JD-XQTOQ+)K.M^%+"]=C9BYTJXLH9]0\AKE-2)C6R MFD_3?QKX#\&_$;0;CPQXY\-:-XJT"YEBGDTO6K**]M1_D MW5N\5Q$'<1RJ'8&+P-\//!'PTT)/#7@+PMHOA/0TGENSIVBV4=I#+=S!5FO+ MEEW37=W*B1H]U=2S7#1QQQM(4C15_/)<"\T M^K.C[)9S>'Y8* M?-[+D$;\U M*='!0A.\;+FE2PU.HK/WERSCJDG>-T_ST_X*P?$+QU\(_P#@G%^V9\5?ACXM M\1>!/B+\-?@#X_\ '/@CQ=X4OSI^NZ%XG\-:4VHZ3>V,C++:W#+<1A'L=0M[ MK3KQ7,-Y;RQ-Q\AQ_M.>.?A3^T?\=_A[XCF_: TSX,^'O^"=OQ'^/^D?"3X^ M^*=,TCXN_$_X@_#K7(CXJUO]FKXJZ1JFKZK!I_AOP7J<.A?%N/Q+\18;SP7X MQ\5?"#Q#X,\/Z+ID_B?7KS]7?VBO@)X"_:A^"GQ&_9_^*2:W/\./BOX:OO!W MCBP\/:U<>'-5U7PSJBK'JFDP:[8QMJ6EQZA OV>XNM+EM-06%G6WNX"S,?'M M2_89^#'B34O%7B;QS?\ Q'^(?COQ1\$O'7[.T?C_ ,;_ ! U?6O$_A3X1?$Q M[.7Q_P"&/ 2+%:>&_!-SXPETS1G\1^)] \.6OBW6AH'AR'4M=N;;P[HT%E[I MW'A^L_\ !1KP'X)^''C;Q[I'@+Q9XG^&O[.7@?\ 9U\2?M$:U+XK2_\ %_P\ MT'XY^#_#?C/3[C3=/U:WO]1^)^I_#_X>>)?#WQ ^)D]YKWA_4;KP]J?G^%9/ M&_B[[9X>C\E_X*4_MK^ '_9/_:=L/V:/VBK=?CS^SS\3/V>/#'Q#T[X-^,K= M_B7\.+CQA^U+\-/A7XGT#5M-M6E%IJ>N:)J/C+PO;V&JVTRC46>6W2#4[&TN M[7Z\'[ /[/2W%YMTWQ0-(\3_ V^$?PI^*7AE_$T\WAOXT^$?@2$C^%<7Q5T MV>TD/B'5_#5DK:+>:_I\^AZOXO\ #$@\(^.;KQ+X5M[+1K7V+]H_]G;X??M2 M_"C5_@Q\4&\1GP/KNN>#O$&JVWA?Q!<^&-4NK_P%XQT/X@>&"NM6,3ZA:16' MB_PSH.LO'8RVS7;Z;'97^"-?\ A[8'UOX<_P#!0?0?BKK.A_#7 MPMX!:X^,^N?'#]H+X+1>%1XU@;P1+;_LU6>A:I\2?B7IGQ&@\._;M0^'\FF^ M,O 5IX9O$\$6NOZKXB\;Z%83:+IVD1ZEXEL?0?BI^P+\!?BWJ_QLUS71X]T+ M4?VB?!W@'PS\87\$^.M6\(V/C+7OA3JVEZQ\,OBG>:+I<:Z%:_%SP5<:'H=A M8>.[#3;6_P!7\-:%H7@SQ9;^(O!VB:3H-GDM_P $[_@+%KFF>,]+U'XI:%\1 M="^/WBS]I#0?B3HWQ$U*T\:Z-\0OB1X/\/>!OBQ8VNHO:364_@'XJZ!X=M$\ M;_#K4],U#PAL:+I>A:II/ANZT( M?\ !-3QGXR^(7["_P"S3XR^(6M^ M)_$/C77OAQ;7?B35O&FM#Q'XLN=336=9M9D\1:\LUQ'K&L6BVZ6-_J4$\UO> M3VS36TKV[1,?N6O)?@9\%O!'[._PI\'_ :^'$>MQ>"O UG?6&@1>(_$.J^* MM9BM+_6-2UR6&[U[6Y[G4[]8KS5+F.U^U3R&ULUM[.(K!;Q*OK5 !1110 44 M44 %<;\0O%&J^"O!7B/Q5H?@CQ/\2-6T/3)K^P\#>#'T)/%'B:XC:-5TO1'\ M3:QX?T%;^8.7B.J:SIUIMC??",CT-73E&%2$IPC5C&<92IR@ KU+NQ1/$&H) MH_Q<\4ZJ]M:H\D;KI_AO6[DF9=M@Z>9+#^RFQ/[J_P#?(_PKA?B9\,O GQB\ M!^*?AC\2?#MKXI\">-=)FT/Q1X>NKB^L[?5M*N'BDFLYKG2[JQU"%'>&)B]I M=V\P*#;(!G/T6 SC)\/CL%B*_#N!E0H8O#5JT85\SK3E2I5JFKSI-5$F?Q6?LO?\%+?V[M9_:2^!VD>(?C3\9?BW MH.I?%+PM9:O\+=(_X5['JOQ!TZ>^*W'A'3GU;3?#>EK>:NG^CPM?>(=%M P_ M>ZI:K^\K^I$?ME?&G _XUV?MAG@<_;/V;>>/^R]#^0J3P'_P2\_8-^&7C?PK M\1O O[._ASP]XU\$:_I_BCPMKUOXE^(-S/I&O:7+Y]AJ,-MJ'B^[L9Y;:4ET MCN[6XMV/$D+CBOOC8@_@7_OD?X5]'Q?Q5PMG.+PE;*.&,/1HT<,Z56.(HO+I M.JZLI7C3R?'TZ-2/(TO:5DZMURIJ%K?)+O#7AK5OV% M?VI? VF:]K5CI6H>,O%%W\ V\.>%[2[DV3:YKBZ#\:-:UMM+L%_>W8TK2=2O MRG_'O9SO\M?:DA*QNPX*HS#V(4D?KU[&E"J.0J@^H _PI2 P(/((P1Z@]1^( MXKX+%XC#XB<)8? T,#&,;2A0JXJK&'X8?%[]K MC5?C)\3+SX:>.OC'XOM?AC_P5U^*WPP^*\7C>XCUGX"^!_V"? WPY\)^(/'] MCK>L^*($ATKQ!X3F\0/?_"]_ ^J7/Q0U3QO)IVF^(8M6^',&OBP^Z] _X*6> M%M4TO_A)]1^"OQFTKP'XJ\'_ /\4?![Q])X!^(7_"-_$G4_CYXZT[P%X+^' M:&_^'^DZC#\2XY]>\.>,K_P]X'L?B;IMU\/-7;Q)X=U[7KS2=5T2V^M?@I^S M=\._@-/\9)O!C>(KS_A>_P 7/%7QP^(47B?6CK]O>_$/QMI^CZ7XHU+2[>:S MMXM$TS5;#P_HUL_AW3UCT&U6QWV.GVTMYJ#W?@6A_P#!-W]GC0_@UXS_ &?Q MJ?QLU7X2^()- _X0?PMK/QU^)EZ_P#M/!GB;3?&WP^L/V>O$"Z[!XG^%4'PX M\9:+H?B+X?W6DZU=:MX4FT#P]HVEZG'X6\/Z/H%ER'>'C;Q/XE^%?P M_P!-_9:^(^C?$#XG>(/VB=!L[#XAZM-\,O#BVW[/-_X"ENO&6AZEXT\&Z7XO M\2^ /B7X4\=P>(OAQXA3X>Z3>7%SIMUX?\5Z+X6OUN)[*;XX?&'QIXJ_;V_9 MU_8JTCQ#KWPZ\">*/V>OCQ^U+\1_%'AZ>;1O$GQ$MOA-X^^#WPO\,?!_POXM MMVCU#PU8-JGQ8NO'OQ$U'PS-8>+VTS0/"FBZ9K.E:3KFO->>Y^&?V2O GAWQ M/\$?&]WXQ^+GB_QG\"K#XC67A_Q3XW^(NI>)-8\4R_%;3=$TGQKJ'Q!ENK6. M#Q3=WMEX;T*'2XC;Z?IOAE=+M4\-:?I,0DCD[+XQ?L[?#;XV:S\-O%WBBSU; M2OB)\&M>U3Q)\)_B;X0UF[\,^/? .HZ_IG]A^*+;1];LP\5[X<\8:($TGQEX M+\16.N>"_%EI;:<=?\/7]SI&CW.G@'Q*_P"UOHWP1^(/QC^&OA:W^.OQEUK0 M/VI_V,M0M[/[2+5_"^C>A2?M\V%E-#J.H_#"^D\%^'_VFOA7^ MQI\5_%6A>,--UAOA]^T1\5#X!\/66G6NCSZ+I4WBOX:>&_BI\3O!?PJ\3>/( M+S1=:M]>U.;7=/\ .H>$=-U'6K?OYOV%O@U>:AJ7B+4M1^(NH^-O$/Q[^$_ M[2/B[QS/XTEM_$/BWXG_ 1\/:#X3^&MWK,&G:;8^&XO#OA[PYX8T32G\'Z' MX=T;PYK$-F\VM6&H7=Y?7%ST\G['GP8?XB^+/B#'I^NV\/CSXJ> OCQXT\ V M^NSQ_#;Q'\<_AC8>'].\$_%V]\*F!_LWC/28?!_@NZNFTG4=-T#Q!KO@OPGX MJ\2Z#K/BG0;#6HP#Y3UC_@J%X\;?!;Q7\,=5^&GBW1/@_\'OV@_!<\_B;2/%^C>.O@_P#& M>X\5Z)HVJK>Z19V,OAOQ=X7\7^!_$7ASQEX1U&VNK>V1]!UKP[XD\2Z;JUP^ ME_/7Q[_X)H?#_P 0?!7XWZ!\(9O%/_"Q?$?PU_;@\/?!C1/&/Q-\06OPQ\"^ M)_VX_"VIV?Q,TYM.L]/O6M_ &H^.]0/CHZ9=V'B:Y\,:A<:@?"L$5K'I.CV7 MUC^SI^SOH_PBTG2O$^MOJNN_%[4_A+\)?AAXM\5>(-?'B>]L?#?PLT:_CT'P M/X?U-=-TB >%=$\0>(O%NM07ATJWUKQ)JNO7FO\ BJZU'598VM0#PSP%\=O' M7QF_9L_:_P#C9I'B.Y\(3:/XT_;"^&7PCN]%@TV[NO!6G_LR^)?B)\%=/\61 M6>NZ;J>C:CXFUCQ_\.?$GCN0ZWIFJ::+/4=#T&ZL+FPTIX[CGO$7[1OCWX:? ML6_L@?M1ZWK-SX@N[\?L6Z;\9;:>WML>+] _:7USX3_"7QAKOV.T6SM[;7/# M?B7XGZ=\1=,ETZ*W+/H-[H"0_P!F:S=6]?1/@+]F;2/!/@_X_P#PE@U34%^% MOQG\=_%KX@6%KIM\VGZ_X5N?V@K_ %3Q-\7M T^\%K)':VM[X^\0>,/%WA[5 M+0+"70;/4K^IXO_96\-^(OA)\"OV>K?4-1'P?^$/BOX(^(+ZS MUF\76=<\2:)^SAKOASQE\*O!^H7TUFGV^W_X33P5X%U'Q'K&H&2\U/1_#%UI MEU'>WWB&YU2S /K)3D9]R#QCE25.!DX&0<'-*_8?_:?\;Z9H>LWNEV'C#PQ=? A/#OB>UM) M-D6MZ(NN_&/1M:73+Y?WEJ-4TG3K[9_K[.%OEK[.II53R54GU('^% 'P=_PV M%\9?^D>_[7?_ (&?LY__ #]J_&;]N+_@K/\ $WPG^T]\"M-\-_#GXA_"&P_9 M\\4?\)9\8?AGXUU7P@VO^.)?%&CQZ?/X9U0>!?%?C#P[_9UM\.=;U.\TB&ZU M0WEKXHURQU&]T^UET6QD;^HDHA&-J_\ ?(_7ID>H[CBOQ4\-_$NL^+?$>J3>(OAYYE[K6NZA/J-],%_P"%<$1Q++/Y M-I IV6MG#;VL6(H4 /J3P_^W#\2O%>A:+XG\,_L%_M8:YX<\1Z3INO:!K5A MJ'[.4MEJ^B:Q9PZCI6IVL@^.WS07UA<07,><,JR;7575E&P/VP?C*2!_P[W_ M &NQDXR;S]G/ ]SCXZDX_"O=OV:/V?\ 0OV8O@[X6^"?AGQ7XQ\8^%_!?]HV M_AN_\=W.C7^O:?H]_J%QJ4&A"\T71M#MIM+TB:[N(-(26S,]I8-%8F>2"V@5 M/>MB?W5_[Y'^% '(^ /$^J>,_!OAWQ1K7@OQ+\.M5UO38K^^\$>,6T-_$_AJ M>1Y%;2]:?PWJ^O:$U]"$5Y#IFL:A:[9$V7+MN"_GK^WE\3?C9\&/'7PM^(Z? M#OX[_$[]DC3O!?Q%TKXZ1?LIZM/A%XRU#4?",O@#XWR?#;1KNP\9?&;X M9^%]$M?&6G^)O"7@63Q#KF@7E[:^*+KX8?$G3X&MM _3H #@# ]!7C'COX*: M5XU\66GCFU\9_$CP/XJM?".I>!CJ7@;Q?+I5K=>&]6U>RUNZ@O?#VIV.N>%[ MG58+ZQ1M(\3OHG_"4^'H;G4;?P_K6F1:IJ"W(!^0_P"UM^VS#X7^"O['.N_! M?X]ZC\7/A9]E^!_BC]ISXU^'M7U#P@MA\ _VC/AUXX^$G[/?[37Q.^('A+3K M"^\$>"]3_:-G\$?$#QIHOAJPT_7+_P +>'/&NHZEI&F_#WPOXNMSZ!^U[\<_ MC7;?L'P>/+37?'?@#Q3X;_:\_9+^">F?%#P!XKT]/$7QJ\ :O^V-\%OV?_B+ M\2]&TOPE:/8Z+H?QG\.Z[XWN/#7AY?M]_9V6J:?K.B7%K-_8=\OT['_P3._9 M6T[5+AO#7ASQ5X1\&>(?@%X*_9B^)OPF\.^-=9M_A1\9?@K\-[#Q%I/@7PA\ M5?!M^VHP^)GT#2?%_BS1IO$%K>Z1XD\3:)XEU?1?&6K>(]*N$LXI+/\ X)Q_ M ^U^ ]M^S=/XP^/NM?"G1OB%\+/'WA#1_$WQO\9>)M3\"Q_ WQCX>\??!OP1 MX0\1Z_+J.MZ7X"^''BOPIX>U+0]!FO+V[O8=)LM)\2:OKVC01Z>H!?\ V.G_ M &B=6_X:JT[XSGQX/A%%^T#K^D_LFZI\2TM_#OQHU#X$'X<^!%U6Z\32Z.+' MQ#::3:?&"7XF6'PKUKQM#I_Q:NO %GH.I>,5>\;3M2O/@C]E/]JS]H"']F'X ME?LV_$?XB:MXL_:_\*>'?".J?"#XN>*+"P;6_'WP2_:7^&^O_%_X/?'G6[:. MPM-%U.]^#VBZ-\6O /C8PZ:ECK'BS]GZ4WJ--XOMOM/[KW5BUUIMUIZWMY:R M75G/:G4;1K>'4())X6B:^MW-L]K'>H[FXCZ^(FD_!3Q)>Z#J&H>%(O$#VPAGD2Z\ M-:/)8ZS=:;/K%B\%R]O>))J>J/>@'YY?LL?MPZ1\/_V3/V)OBG^T3JOQ1\5Z MWK?_ 27U']L[XD?%O4_',NI6_B*3PWI7[-^H?$RSU?X?IJFG:7KWQ$\0^(? MBAH5SX,U=]+M++P_;W.M>%/#EUHVGZYJ%G)Y_P#M$?M>_M.?"OXL_M%:!;6> MO?#'Q1\4=>_X)%_ CX>+JGBS2_BMX%^!6H?MB_'[XV_"'Q]\7M'TBXT[3_#^ MG>)="T&TM;*]TK4]+N_#&K_%+PQX5:XN/%WA6Y@;4OT)TK_@G)^S/8> ?AU\ M*=1T;Q=XH^&/PR_92\-=6U70+S]G7XA6O@NP\1>"?$(1;34M= MNY-/^'7@>RL/%=WJ(\5Z9%XE_P#!/;X!'PU\1_"WCVY^ M*/QFL?BQ\+?A;\(/'-W\7OBCXI\6ZQJOA/X)^(?%OBGX47UOJUO<:-?:1XZ\ M":[XQU#5]"^)NCRV/Q#AUVRT;Q//XEG\5:9%KC '3^-?"VI_L]:7J7QK\/\ MB[X[_$S2_A_\./%=IKGP?U'X@V/B6R^(&L:C?^%I=.\;7NM?$S6+.T\'ZMX3 MBTC5)+R^L?$&@^"-/\,Z[XJU"Y\,3W6GZ.MM\^:!_P %(F\9:WX!\!^#/@I= M^(?B1X]_:*_:9_9@L[2/XE:':?#RW^(O[.7PN\0_%B368/'DWAQM7U3X>>.O M#NAQC0_$EKX"75[&6\\R[\,7$,4!O?IOQU^R;X,^*?P5\5? SXG>.OB[XZ\, M^*-.TG3O[>UCQU]B\:Z(?#NOZ'XJ\-ZEH_B+PYH^A>9K>A^)?#.A:U#K.NV. MNZAJEUI_D^(Y];L+W4[.^^5/'G_!/_4-,^./[-GC?X+Z]XAT7P_X6_:F^._[ M3?QM\4:M\0Y9/':^+/C#^S#XB^ ]QJ/@&TU;PIXAT&_74?$&J:;XJU_PGJ]O MI_A2T0:W<:1:-+-I6B6@!]!> ?VW?AAXM_9!L/VOO$]M<_"KPK]FU[2?$?AO MXB:YX7T.^\+?$CPM\1-7^#>O_#O4?$TFJCP<]]'\7-#OO!.E>(UU>+PYJTDE MCK45W#IEV'C_ "^^''[=GQ&^(>JZ]\,]"_: \+?%&\^*7_!8+3_V7;GQY\*] M9\)^(+#X4? #4OV4[;]H@Z!X'U#P]*XTW2==U+X;>,OA;X3\>:Q%>>(+NYUS MQ%XDL;NW\4V, TC]P_AQ\'?AW\*?AKH?PD\&>'+6Q\"Z!:W4%MI%\\NM->7& MI:K>:_K6K:S>:N]Y=:UKFO\ B'4M3\1:]K&IRW-_J^NZE?:K>S2W=S)(?*A^ MQQ\ H]-^(^G6G@]]/D^)OQSTS]I/5]5L-3O+76M$^-FA:5X/T?0/'G@W4HV6 M?PKJ6BVG@;0EL[33-NERHVL6NHV-_IWB'7;&_ /R^^%7[4OQW^./Q\\6_LGW M7Q(\3^"K#X*Z!_P48U5?C1I-IHD6J>.-0_9X^/GPG^$_P*;Q%J4^F?V7>2?# MS0OB;?WWQ-TN&QAT_P >^)O#FB7'B2'^R+K7="U+]4_V./C%KW[0_P"R5^S% M\>O%6FVFC^)OC3^S_P#!_P"*OB'2]/BFATZPUSQ]X T#Q1JUMIL5Q)+.FFQW M^IW']G+-+)*MD8%DD=@7;"U3]BSX ZEX<\.>'8_#6L:2/#D'Q8LEU[0_%OB3 M2/%VN:=\?=5CU[X[:?XH\5VFHIKGB"W^,&O0V_B#QU+J%X]]?^(K'2O$&G7F ME:UH^D7]C]+^'] T3PIH6B^&/#6DZ?H/ASPYI.FZ#H&AZ1:06&E:-HNCV4&G M:5I.F6-LD=O9:?IUA;6]E96D$:0VUM!%#$BHB@ &O1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9 end XML 14 a10k123117_htm.xml IDEA: XBRL DOCUMENT 0000012208 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:DiscountrateMember 2017-01-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:CostofdebtMember 2017-01-01 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-01-01 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2017-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2017-01-01 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 2015-01-01 2015-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 2014-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 2017-06-30 0000012208 us-gaap:RetainedEarningsMember 2015-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000012208 bio:CellsorterMember 2017-01-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-01-01 2017-12-31 0000012208 bio:CellsorterMember 2012-09-30 2017-02-01 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:ScenarioForecastMember 2017-12-30 2020-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2017-12-31 0000012208 bio:CellsorterMember 2017-12-31 0000012208 bio:CellsorterMember 2012-09-30 2016-12-31 0000012208 bio:CellsorterMember 2012-09-30 0000012208 bio:GnuBIOMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-07-01 2017-09-30 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2017-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2017-12-31 0000012208 bio:GnuBIOMember 2014-04-10 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2017-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:TradeNamesMember 2017-02-15 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:DevelopedTechnologyRightsMember 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-03-31 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:LicensingAgreementsMember 2017-02-15 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-03-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember 2016-12-31 0000012208 us-gaap:TradeNamesMember 2016-12-31 0000012208 bio:KnowHowMember 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000012208 bio:LifeScienceMember 2015-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 bio:LifeScienceMember 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000012208 us-gaap:TradeNamesMember 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000012208 bio:KnowHowMember 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TreasuryStockMember 2014-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonStockMember 2014-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0000012208 us-gaap:NoncompeteAgreementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 bio:KnowHowMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:TradeNamesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:CustomerRelationshipsMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2018-04-10 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2016-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2016-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2017-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2017-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2017-12-31 0000012208 us-gaap:LineOfCreditMember 2014-06-30 0000012208 us-gaap:StandbyLettersOfCreditMember 2016-12-31 0000012208 us-gaap:StandbyLettersOfCreditMember 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 bio:QuantalifeMember us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2017-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2017-12-31 0000012208 bio:NetofprepaidtaxesMember 2017-12-31 0000012208 us-gaap:ForeignCountryMember 2017-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2015-01-01 2015-12-31 0000012208 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2016-01-01 2016-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-01-01 2015-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassAMember 2015-12-31 0000012208 us-gaap:CommonClassAMember 2014-12-31 0000012208 us-gaap:CommonClassAMember 2015-01-01 2015-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2015-12-31 0000012208 us-gaap:CommonClassBMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassBMember 2014-12-31 0000012208 bio:TreasuryClassBMember 2012-04-01 2012-06-30 0000012208 bio:TreasuryClassAMember 2017-01-01 2017-12-31 0000012208 bio:TreasuryClassAMember 2012-04-01 2012-06-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000012208 us-gaap:ParentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ParentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:ParentMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:ParentMember 2015-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2016-01-01 2016-12-31 0000012208 us-gaap:EmployeeStockMember 2015-01-01 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2015-12-31 0000012208 us-gaap:EmployeeStockMember 2016-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2017-12-31 0000012208 bio:StockAwardPlansMember 2017-01-01 2017-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2015-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2017-01-01 2017-12-31 0000012208 country:US 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-12-31 0000012208 bio:LifeScienceMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2015-01-01 2015-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2015-01-01 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2016-01-01 2016-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonClassAMember 2018-04-10 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 bio:PropertyPlantandEquipmentexcludingsegmentspecificMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:OtherNoncurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OperatingSegmentsMember 2016-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:GoodwillMember us-gaap:MaterialReconcilingItemsMember 2017-12-31 0000012208 us-gaap:OtherCurrentAssetsMember us-gaap:MaterialReconcilingItemsMember 2016-12-31 0000012208 us-gaap:AmericasMember 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AmericasMember 2016-01-01 2016-12-31 0000012208 us-gaap:EuropeMember 2015-01-01 2015-12-31 0000012208 us-gaap:AsiaPacificMember 2016-01-01 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2015-01-01 2015-12-31 0000012208 country:US 2015-01-01 2015-12-31 0000012208 us-gaap:EuropeMember 2016-01-01 2016-12-31 0000012208 us-gaap:CommonStockMember 2015-12-31 0000012208 country:US 2016-01-01 2016-12-31 0000012208 us-gaap:AmericasMember 2017-01-01 2017-12-31 0000012208 us-gaap:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 us-gaap:EuropeMember 2016-12-31 0000012208 us-gaap:AmericasMember 2016-12-31 0000012208 us-gaap:AmericasMember 2017-12-31 0000012208 country:US 2017-12-31 0000012208 us-gaap:AsiaPacificMember 2016-12-31 0000012208 us-gaap:EuropeMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 country:US 2016-12-31 0000012208 us-gaap:AsiaPacificMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember 2015-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2016-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2015-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-01-01 2016-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2016-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2015-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2016-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:EmployeeSeveranceMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2016-01-01 2016-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:OtherOperatingIncomeExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:GnuBIOMember us-gaap:ResearchAndDevelopmentExpenseMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2017-01-01 2017-03-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2017-07-01 2017-09-30 0000012208 us-gaap:ScenarioAdjustmentMember 2016-07-01 2016-09-30 0000012208 us-gaap:ScenarioAdjustmentMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-04-01 2016-06-30 0000012208 us-gaap:ScenarioAdjustmentMember 2017-04-01 2017-06-30 0000012208 us-gaap:ScenarioAdjustmentMember 2016-01-01 2016-03-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-10-01 2016-12-31 0000012208 2017-10-01 2017-12-31 0000012208 2016-04-01 2016-06-30 0000012208 2017-07-01 2017-09-30 0000012208 us-gaap:RetainedEarningsMember 2014-12-31 0000012208 2016-10-01 2016-12-31 0000012208 2017-01-01 2017-03-31 0000012208 2016-07-01 2016-09-30 0000012208 2017-04-01 2017-06-30 0000012208 2016-01-01 2016-03-31 0000012208 us-gaap:InventoriesMember 2017-07-01 2017-09-30 0000012208 bio:RainDanceTechnologiesInc.Member us-gaap:ScenarioAdjustmentMember 2017-10-01 2017-12-31 0000012208 bio:EmployeeBenefitExpenseMisstatementMember 2017-10-01 2017-12-31 0000012208 bio:TaxMisstatementMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-04-01 2016-06-30 0000012208 us-gaap:ScenarioAdjustmentMember 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-07-01 2016-09-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-03-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-10-01 2017-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-10-01 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-04-01 2017-06-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-07-01 2017-09-30 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2017-01-01 2017-03-31 0000012208 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2018-04-13 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2017-01-01 2017-12-31 0000012208 2016-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000012208 us-gaap:AllowanceForDoubtfulAccountsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2015-01-01 2015-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2016-01-01 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2014-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember 2015-01-01 2015-12-31 0000012208 us-gaap:ScenarioPreviouslyReportedMember 2015-01-01 2015-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2016-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-01-01 0000012208 us-gaap:ScenarioAdjustmentMember 2015-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000012208 2017-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 bio:ReagentRentalEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2017-12-31 0000012208 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2015-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2016-01-01 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:EquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 bio:TreasuryClassBMember 2017-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:SecondTaxMisstatementMember 2016-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:FirstTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:ScenarioAdjustmentMember bio:ThirdTaxMisstatementMember 2015-01-01 2015-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000012208 us-gaap:ComputerSoftwareIntangibleAssetMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000012208 bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-01 2016-03-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2017-12-31 0000012208 us-gaap:DeferredRevenueArrangementTypeDomain bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 bio:TreasuryClassBMember 2016-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-01-06 0000012208 bio:RainDanceTechnologiesInc.Member 2017-01-01 2017-03-31 0000012208 us-gaap:DeferredTaxAssetDomain bio:RainDanceTechnologiesInc.Member 2017-02-15 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2016-12-31 0000012208 bio:TreasuryClassAMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestBearingDepositsMember 2016-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2016-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2016-12-31 iso4217:USD shares iso4217:USD pure shares 0.07 false --12-31 FY 2017 2017-12-31 10-K 0000012208 24701407 5103283 Yes Large Accelerated Filer 4795291430 BIO RAD LABORATORIES INC No No 23367000 25549000 0.0001 0.0001 0.0001 0.0001 80000000 20000000 80000000 20000000 24454048 5123883 24679127 5107674 24453926 5122966 24678545 5106757 .10 1 P9Y P1Y P8Y P1Y P12Y P3Y P9Y P1Y P9Y P2Y P0Y P0Y P8Y P4Y P8Y P1Y P7Y P1Y P12Y P1Y P12Y P1Y P8Y P1Y P0Y P0Y P6Y P1Y -181000 0 0 -17000000 0.0001 0.0001 7500000 7500000 0 0 0 0 P12Y P3Y -120100000 P5Y P5Y 0 0 122 917 582 917 383824000 456264000 371154000 383176000 5560000 4560000 464847000 372348000 113925000 116540000 142589000 125982000 338290000 282439000 594804000 524961000 146135000 91014000 10325000 12201000 1976649000 1844524000 18026000 17895000 315984000 300834000 971140000 908659000 1305150000 1227388000 811654000 738774000 493496000 488614000 506069000 477115000 174113000 161609000 1027736000 830790000 94949000 47852000 4273012000 3850504000 135182000 133109000 171632000 163364000 420000 334000 39941000 28124000 28233000 31003000 127288000 115388000 502696000 471322000 434581000 434186000 222209000 225299000 183276000 140537000 1342762000 1271344000 0 0 2000 2000 1000 1000 361231000 332911000 128000 12000 89000 89000 1830439000 1828581000 738794000 417766000 2930250000 2579160000 4273012000 3850504000 2160153000 2068172000 2019441000 972754000 930085000 897771000 1187399000 1138087000 1121670000 808942000 816724000 761990000 250301000 205864000 192972000 11506000 62305000 0 116650000 53194000 166708000 21914000 21942000 21692000 -9128000 -4542000 -10249000 12197000 14850000 11080000 97805000 41560000 145847000 -24444000 15560000 36608000 122249000 26000000 109239000 4.12 0.88 3.74 29655000 29440000 29186000 4.07 0.88 3.71 30034000 29646000 29409000 122249000 26000000 109239000 76050000 -32394000 -37536000 3767000 -2086000 4403000 248745000 65936000 205132000 321028000 35628000 163193000 443277000 61628000 272432000 2093948000 2074024000 1956084000 1918971000 1810844000 1730062000 21124000 21318000 20793000 52136000 38442000 31715000 19892000 15683000 11953000 0 1506000 3610000 -17724000 -1164000 4353000 103885000 216433000 186210000 111332000 141436000 112000000 86000 398000 79000 76645000 14165000 4356000 3795000 135000 1372000 1000000 350000 4210000 282656000 278071000 294497000 97523000 76859000 78664000 202247000 143020000 170823000 -175572000 -213880000 -166869000 -36000 37000 0 316000 303000 282000 7294000 11280000 8236000 2920000 0 0 3681000 3500000 2983000 0 1506000 3610000 341000 9020000 8581000 -1094000 -12858000 16376000 -72440000 -1285000 44298000 456264000 457549000 413251000 383824000 456264000 457549000 3000 271346000 -101000 1693342000 218945000 2183535000 109239000 109239000 163193000 163193000 8236000 8236000 16983000 16983000 3843000 3843000 3000 300408000 -101000 1802581000 382138000 2485029000 26000000 26000000 35628000 35628000 11280000 11280000 19730000 19730000 1493000 1493000 3000 332911000 -101000 1828581000 417766000 2579160000 391000 -256000 135000 122249000 122249000 200893000 200893000 -120135000 120135000 0 4490000 4490000 23439000 23439000 -2920000 -2920000 2804000 2804000 3000 361231000 -217000 1830439000 738794000 2930250000 1.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Short-term Restricted Investments</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively, represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Available-for-Sale Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span><span style="font-family:inherit;font-size:11pt;">Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> year period, equipment and capitalized software is depreciated over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Lived Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available. We expect to complete the relevant analysis no later than December 31, 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) cost per test conducted and reported. Revenue on a cost per reported basis is estimated in the current period, and billed at actual in the month reported by our customer.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranty</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">RECLASSIFICATION OF CERTAIN AMOUNTS, AND CORRECTION OF IMMATERIAL ERRORS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">2016 Reclassification of Buildings and leasehold improvements, and Equipment</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Upon our implementation of our global single instance enterprise resource planning ("ERP") platform in Europe during the second quarter of 2017, </span><span style="font-family:inherit;font-size:11pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> of assets in France were misclassified as Equipment that should have been reported as Buildings and leasehold improvements in periods prior to 2017. The reclassification on the 2016 balance conforms to the correct balance sheet presentation as of December 31, 2017, and there was no impact on the Consolidated Statements of Income or Cash Flows. Please see the table below for the corrected amounts for Buildings and leasehold improvements, and Equipment.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">2016 and 2015 Misstatement of Income Taxes</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. As a consequence, Deferred income taxes in 2016 were understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and the Provision for income taxes was understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2015.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. As a consequence, Retained earnings were overstated by </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016 and the Provision for income taxes was understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016 and 2015, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The third misstatement was related to a design deficiency associated with transfer pricing. As a consequence, our Retained earnings were overstated by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016 and the Provision for income taxes was understated by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> in both 2016 and 2015.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the reclassification, and the immaterial error corrections, both described above on our Consolidated Balance Sheet and Consolidated Statements of Income for the periods presented is as follows (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>290,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,467</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,834</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,126</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,467</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908,659</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>222,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,318</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,219</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,537</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,263,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,271,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,836,180</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,599</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,828,581</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders' equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,599</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,579,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,435</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,125</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,560</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,754</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,854</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36,608</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,093</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,854</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per basic share </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per diluted share </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Standards Updates</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018,</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:11pt;">the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$120.1 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment. </span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition, we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and increased Additional paid-in capital and Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, in the Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP. Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard. </span> Basis of Presentation<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions. Cash and Cash Equivalents<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span>, respectively, represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets. 5600000 4600000 Available-for-Sale Investments<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span>Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10). Concentration of Credit Risk<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><br/> Accounts Receivable<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Inventory<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold. Property, Plant and Equipment<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>15</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> year period, equipment and capitalized software is depreciated over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span> years. P15Y P30Y P1Y P5Y P3Y P12Y Goodwill<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.</span></div><br/> Long-Lived Assets<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. Income Taxes <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. Revenue Recognition<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent </span></div>agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) cost per test conducted and reported. Revenue on a cost per reported basis is estimated in the current period, and billed at actual in the month reported by our customer. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Warranty</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:425px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:237px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:76px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(33.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><br/> 17600000 17400000 29900000 33400000 28800000 33200000 18700000 17600000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.   <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.   <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:372px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:93px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:92px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 29655000 29440000 29186000 379000 206000 223000 30034000 29646000 29409000 13000 113000 109000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). 10500000 2400000 -2400000 -1400000 4600000 -1900000 -1300000 -200000 600000 -200000 The impact of the reclassification, and the immaterial error corrections, both described above on our Consolidated Balance Sheet and Consolidated Statements of Income for the periods presented is as follows (in thousands, except per share data):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>290,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,467</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,834</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,126</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,467</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908,659</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>222,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135,318</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,219</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,537</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,263,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,271,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,836,180</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,599</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,828,581</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders' equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586,759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,599</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,579,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As reported</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustment</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As revised</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,435</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,125</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,560</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,754</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,854</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36,608</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,093</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,854</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per basic share </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.08</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per diluted share </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 290367000 10467000 300834000 919126000 -10467000 908659000 222919000 2380000 225299000 135318000 5219000 140537000 1263745000 7599000 1271344000 1836180000 -7599000 1828581000 2586759000 -7599000 2579160000 13435000 2125000 15560000 32754000 3854000 36608000 28125000 -2125000 26000000 113093000 -3854000 109239000 0.96 -0.08 0.88 3.87 -0.13 3.74 0.95 -0.07 0.88 3.85 -0.14 3.71 Recent Accounting Standards Updates<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2018,</span><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:11pt;">the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by </span><span style="font-family:inherit;font-size:11pt;"><span>$120.1 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment. </span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.</span><span> </span><span style="font-size:11pt;">Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:11pt;">ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$17 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition, we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and increased Additional paid-in capital and Deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, in the Consolidated Balance Sheet. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-size:11pt;">In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. </span><span style="font-size:12pt;"> </span><span style="font-size:11pt;">For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements. </span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-size:11pt;">In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP. Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard. </span> 120100000 -17000000 -300000 400000 100000 2.    ACQUISITIONS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">RainDance Technologies, Inc.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$72.7 million</span></span><span style="font-family:inherit;font-size:11pt;">. Cash payments at closing were </span><span style="font-family:inherit;font-size:11pt;"><span>$72.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. In addition, we had a cash payment of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The final allocation for the payments of </span><span style="font-family:inherit;font-size:11pt;"><span>$72.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$37.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> to definite-lived intangibles, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to acquired net assets, </span><span style="font-family:inherit;font-size:11pt;"><span>$26.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to goodwill, a deferred tax liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> primarily related to the purchased intangibles and a deferred tax asset of </span><span style="font-family:inherit;font-size:11pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> primarily related to the acquired net operating losses. The final allocation of the payments reflect the effects of correcting an error that were recorded in the fourth </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">quarter of 2017. These corrections reduced goodwill, deferred revenue and deferred tax assets by </span><span style="font-family:inherit;font-size:11pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, and had no significant impact on our Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Propel Labs, Inc.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the consideration as of the acquisition date was </span><span style="font-family:inherit;font-size:11pt;"><span>$32.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, which included </span><span style="font-family:inherit;font-size:11pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> paid in cash at the closing date and </span><span style="font-family:inherit;font-size:11pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$16.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> (see Note 3, "Fair Value Measurements").</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair values of the net assets acquired from Propel as of the acquisition date were determined to be </span><span style="font-family:inherit;font-size:11pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill. The goodwill related to this acquisition is deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving manufacturing, engineering and marketing support from Propel on which payments are made upon the successful completion of all contracted services. As a result, these services were not included in the total purchase consideration and have been and will be expensed. 72700000 72900000 10000000.0 72900000 37600000 200000 26200000 13600000 22500000 -1900000 -3300000 -1400000 32800000 9500000 23300000 16700000 32700000 100000 3. FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2012, we recognized a contingent consideration liability for certain milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$44.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid </span><span style="font-family:inherit;font-size:11pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the milestones and have reduced the valuation of the milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. The remaining liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> was paid in </span><span style="font-family:inherit;font-size:10pt;">February 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. The current contingent consideration is built on a sales forecast of </span><span style="font-family:inherit;font-size:11pt;"><span>$78 million</span></span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">December 31, 2020</span><span style="font-family:inherit;font-size:11pt;">. In the third quarter of 2017, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$16.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> in the amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is Securities Evaluations as the primary pricing source and then our custodian as the secondary pricing source. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For commercial paper as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Prices outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> are investigated and resolved.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign currency exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2018 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2018 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>413.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>126.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>329.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>35%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span>.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is too thinly traded and the fair value is not readily determinable in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock. Financial assets and liabilities carried at fair value and measured on a recurring basis as of <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>973.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,026.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>385.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Assets Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents (a):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic time deposits</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments (b):</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>767.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>347.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>790.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,173.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial Liabilities Carried at Fair Value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (e)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0 36000000.0 0 36000000.0 43700000 10000000.0 0 53700000 0 11200000 0 11200000 3400000 0 0 3400000 47100000 57200000 0 104300000 5600000 0 0 5600000 0 185700000 0 185700000 0 67600000 0 67600000 0 3400000 0 3400000 0 700000 0 700000 0 15000000.0 0 15000000.0 973400000 0 0 973400000 0 55600000 0 55600000 973400000 328000000.0 0 1301400000 0 500000 0 500000 1026100000 385700000 0 1411800000 0 1600000 0 1600000 0 0 16700000 16700000 0 1600000 16700000 18300000 0 14100000 0 14100000 11800000 0 0 11800000 0 20000000.0 0 20000000.0 0 1100000 0 1100000 5900000 0 0 5900000 17700000 35200000 0 52900000 4600000 0 0 4600000 0 179400000 0 179400000 0 82500000 0 82500000 0 4400000 0 4400000 0 3600000 0 3600000 0 15400000 0 15400000 767800000 0 0 767800000 0 62500000 0 62500000 767800000 347800000 0 1115600000 0 600000 0 600000 790100000 383600000 0 1173700000 0 1300000 0 1300000 0 0 38500000 38500000 0 1300000 38500000 39800000 371200000 383200000 930200000 732400000 1301400000 1115600000 2700000 14500000 14000000.0 24000000.0 16700000 38500000 44600000 32000000.0 12600000 3100000 0.39 0.20 0 78000000 600000 -6000000.0 16700000 The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> (in millions):</span><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cell sorting system:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 28500000 3100000 8100000 600000 16700000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div> 0.108 0.042 10700000 10000000.0 0.05 0.01 Available-for-sale investments consist of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>185.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>371.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>875.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>930.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>418.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>884.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,301.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>179.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Brokered certificates of deposit</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>383.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Marketable equity securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>677.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>732.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>681.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,115.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 185900000 300000 500000 185700000 700000 0 0 700000 15100000 0 100000 15000000.0 55600000 0 200000 55400000 68300000 0 700000 67600000 3400000 0 0 3400000 34400000 9000000.0 0 43400000 363400000 9300000 1500000 371200000 54500000 875500000 0 930000000.0 200000 0 0 200000 54700000 875500000 0 930200000 418100000 884800000 1500000 1301400000 179700000 200000 500000 179400000 3600000 0 0 3600000 15500000 0 100000 15400000 62200000 100000 100000 62200000 83100000 100000 700000 82500000 4400000 0 0 4400000 32400000 3700000 400000 35700000 380900000 4100000 1800000 383200000 54500000 677600000 0 732100000 300000 0 0 300000 54800000 677600000 0 732400000 435700000 681700000 1800000 1115600000 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>168.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>160.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 43900000 11800000 168700000 160500000 700000 300000 800000 1500000 The following is a summary of our forward foreign currency exchange contracts (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2018 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2018 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>413.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 52000000.0 100000 413200000 1000000.0 The following is a summary of the amortized cost and estimated fair value of our debt securities at <span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>126.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>157.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>329.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>328.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 126300000 126100000 157900000 157200000 45000000.0 44700000 329200000 328000000.0 The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Carrying </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-align:center;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,249.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>984.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>449.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>454.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div> 91800000 1249400000 92800000 984200000 423100000 449800000 422500000 454200000 0.35 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:667px;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:244px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$26.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$37.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets: </span><span style="font-family:inherit;font-size:11pt;"><span>$36.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of licenses, </span><span style="font-family:inherit;font-size:11pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of developed product technology and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of tradenames.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets: </span><span style="font-family:inherit;font-size:11pt;"><span>$29.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of developed product technology and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of covenants not to compete.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations. In 2016, we fully impaired goodwill and in-process research and development in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$46.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, associated with our 2014 acquisition of GnuBIO, Inc., which is included in our Clinical Diagnostics segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets for the years ended December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$30.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$36.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2022</span><span style="font-family:inherit;font-size:11pt;"> and thereafter is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$28.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$22.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$22.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$57.7 million</span></span>, respectively. <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:667px;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:244px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:58px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:61px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:6px;"/><td style="width:41px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>316.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>524.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>180.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>495.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>207.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>311.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>518.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(27.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>179.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>297.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 207100000 311700000 518800000 207200000 316900000 524100000 27200000 14500000 41700000 27200000 1000000.0 28200000 179900000 297200000 477100000 180000000.0 315900000 495900000 26200000 0 26200000 100000 0 100000 8700000 2800000 11500000 0 13500000 13500000 1400000 12900000 14300000 -200000 -5200000 -5400000 234700000 324600000 559300000 207100000 311700000 518800000 35900000 17300000 53200000 27200000 14500000 41700000 198800000 307300000 506100000 179900000 297200000 477100000 26200000 37600000 36400000 1000000.0 200000 100000 32700000 29700000 3000000.0 2800000 8700000 13500000 46400000 Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>92.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(157.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-12</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>509.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(334.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(52.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>182.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(136.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3-12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>125.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(56.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">1-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2-9</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>443.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(281.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>161.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 92300000 64400000 27900000 194900000 157900000 37000000.0 133300000 70300000 63000000.0 76700000 36000000.0 40700000 3900000 3000000.0 900000 7900000 3300000 4600000 509000000.0 334900000 174100000 84400000 52800000 31600000 182600000 136900000 45700000 125900000 56300000 69600000 39000000.0 30600000 8400000 3500000 2500000 1000000.0 7800000 2500000 5300000 443200000 281600000 161600000 30800000 35200000 36500000 28400000 25000000.0 22900000 22100000 18000000.0 57700000 5.<span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">NOTES PAYABLE AND LONG-TERM DEBT</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had </span><span style="font-family:inherit;font-size:11pt;"><span>$208.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> available for borrowing and usage as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, which was reduced by </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due 2020 (</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2014, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, however, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> were utilized for domestic standby letters of credit that reduced our borrowing availability as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;">June 2019</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>2.94%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of long-term debt at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">thereafter</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 208400000 4200000 The principal components of long-term debt are as follows (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>422.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>434.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 425000000.0 425000000.0 1900000 2500000 423100000 422500000 11900000 12000000.0 435000000.0 434500000 400000 300000 434600000 434200000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 0.04875 0.04875 0.04875 200000000.0 500000 800000 0.0294 400000 300000 425300000 300000 300000 10300000 6. INCOME TAXES <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, comprehensive tax legislation (the “Tax Act”) was enacted into law. The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including, but not limited to, (1) a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings (“Transition Tax”) that is payable over eight years; (2) bonus depreciation that allows for full expensing of qualified property; and (3) a reduction in the U.S. federal corporate tax rate from 35% to 21% effective in 2018, which requires us to remeasure our deferred tax assets and liabilities as of December 31, 2017. The Tax Act also includes provisions that may affect our 2018 financial statements, including, but not limited to, (1) the elimination of the corporate alternative minimum tax; (2) the creation of the base erosion anti-abuse tax, a new minimum tax; (3) a change from a worldwide tax system to a modified territorial system; (4) a new provision designed to tax global intangible low-taxed income, which allows for the possibility of using foreign tax credits and a deduction of up to 50 percent to offset the income tax liability (subject to some limitations); (5) a new limitation on deductible interest expense; (6) the repeal of the domestic production activity deduction; (7) limitations on the deductibility of certain executive compensation; (8) limitations on the use of foreign tax credits to reduce the U.S. income tax liability; and (9) limitations on net operating losses generated after December 31, 2017 to 80 percent of taxable income. We are currently reviewing and evaluating the Tax Act and its impacts to our financial statements. </span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The U.S. and international components of income before taxes are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The provision for income taxes consists of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax (benefit) expense:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Benefit from) provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Benefit from) provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>(25)%</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>37%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>25%</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively. The lower effective tax rate in 2017 is primarily due to an estimated provisional tax benefit from the Tax Act of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;">. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In accordance with SAB 118, our accounting for the following elements of the Tax Act is incomplete. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">–</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our deferred tax assets and liabilities are measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled. In connection with the Tax Act, we have provisionally recorded a deferred income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the statutory corporate tax rate reduction as our U.S. federal deferred tax liabilities exceed our deferred tax assets. This deferred tax benefit is primarily related to the remeasurement of the deferred tax liability for our investment in the preferred shares of Sartorius AG. </span></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">–</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. We recorded a provisional income tax expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$55 million</span></span><span style="font-family:inherit;font-size:11pt;"> for Transition Tax. As additional information and guidance become available, the determination of the Transition Tax will be completed within the measurement period in accordance with SAB 118.</span></div></td></tr></table><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our accounting for certain other elements of the Tax Act is incomplete, and we are not yet able to make reasonable estimates of those effects. For example, we have not made a determination as to our accounting policy with respect to the new Global Intangible Low Tax Income ("GILTI"). Therefore, no provisional adjustments were recorded.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Many jurisdictions in which we operate have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>287.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>252.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>310.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(173.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(192.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of </span><span style="font-family:inherit;font-size:11pt;"><span>$207.2 million</span></span><span style="font-family:inherit;font-size:11pt;">.  Of these loss carryforwards, </span><span style="font-family:inherit;font-size:11pt;"><span>$150.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> have no expiration date.  We believe that it is more likely than not that the benefit from approximately half of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of </span><span style="font-family:inherit;font-size:11pt;"><span>$27.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> relating to these net operating loss carryforwards.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$53 million</span></span><span style="font-family:inherit;font-size:11pt;"> of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, Bio-Rad had a deferred tax asset of </span><span style="font-family:inherit;font-size:11pt;"><span>$29.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> relating to California research tax credit carryforwards, including </span><span style="font-family:inherit;font-size:11pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Although we believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future, if or when recognized, the tax benefits relating to any reversal of the valuation allowance will be recognized as a reduction of income tax expense.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions an</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">d allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2017, 2016 and 2015, respectively was </span><span style="font-family:inherit;font-size:11pt;"><span>$10.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$11.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;">. Bio-Rad accrued interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.9) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$8.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.7) million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively. The total unrecognized tax benefits and interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$65.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> was partially offset by deferred tax assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and prepaid taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, for a net amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$48.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:11pt;">. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Act, which also repeals U.S. taxation on the subsequent repatriation of those earnings. It is generally our intention to repatriate those foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. While we currently estimate that the repatriation of those earnings would not trigger material costs, these estimates are provisional, and we are still evaluating the full impact of these potential repatriations in accordance with SAB 118. The U.S. and international components of income before taxes are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 72800000 -38500000 48400000 25000000.0 80100000 97400000 97800000 41600000 145800000 The provision for income taxes consists of the following (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>44.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax (benefit) expense:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(42.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.0</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Benefit from) provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 6700000 16100000 8700000 3400000 3100000 1700000 32000000.0 30400000 34100000 42100000 49600000 44500000 -69800000 -42400000 2000000.0 4300000 -2800000 1400000 -19300000 -6000000.0 -7100000 -84800000 -51200000 -3700000 18300000 17200000 -4200000 -24400000 15600000 36600000 The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign dividends, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax settlements and changes to unrecognized tax benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Domestic manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fines and penalties</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior period adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Benefit from) provision for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr></table></div> 0.35 0.35 0.35 0.07 -0.15 -0.04 0 0.40 0.04 0.04 0.09 0.02 0.02 0.04 0.01 0 0.47 -0.03 0 0.11 0 0 0.04 0.02 0.05 0.03 0.01 0.02 0.03 0.01 0 0.02 0 0 0.04 0.03 0.03 0.02 0 0.10 0 0 -0.71 0 0 0.03 0.01 0.01 -0.03 0.01 0 -0.25 0.37 0.25 -0.25 0.37 0.25 -70000000 125000000 55000000 Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>73.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>96.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>184.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(66.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>287.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>252.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>310.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(173.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(192.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 28600000 25800000 24000000.0 26300000 73300000 96400000 19700000 35700000 145600000 184200000 66400000 66400000 79200000 117800000 33500000 22200000 219100000 287800000 252600000 310000000.0 173400000 192200000 207200000 150600000 27800000 53000000 29600000 2000000.0 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.3</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 21100000 11900000 15800000 1300000 10400000 700000 1000000.0 0 200000 34800000 3400000 2900000 200000 2400000 500000 3400000 2300000 6300000 2300000 100000 500000 54900000 21100000 11900000 10900000 11800000 3100000 -900000 8700000 -700000 65800000 2800000 14500000 48500000 2300000 7.    STOCKHOLDERS' EQUITY<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>25%</span></span><span style="font-family:inherit;font-size:11pt;"> of the Board of Directors and Class B stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>75%</span></span><span style="font-family:inherit;font-size:11pt;"> of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to Bio-Rad's issued common stock shares are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:49%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,972</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,099</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Treasury Shares</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">On November 28, 2017, we announced that the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to </span><span style="font-family:inherit;font-size:11pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of outstanding shares of our common stock. This new authorization superseded the prior authorization of up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Bio-Rad's common stock. During the second and third quarters of 2017, we made open market purchases of </span><span style="font-family:inherit;font-size:11pt;"><span>13,200 shares</span></span><span style="font-family:inherit;font-size:11pt;"> of our Class A common stock. In September 2017, we used </span><span style="font-family:inherit;font-size:11pt;"><span>12,740</span></span><span style="font-family:inherit;font-size:11pt;"> of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld </span><span style="font-family:inherit;font-size:11pt;"><span>122 shares</span></span><span style="font-family:inherit;font-size:11pt;"> of our Class A common stock and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>917 shares</span></span><span style="font-family:inherit;font-size:11pt;"> of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. We had no other repurchases of our stock during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> or </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span>. 0.25 0.75 Changes to Bio-Rad's issued common stock shares are as follows (in thousands):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:49%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,972</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,099</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><br/> 23972000 5099000 18000 -18000 240000 50000 24230000 5131000 13000 -13000 211000 6000 24454000 5124000 34000 -34000 191000 18000 24679000 5108000 250000000.0 18000000.0 13200 12740 122 917 8.    <span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2018-02**</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes<br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>738.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">*</span><span style="font-family:inherit;font-size:10pt;">*See Note 1, "Significant Accounting Policies" under "Recent Accounting Standards Update"</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The increases in 2017 and 2016 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:5%;"/><td style="width:5%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains on available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>417.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of adoption of ASU 2018-02**</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes<br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>683.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>738.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 33700000 -20700000 369100000 382100000 -32400000 500000 105100000 73200000 0 2500000 -800000 1700000 0 900000 38400000 39300000 -32400000 2100000 65900000 35600000 1300000 -18600000 435000000.0 417700000 76100000 -6500000 203600000 273200000 0 2100000 -100000 2000000.0 0 -700000 74900000 74200000 0 0 120100000 120100000 76100000 -3700000 248700000 321100000 77400000 -22300000 683700000 738800000 reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:23%;"/><td style="width:5%;"/><td style="width:5%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before taxes impact (in millions):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains on available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Reclassification adjustments are calculated using the specific identification method. -2100000 -2500000 100000 800000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Description of Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe our share-based compensation plans align the interests of our employees with those of our shareholders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Equity Award Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In April 2017, our stockholders approved the 2017 Plan. The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of </span><span style="font-family:inherit;font-size:11pt;"><span>1,999,714</span></span><span style="font-family:inherit;font-size:11pt;"> shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2017, there were </span><span style="font-family:inherit;font-size:11pt;"><span>1,771,794</span></span><span style="font-family:inherit;font-size:11pt;"> shares available to be granted.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;"> years and vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10%</span></span><span style="font-family:inherit;font-size:11pt;"> of their compensation up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$25,000</span></span><span style="font-family:inherit;font-size:11pt;"> annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>85%</span></span><span style="font-family:inherit;font-size:11pt;"> of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;"><span>1,300,000</span></span><span style="font-family:inherit;font-size:11pt;"> shares of Class A common stock under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, we recognized share-based compensation expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$23.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$17.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  The income tax benefit related to share-based compensation expense was </span><span style="font-family:inherit;font-size:11pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> for </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> and 2015, respectively. We did not capitalize any share-based compensation expense in inventory.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The tax benefit from share-based compensation vested or exercised during </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. The actual tax benefit realized for the tax deductions from share-based </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled </span><span style="font-family:inherit;font-size:11pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$9.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> in 2016 and 2015, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:305px;"/><td style="width:5px;"/><td style="width:83px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,570</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215.98</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,890</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,200</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177.99</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,720</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.29</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,760</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.66</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. The total fair value of options vested during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash received from stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, there was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> under the 2007 Plan and in </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>448,822</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,860</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215.98</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127,189</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,263</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151.36</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total fair value of restricted stock units vested in </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$18.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, there was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$74.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>74,409</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>93,605</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$11.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>96,634</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> under the 2011 ESPP to employees in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively.  At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>721,712</span></span><span style="font-family:inherit;font-size:11pt;"> shares remain authorized and available for issuance under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases. 1999714 1771794 P10Y 0.20 0.20 0.10 25000 0.85 1300000 23400000 19700000 17000000.0 5800000 5100000 4300000 6300000 1500000 3600000 6000000.0 9300000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:678px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:305px;"/><td style="width:5px;"/><td style="width:83px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:89px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,570</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,000</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215.98</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,890</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,200</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177.99</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,720</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.29</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,760</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.66</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 449570 106.52 44000 215.98 78890 89.41 7200 177.99 407480 120.39 P5Y1M2D 48.2 125720 164.84 P8Y3M14D 9.3 281760 100.56 P3Y7M28D 38.9 10000000 1000000 13000000 4200000 2100000 1600000 1600000 1200000 2900000 5500000 P3Y <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.20 0.21 0.23 0.0187 0.0135 0.0190 P7Y2M12D P7Y4M24D P7Y8M12D 0 0 0 58.65 42.40 42.74 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>448,822</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,860</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215.98</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127,189</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41,263</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151.36</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 448822 141.09 192860 215.98 127189 133.54 41263 151.36 473230 172.75 P2Y1M20D 112.9 27700000 18700000 15800000 74700000 P4Y The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 0.19 0.20 0.18 0.0083 0.0026 0.0002 P0M7D P0M7D P0M7D 0 0 0 38.86 27.36 25.08 74409 13000000.0 93605 11500000 96634 10800000 721712 10. OTHER INCOME AND EXPENSE, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:401px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:79px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(14.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments were recorded in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span> in light of continuing declines in the investment market prices and investees' financial conditions at that time. Other (income) expense, net includes the following components (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:401px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:79px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:75px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(14.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(14.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 19100000 14700000 10100000 100000 800000 1600000 7000000.0 600000 600000 12200000 11100000 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(54.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>103.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11. SUPPLEMENTAL CASH FLOW INFORMATION<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:298px;"/><td style="width:9px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:77px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>109.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>142.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>131.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Excess tax benefits from share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(39.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in inventories, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(57.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(54.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase in accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Decrease) increase in income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in other long term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>103.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>186.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 122200000 26000000.0 109200000 148700000 142900000 131800000 23400000 19700000 17000000.0 100000 800000 1600000 7000000.0 600000 600000 -8100000 -600000 -300000 0 1500000 3600000 -18100000 -400000 -5600000 64100000 -12500000 39000000.0 47700000 57100000 54200000 36100000 6600000 -100000 7800000 30100000 28600000 -22400000 10700000 12700000 82000000.0 51400000 4000000.0 -2400000 -12700000 -300000 -38100000 -10400000 10700000 11500000 62300000 0 -5200000 -5700000 -4300000 103900000 216400000 186200000 0 7200000 0 2800000 600000 2200000 12. COMMITMENTS AND CONTINGENT LIABILITIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Rents and Leases</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Rental expense under operating leases was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$43.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$44.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$45.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Annual future minimum lease payments at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> under operating leases are as follows: </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$39.3 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$33.2 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$27.1 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> and beyond - </span><span style="font-family:inherit;font-size:11pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Profit Sharing Retirement Plan</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$14.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Other Post-Employment Benefits</span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2017 and 2016 of </span><span style="font-family:inherit;font-size:11pt;"><span>$74.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$63.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Obligations and Funded Status</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$122.7</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$120.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(63.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(0.5)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(63.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Components of Net Periodic Benefit Cost</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$5.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.6</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Assumptions</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">In some foreign locations we have service award plans that are paid based upon the number of years of employment.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Under these plans, the liability at December 31, 2017 and 2016 was </span><span style="font-family:inherit;font-size:11pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Purchase Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, we had obligations that have been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$131.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$10.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$6.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$86.5 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, we had purchase obligations that have not been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$24.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:10pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Letters of Credit/Guarantees</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of standby letters of credit/guarantees with financial institutions as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Contingent Consideration</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;">. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. The current contingent consideration is built on a sales forecast of </span><span style="font-family:inherit;font-size:11pt;"><span>$78 million</span></span><span style="font-family:inherit;font-size:11pt;"> through </span><span style="font-family:inherit;font-size:11pt;">December 31, 2020</span><span style="font-family:inherit;font-size:11pt;">. In the third quarter of 2017, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$16.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at </span><span style="font-family:inherit;font-size:11pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2016</span><span style="font-family:inherit;font-size:11pt;"> in the amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2012, we recognized a contingent consideration liability for certain milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$44.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid </span><span style="font-family:inherit;font-size:11pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> upon reaching the milestones and have reduced the valuation of the milestones by </span><span style="font-family:inherit;font-size:11pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. The remaining liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> was paid in </span><span style="font-family:inherit;font-size:10pt;">February 2017</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentrations of Labor Subject to Collective Bargaining Agreements</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, approximately </span><span style="font-family:inherit;font-size:11pt;">seven</span><span style="font-family:inherit;font-size:11pt;"> percent of Bio-Rad's approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3,270</span></span> U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements. 43600000 44400000 45000000.0 39300000 33200000 27100000 17800000 27500000 16000000.0 15100000 14700000 74900000 63900000 Obligations and Funded Status<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$122.7</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$120.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(63.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(0.5)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(74.9)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(63.9)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 122700000 120800000 6500000 6100000 1100000 1400000 2800000 2600000 3300000 0 3200000 3300000 1100000 0 2000000.0 0 -5100000 -2500000 9400000 -2400000 136600000 122700000 58800000 56700000 500000 1300000 4000000.0 4700000 2800000 2600000 2300000 2900000 5100000 2500000 3000000.0 -1100000 61700000 58800000 -74900000 -63900000 1100000 500000 73800000 63400000 74900000 63900000 Components of Net Periodic Benefit Cost<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$5.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.6</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.7</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 6500000 6100000 5300000 1100000 1400000 1400000 1100000 1000000.0 1200000 -1400000 -1700000 -800000 0 0 400000 -1200000 -400000 0 9100000 8600000 6700000 Assumptions<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.008 0.009 0.018 0.016 0.009 0.011 0.013 0.019 0.016 0.023 3700000 3500000 131200000 10300000 14300000 10600000 6900000 2600000 86500000 24500000 3700000 3800000 3700000 3800000 3700000 5800000 4200000 0.39 0.20 0 78000000 600000 -6000000.0 16700000 10700000 10000000.0 44600000 32000000.0 12600000 3100000 3270 13.    LEGAL PROCEEDINGS<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleged that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. In January 2018, we entered into a settlement agreement with the District pursuant to which we paid the District </span><span style="font-family:inherit;font-size:11pt;"><span>$990,000</span></span><span style="font-family:inherit;font-size:11pt;"> to settle all claims and/or potential claims arising out of our use of the three power generation units. This settlement amount was accrued for as of December 31, 2017. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><br/> 10920000 141608 990000 14. SEGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>9,000</span></span><span style="font-family:inherit;font-size:11pt;"> different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other Operations include the remainder of our Analytical Instruments segment.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>695.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,310.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment (loss) profit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>112.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,038.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>909.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign exchange losses</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense, net not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following reconciles total segment assets to consolidated total assets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:421px;"/><td style="width:8px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,496.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,294.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>965.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,007.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,850.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been revised (see Note 1 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:317px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:84px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>763.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>735.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,019.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:374px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,305.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,084.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,567.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,334.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 9000 <br/><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2016</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2015</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>730.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,323.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>695.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,310.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment (loss) profit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>112.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>453.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,038.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>380.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>909.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>67.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 785200000 1360800000 14200000 730700000 1323300000 14200000 695000000.0 1310400000 14000000.0 7000000.0 14900000 0 6400000 15500000 0 6100000 15400000 100000 36200000 80200000 0 31700000 80500000 0 30700000 77800000 100000 -10100000 112500000 1400000 -19200000 57000000.0 900000 -700000 152400000 700000 453000000.0 1038400000 4800000 380800000 909100000 4900000 12600000 59000000.0 0 14300000 67100000 0 he following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>103.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>152.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign exchange losses</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense, net not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><br/> 103800000 38700000 152400000 -9100000 -4500000 -10200000 -9100000 -7500000 -7500000 12200000 14900000 11100000 97800000 41600000 145800000 The following reconciles total segment assets to consolidated total assets (in millions):<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:421px;"/><td style="width:8px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:68px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,496.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,294.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>965.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>980.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, excluding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  segment specific gross machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>91.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>477.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,247.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,007.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,273.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,850.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1496200000 1294800000 965800000 980300000 57000000.0 91100000 506100000 477100000 1247900000 1007200000 4273000000.0 3850500000 The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:317px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:84px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>742.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>763.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>427.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>735.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>128.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,068.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,019.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:583px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:374px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:85px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>221.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Pacific Rim</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,305.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,084.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,567.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,334.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 758500000 742200000 763700000 461300000 427100000 392200000 800200000 770600000 735000000.0 140200000 128300000 128500000 2160200000 2068200000 2019400000 230600000 221100000 18400000 16100000 1305200000 1084700000 13100000 12300000 1567300000 1334200000 RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for European Reorganization</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in restructuring charges related to severance and other employee benefits for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other long-term liabilities in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses (gains)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for GnuBIO, Inc.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It is included in our Clinical Diagnostics segment’s results of operations as a division, and is primarily based in Massachusetts. In September 2017, we announced that we are closing the GnuBIO research program facilities in Massachusetts. As a result, we recorded restructuring charges in September 2017 related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and asset write-offs of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;">. The amounts recorded were reflected in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$7.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. The liability balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and is recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. We expect the remainder to be paid in early 2018.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for Termination of an Infectious Disease Research and Development Project</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2017, we announced the termination of an infectious disease research and development project, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded restructuring charges related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, and asset write-offs and exit costs of </span><span style="font-family:inherit;font-size:11pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Research and development expense </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of </span><span style="font-family:inherit;font-size:11pt;"><span>$15.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$14.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$11.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other current liabilities in the Consolidated Balance Sheets. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity for the termination of the infectious disease research and development project restructuring reserves for severance and exit costs (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:67%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses </span></div><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 500000 12500000 6300000 6200000 100000 -200000 2100000 700000 10400000 The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses (gains)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the activity for the termination of the infectious disease research and development project restructuring reserves for severance and exit costs (in millions): <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.1640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:67%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses </span></div><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 3200000 5800000 9000000.0 0 0 0 0 0 0 4100000 7600000 11700000 200000 300000 500000 300000 500000 800000 1500000 2700000 4200000 1000000.0 2000000.0 3000000.0 -300000 -700000 -1000000.0 200000 300000 500000 2200000 4100000 6300000 3200000 5800000 9000000.0 2900000 5500000 800000 7600000 1400000 11000000.0 10100000 2300000 3300000 15500000 14100000 11100000 3000000.0 0 14000000.0 0 -100000 14100000 16. QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. The third misstatement was related to a design deficiency associated with transfer pricing. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the fourth quarter of 2017, we identified errors in the unaudited interim condensed consolidated financial statements for the three months ended September 30, 2017. We identified an error in the recording of deferred revenue acquired in our acquisition of RainDance (see Note 2, "Acquisitions"). This resulted in an overstatement of revenue recorded in the third quarter of 2017 of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was corrected in the fourth quarter of 2017. In addition, we identified an error in an estimated employee benefit expense that resulted in an understatement of expenses reported in Cost of goods sold, Selling, general and administrative expense and Research and development expense, net, in the third quarter of 2017 of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was corrected in the fourth quarter of 2017. Finally, we identified an error during our reconciliation of various inventory accounts which resulted in an understatement of Cost of goods sold in the third quarter of 2017 of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was corrected in the fourth quarter of 2017. The impact of these errors resulted in an overstatement of our Provision for income taxes reported in the third quarter of 2017 of </span><span style="font-family:inherit;font-size:11pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was corrected in the fourth quarter of 2017.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Management evaluated the materiality of all the errors described in the previous paragraph from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of SAB 108. Accordingly, we are correcting these errors in the financial statements for the quarter ended September 30, 2017 included in this Form 10-K.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impact of the immaterial error corrections described above are presented on a as reported, adjustment and as revised basis in the following summarized quarterly financial data for </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;"> (in millions, except per share data):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">As reported:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>535.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>620.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>304.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>339.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>196.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>61.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>236.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>229.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>189.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Adjustments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">As revised:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>534.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>621.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>235.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>298.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.78</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>236.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>229.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>189.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.58</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.63</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Note: As a result of the net loss for the three months ended December 31, 2016, </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> all potentially issuable common shares have been excluded from the diluted shares</span></div> used in the computation of earnings per share as their effect was anti-dilutive. 900000 3800000 3500000 2900000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">As reported:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>535.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>620.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>304.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>339.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>196.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>61.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>37.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.35</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>236.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>229.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>189.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.70</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Adjustments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.04</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:673px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:253px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">As revised:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>500.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>504.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>534.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>621.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>230.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>231.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>235.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>276.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>270.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>273.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>298.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>345.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>194.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>213.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>202.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>45.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.78</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>471.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>516.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>508.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>571.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>236.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>229.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>257.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>279.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>314.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>189.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>201.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>49.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(28.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Provision for) benefit from income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.56</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.58</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.63</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div> 500100000 504700000 535000000.0 620400000 230100000 231400000 230500000 280800000 270000000.0 273300000 304500000 339600000 194900000 213000000.0 196800000 204200000 49500000 62600000 61400000 76800000 20100000 1100000 38900000 37700000 7700000 -3900000 11500000 -32200000 12400000 5000000.0 27400000 69900000 0.42 0.17 0.92 2.35 0.41 0.17 0.91 2.32 471200000 516800000 508700000 571500000 207200000 236600000 229200000 257100000 264000000.0 280200000 279500000 314400000 189700000 205500000 201500000 220000000.0 48600000 49800000 49900000 57600000 20200000 26900000 22700000 -28200000 7900000 8900000 4300000 -7600000 12300000 18000000.0 18400000 -20600000 0.42 0.61 0.63 -0.70 0.42 0.61 0.62 -0.70 0 0 -900000 900000 0 0 4700000 -4700000 0 0 -5600000 5600000 0 0 1900000 -1900000 0 0 700000 -700000 0 0 -8200000 8200000 0 0 -2900000 -4600000 0 0 -5300000 12800000 0 0 -0.18 0.43 0 0 -0.18 0.43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1300000 1400000 1300000 -1900000 -1300000 -1400000 -1300000 1900000 -0.04 -0.05 -0.05 0.07 -0.05 -0.05 -0.04 0.07 500100000 504700000 534100000 621300000 230100000 231400000 235200000 276100000 270000000.0 273300000 298900000 345200000 194900000 213000000.0 198700000 202300000 49500000 62600000 62100000 76100000 20100000 1100000 30700000 45900000 7700000 -3900000 8600000 -36800000 12400000 5000000.0 22100000 82700000 0.42 0.17 0.74 2.78 0.41 0.17 0.73 2.75 471200000 516800000 508700000 571500000 207200000 236600000 229200000 257100000 264000000.0 280200000 279500000 314400000 189700000 205500000 201500000 220000000.0 48600000 49800000 49900000 57600000 20200000 26900000 22700000 -28200000 9200000 10300000 5600000 -9500000 11000000.0 16600000 17100000 -18700000 0.38 0.56 0.58 -0.63 0.37 0.56 0.58 -0.63 17. SUBSEQUENT EVENT<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>Subsequent to December 31, 2017, the Company obtained an extension of time to provide its annual audited financial statements for its 2017 fiscal year and related compliance certificate and other deliveries as currently required by the Credit Agreement discussed in Note 5. This extension provides that the Company may provide its annual audited financial statements for its 2017 fiscal year within 120 days after the end of its 2017 fiscal year and its compliance certificate in respect of its 2017 fiscal year within 130 days after the end of its 2017 fiscal year. No amounts were outstanding under this Credit Agreement at December 31, 2017 and no amounts have been borrowed since. BIO-RAD LABORATORIES, INC.<div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Years Ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2017</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2016</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2015</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(in thousands)</span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Allowance for doubtful accounts receivable</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:561px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:109px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged to Costs</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,174</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,992</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,785</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,836</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,973</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,783</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,338</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,418</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Valuation allowance for long-term deferred tax assets</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:561px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:109px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:95px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions Charged</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Credited) to Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,356</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,615</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,277</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 23367000 11174000 8992000 25549000 24418000 3785000 4836000 23367000 27973000 8783000 12338000 24418000 66403000 -47000 0 66356000 58277000 8126000 0 66403000 58615000 -338000 0 58277000 Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2017 December 31, 2016    Short-term investments$371.2 $383.2Other investments930.2 732.4Total$1,301.4 $1,115.6 Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2017 December 31, 2016    Other current liabilities$2.7 $14.5Other long-term liabilities14.0 24.0   Total$16.7 $38.5 Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. XML 15 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2017
Apr. 10, 2018
Jun. 30, 2017
Entity Registrant Name BIO RAD LABORATORIES INC    
Document Type 10-K    
Document Period End Date Dec. 31, 2017    
Amendment Flag false    
Entity Central Index Key 0000012208    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    
Entity Public Float     $ 4,795,291,430
Common Class A [Member]      
Entity Common Stock, Shares Outstanding   24,701,407  
Common Class B [Member]      
Entity Common Stock, Shares Outstanding   5,103,283  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
ASSETS:    
Cash and cash equivalents $ 383,824 $ 456,264
Short-term investments 371,154 383,176
Restricted investments 5,560 4,560
Accounts receivable, less allowance for doubtful accounts 464,847 372,348
Inventories:    
Raw materials 113,925 116,540
Work in process 142,589 125,982
Finished goods 338,290 282,439
Total inventories 594,804 524,961
Prepaid expenses 146,135 91,014
Other current assets 10,325 12,201
Total current assets 1,976,649 1,844,524
Property, plant and equipment:    
Land and improvements 18,026 17,895
Buildings and leasehold improvements 315,984 300,834
Equipment 971,140 908,659
Total property, plant and equipment 1,305,150 1,227,388
Less: accumulated depreciation and amortization (811,654) (738,774)
Property, plant and equipment, net 493,496 488,614
Goodwill, net 506,069 477,115
Purchased intangibles, net 174,113 161,609
Other investments 1,027,736 830,790
Other assets 94,949 47,852
Total assets 4,273,012 3,850,504
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 135,182 133,109
Accrued payroll and employee benefits 171,632 163,364
Notes payable and current maturities of long-term debt 420 334
Income and other taxes payable 39,941 28,124
Deferred revenue 28,233 31,003
Other current liabilities 127,288 115,388
Total current liabilities 502,696 471,322
Long-term debt, net of current maturities 434,581 434,186
Deferred income taxes 222,209 225,299
Other long-term liabilities 183,276 140,537
Total liabilities 1,342,762 1,271,344
Commitments and contingent liabilities
Stockholders' equity:    
Preferred stock 0 0
Additional paid-in capital 361,231 332,911
Retained earnings 1,830,439 1,828,581
Accumulated other comprehensive income 738,794 417,766
Total stockholders' equity 2,930,250 2,579,160
Total liabilities and stockholders' equity 4,273,012 3,850,504
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class-A [Member]    
Stockholders' equity:    
Treasury Stock, Value (128) (12)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ (89) $ (89)
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Allowance for doubtful accounts $ 25,549 $ 23,367
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock authorized 7,500,000 7,500,000
Preferred stock issued 0 0
Preferred stock outstanding 0 0
Common Class A [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 80,000,000 80,000,000
Common stock issued 24,679,127 24,454,048
Common stock outstanding 24,678,545 24,453,926
Common Class B [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 20,000,000 20,000,000
Common stock issued 5,107,674 5,123,883
Common stock outstanding 5,106,757 5,122,966
Treasury Class-A [Member]    
Treasury Stock, Shares 582 122
Treasury Class B [Member]    
Treasury Stock, Shares 917 917
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Net sales $ 2,160,153 $ 2,068,172 $ 2,019,441
Cost of goods sold 972,754 930,085 897,771
Gross profit 1,187,399 1,138,087 1,121,670
Selling, general and administrative expense 808,942 816,724 761,990
Research and development expense 250,301 205,864 192,972
Impairment losses on goodwill and long-lived assets 11,506 62,305 0
Income from operations 116,650 53,194 166,708
Interest expense 21,914 21,942 21,692
Foreign exchange losses, net 9,128 4,542 10,249
Other (income) expense, net (12,197) (14,850) (11,080)
Income before income taxes 97,805 41,560 145,847
Provision for income taxes 24,444 (15,560) (36,608)
Net Income (Loss) Attributable to Parent $ 122,249 $ 26,000 $ 109,239
Basic earnings per share:      
Earnings Per Share, Basic $ 4.12 $ 0.88 $ 3.74
Weighted average common shares - basic 29,655 29,440 29,186
Diluted earnings per share:      
Earnings Per Share, Diluted $ 4.07 $ 0.88 $ 3.71
Weighted average common shares - diluted 30,034 29,646 29,409
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:      
Cash received from customers $ 2,093,948 $ 2,074,024 $ 1,956,084
Cash paid to suppliers and employees (1,918,971) (1,810,844) (1,730,062)
Interest paid (21,124) (21,318) (20,793)
Income tax payments (52,136) (38,442) (31,715)
Investment proceeds and miscellaneous receipts, net 19,892 15,683 11,953
Excess tax benefits from share-based compensation 0 (1,506) (3,610)
(Payments for) proceeds from forward foreign exchange contracts, net (17,724) (1,164) 4,353
Net cash provided by operating activities 103,885 216,433 186,210
Cash flows from investing activities:      
Capital expenditures (111,332) (141,436) (112,000)
Proceeds from dispositions of property, plant and equipment 86 398 79
Payments for acquisitions, net of cash received, and long-term investments (76,645) (14,165) (4,356)
Payments for purchases of intangible assets (3,795) (135) (1,372)
Payments for purchases of restricted investment (1,000) (350) (4,210)
Payments for purchases of marketable securities and investments (282,656) (278,071) (294,497)
Proceeds from sales of marketable securities and investments 97,523 76,859 78,664
Proceeds from maturities of marketable securities and investments 202,247 143,020 170,823
Net cash used in investing activities (175,572) (213,880) (166,869)
Cash flows from financing activities:      
Net (payments) borrowings on line-of-credit arrangements and notes payable (36) 37 0
Payments on long-term borrowings (316) (303) (282)
Proceeds from issuance of common stock 7,294 11,280 8,236
Payments for Repurchase of Common Stock (2,920) 0 0
Payment for Contingent Consideration Liability, Financing Activities 3,681 3,500 2,983
Excess tax benefits from share-based compensation 0 1,506 3,610
Net cash provided by financing activities 341 9,020 8,581
Effect of foreign exchange rate changes on cash (1,094) (12,858) 16,376
Net (decrease) increase in cash and cash equivalents (72,440) (1,285) 44,298
Cash and cash equivalents at beginning of year 456,264 457,549 413,251
Cash and cash equivalents at end of year $ 383,824 $ 456,264 $ 457,549
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total Bio Rad [Member]
Balance at Dec. 31, 2014 $ 2,183,535 $ 3 $ 271,346 $ (101) $ 1,693,342 $ 218,945  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 109,239       109,239    
Other comprehensive income, net of tax           163,193  
Issuance of common stock 8,236   8,236        
Stock compensation expense     16,983        
Tax benefit-exercise stock options     3,843        
Balance at Dec. 31, 2015 2,485,029 3 300,408 (101) 1,802,581 382,138  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 26,000       26,000    
Other comprehensive income, net of tax           35,628  
Issuance of common stock 11,280   11,280        
Stock compensation expense     19,730        
Tax benefit-exercise stock options     1,493        
Balance at Dec. 31, 2016 2,579,160 3 332,911 (101) 1,828,581 417,766  
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 135   391   (256)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 122,249       122,249    
Other comprehensive income, net of tax           200,893  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 0       (120,135) 120,135 $ 120,100
Issuance of common stock 7,294   4,490        
Stock compensation expense     23,439        
Treasury Stock, Value, Acquired, Cost Method       (2,920)      
Stock Issued During Period, Value, Treasury Stock Reissued       2,804      
Balance at Dec. 31, 2017 $ 2,930,250 $ 3 $ 361,231 $ (217) $ 1,830,439 $ 738,794  
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Net Income (Loss) Attributable to Parent $ 122,249 $ 26,000 $ 109,239
Foreign currency translation adjustments 76,050 (32,394) (37,536)
Other post-employment benefits adjustments, net of tax (3,767) 2,086 (4,403)
Net unrealized holding gains on available-for-sale investments, net of tax 248,745 65,936 205,132
Other comprehensive income, net of tax 321,028 35,628 163,193
Comprehensive income attributable to Bio-Rad $ 443,277 $ 61,628 $ 272,432
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies
 12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies 1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million and $4.6 million at December 31, 2017 and 2016, respectively, represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating
segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The new legislation contains significant tax provisions that affect us, including a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings ("Transition Tax"), a reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, and a change from a worldwide tax system to a modified territorial system.

We are required to recognize the effect of the tax law changes in the period of enactment, such as the computation of the Transition Tax, remeasurement of our U.S. deferred tax assets and liabilities, as well as reassessment of the net realizability of our deferred tax assets and liabilities.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available. We expect to complete the relevant analysis no later than December 31, 2018.

Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent
agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) cost per test conducted and reported. Revenue on a cost per reported basis is estimated in the current period, and billed at actual in the month reported by our customer.

Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.

Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2017
 
2016
January 1
 
$
17.6

 
$
17.4

Provision for warranty
 
29.9

 
33.4

Actual warranty costs
 
(28.8
)
 
(33.2
)
December 31
 
$
18.7

 
$
17.6



Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Basic weighted average shares outstanding
 
29,655

 
29,440

 
29,186

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
379

 
206

 
223

Diluted weighted average common shares
 
30,034

 
29,646

 
29,409

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
13

 
113

 
109



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

RECLASSIFICATION OF CERTAIN AMOUNTS, AND CORRECTION OF IMMATERIAL ERRORS

2016 Reclassification of Buildings and leasehold improvements, and Equipment

Upon our implementation of our global single instance enterprise resource planning ("ERP") platform in Europe during the second quarter of 2017, $10.5 million of assets in France were misclassified as Equipment that should have been reported as Buildings and leasehold improvements in periods prior to 2017. The reclassification on the 2016 balance conforms to the correct balance sheet presentation as of December 31, 2017, and there was no impact on the Consolidated Statements of Income or Cash Flows. Please see the table below for the corrected amounts for Buildings and leasehold improvements, and Equipment.

2016 and 2015 Misstatement of Income Taxes

During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. As a consequence, Deferred income taxes in 2016 were understated by $2.4 million and the Provision for income taxes was understated by $2.4 million in 2015.

The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. As a consequence, Retained earnings were overstated by $1.4 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $4.6 million in 2016 and the Provision for income taxes was understated by $1.9 million and $1.3 million in 2016 and 2015, respectively.

The third misstatement was related to a design deficiency associated with transfer pricing. As a consequence, our Retained earnings were overstated by $0.2 million in 2015, Other tax liabilities - noncurrent, reported in Other long-term liabilities, were understated by $0.6 million in 2016 and the Provision for income taxes was understated by $0.2 million in both 2016 and 2015.

The impact of the reclassification, and the immaterial error corrections, both described above on our Consolidated Balance Sheet and Consolidated Statements of Income for the periods presented is as follows (in thousands, except per share data):
 
 
December 31, 2016
 
 
As reported
 
Adjustment
 
As revised
Buildings and leasehold improvements
 
$
290,367

 
$
10,467

 
$
300,834

Equipment
 
919,126

 
(10,467
)
 
908,659

Deferred income taxes
 
222,919

 
2,380

 
225,299

Other long-term liabilities
 
135,318

 
5,219

 
140,537

Total liabilities
 
1,263,745

 
7,599

 
1,271,344

Retained earnings
 
1,836,180

 
(7,599
)
 
1,828,581

Total stockholders' equity
 
$
2,586,759

 
$
(7,599
)
 
$
2,579,160



 
Year ended December 31,
 
2016
 
2015
 
As reported
Adjustment
As revised
 
As reported
Adjustment
As revised
Provision for income taxes
$
(13,435
)
$
(2,125
)
$
(15,560
)
 
$
(32,754
)
$
(3,854
)
$
(36,608
)
Net income
$
28,125

$
(2,125
)
$
26,000

 
$
113,093

$
(3,854
)
$
109,239

Net income per basic share
$
0.96

$
(0.08
)
$
0.88

 
$
3.87

$
(0.13
)
$
3.74

Net income per diluted share
$
0.95

$
(0.07
)
$
0.88

 
$
3.85

$
(0.14
)
$
3.71



Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.

Recent Accounting Standards Updates

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc.

In February 2018, the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by $120.1 million.

In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately $17 million.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition, we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP. Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
2. Acquisitions
 12 Months Ended
Dec. 31, 2017
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block] 2.    ACQUISITIONS

RainDance Technologies, Inc.
In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $72.7 million. Cash payments at closing were $72.9 million. In addition, we had a cash payment of $10.0 million for a preexisting condition concurrent with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.
The final allocation for the payments of $72.9 million was $37.6 million to definite-lived intangibles, $0.2 million to acquired net assets, $26.2 million to goodwill, a deferred tax liability of $13.6 million primarily related to the purchased intangibles and a deferred tax asset of $22.5 million primarily related to the acquired net operating losses. The final allocation of the payments reflect the effects of correcting an error that were recorded in the fourth
quarter of 2017. These corrections reduced goodwill, deferred revenue and deferred tax assets by $1.9 million, $3.3 million and $1.4 million, respectively, and had no significant impact on our Consolidated Statements of Income.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers solutions for a wide range of nucleic acid detection applications.

Propel Labs, Inc.

In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date.

The fair value of the consideration as of the acquisition date was $32.8 million, which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $16.7 million as of December 31, 2017 (see Note 3, "Fair Value Measurements").

The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. The goodwill related to this acquisition is deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

In addition, Bio-Rad contracted with Propel to provide development services concurrent with and included in the purchase agreement. Bio-Rad is receiving manufacturing, engineering and marketing support from Propel on which payments are made upon the successful completion of all contracted services. As a result, these services were not included in the total purchase consideration and have been and will be expensed.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements
 12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements 3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (c)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.6

 
$
—

 
$
1.6

     Contingent consideration (e)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
$
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
—

 
$
1.3

 Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
Short-term investments
$
371.2

 
$
383.2

Other investments
930.2

 
732.4

Total
$
1,301.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5




In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. The current contingent consideration is built on a sales forecast of $78 million through December 31, 2020. In the third quarter of 2017, we paid $0.6 million upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by $6.0 million. The contingent consideration was accrued at its estimated fair value of $16.7 million as of December 31, 2017.

The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2017 (in millions):

 
2017
 
 
January 1
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(8.1
)
Payment of sales milestone
$
(0.6
)
December 31
$
16.7




The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.8
%
 
 
Cost of debt
4.2
%



In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of December 31, 2016 in the amount of $10.0 million and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc.

To estimate the fair value of Level 2 debt securities as of December 31, 2017 and 2016, our primary pricing provider uses Securities Evaluations as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is Securities Evaluations as the primary pricing source and then our custodian as the secondary pricing source. If Securities Evaluations does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing.

For commercial paper as of December 31, 2017 and 2016, pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In the event that an additional lot of the same commercial paper issue has been purchased within the same account, then the price of all holdings of that issue in that account will be the price of the most recent lot purchased.

Our primary pricing provider performs daily reasonableness testing of the Securities Evaluations prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the Securities Evaluations prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4


 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
$
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6



The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares.

The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2017
 
December 31, 2016
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
43.9

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
168.7

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.7

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2017 or at December 31, 2016.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2017 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2017
Contracts maturing in January through March 2018 to sell foreign currency:
 
Notional value
$
52.0

Unrealized loss
$
0.1

Contracts maturing in January through March 2018 to purchase foreign currency:
 
Notional value
$
413.2

Unrealized loss
$
1.0



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
126.3

 
$
126.1

Mature in one to five years
157.9

 
157.2

Mature in more than five years
45.0

 
44.7

Total
$
329.2

 
$
328.0



The estimated fair value of financial instruments that are not recognized at fair value in the Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.  Other investments include financial instruments, the majority of which has fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability.  Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
91.8

 
$
1,249.4

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases
and current maturities
$
423.1

 
$
449.8

 
2
 
$
422.5

 
$
454.2

 
2


We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries.  We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2017.  The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method.  The carrying value of this investment is included in Other investments in our Consolidated Balance Sheets. As the stock is too thinly traded and the fair value is not readily determinable in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
4. Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure 4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2017
 
 
2016
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.1

 
$
311.7

 
$
518.8

 
 
$
207.2

 
$
316.9

 
$
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
179.9

 
297.2

 
477.1

 
 
180.0

 
315.9

 
495.9

Acquisitions
 
26.2

 
—

 
26.2

 
 
0.1

 
—

 
0.1

Impairment
 
(8.7
)
 
(2.8
)
 
(11.5
)
 
 
—

 
(13.5
)
 
(13.5
)
Currency fluctuations
 
1.4

 
12.9

 
14.3

 
 
(0.2
)
 
(5.2
)
 
(5.4
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.7

 
324.6

 
559.3

 
 
207.1

 
311.7

 
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
$
198.8

 
$
307.3

 
$
506.1

 
 
$
179.9

 
$
297.2

 
$
477.1



In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions"), we recorded $26.2 million of goodwill and $37.6 million of definite-lived intangible assets: $36.4 million of licenses, $1.0 million of developed product technology and $0.2 million of tradenames.

In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively. Impairment for the Pasteur Sanofi Diagnostics S.A. was included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations. In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc., which is included in our Clinical Diagnostics segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6




Amortization expense related to purchased intangible assets for the years ended December 31, 2017, 2016 and 2015 was $30.8 million, $35.2 million and $36.5 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2018, 2019, 2020, 2021, 2022 and thereafter is $28.4 million, $25.0 million, $22.9 million, $22.1 million, $18.0 million, and $57.7 million, respectively.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
5. Notes Payable and Long-Term Debt
 12 Months Ended
Dec. 31, 2017
Debt Disclosure [Abstract]  
Notes Payable and Long-term Debt 5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $208.4 million available for borrowing and usage as of December 31, 2017, which was reduced by $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.9
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
423.1

 
422.5

Capital leases and other debt
11.9

 
12.0

 
435.0

 
434.5

Less current maturities
(0.4
)
 
(0.3
)
Long-term debt
$
434.6

 
$
434.2



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including
limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2017. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2017 or 2016, however, $0.5 million and $0.8 million were utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2017 and 2016, respectively. The Credit Agreement matures in June 2019. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.94% at December 31, 2017.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2017.

Maturities of long-term debt at December 31, 2017 are as follows: 2018 - $0.4 million; 2019 - $0.3 million; 2020 - $425.3 million; 2021 - $0.3 million; 2022 - $0.3 million; thereafter - $10.3 million.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
6. Income Taxes
 12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Taxes [Text Block] 6. INCOME TAXES

On December 22, 2017, comprehensive tax legislation (the “Tax Act”) was enacted into law. The Tax Act made broad and complex changes to the U.S. tax code that affect our 2017 financial statements, including, but not limited to, (1) a one-time mandatory deemed repatriation tax on certain unrepatriated foreign earnings (“Transition Tax”) that is payable over eight years; (2) bonus depreciation that allows for full expensing of qualified property; and (3) a reduction in the U.S. federal corporate tax rate from 35% to 21% effective in 2018, which requires us to remeasure our deferred tax assets and liabilities as of December 31, 2017. The Tax Act also includes provisions that may affect our 2018 financial statements, including, but not limited to, (1) the elimination of the corporate alternative minimum tax; (2) the creation of the base erosion anti-abuse tax, a new minimum tax; (3) a change from a worldwide tax system to a modified territorial system; (4) a new provision designed to tax global intangible low-taxed income, which allows for the possibility of using foreign tax credits and a deduction of up to 50 percent to offset the income tax liability (subject to some limitations); (5) a new limitation on deductible interest expense; (6) the repeal of the domestic production activity deduction; (7) limitations on the deductibility of certain executive compensation; (8) limitations on the use of foreign tax credits to reduce the U.S. income tax liability; and (9) limitations on net operating losses generated after December 31, 2017 to 80 percent of taxable income. We are currently reviewing and evaluating the Tax Act and its impacts to our financial statements.

Subsequent to the enactment of the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under Accounting Standards Codification ("ASC") 740, "Income Taxes." In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate can be determined, the company must record a provisional estimate in the financial statements. For the year ended December 31, 2017, we recorded those amounts for which the accounting was complete or for which we were able to make reasonable
estimates. The provisional estimates of the Transition Tax and remeasurement of our deferred tax assets and liabilities will be adjusted as additional information and guidance become available.

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U.S.
 
$
72.8

 
$
(38.5
)
 
$
48.4

International
 
25.0

 
80.1

 
97.4

Income before taxes
 
$
97.8

 
$
41.6

 
$
145.8



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
6.7

 
$
16.1

 
$
8.7

State
 
3.4

 
3.1

 
1.7

International
 
32.0

 
30.4

 
34.1

Current tax expense
 
42.1

 
49.6

 
44.5

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(69.8
)
 
(42.4
)
 
2.0

State
 
4.3

 
(2.8
)
 
1.4

International
 
(19.3
)
 
(6.0
)
 
(7.1
)
Deferred tax benefit
 
(84.8
)
 
(51.2
)
 
(3.7
)
Non-current tax expense (benefit)
 
18.3

 
17.2

 
(4.2
)
(Benefit from) provision for income taxes
 
$
(24.4
)
 
$
15.6

 
$
36.6



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U. S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
7

 
(15
)
 
(4
)
Foreign dividends, net
 
—

 
(40
)
 
(4
)
Research tax credits
 
(4
)
 
(9
)
 
(2
)
Nontaxable subsidies
 
(2
)
 
(4
)
 
(1
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
47

 
(3
)
Goodwill impairment
 
—

 
11

 
—

Domestic manufacturing deduction
 
—

 
(4
)
 
(2
)
Stock-based compensation
 
(5
)
 
3

 
1

Nondeductible executive compensation
 
2

 
3

 
1

Fines and penalties
 
—

 
2

 
—

Prior period adjustments
 
—

 
4

 
3

U.S. taxation of foreign income
 
3

 
2

 
—

Acquisition-related
 
10

 
—

 
—

U.S. tax reform
 
(71
)
 
—

 
—

State taxes
 
3

 
1

 
1

Other
 
(3
)
 
1

 
—

(Benefit from) provision for income taxes
 
(25
)%
 
37
 %
 
25
 %


Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Our effective income tax rate was (25)%, 37% and 25% in 2017, 2016 and 2015, respectively. The lower effective tax rate in 2017 is primarily due to an estimated provisional tax benefit from the Tax Act of approximately $70 million. The effective tax rates for 2016 and 2015 included tax benefits from the repatriation of foreign earnings. The effective tax rate for 2016 included additional tax liabilities for unrecognized tax benefits related to the non-deductibility of interest expense in our foreign jurisdictions.
  
In accordance with SAB 118, our accounting for the following elements of the Tax Act is incomplete. However, we were able to make reasonable estimates of certain effects and, therefore, recorded provisional estimates as follows:

–
Our deferred tax assets and liabilities are measured at the enacted tax rate that will apply when these temporary differences are expected to be realized or settled. In connection with the Tax Act, we have provisionally recorded a deferred income tax benefit of $125 million for the statutory corporate tax rate reduction as our U.S. federal deferred tax liabilities exceed our deferred tax assets. This deferred tax benefit is primarily related to the remeasurement of the deferred tax liability for our investment in the preferred shares of Sartorius AG.

–
The Tax Act imposes a Transition Tax payable over eight years. The Transition Tax is assessed on the U.S. shareholders’ share of certain foreign corporations’ accumulated untaxed foreign earnings. Earnings in the form of cash and cash equivalents are taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. We recorded a provisional income tax expense of $55 million for Transition Tax. As additional information and guidance become available, the determination of the Transition Tax will be completed within the measurement period in accordance with SAB 118.

Our accounting for certain other elements of the Tax Act is incomplete, and we are not yet able to make reasonable estimates of those effects. For example, we have not made a determination as to our accounting policy with respect to the new Global Intangible Low Tax Income ("GILTI"). Therefore, no provisional adjustments were recorded.

Many jurisdictions in which we operate have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2017
 
2016
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.6

 
$
25.8

Other post-employment benefits, vacation and other reserves
 
24.0

 
26.3

Tax credit and net operating loss carryforwards
 
73.3

 
96.4

Other
 
19.7

 
35.7

    Total gross deferred tax assets
 
145.6

 
184.2

Valuation allowance
 
(66.4
)
 
(66.4
)
       Total deferred tax assets
 
79.2

 
117.8

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
33.5

 
22.2

Investments and intangible assets
 
219.1

 
287.8

        Total deferred tax liabilities
 
252.6

 
310.0

Net deferred tax liabilities
 
$
(173.4
)
 
$
(192.2
)


Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

At December 31, 2017, Bio-Rad’s international subsidiaries had combined net operating loss carryforwards of $207.2 million.  Of these loss carryforwards, $150.6 million have no expiration date.  We believe that it is more likely than not that the benefit from approximately half of these net operating loss carryforwards will not be realized. We have provided a valuation allowance of $27.8 million relating to these net operating loss carryforwards.

At December 31, 2017, Bio-Rad had approximately $53 million of California net operating loss carryforwards related to the acquisition of QuantaLife. We believe that it is more likely than not that the benefit from these net operating loss carryforwards will not be realized and have recorded a full valuation allowance against these losses. At December 31, 2017, Bio-Rad had a deferred tax asset of $29.6 million relating to California research tax credit carryforwards, including $2.0 million from the acquisition of QuantaLife, which may be carried forward indefinitely.  Based on our judgment and consistent with prior years, we have recorded a full valuation allowance against the deferred tax asset.

Although we believe that it is more likely than not that certain of these deferred tax assets described above will not be realized in the foreseeable future, if or when recognized, the tax benefits relating to any reversal of the valuation allowance will be recognized as a reduction of income tax expense.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2014 and forward for the U.S. and the years 2012 and forward for certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions an
d allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2017
 
2016
 
2015
Unrecognized tax benefits – January 1
 
$
21.1

 
$
11.9

 
$
15.8

Additions to tax positions related to prior years
 
1.3

 
10.4

 
0.7

Reductions to tax positions related to prior years
 
(1.0
)
 
—

 
(0.2
)
Additions to tax positions related to the current year
 
34.8

 
3.4

 
2.9

Settlements
 
(0.2
)
 
(2.4
)
 
(0.5
)
Lapse of statute of limitations
 
(3.4
)
 
(2.3
)
 
(6.3
)
Currency translation
 
2.3

 
0.1

 
(0.5
)
Unrecognized tax benefits – December 31
 
$
54.9

 
$
21.1

 
$
11.9



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2017, 2016 and 2015, respectively was $10.9 million, $11.8 million and $3.1 million. Bio-Rad accrued interest and penalties of $(0.9) million, $8.7 million, and $(0.7) million in 2017, 2016, and 2015, respectively. The total unrecognized tax benefits and interest and penalties of $65.8 million in 2017 was partially offset by deferred tax assets of $2.8 million and prepaid taxes of $14.5 million, for a net amount of $48.5 million.

As of December 31, 2017, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.3 million. Substantially all such amounts will impact our effective income tax rate if recognized.

Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Act, which also repeals U.S. taxation on the subsequent repatriation of those earnings. It is generally our intention to repatriate those foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. While we currently estimate that the repatriation of those earnings would not trigger material costs, these estimates are provisional, and we are still evaluating the full impact of these potential repatriations in accordance with SAB 118.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
7. Stockholders' Equity
 12 Months Ended
Dec. 31, 2017
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block] 7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2015
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108


Treasury Shares

On November 28, 2017, we announced that the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock. During the second and third quarters of 2017, we made open market purchases of 13,200 shares of our Class A common stock. In September 2017, we used 12,740 of the repurchased shares in connection with the vesting of restricted stock units under the 2007 Incentive Award Plan in order to obtain a tax deduction in some of our foreign entities. The Credit Agreement may limit our ability to repurchase our stock. In accordance with the terms of awards under the 2007 Incentive Award Plan, in June 2012, we withheld 122 shares of our Class A common stock and 917 shares of our Class B common stock to satisfy tax obligations due upon the vesting of restricted stock of certain of our employees, which is considered a repurchase of our stock. We had no other repurchases of our stock during 2017 or 2016.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Accumulated Other Comprehensive Income
 12 Months Ended
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
accumulated other comprehensive income [Text Block] 8.    ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2016
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02**
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8


**See Note 1, "Significant Accounting Policies" under "Recent Accounting Standards Update"

The increases in 2017 and 2016 for net unrealized holding gains on available-for-sale investments were primarily from our ownership in the preferred shares of Sartorius.

The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2017
2016
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.1
)
$
(2.5
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.1

$
0.8

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
9. Share-based Compensation
 12 Months Ended
Dec. 31, 2017
Share-based Compensation [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments
9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have three equity award plans for officers and certain other employees: the 2003 Stock Option Plan (2003 Plan), the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2003 Plan authorized the grant of incentive stock options and non-qualified stock options to employees. The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2003 Plan or 2007 Plan. From 2007 through 2016, all share-based compensation grants were from the 2007 Plan.

In April 2017, our stockholders approved the 2017 Plan. The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 1,999,714 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2017, there were 1,771,794 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  Stock awards issued under the 2007 Plan and 2017 Plan generally vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2017, 2016 and 2015, we recognized share-based compensation expense of $23.4 million, $19.7 million and $17.0 million, respectively.  The income tax benefit related to share-based compensation expense was $5.8 million, $5.1 million and $4.3 million for 2017, 2016 and 2015, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2017, 2016 and 2015 was $6.3 million, $1.5 million, and $3.6 million, respectively. The actual tax benefit realized for the tax deductions from share-based
compensation vested or exercised, including excess tax benefits that were recognized in stockholders’ equity, totaled $6.0 million and $9.3 million in 2016 and 2015, respectively.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
 
 
 
Granted
 
44,000

 
$
215.98

 
 
 
 
Exercised
 
(78,890
)
 
$
89.41

 
 
 
 
Forfeited/expired
 
(7,200
)
 
$
177.99

 
 
 
 
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
5.09
 
$
48.2

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2017
 
125,720

 
$
164.84

 
8.29
 
$
9.3

Exercisable, December 31, 2017
 
281,760

 
$
100.56

 
3.66
 
$
38.9




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2017, 2016 and 2015 was approximately $10 million, $1 million and $13 million, respectively. The total fair value of options vested during 2017, 2016 and 2015 was $4.2 million, $2.1 million and $1.6 million, respectively.

Cash received from stock options exercised during 2017, 2016 and 2015 was $1.6 million, $1.2 million and $2.9 million, respectively.  

As of December 31, 2017, there was $5.5 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Expected volatility
 
20
%
 
21
%
 
23
%
Risk-free interest rate
 
1.87
%
 
1.35
%
 
1.90
%
Expected life (in years)
 
7.2

 
7.4

 
7.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
58.65

 
$
42.40

 
$
42.74



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and in 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
 
 
 
Granted
 
192,860

 
$
215.98

 
 
 
 
Vested
 
(127,189
)
 
$
133.54

 
 
 
 
Forfeited
 
(41,263
)

$
151.36

 
 
 
 
Outstanding, December 31, 2017
 
473,230

 
$
172.75

 
2.14
 
$
112.9



The total fair value of restricted stock units vested in 2017, 2016 and 2015 was $27.7 million, $18.7 million and $15.8 million, respectively. As of December 31, 2017, there was approximately $74.7 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 4 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2017
 
 
 
2016
 
 
 
2015
Expected volatility
19
%
 
 
 
20
%
 
 
 
18
%
Risk-free interest rate
0.83
%
 
 
 
0.26
%
 
 
 
0.02
%
Expected life (in years)
0.24

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
38.86

 
 
 
$
27.36

 
 
 
$
25.08



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 74,409 shares for $13.0 million, 93,605 shares for $11.5 million and 96,634 shares for $10.8 million under the 2011 ESPP to employees in 2017, 2016 and 2015, respectively.  At December 31, 2017, 721,712 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
10. Other Income and Expenses
 12 Months Ended
Dec. 31, 2017
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure 10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
 
 
 
 
 
 
Interest and investment income
 
$
(19.1
)
 
$
(14.7
)
 
$
(10.1
)
Net realized gains on investments
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Other (income) expense, net
 
$
(12.2
)
 
$
(14.9
)
 
$
(11.1
)


Other-than-temporary impairment losses on investments were recorded in 2017, 2016 and 2015 in light of continuing declines in the investment market prices and investees' financial conditions at that time.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
11. Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2017
Supplemental Cash Flow Information [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Net income
 
$
122.2

 
$
26.0

 
$
109.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
148.7

 
142.9

 
131.8

Share-based compensation
 
23.4

 
19.7

 
17.0

Gains on dispositions of securities
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Losses on dispositions of fixed assets
 
8.1

 
0.6

 
0.3

Excess tax benefits from share-based compensation
 
—

 
(1.5
)
 
(3.6
)
Changes in fair value of contingent consideration
 
(18.1
)
 
(0.4
)
 
(5.6
)
(Increase) decrease in accounts receivable, net
 
(64.1
)
 
12.5

 
(39.0
)
Increase in inventories, net
 
(47.7
)
 
(57.1
)
 
(54.2
)
(Increase) decrease in other current assets
 
(36.1
)
 
(6.6
)
 
0.1

Increase in accounts payable
 


 


 


and other current liabilities
 
7.8

 
30.1

 
28.6

(Decrease) increase in income taxes payable
 
(22.4
)
 
10.7

 
12.7

Decrease in deferred income taxes
 
(82.0
)
 
(51.4
)
 
(4.0
)
Decrease in other long term assets
 
2.4

 
12.7

 
0.3

Increase (decrease) in other long term liabilities
 
38.1

 
10.4

 
(10.7
)
Impairment losses on goodwill and long-lived assets
 
11.5

 
62.3

 
—

Other
 
5.2

 
5.7

 
4.3

Net cash provided by operating activities
 
$
103.9

 
$
216.4

 
$
186.2

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
—

 
7.2

 
—

   Purchased marketable securities and investments
 
$
2.8

 
$
0.6

 
$
2.2
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities
 12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] 12. COMMITMENTS AND CONTINGENT LIABILITIES

Rents and Leases

Rental expense under operating leases was $43.6 million, $44.4 million and $45.0 million in 2017, 2016 and 2015, respectively.  Leases are principally for facilities and automobiles. We had no sublease income.

Annual future minimum lease payments at December 31, 2017 under operating leases are as follows: 2018 - $39.3 million; 2019 - $33.2 million; 2020 - $27.1 million; 2021 - $17.8 million; and 2022 and beyond - $27.5 million.

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $16.0 million, $15.1 million and $14.7 million in 2017, 2016 and 2015, respectively.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2017 and 2016 of $74.9 million and $63.9 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2017
2016
Benefit obligation at beginning of year
$122.7
$120.8
Service cost
6.5

6.1

Interest cost
1.1

1.4

Plan participants' contributions
2.8

2.6

Actuarial (gain) loss
3.3

—

Gross benefits paid
(3.2
)
(3.3
)
Plan amendments
1.1

—

Special termination benefits
(2.0
)
—

Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
9.4

(2.4
)
 
 
 
Benefit obligation at end of year
136.6

122.7

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
58.8

56.7

Actual return on plan assets
0.5

1.3

Employer contributions
4.0

4.7

Plan participants' contributions
2.8

2.6

Gross benefits paid
(2.3
)
(2.9
)
Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
3.0

(1.1
)
 
 
 
Fair value of plan assets at end of year
61.7

58.8

 
 
 
Under funded status of plans
$(74.9)
$(63.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(0.5)
Noncurrent liabilities (Other long-term liabilities)
(73.8
)
(63.4
)
 
 
 
Net liability, end of fiscal year
$(74.9)
$(63.9)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2017
2016
2015
Service costs
$6.5
$6.1
$5.3
Interest costs
1.1

1.4

1.4

Expected returns on plan assets
(1.1
)
(1.0
)
(1.2
)
Amortization of actuarial losses
1.4

1.7

0.8

Amortization of prior service costs
—

—

0.4

Settlements
1.2

0.4

—

 
 
 
 
Net periodic benefit costs
$9.1
$8.6
$6.7
 
 
 
 


Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2017
2016
Discount rate
0.8
%
0.9
%
Compensation rate increase
1.8
%
1.6
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2017
2016
2015
Discount rate
0.9
%
1.1
%
1.3
%
Expected long-term rate of return on plan assets
1.9
%
1.6
%
2.3
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2017 and 2016 was $3.7 million and $3.5 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Purchase Obligations

As of December 31, 2017, we had obligations that have been recognized on our balance sheet of $131.2 million, which include purchases of goods and services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. These obligations also include other post-employment benefits in some of our foreign locations as indicated above.

The annual future fixed and determinable portion of our purchase obligations that have been recognized on our balance sheet as of December 31, 2017 are as follows: 2018 - $10.3 million, 2019 - $14.3 million, 2020 - $10.6 million, 2021 - $6.9 million, 2022 - $2.6 million and after 2022 - $86.5 million.

As of December 31, 2017, we had purchase obligations that have not been recognized on our balance sheet of $24.5 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2017 are as follows: 2018 - $3.7 million, 2019 - $3.8 million, 2020 - $3.7 million, 2021 - $3.8 million, 2022 - $3.7 million and after 2022 - $5.8 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.2 million of standby letters of credit/guarantees with financial institutions as of December 31, 2017.

Contingent Consideration

During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. The current contingent consideration is built on a sales forecast of $78 million through December 31, 2020. In the third quarter of 2017, we paid $0.6 million upon reaching the first milestone and since 2016 we have decreased the valuation of the sales milestones by $6.0 million. The contingent consideration was accrued at its estimated fair value of $16.7 million as of December 31, 2017.

In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. This amount had been accounted for as a contingent liability as of December 31, 2016 in the amount of $10.0 million and was reversed to selling, general and administrative expense during the first quarter of 2017 due to reaching a favorable resolution of the contingency with the previous owners of GnuBIO, Inc.

In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million. The remaining liability of $3.1 million was paid in February 2017.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2017, approximately seven percent of Bio-Rad's approximately 3,270 U.S. employees were covered by a collective bargaining agreement, which will expire on November 7, 2019.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
13. Legal Proceedings
 12 Months Ended
Dec. 31, 2017
Legal Proceedings [Abstract]  
Legal Matters and Contingencies 13.    LEGAL PROCEEDINGS

On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption
was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”.

On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015.  The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”.

The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement.

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017 we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit.

Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleged that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. In January 2018, we entered into a settlement agreement with the District pursuant to which we paid the District $990,000 to settle all claims and/or potential claims arising out of our use of the three power generation units. This settlement amount was accrued for as of December 31, 2017.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any
assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


XML 35 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Reporting
 12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segment Information 14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2017, 2016, and 2015 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2017
 
$
785.2

 
$
1,360.8

 
$
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
 
 
 
 
 
 
 
Allocated interest expense
2017
 
$
7.0

 
$
14.9

 
$
—

 
2016
 
6.4

 
15.5

 
—

 
2015
 
6.1

 
15.4

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2017
 
$
36.2

 
$
80.2

 
$
—

 
2016
 
31.7

 
80.5

 
—

 
2015
 
30.7

 
77.8

 
0.1

 
 
 
 
 
 
 
 
Segment (loss) profit
2017
 
$
(10.1
)
 
$
112.5

 
$
1.4

 
2016
 
(19.2
)
 
57.0

 
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
 
 
 
 
 
 
 
Segment assets
2017
 
$
453.0

 
$
1,038.4

 
$
4.8

 
2016
 
380.8

 
909.1

 
4.9

 
 
 
 
 
 
 
 
Capital expenditures
2017
 
$
12.6

 
$
59.0

 
$
—

 
2016
 
14.3

 
67.1

 
—

Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Total segment profit
$
103.8

 
$
38.7

 
$
152.4

Foreign exchange losses
(9.1
)
 
(4.5
)
 
(10.2
)
Net corporate operating, interest and other expense, net not allocated to segments
(9.1
)
 
(7.5
)
 
(7.5
)
Other income (expense), net
12.2

 
14.9

 
11.1

Consolidated income before taxes
$
97.8

 
$
41.6

 
$
145.8




The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2017
 
2016
Total segment assets
 
$
1,496.2

 
$
1,294.8

Cash and other current assets
 
965.8

 
980.3

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
57.0

 
91.1

Goodwill, net
 
506.1

 
477.1

Other long-term assets
 
1,247.9

 
1,007.2

Total assets
 
$
4,273.0

 
$
3,850.5



Prior year amounts have been revised (see Note 1 to the consolidated financial statements).

The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Europe
 
$
758.5

 
$
742.2

 
$
763.7

Pacific Rim
 
461.3

 
427.1

 
392.2

United States
 
800.2

 
770.6

 
735.0

Other (primarily Canada and Latin America)
 
140.2

 
128.3

 
128.5

Total net sales
 
$
2,160.2

 
$
2,068.2

 
$
2,019.4


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2017
 
2016
Europe
 
$
230.6

 
$
221.1

Pacific Rim
 
18.4

 
16.1

United States  
 
1,305.2

 
1,084.7

Other (primarily Canada and Latin America)
 
13.1

 
12.3

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,567.3

 
$
1,334.2
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
15. Restructuring Costs (Notes)
 12 Months Ended
Dec. 31, 2017
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded approximately $0.5 million and $12.5 million in restructuring charges related to severance and other employee benefits for the years ended December 31, 2017 and 2016, respectively. The liability of $6.3 million as of December 31, 2017 consisted of $6.2 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(0.2) million and $2.1 million, and in Selling, general and administrative expense of $0.7 million and $10.4 million in the Consolidated Statements of Income for the years ended December 31, 2017 and 2016, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2017
 
2016
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
3.2

 
$
5.8

 
$
9.0

 
$
—

 
$
—

 
$
—

Charged to expense
 
—

 
—

 
—

 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.2

 
0.3

 
0.5

 
0.3

 
0.5

 
0.8

Cash payments
 
(1.5
)
 
(2.7
)
 
(4.2
)
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation losses (gains)
 
0.3

 
0.7

 
1.0

 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance as of December 31
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0




Restructuring Costs for GnuBIO, Inc.

In 2014, we acquired GnuBIO, Inc. (GnuBIO) as a business acquisition. It is included in our Clinical Diagnostics segment’s results of operations as a division, and is primarily based in Massachusetts. In September 2017, we announced that we are closing the GnuBIO research program facilities in Massachusetts. As a result, we recorded restructuring charges in September 2017 related to severance and employee benefits of $2.9 million and asset write-offs of $5.5 million. The amounts recorded were reflected in Selling, general and administrative expense of $0.8 million and in Research and development expense of $7.6 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability balance as of December 31, 2017 was $1.4 million and is recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. We expect the remainder to be paid in early 2018.

Restructuring Costs for Termination of an Infectious Disease Research and Development Project

In December 2017, we announced the termination of an infectious disease research and development project, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded restructuring charges related to severance and employee benefits of $11.0 million, and asset write-offs and exit costs of $10.1 million for the year ended December 31, 2017. The amounts recorded were reflected in Cost of goods sold of $2.3 million, in Selling, general and administrative expense of $3.3 million, and in Research and development expense
of $15.5 million in the Consolidated Statements of Income for the year ended December 31, 2017. The liability of $14.1 million as of December 31, 2017 consisted of $11.1 million recorded in Accrued payroll and employee benefits and $3.0 million recorded in Other current liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the infectious disease research and development project restructuring reserves for severance and exit costs (in millions):

 
 
2017
Balance as of January 1
 
$
—

Charged to expense
 
14.0

Cash payments
 
—

Foreign currency translation losses

 
0.1

Balance as of December 31
 
$
14.1
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
16. Quarterly Financial Data
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Data [Abstract]  
Quarterly Financial Data [Text Block] 16. QUARTERLY FINANCIAL DATA (UNAUDITED)

During 2016 and 2015, there were three different misstatements associated with income taxes. The first misstatement was related to our second implementation of our global single instance ERP platform in the U.S. in the third quarter of 2015. Part of the data migrated was not reconciled timely, resulting in the double counting of a deferred tax asset. The second misstatement was related to the misapplication of a tax rule related to foreign dividend income. The third misstatement was related to a design deficiency associated with transfer pricing.

Management evaluated the materiality of all the errors described above from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 108, Considering the Effect of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). Accordingly, we are correcting these errors in every affected period in the 2015 and 2016 consolidated financial statements included in this Form 10-K.

During the fourth quarter of 2017, we identified errors in the unaudited interim condensed consolidated financial statements for the three months ended September 30, 2017. We identified an error in the recording of deferred revenue acquired in our acquisition of RainDance (see Note 2, "Acquisitions"). This resulted in an overstatement of revenue recorded in the third quarter of 2017 of $0.9 million that was corrected in the fourth quarter of 2017. In addition, we identified an error in an estimated employee benefit expense that resulted in an understatement of expenses reported in Cost of goods sold, Selling, general and administrative expense and Research and development expense, net, in the third quarter of 2017 of $3.8 million that was corrected in the fourth quarter of 2017. Finally, we identified an error during our reconciliation of various inventory accounts which resulted in an understatement of Cost of goods sold in the third quarter of 2017 of $3.5 million that was corrected in the fourth quarter of 2017. The impact of these errors resulted in an overstatement of our Provision for income taxes reported in the third quarter of 2017 of $2.9 million that was corrected in the fourth quarter of 2017.

Management evaluated the materiality of all the errors described in the previous paragraph from a qualitative and quantitative perspective. Based on such evaluation, we have concluded that they are not material to any individual prior period, nor did they have an effect on the trend of financial results, taking into account the requirements of SAB 108. Accordingly, we are correcting these errors in the financial statements for the quarter ended September 30, 2017 included in this Form 10-K.


The impact of the immaterial error corrections described above are presented on a as reported, adjustment and as revised basis in the following summarized quarterly financial data for 2017 and 2016 (in millions, except per share data):

As reported:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
535.0

 
$
620.4

Cost of goods sold
 
230.1

 
231.4

 
230.5

 
280.8

Gross profit
 
270.0

 
273.3

 
304.5

 
339.6

Selling, general and administrative expense
 
194.9

 
213.0

 
196.8

 
204.2

Research and development expense
 
49.5

 
62.6

 
61.4

 
76.8

Income before income taxes
 
20.1

 
1.1

 
38.9

 
37.7

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(11.5
)
 
32.2

Net income
 
12.4

 
5.0

 
27.4

 
69.9

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.92

 
$
2.35

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.91

 
$
2.32

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(7.9
)
 
(8.9
)
 
(4.3
)
 
7.6

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)


Adjustments:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
(0.9
)
 
$
0.9

Cost of goods sold
 
—

 
—

 
4.7

 
(4.7
)
Gross profit
 
—

 
—

 
(5.6
)
 
5.6

Selling, general and administrative expense
 
—

 
—

 
1.9

 
(1.9
)
Research and development expense
 
—

 
—

 
0.7

 
(0.7
)
Income before income taxes
 
—

 
—

 
(8.2
)
 
8.2

(Provision for) benefit from income taxes
 
—

 
—

 
2.9

 
4.6

Net income
 
—

 
—

 
(5.3
)
 
12.8

Basic earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

Diluted earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
—

 
$
—

Cost of goods sold
 
—

 
—

 
—

 
—

Gross profit
 
—

 
—

 
—

 
—

Selling, general and administrative expense
 
—

 
—

 
—

 
—

Research and development expense
 
—

 
—

 
—

 
—

Income (loss) before income taxes
 
—

 
—

 
—

 
—

(Provision for) benefit from income taxes
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Net income (loss)
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Basic earnings (loss) per share
 
$
(0.04
)
 
$
(0.05
)
 
$
(0.05
)
 
$
0.07

Diluted earnings (loss) per share
 
$
(0.05
)
 
$
(0.05
)
 
$
(0.04
)
 
$
0.07


As revised:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Cost of goods sold
 
230.1

 
231.4

 
235.2

 
276.1

Gross profit
 
270.0

 
273.3

 
298.9

 
345.2

Selling, general and administrative expense
 
194.9

 
213.0

 
198.7

 
202.3

Research and development expense
 
49.5

 
62.6

 
62.1

 
76.1

Income before income taxes
 
20.1

 
1.1

 
30.7

 
45.9

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(8.6
)
 
36.8

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(9.2
)
 
(10.3
)
 
(5.6
)
 
9.5

Net income (loss)
 
11.0

 
16.6

 
17.1

 
(18.7
)
Basic earnings (loss) per share
 
$
0.38

 
$
0.56

 
$
0.58

 
$
(0.63
)
Diluted earnings (loss) per share
 
$
0.37

 
$
0.56

 
$
0.58

 
$
(0.63
)



Note: As a result of the net loss for the three months ended December 31, 2016,
all potentially issuable common shares have been excluded from the diluted shares
used in the computation of earnings per share as their effect was anti-dilutive.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Schedule II - Valuation and Qualifying Accoutns
 12 Months Ended
Dec. 31, 2017
Valuation and Qualifying Accounts Disclosure [Line Items]  
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2017, 2016, and 2015
(in thousands)


Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 
Additions
Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549

2016
 
$
24,418

 
$
3,785

 
$
(4,836
)
 
$
23,367

2015
 
$
27,973

 
$
8,783

 
$
(12,338
)
 
$
24,418



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Additions Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356

2016
 
$
58,277

 
$
8,126

 
$
—

 
$
66,403

2015
 
$
58,615

 
$
(338
)
 
$
—

 
$
58,277
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
17. Subsequent Event (Notes)
 12 Months Ended
Dec. 31, 2017
Subsequent Events [Abstract]  
Subsequent Events [Text Block] 17. SUBSEQUENT EVENT

Subsequent to December 31, 2017, the Company obtained an extension of time to provide its annual audited financial statements for its 2017 fiscal year and related compliance certificate and other deliveries as currently required by the Credit Agreement discussed in Note 5. This extension provides that the Company may provide its annual audited financial statements for its 2017 fiscal year within 120 days after the end of its 2017 fiscal year and its compliance certificate in respect of its 2017 fiscal year within 130 days after the end of its 2017 fiscal year. No amounts were outstanding under this Credit Agreement at December 31, 2017 and no amounts have been borrowed since.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Research and Development Expense, Policy [Policy Text Block]
Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.  
Basis of Presentation Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.
Cash and Cash Equivalents Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments

Short-term restricted investments of $5.6 million and $4.6 million at December 31, 2017 and 2016, respectively, represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.
Available-for-sale Investments Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale investments for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).
Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. Bio-Rad has not sustained significant losses from instruments held at financial institutions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  However, we do not expect to record any losses as a result of counterparty default.

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.
Accounts Receivable Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.
Inventory Inventory

Inventories are valued at the lower of actual cost or market (net realizable value) and include material, labor and overhead costs.  The first-in, first-out method is used to relieve inventory for products sold.
Property, Plant and Equipment Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the term of the leases or life of the improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment and capitalized software is depreciated over 3-12 years.
Goodwill Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating
segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

Effective January 1, 2017 in accordance with Accounting Standards Update No. 2017-04, "Simplifying the Test for Goodwill Impairment," the goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Prior to January 1, 2017, the goodwill impairment test consisted of a two-step process.  The first step of the goodwill impairment test, used to identify potential impairment, compared the fair value of a reporting unit to its carrying value, including goodwill. We used a projected discounted cash flow model to determine the fair value of a reporting unit.  If the fair value of the reporting unit exceeded its carrying amount, goodwill of the reporting unit was considered not impaired, and the second step of the impairment test was not required.  The second step, if required, compared the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit was allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit.  If the carrying amount of the reporting unit’s goodwill exceeded its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Long-Lived Assets Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
Income Taxes Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. To the extent we determine that we are able to realize our deferred income tax assets in the future in excess of their net recorded amount, we make an adjustment to the valuation allowance which may reduce the provision for income taxes. When we establish or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.
Revenue Recognition Revenue Recognition

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, collectability is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  At the time revenue is recognized, a provision is recognized for estimated product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement, or as services are performed if not under contract. Net sales are the actual selling price of products to customers. Any taxes billed to the customer (sales tax, value added tax, etc.) shall be credited to the tax liability accounts and excluded from net sales.

Reagent agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis.  We evaluate our reagent agreements and account for these contracts under the guidance pertaining to accounting for revenue arrangements with multiple deliverables.  Our reagent
agreements represent one unit of accounting as the instrument and consumables are interdependent in producing a diagnostic result that neither has a stand-alone value with respect to these agreements. All revenues that we earn under our reagent agreements are recognized pursuant to the terms of each agreement and are based and entirely contingent upon either (i) when the consumables to conduct a fixed number of tests are delivered or (ii) cost per test conducted and reported. Revenue on a cost per reported basis is estimated in the current period, and billed at actual in the month reported by our customer.
Shipping and Handling
Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are included in Cost of goods sold.
Warranty
Warranty

We warrant certain equipment against defects in design, materials and workmanship, mostly for a period of one year.  Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2017
 
2016
January 1
 
$
17.6

 
$
17.4

Provision for warranty
 
29.9

 
33.4

Actual warranty costs
 
(28.8
)
 
(33.2
)
December 31
 
$
18.7

 
$
17.6
Foreign Currency
Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  
Share-based Compensation Plans
Share-Based Compensation Plans

Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs net of forfeitures over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Starting in 2017, we recognize forfeitures as they occur due to a change in accounting principle, and in prior periods we estimated the forfeiture rate based on our historical experience.  These plans are described more fully in Note 9.
Earnings Per Share

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Basic weighted average shares outstanding
 
29,655

 
29,440

 
29,186

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
379

 
206

 
223

Diluted weighted average common shares
 
30,034

 
29,646

 
29,409

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
13

 
113

 
109
Fair Value of Financial Instruments
Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Standards Updates

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities." ASU 2018-03 amends certain items in ASU 2016-01 (see below) such as equity securities without a readily determinable fair value. ASU 2018-03 clarifies that an entity that uses the measurement alternative for equity securities without readily determinable fair values can change its measurement approach to fair value and once made the election is irrevocable. If an entity measures equity securities without readily determinable fair values at fair value, it must record a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year in which the guidance is adopted. ASU 2018-03 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years beginning after June 15, 2018, with early adoption permitted. As of December 31, 2017, we accounted for our investment of the ordinary shares of Sartorius AG at cost and the fair value is not readily determinable as the stock is too thinly traded (see Note 3 to the consolidated financial statements). Under ASU 2016-01 (see below), we will account for the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes as we do not anticipate a material transaction that would provide an observable price change to the ordinary shares of Sartorius AG based on the current ownership interests by the Sartorius family trust, Sartorius family members, and Bio-Rad Laboratories, Inc.

In February 2018, the FASB issued ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income." ASU 2018-02 gives entities the option to reclassify to retained earnings tax effects related to items in Accumulated other comprehensive income ("OCI") that the FASB refers to as having been stranded in Accumulated OCI as a result of the Tax Act. We early adopted ASU 2018-02 in the period of adoption of the Tax Act during the fourth quarter of 2017. We elected to reclassify the income tax effects of the Tax Act on the remeasurement of our deferred tax liabilities related to our available-for-sale equity securities, including our preferred shares in Sartorius AG, by increasing OCI and decreasing Retained earnings by $120.1 million.

In May 2017, the FASB issued ASU 2017-09, "Scope of Modification Accounting." ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. ASU 2017-09 will allow companies to make certain changes to awards, such as vesting conditions, without accounting for them as modifications. It does not change the accounting for modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. We early adopted ASU 2017-09 during the second quarter of 2017, which has not affected our consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. We do not expect ASU 2017-07 to have a material impact to our financial statements.

In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 provides a more stream-lined approach to evaluating goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. See Note 4 to the consolidated financial statements for an update on goodwill impairment.

In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis, and it has not had a material impact to our consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. We do not expect ASU 2016-18 to have a material impact to our financial statements and will only impact our statements of cash flows presentation.

In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers.  Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements.  ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-16 will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We estimate the impact to be a cumulative-effect decrease to Retained earnings and predominately a decrease to Other assets of approximately $17 million.

In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We do not expect ASU 2016-15 to have a material impact to our statements of cash flows.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee’s shares than permitted today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principle on January 1, 2017, and prior periods have not been adjusted. In addition, we made a policy election to account for forfeitures as they occur. ASU 2016-09 also requires to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million, and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million, respectively, in the Consolidated Balance Sheet.

In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities.

In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the consolidated financial statements, which primarily consists of our investment in Sartorius AG preferred shares. We expect that the impact of adoption may be material to our consolidated statement of income. In addition to the affected securities per Note 3, we own ordinary voting stock of Sartorius AG and accounted for this investment under the cost method. Effective January 1, 2018 under 2016-01, we will account for our investment of the ordinary shares of Sartorius AG at cost, less any impairment, and plus or minus subsequent adjustments for observable price changes.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectability, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method when we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. Upon adoption, we will recognize the cumulative effect of adopting this guidance as an adjustment to our opening balance of retained earnings. Prior periods will not be retrospectively adjusted. We have completed our preliminary assessment of individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP. Based on our preliminary assessment we have not identified any material changes in the timing of revenue recognition that could result in a significant transition adjustment upon our adoption of the new accounting standard on January 1, 2018 and the accounting for costs incurred to obtain a contract is immaterial. However, we are still in the process of the following: Assessing the impact of the accounting on our reagent agreements to determine if there are any differences in the timing of revenue recognition; finalizing the required changes to our accounting policies, systems and internal control over financial reporting, and assessing the new disclosure requirements that will be implemented upon our adoption of the new standard.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Schedule of Product Warranty Liability
Changes in the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):
 
 
2017
 
2016
January 1
 
$
17.6

 
$
17.4

Provision for warranty
 
29.9

 
33.4

Actual warranty costs
 
(28.8
)
 
(33.2
)
December 31
 
$
18.7

 
$
17.6
Schedule of Weighted Average Number of Shares
The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Basic weighted average shares outstanding
 
29,655

 
29,440

 
29,186

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
379

 
206

 
223

Diluted weighted average common shares
 
30,034

 
29,646

 
29,409

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
13

 
113

 
109
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Prior Year Misstatements (Tables)
 12 Months Ended
Dec. 31, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]  
Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block] The impact of the reclassification, and the immaterial error corrections, both described above on our Consolidated Balance Sheet and Consolidated Statements of Income for the periods presented is as follows (in thousands, except per share data):
 
 
December 31, 2016
 
 
As reported
 
Adjustment
 
As revised
Buildings and leasehold improvements
 
$
290,367

 
$
10,467

 
$
300,834

Equipment
 
919,126

 
(10,467
)
 
908,659

Deferred income taxes
 
222,919

 
2,380

 
225,299

Other long-term liabilities
 
135,318

 
5,219

 
140,537

Total liabilities
 
1,263,745

 
7,599

 
1,271,344

Retained earnings
 
1,836,180

 
(7,599
)
 
1,828,581

Total stockholders' equity
 
$
2,586,759

 
$
(7,599
)
 
$
2,579,160



 
Year ended December 31,
 
2016
 
2015
 
As reported
Adjustment
As revised
 
As reported
Adjustment
As revised
Provision for income taxes
$
(13,435
)
$
(2,125
)
$
(15,560
)
 
$
(32,754
)
$
(3,854
)
$
(36,608
)
Net income
$
28,125

$
(2,125
)
$
26,000

 
$
113,093

$
(3,854
)
$
109,239

Net income per basic share
$
0.96

$
(0.08
)
$
0.88

 
$
3.87

$
(0.13
)
$
3.74

Net income per diluted share
$
0.95

$
(0.07
)
$
0.88

 
$
3.85

$
(0.14
)
$
3.71
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2017
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the year ended December 31, 2017 (in millions):

 
2017
 
 
January 1
$
28.5

Cell sorting system:
 
Payment of sales milestone
(3.1
)
 
 
Analytical flow cytometer platform:
 
Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(8.1
)
Payment of sales milestone
$
(0.6
)
December 31
$
16.7
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]
The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2017. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
Discount rate
10.8
%
 
 
Cost of debt
4.2
%
Schedule of Derivative Instruments [Table Text Block] The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2017
Contracts maturing in January through March 2018 to sell foreign currency:
 
Notional value
$
52.0

Unrealized loss
$
0.1

Contracts maturing in January through March 2018 to purchase foreign currency:
 
Notional value
$
413.2

Unrealized loss
$
1.0
Financial assets and liabilities carried at fair value on a recurring basis Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2017 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
36.0

 
$
—

 
$
36.0

Time deposits
43.7

 
10.0

 
—

 
53.7

U.S. government sponsored agencies
—

 
11.2

 
—

 
11.2

Money market funds
3.4

 
—

 
—

 
3.4

Total cash equivalents
47.1

 
57.2

 
—

 
104.3

Restricted investment:
5.6

 
—

 
—

 
5.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
185.7

 
—

 
185.7

U.S. government sponsored agencies
—

 
67.6

 
—

 
67.6

Foreign government obligations
—

 
3.4

 
—

 
3.4

Brokered certificates of deposit
—

 
0.7

 
—

 
0.7

Municipal obligations
—

 
15.0

 
—

 
15.0

Marketable equity securities
973.4

 
—

 
—

 
973.4

Asset-backed securities
—

 
55.6

 
—

 
55.6

Total available-for-sale investments
973.4

 
328.0

 
—

 
1,301.4

Forward foreign exchange contracts (c)
—

 
0.5

 
—

 
0.5

Total financial assets carried at fair value
$
1,026.1

 
$
385.7

 
$
—

 
$
1,411.8

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (d)
$
—

 
$
1.6

 
$
—

 
$
1.6

     Contingent consideration (e)
—

 
—

 
16.7

 
16.7

Total financial liabilities carried at fair value
$
—

 
$
1.6

 
$
16.7

 
$
18.3



Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial Assets Carried at Fair Value:
 
 
 
 
 
 
 
Cash equivalents (a):
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
14.1

 
—

 
$
14.1

Foreign time deposits
11.8

 
—

 
—

 
11.8

Domestic time deposits
—

 
$
20.0

 
—

 
20.0

U.S. government sponsored agencies
—

 
1.1

 
—

 
1.1

Money market funds
5.9

 
—

 
—

 
5.9

Total cash equivalents
17.7

 
35.2

 
—

 
52.9

Restricted investment:
4.6

 
—

 
—

 
4.6

Available-for-sale investments (b):
 
 
 
 
 
 
 
Corporate debt securities
—

 
179.4

 
—

 
179.4

U.S. government sponsored agencies
—

 
82.5

 
—

 
82.5

Foreign government obligations
—

 
4.4

 
—

 
4.4

Brokered certificates of deposit
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
15.4

 
—

 
15.4

Marketable equity securities
767.8

 
—

 
—

 
767.8

Asset-backed securities
—

 
62.5

 
—

 
62.5

Total available-for-sale investments
767.8

 
347.8

 
—

 
1,115.6

Forward foreign exchange contracts (c)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
790.1

 
$
383.6

 
—

 
$
1,173.7

 
 
 
 
 
 
 
 
Financial Liabilities Carried at Fair Value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (d)
$
—

 
$
1.3

 
—

 
$
1.3

 Contingent consideration (e)
—

 
—

 
38.5

 
38.5

Total financial liabilities carried at fair value
$
—

 
$
1.3

 
$
38.5

 
$
39.8


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
Short-term investments
$
371.2

 
$
383.2

Other investments
930.2

 
732.4

Total
$
1,301.4

 
$
1,115.6



(c)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(d)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(e)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5
Schedule of available-for-sale investments Available-for-sale investments consist of the following (in millions):

 
December 31, 2017
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
185.9

 
$
0.3

 
$
(0.5
)
 
$
185.7

Brokered certificates of deposit
0.7

 
—

 
—

 
0.7

Municipal obligations
15.1

 
—

 
(0.1
)
 
15.0

Asset-backed securities
55.6

 
—

 
(0.2
)
 
55.4

U.S. government sponsored agencies
68.3

 
—

 
(0.7
)
 
67.6

Foreign government obligations
3.4

 
—

 
—

 
3.4

Marketable equity securities
34.4

 
9.0

 
—

 
43.4

 
363.4

 
9.3

 
(1.5
)
 
371.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
875.5

 
—

 
930.0

Asset-backed securities
0.2

 
—

 
—

 
0.2

 
54.7

 
875.5

 
—

 
930.2

Total
$
418.1

 
$
884.8

 
$
(1.5
)
 
$
1,301.4


 
December 31, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
179.7

 
$
0.2

 
$
(0.5
)
 
$
179.4

Brokered certificates of deposit
3.6

 
—

 
—

 
$
3.6

Municipal obligations
15.5

 
—

 
(0.1
)
 
15.4

Asset-backed securities
62.2

 
0.1

 
(0.1
)
 
62.2

U.S. government sponsored agencies
83.1

 
0.1

 
(0.7
)
 
82.5

Foreign government obligations
4.4

 
—

 
—

 
4.4

Marketable equity securities
32.4

 
3.7

 
(0.4
)
 
35.7

 
380.9

 
4.1

 
(1.8
)
 
383.2

Long-term investments:
 
 
 
 
 
 
 
Marketable equity securities
54.5

 
677.6

 
—

 
732.1

Asset-backed securities
0.3

 
—

 
—

 
0.3

 
54.8

 
677.6

 
—

 
732.4

Total
$
435.7

 
$
681.7

 
$
(1.8
)
 
$
1,115.6
Summary of investments with gross unrealized losses and the associated fair value The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2017
 
December 31, 2016
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
43.9

 
$
11.8

Fair value of investments in a loss position less than 12 months
$
168.7

 
$
160.5

Gross unrealized losses for investments in a loss position 12 months or more
$
0.7

 
$
0.3

Gross unrealized losses for investments in a loss position less than 12 months
$
0.8

 
$
1.5
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2017 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
 
 
 
 
Mature in less than one year
$
126.3

 
$
126.1

Mature in one to five years
157.9

 
157.2

Mature in more than five years
45.0

 
44.7

Total
$
329.2

 
$
328.0
Estimated fair value of financial instruments The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):


 
December 31, 2017
 
December 31, 2016
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Other investments
$
91.8

 
$
1,249.4

 
2
 
$
92.8

 
$
984.2

 
2
Total long-term debt, excluding leases
and current maturities
$
423.1

 
$
449.8

 
2
 
$
422.5

 
$
454.2

 
2
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
4. Intangible Assets, Goodwill and Other (Tables)
 12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment were as follows (in millions):
 
 
2017
 
 
2016
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
207.1

 
$
311.7

 
$
518.8

 
 
$
207.2

 
$
316.9

 
$
524.1

Accumulated impairment losses and write-offs
 
(27.2
)
 
(14.5
)
 
(41.7
)
 
 
(27.2
)
 
(1.0
)
 
(28.2
)
Goodwill, net
 
179.9

 
297.2

 
477.1

 
 
180.0

 
315.9

 
495.9

Acquisitions
 
26.2

 
—

 
26.2

 
 
0.1

 
—

 
0.1

Impairment
 
(8.7
)
 
(2.8
)
 
(11.5
)
 
 
—

 
(13.5
)
 
(13.5
)
Currency fluctuations
 
1.4

 
12.9

 
14.3

 
 
(0.2
)
 
(5.2
)
 
(5.4
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
234.7

 
324.6

 
559.3

 
 
207.1

 
311.7

 
518.8

Accumulated impairment losses and write-offs
 
(35.9
)
 
(17.3
)
 
(53.2
)
 
 
(27.2
)
 
(14.5
)
 
(41.7
)
Goodwill, net
 
$
198.8

 
$
307.3

 
$
506.1

 
 
$
179.9

 
$
297.2

 
$
477.1
Schedule of Finite-Lived Intangible Assets by Major-Class Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions):
 
December 31, 2017
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-7
 
$
92.3

 
$
(64.4
)
 
$
27.9

Know how
1-8
 
194.9

 
(157.9
)
 
37.0

Developed product technology
1-12
 
133.3

 
(70.3
)
 
63.0

Licenses
1-12
 
76.7

 
(36.0
)
 
40.7

Tradenames
1-6
 
3.9

 
(3.0
)
 
0.9

Covenants not to compete
1-8
 
7.9

 
(3.3
)
 
4.6

     Total definite-lived intangible assets
 
 
$
509.0

 
$
(334.9
)
 
$
174.1


 
December 31, 2016
 
Average
Remaining
Life (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
1-8
 
$
84.4

 
$
(52.8
)
 
$
31.6

Know how
1-9
 
182.6

 
(136.9
)
 
45.7

Developed product technology
3-12
 
125.9

 
(56.3
)
 
69.6

Licenses
1-9
 
39.0

 
(30.6
)
 
8.4

Tradenames
4-8
 
3.5

 
(2.5
)
 
1.0

Covenants not to compete
2-9
 
7.8

 
(2.5
)
 
5.3

     Total definite-lived intangible assets
 
 
$
443.2

 
$
(281.6
)
 
$
161.6
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
5. Notes Payable and Long-Term Debt (Tables)
 12 Months Ended
Dec. 31, 2017
Debt Disclosure [Abstract]  
Principal components of long-term debt [Table Text Block] The principal components of long-term debt are as follows (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(1.9
)
 
(2.5
)
Long-term debt less unamortized discount and debt issuance costs
423.1

 
422.5

Capital leases and other debt
11.9

 
12.0

 
435.0

 
434.5

Less current maturities
(0.4
)
 
(0.3
)
Long-term debt
$
434.6

 
$
434.2
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
6. Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
U.S. and international components of income before taxes [Table Text Block] The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U.S.
 
$
72.8

 
$
(38.5
)
 
$
48.4

International
 
25.0

 
80.1

 
97.4

Income before taxes
 
$
97.8

 
$
41.6

 
$
145.8
Provision for income taxes [Table Text Block] The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
6.7

 
$
16.1

 
$
8.7

State
 
3.4

 
3.1

 
1.7

International
 
32.0

 
30.4

 
34.1

Current tax expense
 
42.1

 
49.6

 
44.5

Deferred tax (benefit) expense:
 
 

 
 
 
 

U.S. Federal
 
(69.8
)
 
(42.4
)
 
2.0

State
 
4.3

 
(2.8
)
 
1.4

International
 
(19.3
)
 
(6.0
)
 
(7.1
)
Deferred tax benefit
 
(84.8
)
 
(51.2
)
 
(3.7
)
Non-current tax expense (benefit)
 
18.3

 
17.2

 
(4.2
)
(Benefit from) provision for income taxes
 
$
(24.4
)
 
$
15.6

 
$
36.6
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
U. S. statutory tax rate
 
35
 %
 
35
 %
 
35
 %
Impact of foreign operations
 
7

 
(15
)
 
(4
)
Foreign dividends, net
 
—

 
(40
)
 
(4
)
Research tax credits
 
(4
)
 
(9
)
 
(2
)
Nontaxable subsidies
 
(2
)
 
(4
)
 
(1
)
Tax settlements and changes to unrecognized tax benefits
 
—

 
47

 
(3
)
Goodwill impairment
 
—

 
11

 
—

Domestic manufacturing deduction
 
—

 
(4
)
 
(2
)
Stock-based compensation
 
(5
)
 
3

 
1

Nondeductible executive compensation
 
2

 
3

 
1

Fines and penalties
 
—

 
2

 
—

Prior period adjustments
 
—

 
4

 
3

U.S. taxation of foreign income
 
3

 
2

 
—

Acquisition-related
 
10

 
—

 
—

U.S. tax reform
 
(71
)
 
—

 
—

State taxes
 
3

 
1

 
1

Other
 
(3
)
 
1

 
—

(Benefit from) provision for income taxes
 
(25
)%
 
37
 %
 
25
 %
Significant components of deferred tax assets and liabilities [Table Text Block] Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2017
 
2016
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
28.6

 
$
25.8

Other post-employment benefits, vacation and other reserves
 
24.0

 
26.3

Tax credit and net operating loss carryforwards
 
73.3

 
96.4

Other
 
19.7

 
35.7

    Total gross deferred tax assets
 
145.6

 
184.2

Valuation allowance
 
(66.4
)
 
(66.4
)
       Total deferred tax assets
 
79.2

 
117.8

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
33.5

 
22.2

Investments and intangible assets
 
219.1

 
287.8

        Total deferred tax liabilities
 
252.6

 
310.0

Net deferred tax liabilities
 
$
(173.4
)
 
$
(192.2
)
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2017
 
2016
 
2015
Unrecognized tax benefits – January 1
 
$
21.1

 
$
11.9

 
$
15.8

Additions to tax positions related to prior years
 
1.3

 
10.4

 
0.7

Reductions to tax positions related to prior years
 
(1.0
)
 
—

 
(0.2
)
Additions to tax positions related to the current year
 
34.8

 
3.4

 
2.9

Settlements
 
(0.2
)
 
(2.4
)
 
(0.5
)
Lapse of statute of limitations
 
(3.4
)
 
(2.3
)
 
(6.3
)
Currency translation
 
2.3

 
0.1

 
(0.5
)
Unrecognized tax benefits – December 31
 
$
54.9

 
$
21.1

 
$
11.9
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)
 12 Months Ended
Dec. 31, 2017
Class of Stock [Line Items]  
Schedule of Stock by Class [Table Text Block] Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2015
23,972

 
5,099

B to A conversions
18

 
(18
)
Issuance of common stock
240

 
50

Balance at December 31, 2015
24,230

 
5,131

B to A conversions
13

 
(13
)
Issuance of common stock
211

 
6

Balance at December 31, 2016
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accumulated other comprehensive income included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains on available-for-sale investments
Total Accumulated other comprehensive income
Balances as of January 1, 2016
$
33.7

$
(20.7
)
$
369.1

$
382.1

Other comprehensive (loss) income, before reclassifications
(32.4
)
0.5

105.1

73.2

Amounts reclassified from Accumulated other comprehensive income
—

2.5

(0.8
)
1.7

Income tax effects
—

(0.9
)
(38.4
)
(39.3
)
Other comprehensive (loss) income, net of income taxes
(32.4
)
2.1

65.9

35.6

Balances as of December 31, 2016
$
1.3

$
(18.6
)
$
435.0

$
417.7

Other comprehensive income (loss), before reclassifications
76.1

(6.5
)
203.6

273.2

Amounts reclassified from Accumulated other comprehensive income
—

2.1

(0.1
)
2.0

Income tax effects
—

0.7

(74.9
)
(74.2
)
Effect of adoption of ASU 2018-02**
—

—

120.1

120.1

Other comprehensive income (loss), net of income taxes
76.1

(3.7
)
248.7

321.1

Balances as of December 31, 2017
$
77.4

$
(22.3
)
$
683.7

$
738.8
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
Income before taxes impact (in millions):
 
 
December 31,
 
 
Components of Comprehensive income
 
2017
2016
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(2.1
)
$
(2.5
)
 
Selling, general and administrative expense
 
Net holding gains on available for sale investments
 
$
0.1

$
0.8

 
Other (income) expense, net
 

Reclassification adjustments are calculated using the specific identification method.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
9. Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2017
Share-based Compensation [Abstract]  
Stock Options Activity
Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2016
 
449,570

 
$
106.52

 
 
 
 
Granted
 
44,000

 
$
215.98

 
 
 
 
Exercised
 
(78,890
)
 
$
89.41

 
 
 
 
Forfeited/expired
 
(7,200
)
 
$
177.99

 
 
 
 
Outstanding, December 31, 2017
 
407,480

 
$
120.39

 
5.09
 
$
48.2

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2017
 
125,720

 
$
164.84

 
8.29
 
$
9.3

Exercisable, December 31, 2017
 
281,760

 
$
100.56

 
3.66
 
$
38.9
Stock Options Valuation Assumptions
The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Expected volatility
 
20
%
 
21
%
 
23
%
Risk-free interest rate
 
1.87
%
 
1.35
%
 
1.90
%
Expected life (in years)
 
7.2

 
7.4

 
7.7

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
58.65

 
$
42.40

 
$
42.74
Resticted Stock Activity
The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2016
 
448,822

 
$
141.09

 
 
 
 
Granted
 
192,860

 
$
215.98

 
 
 
 
Vested
 
(127,189
)
 
$
133.54

 
 
 
 
Forfeited
 
(41,263
)

$
151.36

 
 
 
 
Outstanding, December 31, 2017
 
473,230

 
$
172.75

 
2.14
 
$
112.9
Employee Stock Purchase Plan, Valuation Assumptions The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2017
 
 
 
2016
 
 
 
2015
Expected volatility
19
%
 
 
 
20
%
 
 
 
18
%
Risk-free interest rate
0.83
%
 
 
 
0.26
%
 
 
 
0.02
%
Expected life (in years)
0.24

 
 
 
0.25

 
 
 
0.25

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
38.86

 
 
 
$
27.36

 
 
 
$
25.08
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
10. Other Income and Expenses (Tables)
 12 Months Ended
Dec. 31, 2017
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
 
 
 
 
 
 
 
Interest and investment income
 
$
(19.1
)
 
$
(14.7
)
 
$
(10.1
)
Net realized gains on investments
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Other (income) expense, net
 
$
(12.2
)
 
$
(14.9
)
 
$
(11.1
)
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
11. Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2017
Supplemental Cash Flow Information [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] 11. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Net income
 
$
122.2

 
$
26.0

 
$
109.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
148.7

 
142.9

 
131.8

Share-based compensation
 
23.4

 
19.7

 
17.0

Gains on dispositions of securities
 
(0.1
)
 
(0.8
)
 
(1.6
)
Other-than-temporary impairment losses on investments
 
7.0

 
0.6

 
0.6

Losses on dispositions of fixed assets
 
8.1

 
0.6

 
0.3

Excess tax benefits from share-based compensation
 
—

 
(1.5
)
 
(3.6
)
Changes in fair value of contingent consideration
 
(18.1
)
 
(0.4
)
 
(5.6
)
(Increase) decrease in accounts receivable, net
 
(64.1
)
 
12.5

 
(39.0
)
Increase in inventories, net
 
(47.7
)
 
(57.1
)
 
(54.2
)
(Increase) decrease in other current assets
 
(36.1
)
 
(6.6
)
 
0.1

Increase in accounts payable
 


 


 


and other current liabilities
 
7.8

 
30.1

 
28.6

(Decrease) increase in income taxes payable
 
(22.4
)
 
10.7

 
12.7

Decrease in deferred income taxes
 
(82.0
)
 
(51.4
)
 
(4.0
)
Decrease in other long term assets
 
2.4

 
12.7

 
0.3

Increase (decrease) in other long term liabilities
 
38.1

 
10.4

 
(10.7
)
Impairment losses on goodwill and long-lived assets
 
11.5

 
62.3

 
—

Other
 
5.2

 
5.7

 
4.3

Net cash provided by operating activities
 
$
103.9

 
$
216.4

 
$
186.2

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
   Purchased property, plant and equipment
 
—

 
7.2

 
—

   Purchased marketable securities and investments
 
$
2.8

 
$
0.6

 
$
2.2
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)
 12 Months Ended
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]  
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2017
2016
Benefit obligation at beginning of year
$122.7
$120.8
Service cost
6.5

6.1

Interest cost
1.1

1.4

Plan participants' contributions
2.8

2.6

Actuarial (gain) loss
3.3

—

Gross benefits paid
(3.2
)
(3.3
)
Plan amendments
1.1

—

Special termination benefits
(2.0
)
—

Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
9.4

(2.4
)
 
 
 
Benefit obligation at end of year
136.6

122.7

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
58.8

56.7

Actual return on plan assets
0.5

1.3

Employer contributions
4.0

4.7

Plan participants' contributions
2.8

2.6

Gross benefits paid
(2.3
)
(2.9
)
Settlements
(5.1
)
(2.5
)
Change attributable to foreign exchange
3.0

(1.1
)
 
 
 
Fair value of plan assets at end of year
61.7

58.8

 
 
 
Under funded status of plans
$(74.9)
$(63.9)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(0.5)
Noncurrent liabilities (Other long-term liabilities)
(73.8
)
(63.4
)
 
 
 
Net liability, end of fiscal year
$(74.9)
$(63.9)
 
 
 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)
 12 Months Ended
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Net Benefit Costs [Table Text Block] Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2017
2016
2015
Service costs
$6.5
$6.1
$5.3
Interest costs
1.1

1.4

1.4

Expected returns on plan assets
(1.1
)
(1.0
)
(1.2
)
Amortization of actuarial losses
1.4

1.7

0.8

Amortization of prior service costs
—

—

0.4

Settlements
1.2

0.4

—

 
 
 
 
Net periodic benefit costs
$9.1
$8.6
$6.7
 
 
 
 
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)
 12 Months Ended
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Assumptions Used [Table Text Block] Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2017
2016
Discount rate
0.8
%
0.9
%
Compensation rate increase
1.8
%
1.6
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2017
2016
2015
Discount rate
0.9
%
1.1
%
1.3
%
Expected long-term rate of return on plan assets
1.9
%
1.6
%
2.3
%
 
 
 
 
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Information regarding industry segments
Information regarding industry segments at December 31, 2017, 2016, and 2015 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2017
 
$
785.2

 
$
1,360.8

 
$
14.2

 
2016
 
730.7

 
1,323.3

 
14.2

 
2015
 
695.0

 
1,310.4

 
14.0

 
 
 
 
 
 
 
 
Allocated interest expense
2017
 
$
7.0

 
$
14.9

 
$
—

 
2016
 
6.4

 
15.5

 
—

 
2015
 
6.1

 
15.4

 
0.1

 
 
 
 
 
 
 
 
Depreciation and amortization
2017
 
$
36.2

 
$
80.2

 
$
—

 
2016
 
31.7

 
80.5

 
—

 
2015
 
30.7

 
77.8

 
0.1

 
 
 
 
 
 
 
 
Segment (loss) profit
2017
 
$
(10.1
)
 
$
112.5

 
$
1.4

 
2016
 
(19.2
)
 
57.0

 
0.9

 
2015
 
(0.7
)
 
152.4

 
0.7

 
 
 
 
 
 
 
 
Segment assets
2017
 
$
453.0

 
$
1,038.4

 
$
4.8

 
2016
 
380.8

 
909.1

 
4.9

 
 
 
 
 
 
 
 
Capital expenditures
2017
 
$
12.6

 
$
59.0

 
$
—

 
2016
 
14.3

 
67.1

 
—
Reconciliation of segment profit to consolidated income before taxes he following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Total segment profit
$
103.8

 
$
38.7

 
$
152.4

Foreign exchange losses
(9.1
)
 
(4.5
)
 
(10.2
)
Net corporate operating, interest and other expense, net not allocated to segments
(9.1
)
 
(7.5
)
 
(7.5
)
Other income (expense), net
12.2

 
14.9

 
11.1

Consolidated income before taxes
$
97.8

 
$
41.6

 
$
145.8
Reconciliation of Assets from Segment to Consolidated The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2017
 
2016
Total segment assets
 
$
1,496.2

 
$
1,294.8

Cash and other current assets
 
965.8

 
980.3

Property, plant and equipment, net, excluding
 

 

  segment specific gross machinery and equipment
 
57.0

 
91.1

Goodwill, net
 
506.1

 
477.1

Other long-term assets
 
1,247.9

 
1,007.2

Total assets
 
$
4,273.0

 
$
3,850.5
Net sales and assets to external customers by geographic area The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Europe
 
$
758.5

 
$
742.2

 
$
763.7

Pacific Rim
 
461.3

 
427.1

 
392.2

United States
 
800.2

 
770.6

 
735.0

Other (primarily Canada and Latin America)
 
140.2

 
128.3

 
128.5

Total net sales
 
$
2,160.2

 
$
2,068.2

 
$
2,019.4


The following presents Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2017
 
2016
Europe
 
$
230.6

 
$
221.1

Pacific Rim
 
18.4

 
16.1

United States  
 
1,305.2

 
1,084.7

Other (primarily Canada and Latin America)
 
13.1

 
12.3

Total Property, plant and equipment, net, Other investments and other assets, excluding deferred income taxes
 
$
1,567.3

 
$
1,334.2
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
15. Restructuring Costs (Tables)
 12 Months Ended
Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs [Table Text Block] The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2017
 
2016
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
3.2

 
$
5.8

 
$
9.0

 
$
—

 
$
—

 
$
—

Charged to expense
 
—

 
—

 
—

 
4.1

 
7.6

 
11.7

Adjustment to expense
 
0.2

 
0.3

 
0.5

 
0.3

 
0.5

 
0.8

Cash payments
 
(1.5
)
 
(2.7
)
 
(4.2
)
 
(1.0
)
 
(2.0
)
 
(3.0
)
Foreign currency translation losses (gains)
 
0.3

 
0.7

 
1.0

 
(0.2
)
 
(0.3
)
 
(0.5
)
Balance as of December 31
 
$
2.2

 
$
4.1

 
$
6.3

 
$
3.2

 
$
5.8

 
$
9.0

The following table summarizes the activity for the termination of the infectious disease research and development project restructuring reserves for severance and exit costs (in millions):

 
 
2017
Balance as of January 1
 
$
—

Charged to expense
 
14.0

Cash payments
 
—

Foreign currency translation losses

 
0.1

Balance as of December 31
 
$
14.1
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
16. Quarterly Financial Data (Tables)
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Data [Table Text Block]
As reported:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
535.0

 
$
620.4

Cost of goods sold
 
230.1

 
231.4

 
230.5

 
280.8

Gross profit
 
270.0

 
273.3

 
304.5

 
339.6

Selling, general and administrative expense
 
194.9

 
213.0

 
196.8

 
204.2

Research and development expense
 
49.5

 
62.6

 
61.4

 
76.8

Income before income taxes
 
20.1

 
1.1

 
38.9

 
37.7

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(11.5
)
 
32.2

Net income
 
12.4

 
5.0

 
27.4

 
69.9

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.92

 
$
2.35

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.91

 
$
2.32

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(7.9
)
 
(8.9
)
 
(4.3
)
 
7.6

Net income (loss)
 
12.3

 
18.0

 
18.4

 
(20.6
)
Basic earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.63

 
$
(0.70
)
Diluted earnings (loss) per share
 
$
0.42

 
$
0.61

 
$
0.62

 
$
(0.70
)


Adjustments:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
(0.9
)
 
$
0.9

Cost of goods sold
 
—

 
—

 
4.7

 
(4.7
)
Gross profit
 
—

 
—

 
(5.6
)
 
5.6

Selling, general and administrative expense
 
—

 
—

 
1.9

 
(1.9
)
Research and development expense
 
—

 
—

 
0.7

 
(0.7
)
Income before income taxes
 
—

 
—

 
(8.2
)
 
8.2

(Provision for) benefit from income taxes
 
—

 
—

 
2.9

 
4.6

Net income
 
—

 
—

 
(5.3
)
 
12.8

Basic earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

Diluted earnings per share
 
$
—

 
$
—

 
$
(0.18
)
 
$
0.43

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
—

 
$
—

 
$
—

 
$
—

Cost of goods sold
 
—

 
—

 
—

 
—

Gross profit
 
—

 
—

 
—

 
—

Selling, general and administrative expense
 
—

 
—

 
—

 
—

Research and development expense
 
—

 
—

 
—

 
—

Income (loss) before income taxes
 
—

 
—

 
—

 
—

(Provision for) benefit from income taxes
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Net income (loss)
 
(1.3
)
 
(1.4
)
 
(1.3
)
 
1.9

Basic earnings (loss) per share
 
$
(0.04
)
 
$
(0.05
)
 
$
(0.05
)
 
$
0.07

Diluted earnings (loss) per share
 
$
(0.05
)
 
$
(0.05
)
 
$
(0.04
)
 
$
0.07


As revised:
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2017
 
 
 
 
 
 
 
 
Net sales
 
$
500.1

 
$
504.7

 
$
534.1

 
$
621.3

Cost of goods sold
 
230.1

 
231.4

 
235.2

 
276.1

Gross profit
 
270.0

 
273.3

 
298.9

 
345.2

Selling, general and administrative expense
 
194.9

 
213.0

 
198.7

 
202.3

Research and development expense
 
49.5

 
62.6

 
62.1

 
76.1

Income before income taxes
 
20.1

 
1.1

 
30.7

 
45.9

(Provision for) benefit from income taxes
 
(7.7
)
 
3.9

 
(8.6
)
 
36.8

Net income
 
12.4

 
5.0

 
22.1

 
82.7

Basic earnings per share
 
$
0.42

 
$
0.17

 
$
0.74

 
$
2.78

Diluted earnings per share
 
$
0.41

 
$
0.17

 
$
0.73

 
$
2.75

 
 
 
 
 
 
 
 
 
2016
 
 
 
 
 
 
 
 
Net sales
 
$
471.2

 
$
516.8

 
$
508.7

 
$
571.5

Cost of goods sold
 
207.2

 
236.6

 
229.2

 
257.1

Gross profit
 
264.0

 
280.2

 
279.5

 
314.4

Selling, general and administrative expense
 
189.7

 
205.5

 
201.5

 
220.0

Research and development expense
 
48.6

 
49.8

 
49.9

 
57.6

Income (loss) before income taxes
 
20.2

 
26.9

 
22.7

 
(28.2
)
(Provision for) benefit from income taxes
 
(9.2
)
 
(10.3
)
 
(5.6
)
 
9.5

Net income (loss)
 
11.0

 
16.6

 
17.1

 
(18.7
)
Basic earnings (loss) per share
 
$
0.38

 
$
0.56

 
$
0.58

 
$
(0.63
)
Diluted earnings (loss) per share
 
$
0.37

 
$
0.56

 
$
0.58

 
$
(0.63
)
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Jan. 01, 2018
Jan. 01, 2017
Property, Plant and Equipment [Line Items]                          
Long-term Debt and Capital Lease Obligations $ 1,830,439       $ 1,828,581       $ 1,830,439 $ 1,828,581      
Other assets 94,949       47,852       94,949 47,852      
Prepaid Taxes 14,500               14,500        
Equipment 971,140       908,659       971,140 908,659      
Deferred income taxes 222,209       225,299       222,209 225,299      
Income Tax Expense (Benefit) 36,800 $ (8,600) $ 3,900 $ (7,700) 9,500 $ (5,600) $ (10,300) $ (9,200) $ 24,444 (15,560) $ (36,608)    
Minimum [Member] | Software [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 3 years        
Minimum [Member] | Building and Building Improvements [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 15 years        
Minimum [Member] | Reagent Rental Equipment [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 1 year        
Minimum [Member] | Equipment [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 3 years        
Maximum [Member] | Software [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 12 years        
Maximum [Member] | Building and Building Improvements [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 30 years        
Maximum [Member] | Reagent Rental Equipment [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 5 years        
Maximum [Member] | Equipment [Member]                          
Property, Plant and Equipment [Line Items]                          
Property, Plant and Equipment, Useful Life                 12 years        
Adjustments for New Accounting Pronouncement [Member]                          
Property, Plant and Equipment [Line Items]                          
Long-term Debt and Capital Lease Obligations (120,100)               $ (120,100)     $ (17,000) $ (300)
Other assets                       $ (17,000)  
Scenario, Adjustment [Member]                          
Property, Plant and Equipment [Line Items]                          
Long-term Debt and Capital Lease Obligations         (7,599)         (7,599) (200)    
Equipment         (10,467)         (10,467)      
Deferred income taxes         2,380         2,380      
Income Tax Expense (Benefit) $ 4,600 $ 2,900 $ 0 $ 0 $ 1,900 $ (1,300) $ (1,400) $ (1,300)   (2,125) (3,854)    
First Tax Misstatement [Member] | Scenario, Adjustment [Member]                          
Property, Plant and Equipment [Line Items]                          
Income Tax Expense (Benefit)                   $ 200 $ 181    
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Warranty rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Movement in Standard Product Warranty Accrual [Roll Forward]    
Warranty accrual, beginning of period $ 17.6 $ 17.4
Provision for warranty 29.9 33.4
Actual warranty costs (28.8) (33.2)
Warranty accrual, end of period $ 18.7 $ 17.6
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Earnings per share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accounting Policies [Abstract]      
Basic weighted average shares outstanding 29,655 29,440 29,186
Effect of potentially dilutive stock options and restricted stock awards 379 206 223
Diluted weighted average common shares 30,034 29,646 29,409
Anti-dilutive shares excluded from the computation of diluted EPS 13 113 109
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Details (Details) - USD ($)
$ in Thousands
Jan. 01, 2018
Dec. 31, 2017
Jan. 01, 2017
Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Other assets   $ 738,794   $ 417,766
Restricted investments   5,560   4,560
Retained earnings   1,830,439   1,828,581
Additional Paid in Capital   361,231   332,911
Deferred Tax Assets, Gross   145,600   $ 184,200
Adjustments for New Accounting Pronouncement [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Other assets   120,100    
Retained earnings $ (17,000) $ (120,100) $ (300)  
Additional Paid in Capital     400  
Deferred Tax Assets, Gross     $ 100  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit) $ 36,800 $ (8,600) $ 3,900 $ (7,700) $ 9,500 $ (5,600) $ (10,300) $ (9,200) $ 24,444 $ (15,560) $ (36,608)  
Buildings and leasehold improvements 315,984       300,834       315,984 300,834    
Machinery and Equipment, Gross 971,140       908,659       971,140 908,659    
Deferred income taxes 222,209       225,299       222,209 225,299    
Other long-term liabilities 183,276       140,537       183,276 140,537    
Liabilities 1,342,762       1,271,344       1,342,762 1,271,344    
Retained earnings 1,830,439       1,828,581       1,830,439 1,828,581    
Stockholders' Equity Attributable to Parent 2,930,250       2,579,160       2,930,250 2,579,160 2,485,029 $ 2,183,535
Net Income (Loss) Attributable to Parent $ 82,700 $ 22,100 $ 5,000 $ 12,400 $ (18,700) $ 17,100 $ 16,600 $ 11,000 $ 122,249 $ 26,000 $ 109,239  
Earnings Per Share, Basic $ 2.78 $ 0.74 $ 0.17 $ 0.42 $ (0.63) $ 0.58 $ 0.56 $ 0.38 $ 4.12 $ 0.88 $ 3.74  
Earnings Per Share, Diluted $ 2.75 $ 0.73 $ 0.17 $ 0.41 $ (0.63) $ 0.58 $ 0.56 $ 0.37 $ 4.07 $ 0.88 $ 3.71  
Scenario, Previously Reported [Member]                        
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit) $ 32,200 $ (11,500) $ 3,900 $ (7,700) $ 7,600 $ (4,300) $ (8,900) $ (7,900)   $ (13,435) $ (32,754)  
Buildings and leasehold improvements         290,367         290,367    
Machinery and Equipment, Gross         919,126         919,126    
Deferred income taxes         222,919         222,919    
Other long-term liabilities         135,318         135,318    
Liabilities         1,263,745         1,263,745    
Retained earnings         1,836,180         1,836,180    
Stockholders' Equity Attributable to Parent         2,586,759         2,586,759    
Net Income (Loss) Attributable to Parent $ 69,900 $ 27,400 $ 5,000 $ 12,400 $ (20,600) $ 18,400 $ 18,000 $ 12,300   $ 28,125 $ 113,093  
Earnings Per Share, Basic $ 2.35 $ 0.92 $ 0.17 $ 0.42 $ (0.70) $ 0.63 $ 0.61 $ 0.42   $ 0.96 $ 3.87  
Earnings Per Share, Diluted $ 2.32 $ 0.91 $ 0.17 $ 0.41 $ (0.70) $ 0.62 $ 0.61 $ 0.42   $ 0.95 $ 3.85  
Scenario, Adjustment [Member]                        
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit) $ 4,600 $ 2,900 $ 0 $ 0 $ 1,900 $ (1,300) $ (1,400) $ (1,300)   $ (2,125) $ (3,854)  
Buildings and leasehold improvements         10,467         10,467    
Machinery and Equipment, Gross         (10,467)         (10,467)    
Deferred income taxes         2,380         2,380    
Other long-term liabilities         5,219         5,219    
Liabilities         7,599         7,599    
Retained earnings         (7,599)         (7,599) (200)  
Stockholders' Equity Attributable to Parent         (7,599)         (7,599)    
Net Income (Loss) Attributable to Parent $ 12,800 $ (5,300) $ 0 $ 0 $ 1,900 $ (1,300) $ (1,400) $ (1,300)   $ (2,125) $ (3,854)  
Earnings Per Share, Basic $ 0.43 $ (0.18) $ 0 $ 0 $ 0.07 $ (0.05) $ (0.05) $ (0.04)   $ (0.08) $ (0.13)  
Earnings Per Share, Diluted $ 0.43 $ (0.18) $ 0 $ 0 $ 0.07 $ (0.04) $ (0.05) $ (0.05)   $ (0.07) $ (0.14)  
Scenario, Adjustment [Member] | First Tax Misstatement [Member]                        
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit)                     $ 2,400  
Scenario, Adjustment [Member] | Second Tax Misstatement [Member]                        
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit)                   $ 1,900 1,300  
Other long-term liabilities         $ 4,600         4,600    
Retained earnings                     (1,400)  
Scenario, Adjustment [Member] | Third Tax Misstatement [Member]                        
Error Corrections and Prior Period Adjustments Restatement [Line Items]                        
Income Tax Expense (Benefit)                   200 $ 181  
Other long-term liabilities         $ 600         $ 600    
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
2. Acquisitions (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Feb. 15, 2017
Jan. 06, 2016
Dec. 31, 2015
Business Acquisition [Line Items]              
Goodwill     $ 506,069 $ 477,115     $ 495,900
Goodwill, Acquired During Period     26,200 $ 100      
RainDance Technologies, Inc. [Member]              
Business Acquisition [Line Items]              
Business Combination, Consideration Transferred $ 72,700            
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed 10,000            
Payments to Acquire Businesses, Net of Cash Acquired 72,900            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 37,600    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net         200    
Goodwill, Purchase Accounting Adjustments 1,900            
Goodwill, Acquired During Period 26,200            
Business Combination, Consideration Transferred, Liabilities Incurred 13,600            
Analytical Flow Cytometer Platform [Member]              
Business Acquisition [Line Items]              
Business Combination, Consideration Transferred   $ 32,800          
Payments to Acquire Businesses, Net of Cash Acquired   9,500          
Business Combination, Contingent Consideration, Liability     $ 16,700     $ 23,300  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           $ 32,700  
Goodwill, Acquired During Period   $ 100          
Deferred Tax Asset [Domain] | RainDance Technologies, Inc. [Member]              
Business Acquisition [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net         $ 22,500    
Goodwill, Purchase Accounting Adjustments 1,400            
Deferred Revenue [Domain] | RainDance Technologies, Inc. [Member]              
Business Acquisition [Line Items]              
Goodwill, Purchase Accounting Adjustments $ 3,300            
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Millions
Dec. 31, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value $ 5.6 $ 4.6
Available-for-sale investments [1] 1,301.4 1,115.6
Forward foreign exchange contracts, Asset [2] 0.5 0.6
Financial Assets Carried at Fair Value 1,411.8 1,173.7
Forward foreign exchange contracts, Liability [3] 1.6 1.3
Business Combination, Contingent Consideration, Liability [4] 16.7 38.5
Liabilities, Fair Value Disclosure 18.3 39.8
Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.7 3.6
Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 185.7 179.4
US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 67.6 82.5
Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 3.4 4.4
Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 15.0 15.4
Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 973.4 767.8
Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 55.6 62.5
Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 53.7 11.8
US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 11.2 [5] 1.1
Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 3.4 5.9
Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 36.0 14.1
Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 104.3 52.9
Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5]   20.0
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 5.6 4.6
Available-for-sale investments [1] 973.4 767.8
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 1,026.1 790.1
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 973.4 767.8
Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 43.7 11.8
Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 [5] 0.0
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 3.4 5.9
Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 47.1 17.7
Fair Value, Inputs, Level 1 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5]   0.0
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale investments [1] 328.0 347.8
Forward foreign exchange contracts, Asset [2] 0.5 0.6
Financial Assets Carried at Fair Value 385.7 383.6
Forward foreign exchange contracts, Liability [3] 1.6 1.3
Business Combination, Contingent Consideration, Liability [4] 0.0 0.0
Liabilities, Fair Value Disclosure 1.6 1.3
Fair Value, Inputs, Level 2 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.7 3.6
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 185.7 179.4
Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 67.6 82.5
Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 3.4 4.4
Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 15.0 15.4
Fair Value, Inputs, Level 2 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 55.6 62.5
Fair Value, Inputs, Level 2 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 10.0 0.0
Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 11.2 [5] 1.1
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 36.0 14.1
Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 57.2 35.2
Fair Value, Inputs, Level 2 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5]   20.0
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted Investments, at Fair Value 0.0 0.0
Available-for-sale investments [1] 0.0 0.0
Forward foreign exchange contracts, Asset [2] 0.0 0.0
Financial Assets Carried at Fair Value 0.0 0.0
Forward foreign exchange contracts, Liability [3] 0.0 0.0
Business Combination, Contingent Consideration, Liability [4] 16.7 38.5
Liabilities, Fair Value Disclosure 16.7 38.5
Fair Value, Inputs, Level 3 [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments [1] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Foreign Time Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0.0 [5] 0.0
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5] 0.0 0.0
Fair Value, Inputs, Level 3 [Member] | Domestic Time Deposit [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents [5]   0.0
Other Current Liabilities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability 2.7 14.5
Short-term Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 371.2 383.2
Short-term Investments [Member] | Interest-bearing Deposits [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 0.7 3.6
Short-term Investments [Member] | Corporate Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 185.7 179.4
Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 67.6 82.5
Short-term Investments [Member] | Foreign Government Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 3.4 4.4
Short-term Investments [Member] | Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 15.0 15.4
Short-term Investments [Member] | Marketable Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 43.4 35.7
Short-term Investments [Member] | Asset-backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 55.4 62.2
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investments 930.2 732.4
Other Noncurrent Liabilities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability $ 14.0 $ 24.0
[1]
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
Short-term investments
$
371.2

 
$
383.2

Other investments
930.2

 
732.4

Total
$
1,301.4

 
$
1,115.6
[2] Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.
[3] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.
[4] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5
[5] Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2017
USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount $ 413.2
Loss on foreign currency derivative instruments not designated as hedging instruments 1.0
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount 52.0
Loss on foreign currency derivative instruments not designated as hedging instruments $ 0.1
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements Short-term Investments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Millions
Dec. 31, 2017
Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 418.1 $ 435.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 884.8 681.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.5) (1.8)
Estimated Fair Value [1] 1,301.4 1,115.6
Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 185.7 179.4
Interest-bearing Deposits [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value 0.7 3.6
Municipal Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 15.0 15.4
Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 55.6 62.5
Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 973.4 767.8
US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 67.6 82.5
Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value [1] 3.4 4.4
Short-term Investments [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Estimated Fair Value 371.2 383.2
Short-term Investments [Member] | Corporate Debt Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 185.9 179.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.3 0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.5) (0.5)
Estimated Fair Value 185.7 179.4
Short-term Investments [Member] | Interest-bearing Deposits [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0.7 3.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 0.7 3.6
Short-term Investments [Member] | Municipal Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 15.1 15.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.1) (0.1)
Estimated Fair Value 15.0 15.4
Short-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 55.6 62.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.2) (0.1)
Estimated Fair Value 55.4 62.2
Short-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 34.4 32.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 9.0 3.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 (0.4)
Estimated Fair Value 43.4 35.7
Short-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 363.4 380.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 9.3 4.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (1.5) (1.8)
Estimated Fair Value 371.2 383.2
Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 68.3 83.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax (0.7) (0.7)
Estimated Fair Value 67.6 82.5
Short-term Investments [Member] | Foreign Government Obligations [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 3.4 4.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 3.4 4.4
Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0.2 0.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 0.2 0.3
Other Long-term Investments [Member] | Marketable Equity Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.5 54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 875.5 677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value 930.0 732.1
Other Long-term Investments [Member] | Available-for-sale Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 54.7 54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax 875.5 677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Estimated Fair Value $ 930.2 $ 732.4
[1]
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2017
 
December 31, 2016
 
 
 
 
Short-term investments
$
371.2

 
$
383.2

Other investments
930.2

 
732.4

Total
$
1,301.4

 
$
1,115.6
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Dec. 31, 2017
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 126.3
Mature in one to five years 157.9
Mature in more than five years 45.0
Total Amortized Cost 329.2
Mature in less than one year 126.1
Mature in one to five years 157.2
Mature in more than five years 44.7
Estimated Fair Value $ 328.0
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $ 43.9 $ 11.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value 168.7 160.5
Gross unrealized losses for investments in a loss position 12 months or more 0.7 0.3
Gross unrealized losses for investments in a loss position less than 12 months $ 0.8 $ 1.5
Cost Method Investment, Percentage Owned 35.00%  
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2017
Dec. 31, 2016
Carrying (Reported) Amount, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments $ 91.8 $ 92.8
Total long-term debt, excluding leases and current maturities 423.1 422.5
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Other Investments 1,249.4 984.2
Total long-term debt, excluding leases and current maturities $ 449.8 $ 454.2
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
3. Fair Value Measurements Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 13 Months Ended 36 Months Ended 51 Months Ended 52 Months Ended
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2020
Dec. 31, 2016
Feb. 01, 2017
Jan. 06, 2016
Apr. 10, 2014
Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value     $ 28.5       $ 28.5        
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability   $ (18.1) (0.4) $ (5.6)              
Fair Value, Measurements, Recurring [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Combination, Contingent Consideration, Liability [1]   16.7 38.5   $ 16.7   38.5        
CellSorter [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Combination, Contingent Consideration, Liability   3.1     3.1           $ 44.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements   (3.1)           $ (32.0)      
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense             (12.6)        
Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value   16.7     16.7            
Business Combination, Contingent Consideration, Liability   16.7     16.7       $ 23.3    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements $ (0.6) (0.6)                  
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense   $ (8.1)     $ 6.0            
GnuBIO [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Combination, Contingent Consideration, Liability     $ 10.0       $ 10.0     $ 10.7  
Discount rate [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Fair Value Inputs, Discount Rate   10.80%                  
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Acquisition, Contingent Consideration, Potential Percentage Payout   39.00%     39.00%            
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Acquisition, Contingent Consideration, Potential Percentage Payout   20.00%     20.00%            
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low   $ 0.0     $ 0.0            
Cost of debt [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Fair Value Inputs, Discount Rate   4.20%                  
Scenario, Forecast [Member] | Analytical Flow Cytometer Platform [Member]                      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High           $ 78.0          
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Goodwill [Roll Forward]        
Goodwill period start $ 518,800 $ 524,100 $ 518,800 $ 524,100
Accumulated impairment loss period start (41,700) (28,200) (41,700) (28,200)
Goodwill, net period start 477,115 495,900 477,115 495,900
Goodwill, Acquired During Period     26,200 100
Goodwill, Impairment Loss     11,500 13,500
Currency fluctuations     14,300 (5,400)
Goodwill period end     559,300 518,800
Accumulated impairment loss period end     (53,200) (41,700)
Goodwill, net period end     506,069 477,115
Life Science [Member]        
Goodwill [Roll Forward]        
Goodwill period start 207,100 207,200 207,100 207,200
Accumulated impairment loss period start (27,200) (27,200) (27,200) (27,200)
Goodwill, net period start 179,900 180,000 179,900 180,000
Goodwill, Acquired During Period     26,200 100
Goodwill, Impairment Loss     8,700 0
Currency fluctuations     1,400 (200)
Goodwill period end     234,700 207,100
Accumulated impairment loss period end     (35,900) (27,200)
Goodwill, net period end     198,800 179,900
Clinical Diagnostics [Member]        
Goodwill [Roll Forward]        
Goodwill period start 311,700 316,900 311,700 316,900
Accumulated impairment loss period start (14,500) (1,000) (14,500) (1,000)
Goodwill, net period start 297,200 315,900 297,200 315,900
Goodwill, Acquired During Period     0 0
Goodwill, Impairment Loss     2,800 13,500
Currency fluctuations     12,900 (5,200)
Goodwill period end     324,600 311,700
Accumulated impairment loss period end     (17,300) (14,500)
Goodwill, net period end     $ 307,300 $ 297,200
RainDance Technologies, Inc. [Member]        
Goodwill [Roll Forward]        
Goodwill, Acquired During Period $ 26,200      
Analytical Flow Cytometer Platform [Member]        
Goodwill [Roll Forward]        
Goodwill, Acquired During Period   $ 100    
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Feb. 15, 2017
Jan. 06, 2016
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   $ 509,000 $ 443,200      
Future Amortization Expense, Year One   28,400        
Future Amortization Expense, Year Two   25,000        
Future Amortization Expense, Year Three   22,900        
Future Amortization Expense, Year Four   22,100        
Future Amortization Expense, Year Five   18,000        
Finite-Lived Intangible Assets, Amortization Expense, after Year Five   57,700        
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (334,900) (281,600)      
Net Carrying Amount   174,100 161,600      
Amortization [Abstract]            
Amortization expense   30,800 35,200 $ 36,500    
Impairment losses on goodwill and long-lived assets   11,506 62,305 $ 0    
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)     46,400      
Intangible Assets, Net (Excluding Goodwill)   174,113 161,609      
Customer Relationships [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   92,300 84,400      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (64,400) (52,800)      
Net Carrying Amount   27,900 31,600      
Know how [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   194,900 182,600      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (157,900) (136,900)      
Net Carrying Amount   37,000 45,700      
Developed Technology Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   133,300 125,900      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (70,300) (56,300)      
Net Carrying Amount   63,000 69,600      
Licensing Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   76,700 39,000      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (36,000) (30,600)      
Net Carrying Amount   40,700 8,400      
Trade Names [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   3,900 3,500      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (3,000) (2,500)      
Net Carrying Amount   900 1,000      
Noncompete Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Gross   7,900 7,800      
Finite-Lived Intangible Assets, Net [Abstract]            
Accumulated Amortization   (3,300) (2,500)      
Net Carrying Amount   $ 4,600 $ 5,300      
Minimum [Member] | Customer Relationships [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year      
Minimum [Member] | Know how [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year      
Minimum [Member] | Developed Technology Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 3 years      
Minimum [Member] | Licensing Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 1 year      
Minimum [Member] | Trade Names [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 4 years      
Minimum [Member] | Noncompete Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   1 year 2 years      
Minimum [Member] | Other Intangible Assets [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years      
Maximum [Member] | Customer Relationships [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   7 years 8 years      
Maximum [Member] | Know how [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 9 years      
Maximum [Member] | Developed Technology Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   12 years 12 years      
Maximum [Member] | Licensing Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   12 years 9 years      
Maximum [Member] | Trade Names [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   6 years 8 years      
Maximum [Member] | Noncompete Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 9 years      
Maximum [Member] | Other Intangible Assets [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years      
RainDance Technologies, Inc. [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 37,600  
RainDance Technologies, Inc. [Member] | Developed Technology Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         1,000  
RainDance Technologies, Inc. [Member] | Licensing Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         36,400  
RainDance Technologies, Inc. [Member] | Trade Names [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 200  
Analytical Flow Cytometer Platform [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           $ 32,700
Analytical Flow Cytometer Platform [Member] | Developed Technology Rights [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-lived Intangible Assets Acquired $ 29,700          
Analytical Flow Cytometer Platform [Member] | Noncompete Agreements [Member]            
Acquired Finite-Lived Intangible Assets [Line Items]            
Finite-lived Intangible Assets Acquired $ 3,000          
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
5. Notes Payable and Long-Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Jun. 30, 2014
Dec. 31, 2010
Debt Instrument [Line Items]        
Debt and Capital Lease Obligations $ 435,000 $ 434,500    
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year 400 300    
Long-term Debt and Capital Lease Obligations 434,581 434,186    
Maturities of Long-term Debt [Abstract]        
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 400      
Long-term Debt, Maturities, Repayments of Principal in Year Two 300      
Long-term Debt, Maturities, Repayments of Principal in Year Three 425,300      
Long-term Debt, Maturities, Repayments of Principal in Year Four 300      
Long-term Debt, Maturities, Repayments of Principal in Year Five 300      
Long-term Debt, Maturities, Repayments of Principal after Year Five 10,300      
Line of Credit Facility, Remaining Borrowing Capacity 208,400      
Letters of Credit Outstanding, Amount 4,200      
Performance Guarantee [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount 4,200      
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]        
Debt Instrument [Line Items]        
Unsecured Debt 425,000 425,000    
Long-term debt 423,100 422,500   $ 422,600
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net 1,900 2,500    
Debt Instrument, Interest Rate, Effective Percentage       4.946%
Face amount of debt sold       $ 425,000
Debt Instrument, Interest Rate, Stated Percentage       4.875%
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]        
Debt Instrument [Line Items]        
Long-term Debt and Capital Lease Obligations, Including Current Maturities 11,900 12,000    
Line of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 200,000  
Long-term Line of Credit $ 0      
Line of Credit Facility, Interest Rate at Period End 2.94%      
Standby Letters of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount $ 500 $ 800    
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
6. Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Taxes [Line Items]                      
Prepaid Taxes $ 14,500               $ 14,500    
U.S.                 72,800 $ (38,500) $ 48,400
International                 25,000 80,100 97,400
Income before income taxes                 97,805 41,560 145,847
U.S. Federal                 6,700 16,100 8,700
State                 3,400 3,100 1,700
International                 32,000 30,400 34,100
Current Income Tax Expense (Benefit)                 42,100 49,600 44,500
U.S. Federal                 (69,800) (42,400) 2,000
State                 4,300 (2,800) 1,400
International                 (19,300) (6,000) (7,100)
Deferred tax benefit                 (84,800) (51,200) (3,700)
Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisonal Income Tax Benefit                 125,000    
Non-current tax expense (benefit)                 18,300 17,200 (4,200)
Provision for income taxes (36,800) $ 8,600 $ (3,900) $ 7,700 $ (9,500) $ 5,600 $ 10,300 $ 9,200 $ (24,444) $ 15,560 $ 36,608
U.S. statutory tax rate                 35.00% 35.00% 35.00%
Impact of foreign operations                 7.00% (15.00%) (4.00%)
Foreign dividends, net                 0.00% (40.00%) (4.00%)
Research tax credits                 (4.00%) (9.00%) (2.00%)
Nontaxable subsidies                 (2.00%) (4.00%) (1.00%)
Tax settlements and changes to unrecognized tax benefits                 0.00% 47.00% (3.00%)
Goodwill impairment                 0.00% 11.00% 0.00%
Domestic manufacturing deduction                 0.00% (4.00%) (2.00%)
Stock-based compensation                 (5.00%) (3.00%) (1.00%)
Nondeductible executive compensation                 2.00% 3.00% 1.00%
Fines and penalties                 0.00% 2.00% 0.00%
Prior period adjustments                 0.00% 4.00% 3.00%
State taxes                 3.00% 1.00% 1.00%
Other                 (3.00%) 1.00% 0.00%
Provision for income taxes                 (25.00%) 37.00% 25.00%
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)                 $ (70,000)    
Bad debt, inventory and warranty accruals 28,600       25,800       28,600 $ 25,800  
Other post-employment benefits, vacation and other reserves 24,000       26,300       24,000 26,300  
Tax credit and net operating loss carryforwards 73,300       96,400       73,300 96,400  
Other 19,700       35,700       19,700 35,700  
Total gross deferred tax assets 145,600       184,200       145,600 184,200  
Valuation allowance (66,400)       (66,400)       (66,400) (66,400)  
Total deferred tax assets 79,200       117,800       79,200 117,800  
Property and equipment 33,500       22,200       33,500 22,200  
Investments and intangible assets 219,100       287,800       219,100 287,800  
Total deferred tax liabilities 252,600       310,000       252,600 310,000  
Net deferred tax liabilities (173,400)       (192,200)       (173,400) (192,200)  
Unrecognized tax benefits period start       $ 21,100       $ 11,900 21,100 11,900 $ 15,800
Additions to tax positions related to prior years                 1,300 10,400 700
Reductions to tax positions related to prior years                 (1,000) 0 (200)
Additions to tax positions related to the current year                 34,800 3,400 2,900
Settlements                 (200) (2,400) (500)
Lapse of statute of limitations                 (3,400) (2,300) (6,300)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation                 2,300    
Currency translation                   100 500
Unrecognized tax benefits period end 54,900       21,100       54,900 21,100 11,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued 10,900       $ 11,800       10,900 11,800 3,100
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense                 (900) $ 8,700 $ (700)
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit 2,300               2,300    
Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)                 55,000    
Foreign Tax Authority [Member]                      
Income Taxes [Line Items]                      
Operating Loss Carryforward, Valuation Allowance 27,800               27,800    
Operating Loss Carryforward With No Expiration Date 150,600               150,600    
Operating Loss Carryforwards 207,200               $ 207,200    
Domestic Tax Authority [Member]                      
Income Taxes [Line Items]                      
Other reconciling items                 3.00% 2.00% 0.00%
Tax Cuts and Jobs Act [Member]                      
Income Taxes [Line Items]                      
U.S. tax reform                 (71.00%) 0.00% 0.00%
State and Local Jurisdiction [Member]                      
Income Taxes [Line Items]                      
Operating Loss Carryforwards 53,000               $ 53,000    
Including accrued interest and penalties [Member]                      
Income Taxes [Line Items]                      
Other 2,800               2,800    
Unrecognized tax benefits period end 65,800               65,800    
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]                      
Income Taxes [Line Items]                      
Deferred Tax Assets, Tax Credit Carryforwards, Research 29,600               $ 29,600    
Acquisition-related Costs [Member]                      
Income Taxes [Line Items]                      
Other reconciling items                 10.00% 0.00% 0.00%
QuantaLife [Member] | Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]                      
Income Taxes [Line Items]                      
Deferred Tax Assets, Tax Credit Carryforwards, Research 2,000               $ 2,000    
Net of prepaid taxes [Member]                      
Income Taxes [Line Items]                      
Unrecognized tax benefits period end $ 48,500               $ 48,500    
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
7. Stockholders' Equity (Details) - shares
 3 Months Ended 12 Months Ended
Jun. 30, 2012
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Common Class A [Member]          
Class of Stock [Line Items]          
Shares, Issued   24,679,000 24,454,000 24,230,000 23,972,000
Stock Issued During Period, Shares, Conversion of Convertible Securities   34,000 13,000 18,000  
Stock Issued During Period, Shares, New Issues   191,000 211,000 240,000  
Common Stock, Voting Rights   .10      
Election Percentage for Board of Directors   25.00%      
Common Class B [Member]          
Class of Stock [Line Items]          
Shares, Issued   5,108,000 5,124,000 5,131,000 5,099,000
Stock Issued During Period, Shares, Conversion of Convertible Securities   (34,000) (13,000) (18,000)  
Stock Issued During Period, Shares, New Issues   18,000 6,000 50,000  
Common Stock, Voting Rights   1      
Election Percentage for Board of Directors   75.00%      
Treasury Class-A [Member]          
Class of Stock [Line Items]          
Treasury Stock, Shares, Acquired 122 13,200      
Treasury Class B [Member]          
Class of Stock [Line Items]          
Treasury Stock, Shares, Acquired 917        
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
7. Stockholders' Equity Treasury Shares (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2012
Dec. 31, 2017
Dec. 31, 2016
Equity, Class of Treasury Stock [Line Items]      
Stock Repurchase Program, Authorized Amount   $ 250.0 $ 18.0
Treasury Class-A [Member]      
Equity, Class of Treasury Stock [Line Items]      
Treasury Stock, Shares   582 122
Treasury Stock, Shares, Acquired 122 13,200  
Stock Issued During Period, Shares, Treasury Stock Reissued   12,740  
Treasury Class B [Member]      
Equity, Class of Treasury Stock [Line Items]      
Treasury Stock, Shares   917 917
Treasury Stock, Shares, Acquired 917    
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income $ 738,794 $ 417,766  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 0    
Other comprehensive income, net of tax 321,028 35,628 $ 163,193
Foreign currency translation adjustments [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 77,400 1,300 33,700
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 76,100 (32,400)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 0 0  
Other Comprehensive Income (Loss), Tax 0 0  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 0    
Other comprehensive income, net of tax 76,100 (32,400)  
Other Postretirement Benefit Plan [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income (22,300) (18,600) (20,700)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (6,500) 500  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2,100 2,500  
Other Comprehensive Income (Loss), Tax 700 (900)  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 0    
Other comprehensive income, net of tax (3,700) 2,100  
Net Unrealized Investment Gain (Loss) [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 683,700 435,000 369,100
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 203,600 105,100  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (100) (800)  
Other Comprehensive Income (Loss), Tax (74,900) (38,400)  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 120,100    
Other comprehensive income, net of tax 248,700 65,900  
Parent [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive income 738,800 417,700 $ 382,100
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 273,200 73,200  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2,000 1,700  
Other Comprehensive Income (Loss), Tax (74,200) (39,300)  
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect 120,100    
Other comprehensive income, net of tax $ 321,100 $ 35,600  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Selling, general and administrative expense $ (202,300) $ (198,700) $ (213,000) $ (194,900) $ (220,000) $ (201,500) $ (205,500) $ (189,700) $ (808,942) $ (816,724) $ (761,990)
Realized Investment Gains (Losses)                 100 800 $ 1,600
Other Postretirement Benefit Plan [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Selling, general and administrative expense                 2,100 2,500  
Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Realized Investment Gains (Losses)                 $ 100 $ 800  
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
9. Share-based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value $ 4,200,000 $ 2,100,000 $ 1,600,000
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options 6,300,000 1,500,000 3,600,000
Share-based Compensation Expense 23,400,000 19,700,000 17,000,000.0
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense $ 5,800,000 $ 5,100,000 4,300,000
2011 Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 1,300,000    
Stock Option and Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 1,999,714    
Number of Shares Available for Grant 1,771,794    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted Average Remaining Contractual Term (in years) - Outstanding 5 years 1 month 2 days    
Aggregate Intrinsic Value (in millions) - Outstanding $ 48.2    
Options - Weighted-Average Exercise Price $ 120.39 $ 106.52  
Options Granted - Weighted Average Exercise Price 215.98    
Options Exercised - Weighted Average Exercise Price $ 89.41    
Options Granted Term P10Y    
Options Forfeitured/expired - Weighted Average Exercise Price $ 177.99    
Options - Shares Vested and Expected to Vest 125,720    
Options Vested and Expected to Vest - Weighted Average Exercise Price $ 164.84    
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) 8 years 3 months 14 days    
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) $ 9.3    
Weighted Average Exercise Price - Options Exercisable $ 100.56    
Weighted Average Remaining Contractual Term (in years) - Exercisable 3 years 7 months 28 days    
Options Exercisable Aggregate Intrinsic Value (in millions) $ 38.9    
Options, Exercises in Period, Total Intrinsic Value 10,000,000 $ 1,000,000 13,000,000
Cash Received from Exercise of Stock Options 1,600,000 1,200,000 2,900,000
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options   $ 6,000,000.0 $ 9,300,000
Total unrecognized compensation cost from stock options $ 5,500,000    
Options Number Exercisable 281,760    
Options Vesting Period 5 years    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%    
Weighted average fair value of options granted, period for recognition 3 years    
Expected Volatility 20.00% 21.00% 23.00%
Risk Free Interest Rate 1.87% 1.35% 1.90%
Expected life (in years) 7 years 2 months 12 days 7 years 4 months 24 days 7 years 8 months 12 days
Expected dividend $ 0 $ 0 $ 0
Weighted average fair value of options granted $ 58.65 $ 42.40 $ 42.74
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding beginning of period 449,570    
Options - Shares Granted 44,000    
Options - Shares Exercised (78,890)    
Options - Shares Forfeitures/expired (7,200)    
Outstanding end of period 407,480 449,570  
Employee Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Available for Grant 721,712    
Cash Received from Exercise of Stock Options $ 13,000,000.0 $ 11,500,000 $ 10,800,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans 74,409 93,605 96,634
Employee Contribution Rate - Maximum 10.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount $ 25,000    
Employee Purchase Price Discount from Market Price 85.00%    
Expected Volatility 19.00% 20.00% 18.00%
Risk Free Interest Rate 0.83% 0.26% 0.02%
Expected life (in years) 7 days 7 days 7 days
Expected dividend $ 0 $ 0 $ 0
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased $ 38.86 $ 27.36 $ 25.08
Stock Award Plans [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%    
Stock Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options Vesting Period 5 years    
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
9. Share-based Compensation Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 27.7 $ 18.7 $ 15.8
Total unrecognized compensation cost from restricted stock $ 74.7    
Nonvested shares - Weighted Average Grant Date Fair Value $ 172.75 $ 141.09  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]      
Outstanding beginning of period 448,822    
Restricted Stock Units Granted 192,860    
Restricted Stock Units - Vested (127,189)    
Restricted Stock Units - Forfeited (41,263)    
Outstanding end of period 473,230 448,822  
Weighted Average Grant Date Fair Value - Granted $ 215.98    
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value 133.54    
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value $ 151.36    
Weighted Average Remaining Contractual Term (in years) 2 years 1 month 20 days    
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) $ 112.9    
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 4 years    
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
10. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Interest and investment income $ (19,100) $ (14,700) $ (10,100)
Net realized (gains) losses on investments (100) (800) (1,600)
Other-than-temporary impairment losses on investments 7,000 600 600
Other (income) expense, net $ (12,197) $ (14,850) $ (11,080)
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
11. Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Other Significant Noncash Transactions [Line Items]                      
Net Income (Loss) Attributable to Parent $ 82,700 $ 22,100 $ 5,000 $ 12,400 $ (18,700) $ 17,100 $ 16,600 $ 11,000 $ 122,249 $ 26,000 $ 109,239
Depreciation and amortization                 148,700 142,900 131,800
Share-based compensation                 23,400 19,700 17,000
Loss (gain) on disposition of securities                 (100) (800) (1,600)
Other than Temporary Impairment Losses, Investments                 7,000 600 600
Loss on disposition of fixed assets                 8,100 600 300
Excess tax benefits from share-based compensation                 0 (1,506) (3,610)
Changes in fair value of contingent consideration                 (18,100) (400) (5,600)
(Increase) decrease in accounts receivable, net                 (64,100) 12,500 (39,000)
Increase in inventories, net                 (47,700) (57,100) (54,200)
(Increase) decrease in Other Current Assets                 (36,100) (6,600) 100
Increase in accounts payable and other current liabilities                 7,800 30,100 28,600
(Decrease) increase in Income Taxes Payable                 (22,400) 10,700 12,700
Decrease in deferred income taxes                 (82,000) (51,400) (4,000)
Other                 5,200 5,700 4,300
Decrease in other long term assets                 2,400 12,700 300
Increase (Decrease) in Other Long Term Liabilities                 38,100 10,400 (10,700)
Impairment losses on goodwill and long-lived assets                 11,506 62,305 0
Net cash provided by operating activities                 103,885 216,433 186,210
Noncash or Part Noncash Acquisition, Fixed Assets Acquired                 0 7,200 0
Noncash Purchased Marketable Securities and Investments                 $ 2,800 $ 600 $ 2,200
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 13 Months Ended 36 Months Ended 51 Months Ended 52 Months Ended
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2020
Dec. 31, 2016
Feb. 01, 2017
Jan. 06, 2016
Apr. 10, 2014
Sep. 30, 2012
Purchase Commitment, Excluding Long-term Commitment [Line Items]                  
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value         $ 28.5        
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Operating leases, due next twelve months   $ 39.3 $ 39.3            
Operating leases, due in two years   33.2 33.2            
Operating leases, due in three years   27.1 27.1            
Operating leases, due in four years   17.8 17.8            
Operating leases, due thereafter   27.5 27.5            
Post-Employment Benefits Liability   3.7 3.7   3.5        
Recorded Unconditional Purchase Obligation   131.2 131.2            
Recorded Unconditional Purchase Obligation Due in Next Twelve Months   10.3 10.3            
Recorded Unconditional Purchase Obligation Due in Second Year   14.3 14.3            
Recorded Unconditional Purchase Obligation Due in Third Year   10.6 10.6            
Recorded Unconditional Purchase Obligation Due in Fourth Year   6.9 6.9            
Recorded Unconditional Purchase Obligation Due in Fifth Year   2.6 2.6            
Recorded Unconditional Purchase Obligation Due after Fifth Year   86.5 86.5            
Unrecorded Unconditional Purchase Obligation   24.5 24.5            
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months   3.7 3.7            
Unrecorded Unconditional Purchase Obligation, Due within Two Years   3.8 3.8            
Unrecorded Unconditional Purchase Obligation, Due within Three Years   3.7 3.7            
Unrecorded Unconditional Purchase Obligation, Due within Four Years   3.8 3.8            
Unrecorded Unconditional Purchase Obligation, Due within Five Years   3.7 3.7            
Unrecorded Unconditional Purchase Obligation, Due after Five Years   5.8 5.8            
Letters of Credit Outstanding Amount   $ 4.2 $ 4.2            
Employees Covered By Collective Bargaining Agreements U.S., Percentage   7.00% 7.00%            
Analytical Flow Cytometer Platform [Member]                  
Purchase Commitment, Excluding Long-term Commitment [Line Items]                  
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value   $ 16.7 $ 16.7            
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements $ 0.6 0.6              
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings   8.1 (6.0)            
Business Combination, Contingent Consideration, Liability   16.7 16.7       $ 23.3    
GnuBIO [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Combination, Contingent Consideration, Liability         10.0     $ 10.7  
CellSorter [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements   3.1       $ 32.0      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings         12.6        
Business Combination, Contingent Consideration, Liability   $ 3.1 $ 3.1           $ 44.6
UNITED STATES                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Entity Number of Employees   3,270 3,270            
Fair Value, Measurements, Recurring [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Combination, Contingent Consideration, Liability [1]   $ 16.7 $ 16.7   $ 38.5        
Scenario, Forecast [Member] | Analytical Flow Cytometer Platform [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High       $ 78.0          
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Acquisition, Contingent Consideration, Potential Percentage Payout   39.00% 39.00%            
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Acquisition, Contingent Consideration, Potential Percentage Payout   20.00% 20.00%            
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]                  
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low   $ 0.0 $ 0.0            
[1] Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2017
 
December 31, 2016
 
 
 
 
Other current liabilities
$
2.7

 
$
14.5

Other long-term liabilities
14.0

 
24.0

   Total
$
16.7

 
$
38.5
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]      
Letters of Credit Outstanding, Amount $ 4.2    
Operating Leases, Rent Expense, Net 43.6 $ 44.4 $ 45.0
Contribution expense $ 16.0 $ 15.1 $ 14.7
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Commitments & Contingent Liabilities Pensions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 0.90% 1.10% 1.30%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 0.80% 0.90%  
Defined Benefit Plan, Benefit Obligation $ 136.6 $ 122.7 $ 120.8
Defined Benefit Plan, Service Cost 6.5 6.1 5.3
Defined Benefit Plan, Interest Cost 1.1 1.4 1.4
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant 2.8 2.6  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 3.3 0.0  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (3.2) (3.3)  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 1.1 0.0  
Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits (2.0) 0.0  
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement (5.1) (2.5)  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 9.4 (2.4)  
Defined Benefit Plan, Fair Value of Plan Assets 61.7 58.8 56.7
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) 0.5 1.3  
Defined Benefit Plan, Plan Assets, Contributions by Employer 4.0 4.7  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 2.8 2.6  
Defined Benefit Plan, Plan Assets, Benefits Paid (2.3) (2.9)  
Defined Benefit Plan, Plan Assets, Payment for Settlement (5.1) (2.5)  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 3.0 (1.1)  
Defined Benefit Plan, Funded (Unfunded) Status of Plan (74.9) (63.9)  
Liability, Defined Benefit Plan, Current (1.1) (0.5)  
Liability, Defined Benefit Plan, Noncurrent (73.8) (63.4)  
Liability, Defined Benefit Plan (74.9) (63.9)  
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (1.1) (1.0) (1.2)
Defined Benefit Plan, Amortization of Gain (Loss) 1.4 1.7 0.8
Defined Benefit Plan, Amortization of Prior Service Cost (Credit) 0.0 0.0 0.4
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 1.2 0.4 0.0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) $ 9.1 $ 8.6 $ 6.7
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 1.80% 1.60%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 1.90% 1.60% 2.30%
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1
13. Legal Proceedings Legal Proceedings (Details)
 12 Months Ended
Dec. 31, 2017
USD ($)
Legal Proceedings [Abstract]  
Loss Contingency, Damages Awarded, Value $ 10,920,000
Litigation Settlement Interest 141,608
Loss Contingency, Damages Paid, Value $ 990,000
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Reporting (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Segment Reporting Information [Line Items]                      
Number Of Products And Services                 9,000    
Net sales $ 621,300 $ 534,100 $ 504,700 $ 500,100 $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 2,160,153 $ 2,068,172 $ 2,019,441
Interest expense                 21,914 21,942 21,692
Depreciation and amortization                 148,700 142,900 131,800
Segment profit 45,900 $ 30,700 $ 1,100 $ 20,100 (28,200) $ 22,700 $ 26,900 $ 20,200 116,650 53,194 166,708
Total assets 4,273,012       3,850,504       4,273,012 3,850,504  
Payments to Acquire Property, Plant, and Equipment                 111,332 141,436 112,000
Life Science [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 785,200 730,700 695,000
Interest expense                 7,000 6,400 6,100
Depreciation and amortization                 36,200 31,700 30,700
Segment profit                 (10,100) (19,200) (700)
Total assets 453,000       380,800       453,000 380,800  
Payments to Acquire Property, Plant, and Equipment                 12,600 14,300  
Clinical Diagnostics [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 1,360,800 1,323,300 1,310,400
Interest expense                 14,900 15,500 15,400
Depreciation and amortization                 80,200 80,500 77,800
Segment profit                 112,500 57,000 152,400
Total assets 1,038,400       909,100       1,038,400 909,100  
Payments to Acquire Property, Plant, and Equipment                 59,000 67,100  
All Other Segments [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 14,200 14,200 14,000
Interest expense                 0 0 100
Depreciation and amortization                 0 0 100
Segment profit                 1,400 900 $ 700
Total assets $ 4,800       $ 4,900       4,800 4,900  
Payments to Acquire Property, Plant, and Equipment                 $ 0 $ 0  
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Information Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes $ 97,805 $ 41,560 $ 145,847
Operating Segments [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes 103,800 38,700 152,400
Corporate, Non-Segment [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (9,100) (7,500) (7,500)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes (9,100) (4,500) (10,200)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Income before income taxes $ 12,200 $ 14,900 $ 11,100
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Information Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 4,273,012 $ 3,850,504
Operating Segments [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,496,200 1,294,800
Other Current Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 965,800 980,300
Property, Plant and Equipment excluding segment specific [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 57,000 91,100
Goodwill [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 506,100 477,100
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 1,247,900 $ 1,007,200
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1
14. Segment Information Segment Information by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]                      
Net sales $ 621,300 $ 534,100 $ 504,700 $ 500,100 $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 2,160,153 $ 2,068,172 $ 2,019,441
Other assets and property, plant and equipment, net 1,567,300       1,334,200       1,567,300 1,334,200  
Europe [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 758,500 742,200 763,700
Other assets and property, plant and equipment, net 230,600       221,100       230,600 221,100  
Pacific Rim [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 461,300 427,100 392,200
Other assets and property, plant and equipment, net 18,400       16,100       18,400 16,100  
UNITED STATES                      
Segment Reporting Information [Line Items]                      
Net sales                 800,200 770,600 735,000
Other assets and property, plant and equipment, net 1,305,200       1,084,700       1,305,200 1,084,700  
Other (primarily Canada and Latin America) [Member]                      
Segment Reporting Information [Line Items]                      
Net sales                 140,200 128,300 $ 128,500
Other assets and property, plant and equipment, net $ 13,100       $ 12,300       $ 13,100 $ 12,300  
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1
15. Restructuring Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]      
Document Fiscal Year Focus 2017    
GnuBIO [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Current $ 1.4    
GnuBIO [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 5.5    
GnuBIO [Member] | Clinical Diagnostics [Member] | Selling, General and Administrative Expenses [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 0.8    
GnuBIO [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 2.9    
GnuBIO [Member] | Clinical Diagnostics [Member] | Research and Development Expense [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 7.6    
European Reorganization [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 6.3 $ 9.0 $ 0.0
Restructuring Charges 0.5 12.5  
Restructuring Reserve, Accrual Adjustment 0.5 0.8  
Payments for Restructuring (4.2) (3.0)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 1.0 (0.5)  
Restructuring Reserve, Current 6.2    
Restructuring Reserve, Noncurrent 0.1    
European Reorganization [Member] | Cost of Goods, Total [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges (0.2) 2.1  
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 0.7 10.4  
European Reorganization [Member] | Employee Severance [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 0.0 11.7  
European Reorganization [Member] | Life Science [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 2.2 3.2 0.0
Restructuring Charges 0.0 4.1  
Restructuring Reserve, Accrual Adjustment 0.2 0.3  
Payments for Restructuring (1.5) (1.0)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 0.3 (0.2)  
European Reorganization [Member] | Clinical Diagnostics [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 4.1 5.8 $ 0.0
Restructuring Charges 0.0 7.6  
Restructuring Reserve, Accrual Adjustment 0.3 0.5  
Payments for Restructuring (2.7) (2.0)  
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 0.7 (0.3)  
Termination of an Infectious Disease Research and Development Project [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve 14.1 $ 0.0  
Payments for Restructuring 0.0    
Restructuring Reserve, Foreign Currency Translation Gain (Loss) 0.1    
Termination of an Infectious Disease Research and Development Project [Member] | Cost of Goods, Total [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 2.3    
Termination of an Infectious Disease Research and Development Project [Member] | Selling, General and Administrative Expenses [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 3.3    
Termination of an Infectious Disease Research and Development Project [Member] | Research and Development Expense [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 15.5    
Termination of an Infectious Disease Research and Development Project [Member] | Employee Severance [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 14.0    
Termination of an Infectious Disease Research and Development Project [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 10.1    
Termination of an Infectious Disease Research and Development Project [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges 11.0    
Termination of an Infectious Disease Research and Development Project [Member] | Accounts Payable and Accrued Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Current 11.1    
Termination of an Infectious Disease Research and Development Project [Member] | Other Current Liabilities [Member]      
Restructuring Cost and Reserve [Line Items]      
Restructuring Reserve, Current $ 3.0    
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1
16. Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Net sales $ 621,300 $ 534,100 $ 504,700 $ 500,100 $ 571,500 $ 508,700 $ 516,800 $ 471,200 $ 2,160,153 $ 2,068,172 $ 2,019,441
Operating Income (Loss) 45,900 30,700 1,100 20,100 (28,200) 22,700 26,900 20,200 116,650 53,194 166,708
Cost of goods sold 276,100 235,200 231,400 230,100 257,100 229,200 236,600 207,200 972,754 930,085 897,771
Gross profit 345,200 298,900 273,300 270,000 314,400 279,500 280,200 264,000 1,187,399 1,138,087 1,121,670
Selling, general and administrative expense 202,300 198,700 213,000 194,900 220,000 201,500 205,500 189,700 808,942 816,724 761,990
Research and development expense 76,100 62,100 62,600 49,500 57,600 49,900 49,800 48,600 250,301 205,864 192,972
Net Income (Loss) Attributable to Parent $ 82,700 $ 22,100 $ 5,000 $ 12,400 $ (18,700) $ 17,100 $ 16,600 $ 11,000 $ 122,249 $ 26,000 $ 109,239
Earnings Per Share, Basic $ 2.78 $ 0.74 $ 0.17 $ 0.42 $ (0.63) $ 0.58 $ 0.56 $ 0.38 $ 4.12 $ 0.88 $ 3.74
Earnings Per Share, Diluted $ 2.75 $ 0.73 $ 0.17 $ 0.41 $ (0.63) $ 0.58 $ 0.56 $ 0.37 $ 4.07 $ 0.88 $ 3.71
Income Tax Expense (Benefit) $ 36,800 $ (8,600) $ 3,900 $ (7,700) $ 9,500 $ (5,600) $ (10,300) $ (9,200) $ 24,444 $ (15,560) $ (36,608)
Tax Misstatement [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Income Tax Expense (Benefit) (2,900)                    
Scenario, Previously Reported [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Net sales 620,400 535,000 504,700 500,100 571,500 508,700 516,800 471,200      
Operating Income (Loss) 37,700 38,900 1,100 20,100 (28,200) 22,700 26,900 20,200      
Cost of goods sold 280,800 230,500 231,400 230,100 257,100 229,200 236,600 207,200      
Gross profit 339,600 304,500 273,300 270,000 314,400 279,500 280,200 264,000      
Selling, general and administrative expense 204,200 196,800 213,000 194,900 220,000 201,500 205,500 189,700      
Research and development expense 76,800 61,400 62,600 49,500 57,600 49,900 49,800 48,600      
Net Income (Loss) Attributable to Parent $ 69,900 $ 27,400 $ 5,000 $ 12,400 $ (20,600) $ 18,400 $ 18,000 $ 12,300   $ 28,125 $ 113,093
Earnings Per Share, Basic $ 2.35 $ 0.92 $ 0.17 $ 0.42 $ (0.70) $ 0.63 $ 0.61 $ 0.42   $ 0.96 $ 3.87
Earnings Per Share, Diluted $ 2.32 $ 0.91 $ 0.17 $ 0.41 $ (0.70) $ 0.62 $ 0.61 $ 0.42   $ 0.95 $ 3.85
Income Tax Expense (Benefit) $ 32,200 $ (11,500) $ 3,900 $ (7,700) $ 7,600 $ (4,300) $ (8,900) $ (7,900)   $ (13,435) $ (32,754)
Scenario, Adjustment [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Net sales 900 (900) 0 0 0 0 0 0      
Operating Income (Loss) 8,200 (8,200) 0 0 0 0 0 0      
Cost of goods sold (4,700) 4,700 0 0 0 0 0 0      
Gross profit 5,600 (5,600) 0 0 0 0 0 0      
Selling, general and administrative expense (1,900) 1,900 0 0 0 0 0 0      
Research and development expense (700) 700 0 0 0 0 0 0      
Net Income (Loss) Attributable to Parent $ 12,800 $ (5,300) $ 0 $ 0 $ 1,900 $ (1,300) $ (1,400) $ (1,300)   $ (2,125) $ (3,854)
Earnings Per Share, Basic $ 0.43 $ (0.18) $ 0 $ 0 $ 0.07 $ (0.05) $ (0.05) $ (0.04)   $ (0.08) $ (0.13)
Earnings Per Share, Diluted $ 0.43 $ (0.18) $ 0 $ 0 $ 0.07 $ (0.04) $ (0.05) $ (0.05)   $ (0.07) $ (0.14)
Income Tax Expense (Benefit) $ 4,600 $ 2,900 $ 0 $ 0 $ 1,900 $ (1,300) $ (1,400) $ (1,300)   $ (2,125) $ (3,854)
Inventories [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Cost of goods sold   $ 3,500                  
Employee Benefit Expense Misstatement [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Operating Income (Loss) 3,800                    
RainDance Technologies, Inc. [Member] | Scenario, Adjustment [Member]                      
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Net sales $ 900                    
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1
Schedule II - Valuation and Qualifying Accoutns (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Valuation Allowance of Deferred Tax Assets [Member]      
Valuation and Qualifying Accounts Disclosure [Line Items]      
Valuation Allowances and Reserves, Period Increase (Decrease) $ (47) $ 8,126 $ (338)
Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 66,403 58,277 58,615
Deductions 0 0 0
Valuation Allowances and Reserves, Balance Period End 66,356 66,403 58,277
Allowance for Doubtful Accounts [Member]      
Valuation and Qualifying Accounts Disclosure [Line Items]      
Valuation Allowances and Reserves, Additions for Charges to Cost and Expense 11,174 3,785 8,783
Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 23,367 24,418 27,973
Deductions (8,992) (4,836) (12,338)
Valuation Allowances and Reserves, Balance Period End $ 25,549 $ 23,367 $ 24,418
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1
17. Subsequent Event (Details) - Line of Credit [Member] - USD ($)
$ in Thousands
Apr. 13, 2018
Dec. 31, 2017
Subsequent Event [Line Items]    
Long-term Line of Credit   $ 0
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Long-term Line of Credit $ 0  
EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 511 496 1 true 127 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 7 false false R8.htm 2101100 - Disclosure - 1. Significant Accounting Policies Sheet http://www.bio-rad.com/role/A1SignificantAccountingPolicies 1. Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - 2. Acquisitions Sheet http://www.bio-rad.com/role/A2Acquisitions 2. Acquisitions Notes 9 false false R10.htm 2103100 - Disclosure - 3. Fair Value Measurements Sheet http://www.bio-rad.com/role/A3FairValueMeasurements 3. Fair Value Measurements Notes 10 false false R11.htm 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 4. Intangible Assets, Goodwill and Other Notes 11 false false R12.htm 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 5. Notes Payable and Long-Term Debt Notes 12 false false R13.htm 2108100 - Disclosure - 6. Income Taxes Sheet http://www.bio-rad.com/role/A6IncomeTaxes 6. Income Taxes Notes 13 false false R14.htm 2109100 - Disclosure - 7. Stockholders' Equity Sheet http://www.bio-rad.com/role/A7StockholdersEquity 7. Stockholders' Equity Notes 14 false false R15.htm 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome 8. Accumulated Other Comprehensive Income Notes 15 false false R16.htm 2112100 - Disclosure - 9. Share-based Compensation Sheet http://www.bio-rad.com/role/A9ShareBasedCompensation 9. Share-based Compensation Notes 16 false false R17.htm 2114100 - Disclosure - 10. Other Income and Expenses Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 10. Other Income and Expenses Notes 17 false false R18.htm 2115100 - Disclosure - 11. Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 11. Supplemental Cash Flow Information Notes 18 false false R19.htm 2116100 - Disclosure - 12. Commitments & Contingent Liabilities Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities 12. Commitments & Contingent Liabilities Notes 19 false false R20.htm 2121100 - Disclosure - 13. Legal Proceedings Sheet http://www.bio-rad.com/role/A13LegalProceedings 13. Legal Proceedings Notes 20 false false R21.htm 2124100 - Disclosure - 14. Segment Reporting Sheet http://www.bio-rad.com/role/A14SegmentReporting 14. Segment Reporting Notes 21 false false R22.htm 2125100 - Disclosure - 15. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A15RestructuringCostsNotes 15. Restructuring Costs (Notes) Notes 22 false false R23.htm 2127100 - Disclosure - 16. Quarterly Financial Data Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialData 16. Quarterly Financial Data Notes 23 false false R24.htm 2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns Schedule II - Valuation and Qualifying Accoutns Notes 24 false false R25.htm 2129100 - Disclosure - 17. Subsequent Event (Notes) Notes http://www.bio-rad.com/role/A17SubsequentEventNotes 17. Subsequent Event (Notes) Notes 25 false false R26.htm 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies 1. Significant Accounting Policies (Policies) Policies http://www.bio-rad.com/role/A1SignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 1. Significant Accounting Policies (Tables) Tables http://www.bio-rad.com/role/A1SignificantAccountingPolicies 27 false false R28.htm 2301303 - Disclosure - 1. Significant Accounting Policies Prior Year Misstatements (Tables) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables 1. Significant Accounting Policies Prior Year Misstatements (Tables) Tables 28 false false R29.htm 2303301 - Disclosure - 3. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsTables 3. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A3FairValueMeasurements 29 false false R30.htm 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 4. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 30 false false R31.htm 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 5. Notes Payable and Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 31 false false R32.htm 2308301 - Disclosure - 6. Income Taxes (Tables) Sheet http://www.bio-rad.com/role/A6IncomeTaxesTables 6. Income Taxes (Tables) Tables http://www.bio-rad.com/role/A6IncomeTaxes 32 false false R33.htm 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Sheet http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Tables 33 false false R34.htm 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Tables 34 false false R35.htm 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Tables 35 false false R36.htm 2312301 - Disclosure - 9. Share-based Compensation (Tables) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationTables 9. Share-based Compensation (Tables) Tables http://www.bio-rad.com/role/A9ShareBasedCompensation 36 false false R37.htm 2314301 - Disclosure - 10. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 10. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 37 false false R38.htm 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 11. Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 38 false false R39.htm 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables) Tables 39 false false R40.htm 2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables) Tables 40 false false R41.htm 2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables) Tables 41 false false R42.htm 2324301 - Disclosure - 14. Segment Reporting (Tables) Sheet http://www.bio-rad.com/role/A14SegmentReportingTables 14. Segment Reporting (Tables) Tables http://www.bio-rad.com/role/A14SegmentReporting 42 false false R43.htm 2325301 - Disclosure - 15. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A15RestructuringCostsTables 15. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A15RestructuringCostsNotes 43 false false R44.htm 2327301 - Disclosure - 16. Quarterly Financial Data (Tables) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 16. Quarterly Financial Data (Tables) Tables http://www.bio-rad.com/role/A16QuarterlyFinancialData 44 false false R45.htm 2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails 1. Significant Accounting Policies Property, Plant and Equipment (Details) Details 45 false false R46.htm 2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails 1. Significant Accounting Policies Warranty rollforward (Details) Details 46 false false R47.htm 2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails 1. Significant Accounting Policies Earnings per share (Details) Details 47 false false R48.htm 2401407 - Disclosure - 1. Significant Accounting Policies Details (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails 1. Significant Accounting Policies Details (Details) Details http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 48 false false R49.htm 2401408 - Disclosure - 1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails 1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details) Details 49 false false R50.htm 2402401 - Disclosure - 2. Acquisitions (Details) Sheet http://www.bio-rad.com/role/A2AcquisitionsDetails 2. Acquisitions (Details) Details http://www.bio-rad.com/role/A2Acquisitions 50 false false R51.htm 2403402 - Disclosure - 3. Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsDetails 3. Fair Value Measurements (Details) Details http://www.bio-rad.com/role/A3FairValueMeasurementsTables 51 false false R52.htm 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Details 52 false false R53.htm 2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails 3. Fair Value Measurements Short-term Investments (Details) Details 53 false false R54.htm 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Details 54 false false R55.htm 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 55 false false R56.htm 2403407 - Disclosure - 3. Fair Value Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueInvestmentsDetails 3. Fair Value Investments (Details) Details 56 false false R57.htm 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails 3. Fair Value Measurements Contingent Consideration (Details) Details 57 false false R58.htm 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Details 58 false false R59.htm 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 59 false false R60.htm 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails 5. Notes Payable and Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 60 false false R61.htm 2408402 - Disclosure - 6. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A6IncomeTaxesDetails 6. Income Taxes (Details) Details http://www.bio-rad.com/role/A6IncomeTaxesTables 61 false false R62.htm 2409402 - Disclosure - 7. Stockholders' Equity (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityDetails 7. Stockholders' Equity (Details) Details http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 62 false false R63.htm 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails 7. Stockholders' Equity Treasury Shares (Details) Details 63 false false R64.htm 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 64 false false R65.htm 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 65 false false R66.htm 2412402 - Disclosure - 9. Share-based Compensation (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationDetails 9. Share-based Compensation (Details) Details http://www.bio-rad.com/role/A9ShareBasedCompensationTables 66 false false R67.htm 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails 9. Share-based Compensation Restricted Stock (Details) Details 67 false false R68.htm 2414402 - Disclosure - 10. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails 10. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 68 false false R69.htm 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails 11. Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 69 false false R70.htm 2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails 12. Commitments & Contingent Liabilities (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 70 false false R71.htm 2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails 12. Commitments & Contingent Liabilities Period Expense (Details) Details 71 false false R72.htm 2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails 12. Commitments & Contingent Liabilities Pensions (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables 72 false false R73.htm 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) Sheet http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails 13. Legal Proceedings Legal Proceedings (Details) Details 73 false false R74.htm 2424402 - Disclosure - 14. Segment Reporting (Details) Sheet http://www.bio-rad.com/role/A14SegmentReportingDetails 14. Segment Reporting (Details) Details http://www.bio-rad.com/role/A14SegmentReportingTables 74 false false R75.htm 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails 14. Segment Information Segment Profit Reconciliation (Details) Details 75 false false R76.htm 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails 14. Segment Information Segment Asset Reconciliation (Details) Details 76 false false R77.htm 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails 14. Segment Information Segment Information by Geographical Location (Details) Details 77 false false R78.htm 2425402 - Disclosure - 15. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A15RestructuringCostsDetails 15. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A15RestructuringCostsTables 78 false false R79.htm 2427402 - Disclosure - 16. Quarterly Financial Data (Details) Sheet http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails 16. Quarterly Financial Data (Details) Details http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables 79 false false R80.htm 2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails Schedule II - Valuation and Qualifying Accoutns (Details) Details http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns 80 false false R81.htm 2429402 - Disclosure - 17. Subsequent Event (Details) Sheet http://www.bio-rad.com/role/A17SubsequentEventDetails 17. Subsequent Event (Details) Details http://www.bio-rad.com/role/A17SubsequentEventNotes 81 false false All Reports Book All Reports a10k123117.htm bio-20171231.xsd bio-20171231_cal.xml bio-20171231_def.xml bio-20171231_lab.xml bio-20171231_pre.xml ex211123117.htm ex231123117.htm ex311123117.htm ex312123117.htm ex321123117.htm ex322123117.htm http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/country/2017-01-31 true true JSON 102 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10k123117.htm": { "axisCustom": 3, "axisStandard": 32, "contextCount": 511, "dts": { "calculationLink": { "local": [ "bio-20171231_cal.xml" ] }, "definitionLink": { "local": [ "bio-20171231_def.xml" ] }, "inline": { "local": [ "a10k123117.htm" ] }, "labelLink": { "local": [ "bio-20171231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20171231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml" ] }, "schema": { "local": [ "bio-20171231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 870, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2017-01-31": 71, "http://www.bio-rad.com/20171231": 1, "http://xbrl.sec.gov/dei/2014-01-31": 15, "total": 87 }, "keyCustom": 19, "keyStandard": 477, "memberCustom": 35, "memberStandard": 89, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20171231", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 3. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements", "shortName": "3. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther", "shortName": "4. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - 5. Notes Payable and Long-Term Debt", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt", "shortName": "5. Notes Payable and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - 6. Income Taxes", "role": "http://www.bio-rad.com/role/A6IncomeTaxes", "shortName": "6. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 7. Stockholders' Equity", "role": "http://www.bio-rad.com/role/A7StockholdersEquity", "shortName": "7. Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - 8. Accumulated Other Comprehensive Income", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome", "shortName": "8. Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 9. Share-based Compensation", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensation", "shortName": "9. Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 10. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses", "shortName": "10. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 11. Supplemental Cash Flow Information", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation", "shortName": "11. Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - 12. Commitments & Contingent Liabilities", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities", "shortName": "12. Commitments & Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - 13. Legal Proceedings", "role": "http://www.bio-rad.com/role/A13LegalProceedings", "shortName": "13. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - 14. Segment Reporting", "role": "http://www.bio-rad.com/role/A14SegmentReporting", "shortName": "14. Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - 15. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsNotes", "shortName": "15. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - 16. Quarterly Financial Data", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialData", "shortName": "16. Quarterly Financial Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "shortName": "Schedule II - Valuation and Qualifying Accoutns", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129100 - Disclosure - 17. Subsequent Event (Notes)", "role": "http://www.bio-rad.com/role/A17SubsequentEventNotes", "shortName": "17. Subsequent Event (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpensePolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Significant Accounting Policies (Policies)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies", "shortName": "1. Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpensePolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - 1. Significant Accounting Policies (Tables)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables", "shortName": "1. Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301303 - Disclosure - 1. Significant Accounting Policies Prior Year Misstatements (Tables)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "shortName": "1. Significant Accounting Policies Prior Year Misstatements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 3. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "shortName": "3. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables", "shortName": "4. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables", "shortName": "5. Notes Payable and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - 6. Income Taxes (Tables)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesTables", "shortName": "6. Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "shortName": "7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 9. Share-based Compensation (Tables)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationTables", "shortName": "9. Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - 10. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables", "shortName": "10. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables", "shortName": "11. Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - 12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "shortName": "12. Commitments & Contingent Liabilities Pension obligations and funded status (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316302 - Disclosure - 12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "shortName": "12. Commitments & Contingent Liabilities Net Periodic Benefit Cost (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - 12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "shortName": "12. Commitments & Contingent Liabilities Assumptions for Benefit Obligations and Periodic Benefit Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - 14. Segment Reporting (Tables)", "role": "http://www.bio-rad.com/role/A14SegmentReportingTables", "shortName": "14. Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - 15. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsTables", "shortName": "15. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327301 - Disclosure - 16. Quarterly Financial Data (Tables)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables", "shortName": "16. Quarterly Financial Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "shortName": "1. Significant Accounting Policies Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_us-gaap_RangeAxis_us-gaap_MinimumMember", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails", "shortName": "1. Significant Accounting Policies Warranty rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-5", "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "1. Significant Accounting Policies Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - 1. Significant Accounting Policies Details (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "shortName": "1. Significant Accounting Policies Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - 1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "shortName": "1. Significant Accounting Policies Significant Accounting Policies Reclassification & Correction of Immaterial Errors (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2015Q4YTD_us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis_us-gaap_ScenarioAdjustmentMember_us-gaap_StatementScenarioAxis_bio_FirstTaxMisstatementMember", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - 2. Acquisitions (Details)", "role": "http://www.bio-rad.com/role/A2AcquisitionsDetails", "shortName": "2. Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q1QTD_us-gaap_BusinessAcquisitionAxis_bio_RainDanceTechnologiesInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 3. Fair Value Measurements (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "shortName": "3. Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails", "shortName": "3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 3. Fair Value Measurements Short-term Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "shortName": "3. Fair Value Measurements Short-term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 3. Fair Value Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "shortName": "3. Fair Value Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "shortName": "3. Fair Value Measurements Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_bio_AnalyticalFlowCytometerPlatformMember_us-gaap_ContingentConsiderationByTypeAxis_bio_DiscountrateMember", "decimals": "3", "lang": null, "name": "us-gaap:FairValueInputsDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2014Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "shortName": "5. Notes Payable and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PrepaidTaxes", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - 6. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "shortName": "6. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - 7. Stockholders' Equity (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "shortName": "7. Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "shortName": "7. Stockholders' Equity Treasury Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 9. Share-based Compensation (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "shortName": "9. Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails", "shortName": "9. Share-based Compensation Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - 10. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "shortName": "10. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "shortName": "11. Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - 12. Commitments & Contingent Liabilities (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "shortName": "12. Commitments & Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q4", "decimals": "-5", "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "shortName": "12. Commitments & Contingent Liabilities Period Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "shortName": "12. Commitments & Contingent Liabilities Pensions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details)", "role": "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "shortName": "13. Legal Proceedings Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - 14. Segment Reporting (Details)", "role": "http://www.bio-rad.com/role/A14SegmentReportingDetails", "shortName": "14. Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "shortName": "14. Segment Information Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "shortName": "14. Segment Information Segment Asset Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "shortName": "14. Segment Information Segment Information by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember", "decimals": "-5", "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_BusinessAcquisitionAxis_bio_GnuBIOMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - 15. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "shortName": "15. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2017Q4_us-gaap_BusinessAcquisitionAxis_bio_GnuBIOMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SalesRevenueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427402 - Disclosure - 16. Quarterly Financial Data (Details)", "role": "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "shortName": "16. Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2017Q4QTD", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfGoodsSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Significant Accounting Policies", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPolicies", "shortName": "1. Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details)", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "shortName": "Schedule II - Valuation and Qualifying Accoutns (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "body", "html" ], "contextRef": "FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2429402 - Disclosure - 17. Subsequent Event (Details)", "role": "http://www.bio-rad.com/role/A17SubsequentEventDetails", "shortName": "17. Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - 2. Acquisitions", "role": "http://www.bio-rad.com/role/A2Acquisitions", "shortName": "2. Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2017Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 127, "tag": { "bio_A2011EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Employee Stock Purchase Plan [Member]", "label": "2011 Employee Stock Purchase Plan [Member]", "terseLabel": "2011 Employee Stock Purchase Plan [Member]" } } }, "localname": "A2011EmployeeStockPurchasePlanMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_AccumulatedOtherComprehensiveIncomeTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accumulated other comprehensive income [Text Block]", "label": "accumulated other comprehensive income [Text Block]", "terseLabel": "accumulated other comprehensive income [Text Block]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeTextBlock", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_AssumptionsforBenefitObligationsandPeriodicBenefitCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract]", "label": "Assumptions for Benefit Obligations and Periodic Benefit Costs [Abstract]" } } }, "localname": "AssumptionsforBenefitObligationsandPeriodicBenefitCostsAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_BalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Parenthetical [Abstract]", "label": "Balance Sheet Parenthetical [Abstract]" } } }, "localname": "BalanceSheetParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_CellsorterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CellSorter [Member] [Member]", "label": "CellSorter [Member]", "terseLabel": "CellSorter [Member]" } } }, "localname": "CellsorterMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_CostMethodInvestmentPercentageOwned": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost Method Investments, Percentage Owned", "label": "Cost Method Investment, Percentage Owned", "terseLabel": "Cost Method Investment, Percentage Owned" } } }, "localname": "CostMethodInvestmentPercentageOwned", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_CostofdebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cost of debt [Member]", "label": "Cost of debt [Member]", "terseLabel": "Cost of debt [Member]" } } }, "localname": "CostofdebtMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DiscountrateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount rate [Member]", "label": "Discount rate [Member]", "terseLabel": "Discount rate [Member]" } } }, "localname": "DiscountrateMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Document and Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "label": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "terseLabel": "Fines and penalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "terseLabel": "U.S. tax reform" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_ElectionPercentageForBoardOfDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "terseLabel": "Election Percentage for Board of Directors" } } }, "localname": "ElectionPercentageForBoardOfDirectors", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "bio_EmployeeBenefitExpenseMisstatementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Benefit Expense Misstatement [Member]", "label": "Employee Benefit Expense Misstatement [Member]", "terseLabel": "Employee Benefit Expense Misstatement [Member]" } } }, "localname": "EmployeeBenefitExpenseMisstatementMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "bio_EmployeeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Location [Axis]", "label": "Employee Location [Axis]", "terseLabel": "Employee Location [Axis]" } } }, "localname": "EmployeeLocationAxis", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "bio_EmployeeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Employee Location [Axis]", "label": "Employee Location [Domain]", "terseLabel": "Employee Location [Domain]" } } }, "localname": "EmployeeLocationDomain", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "bio_EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees covered by collective bargaining agreements, percentage", "label": "Employees Covered By Collective Bargaining Agreements U.S., Percentage", "terseLabel": "Employees Covered By Collective Bargaining Agreements U.S., Percentage" } } }, "localname": "EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "bio_EuropeanReorganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "European Reorganization [Member]", "label": "European Reorganization [Member]", "terseLabel": "European Reorganization [Member]" } } }, "localname": "EuropeanReorganizationMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_FinesandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fines and penalties [Axis]", "label": "Fines and penalties [Axis]", "terseLabel": "Fines and penalties [Axis]" } } }, "localname": "FinesandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_FinesandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Fines and penalties [Axis]", "label": "Fines and penalties [Domain]", "terseLabel": "Fines and penalties [Domain]" } } }, "localname": "FinesandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_FirstTaxMisstatementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First Tax Misstatement [Member]", "label": "First Tax Misstatement [Member]", "terseLabel": "First Tax Misstatement [Member]" } } }, "localname": "FirstTaxMisstatementMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "bio_ForeignTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Tax Credit Carryforward [Member]", "label": "Foreign Tax Credit Carryforward [Member]", "terseLabel": "Foreign Tax Credit Carryforward [Member]" } } }, "localname": "ForeignTaxCreditCarryforwardMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_GnuBIOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GnuBIO [Member]", "label": "GnuBIO [Member]", "terseLabel": "GnuBIO [Member]" } } }, "localname": "GnuBIOMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_IncentiveAwardPlan2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Award Plan 2017 [Member]", "label": "Incentive Award Plan 2017 [Member]", "terseLabel": "Incentive Award Plan 2017 [Member]" } } }, "localname": "IncentiveAwardPlan2017Member", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Axis]", "label": "Including accrued interest and penalties [Axis]" } } }, "localname": "IncludingaccruedinterestandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_IncludingaccruedinterestandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Domain]", "label": "Including accrued interest and penalties [Domain]", "terseLabel": "Including accrued interest and penalties [Domain]" } } }, "localname": "IncludingaccruedinterestandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Member]", "label": "Including accrued interest and penalties [Member]", "terseLabel": "Including accrued interest and penalties [Member]" } } }, "localname": "IncludingaccruedinterestandpenaltiesMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Legal Proceedings [Abstract]" } } }, "localname": "LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_LimitationsOnUseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Limitations On Use [Member]", "label": "Limitations On Use [Member]", "terseLabel": "Limitations On Use" } } }, "localname": "LimitationsOnUseMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Periodic Benefit Cost [Abstract]", "label": "Net Periodic Benefit Cost [Abstract]" } } }, "localname": "NetPeriodicBenefitCostAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Axis]", "terseLabel": "Net of prepaid taxes [Axis]" } } }, "localname": "NetofprepaidtaxesAxis", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Domain]", "terseLabel": "Net of prepaid taxes [Domain]" } } }, "localname": "NetofprepaidtaxesDomain", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetofprepaidtaxesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Member]", "label": "Net of prepaid taxes [Member]", "terseLabel": "Net of prepaid taxes [Member]" } } }, "localname": "NetofprepaidtaxesMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NonCurrentIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non Current Income Tax Expense", "label": "Non Current Income Tax Expense", "terseLabel": "Non-current tax expense (benefit)" } } }, "localname": "NonCurrentIncomeTaxExpense", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_NumberOfProductsAndServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Products And Services", "label": "Number Of Products And Services", "terseLabel": "Number Of Products And Services" } } }, "localname": "NumberOfProductsAndServices", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "bio_ObligationsandFundedStatusAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Obligations and Funded Status [Abstract]", "label": "Obligations and Funded Status [Abstract]" } } }, "localname": "ObligationsandFundedStatusAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_OperatingLossCarryforwardWithNoExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Loss Carryforward With No Expiration Date", "label": "Operating Loss Carryforward With No Expiration Date", "terseLabel": "Operating Loss Carryforward With No Expiration Date" } } }, "localname": "OperatingLossCarryforwardWithNoExpirationDate", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_Proceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from derivative instruments, operating activities", "label": "Proceeds from derivative instruments, operating activities", "terseLabel": "(Payments for) proceeds from forward foreign exchange contracts, net" } } }, "localname": "Proceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_PropertyPlantandEquipmentexcludingsegmentspecificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property, Plant and Equipment excluding segment specific [Member] -- excludes segment specific gross machinery and equipment", "label": "Property, Plant and Equipment excluding segment specific [Member]", "terseLabel": "Property, Plant and Equipment excluding segment specific [Member]" } } }, "localname": "PropertyPlantandEquipmentexcludingsegmentspecificMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "bio_QuantalifeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "QuantaLife [Member]", "label": "QuantaLife [Member]", "terseLabel": "QuantaLife [Member]" } } }, "localname": "QuantalifeMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_RainDanceTechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RainDance Technologies, Inc. [Member]", "label": "RainDance Technologies, Inc. [Member]", "terseLabel": "RainDance Technologies, Inc. [Member]" } } }, "localname": "RainDanceTechnologiesInc.Member", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Four [Member]", "label": "Range of Exercise Prices, Group Four [Member]" } } }, "localname": "RangeOfExercisePricesGroupFourMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group One [Member]", "label": "Range of Exercise Prices, Group One [Member]" } } }, "localname": "RangeOfExercisePricesGroupOneMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Three [Member]", "label": "Range of Exercise Prices, Group Three [Member]" } } }, "localname": "RangeOfExercisePricesGroupThreeMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_RangeOfExercisePricesGroupTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Exercise Prices, Group Two [Member]", "label": "Range of Exercise Prices, Group Two [Member]" } } }, "localname": "RangeOfExercisePricesGroupTwoMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_ReagentRentalEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reagent Rental Equipment [Member]", "label": "Reagent Rental Equipment [Member]", "terseLabel": "Reagent Rental Equipment [Member]" } } }, "localname": "ReagentRentalEquipmentMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bio_ReclassificationandCorrectionofImmaterialErrorsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reclassification and Correction of Immaterial Errors [Abstract]", "label": "Reclassification and Correction of Immaterial Errors [Abstract]" } } }, "localname": "ReclassificationandCorrectionofImmaterialErrorsAbstract", "nsuri": "http://www.bio-rad.com/20171231", "xbrltype": "stringItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SecondTaxMisstatementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second Tax Misstatement [Member]", "label": "Second Tax Misstatement [Member]", "terseLabel": "Second Tax Misstatement [Member]" } } }, "localname": "SecondTaxMisstatementMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "bio_ShorttermRestrictedInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term Restricted Investments [Policy Text Block]", "label": "Short-term Restricted Investments [Policy Text Block]", "terseLabel": "Short-term Restricted Investments [Policy Text Block]" } } }, "localname": "ShorttermRestrictedInvestmentsPolicyTextBlock", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bio_StockAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Award Plans [Member]", "label": "Stock Award Plans [Member]", "terseLabel": "Stock Award Plans [Member]" } } }, "localname": "StockAwardPlansMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_StockOptionAndAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Award Plans [Member]", "label": "Stock Option and Award Plans [Member]", "terseLabel": "Stock Option and Award Plans [Member]" } } }, "localname": "StockOptionAndAwardPlansMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncompleteAccountingChangeinTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisional Income Tax Benefit", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisional Income Tax Benefit", "terseLabel": "Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Liability, Provisonal Income Tax Benefit" } } }, "localname": "TaxCutsandJobsActIncompleteAccountingChangeinTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActIncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act [Member]", "label": "Tax Cuts and Jobs Act [Member]", "terseLabel": "Tax Cuts and Jobs Act [Member]" } } }, "localname": "TaxCutsandJobsActMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "terseLabel": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect" } } }, "localname": "TaxCutsandJobsActReclassificationfromAOCItoRetainedEarningsTaxEffect", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bio_TaxMisstatementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Misstatement [Member]", "label": "Tax Misstatement [Member]", "terseLabel": "Tax Misstatement [Member]" } } }, "localname": "TaxMisstatementMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an Infectious Disease Research and Development Project [Member]", "label": "Termination of an Infectious Disease Research and Development Project [Member]", "terseLabel": "Termination of an Infectious Disease Research and Development Project [Member]" } } }, "localname": "TerminationofanInfectiousDiseaseResearchandDevelopmentProjectMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_ThirdTaxMisstatementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third Tax Misstatement [Member]", "label": "Third Tax Misstatement [Member]", "terseLabel": "First Tax Misstatement [Member]", "verboseLabel": "Third Tax Misstatement [Member]" } } }, "localname": "ThirdTaxMisstatementMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class-A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20171231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r615" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Entity Number of Employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r615" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r616" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r31", "r37" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r12", "r14", "r49" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r71", "r77", "r342", "r475" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Other Postretirement Benefit Plan [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r240" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r70", "r77", "r475" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r74", "r76", "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "verboseLabel": "Other assets" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r77", "r475" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r68", "r77", "r475" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition-related Costs [Member]" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the types error corrections made to the financial statements.", "label": "Adjustments for Error Correction [Domain]", "terseLabel": "Adjustments for Error Correction [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r357", "r359", "r395", "r396" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation": { "auth_ref": [ "r278", "r285", "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.", "label": "Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation", "terseLabel": "Tax benefit-exercise stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r359", "r389", "r394" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsMember": { "auth_ref": [ "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "Allowance established for amounts due that are unlikely to be received.", "label": "Allowance for Doubtful Accounts [Member]" } } }, "localname": "AllowanceForDoubtfulAccountsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r59", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Other (primarily Canada and Latin America) [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r108", "r228", "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the computation of diluted EPS" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Pacific Rim [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r108", "r238" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses on goodwill and long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r548", "r586" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r66" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial Assets Carried at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r48", "r188" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r180", "r184", "r197" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale investments", "verboseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses": { "auth_ref": [ "r200" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on securities classified as available-for-sale that have been in a loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss", "terseLabel": "Gross unrealized losses for investments in a loss position 12 months or more" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses": { "auth_ref": [ "r200", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on investments in available-for-sale securities that have been in a loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss", "terseLabel": "Gross unrealized losses for investments in a loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [ "r199", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [ "r199", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r48", "r195" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r191", "r195", "r574" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r48", "r194" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r191", "r194", "r573" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r48", "r193" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r191", "r193", "r572" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r180", "r184", "r188", "r570" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of debt securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities, Debt Securities", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r192", "r196", "r201", "r202", "r206", "r571", "r575" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r180", "r181", "r182", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Investments in available-for-sale securities.", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities [Member]" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r360", "r391" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r484", "r487" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r569" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Foreign Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r10", "r239" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r461", "r462", "r464" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r459", "r461", "r462" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r467" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r460", "r463", "r465" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r451", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r451", "r452" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r517", "r518" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r38", "r110" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r100", "r526" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r112", "r120", "r173" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Domestic Time Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r286", "r287", "r288", "r289" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r257", "r563", "r595" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r256", "r260" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r30", "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r80" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Bio-Rad" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r457" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r519", "r520", "r522", "r578", "r579", "r606" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r120", "r473", "r476", "r477" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r86" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated cost of goods (such as cost of goods sold, or purchases) for the period after providing for returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Cost of Goods, Total [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r123", "r436", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r129", "r439" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r436", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r123", "r436", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r560", "r598" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "totalLabel": "Debt and Capital Lease Obligations" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r22", "r23", "r549", "r552", "r581" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r531", "r533" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r51", "r531" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r125", "r279", "r282", "r283", "r284", "r530", "r531", "r533", "r577" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "terseLabel": "Contribution expense" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r438", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r438", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r108", "r123", "r438", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r26", "r27", "r426", "r550", "r580" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r13", "r292" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r13", "r292", "r293", "r294", "r295", "r296", "r297" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r438", "r442" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r427" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r428" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r407", "r408", "r409", "r410", "r427" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Long-term deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r403", "r434", "r435" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r431", "r434", "r435" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit and net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r431", "r434", "r435" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r402", "r434", "r435" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other", "terseLabel": "Other post-employment benefits, vacation and other reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r402", "r434", "r435" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Legal reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r402", "r434", "r435" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Bad debt, inventory and warranty accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r409", "r430" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r407", "r409", "r410" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": { "auth_ref": [ "r403", "r434", "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment.", "label": "Deferred Tax Liabilities, Other Finite-Lived Assets", "terseLabel": "Investments and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r403", "r434", "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r403", "r434", "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "verboseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r339" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Defined Benefit Plan, Amortization of Gain (Loss)" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r340" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "terseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r320", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r334", "r352" ], "lang": { "en-US": { "role": { "documentation": "Information by category of defined benefit plan assets.", "label": "Defined Benefit Plan, Asset Categories [Axis]", "terseLabel": "Defined Benefit Plan, Asset Categories [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r326", "r331", "r332", "r353" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r338" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of assets that have been segregated and restricted to provide pension or postretirement benefits. Assets include, but are not limited to, stocks, bonds, other investments, earnings from investments, and contributions by the employer and employees.", "label": "Defined Benefit Plan, Fair Value of Plan Assets", "terseLabel": "Defined Benefit Plan, Fair Value of Plan Assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r311", "r330" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r316", "r337" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Defined Benefit Plan, Interest Cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r335" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r328", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r341" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r314", "r336" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Defined Benefit Plan, Service Cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r315" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "terseLabel": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r329", "r331", "r332" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.", "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits" } } }, "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan Disclosures [Table Text Block]", "terseLabel": "Defined Contribution Plan Disclosures [Table Text Block]" } } }, "localname": "DefinedContributionPlanDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r485", "r486", "r490", "r492" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r130", "r479", "r480", "r481", "r482", "r483", "r488", "r490", "r493", "r495", "r497" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r120", "r131", "r479", "r480", "r482", "r483", "r494" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Forward Foreign Exchange Contracts" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r458" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r290", "r399" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r83", "r145", "r149", "r151", "r566", "r600" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r83", "r145", "r566", "r600" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r120", "r148", "r149", "r150" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r526" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r128", "r412", "r413" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent", "negatedTerseLabel": "Domestic manufacturing deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Impact of foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Nondeductible executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent", "negatedTerseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other reconciling items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Prior period adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "negatedTerseLabel": "Foreign dividends, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent", "negatedTerseLabel": "Nontaxable subsidies" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r412", "r413", "r441" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements and changes to unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost from stock options", "verboseLabel": "Total unrecognized compensation cost from restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average fair value of options granted, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r389" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit from exercise of stock options granted under share-based compensation arrangement.", "label": "Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options", "terseLabel": "Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock [Member]", "verboseLabel": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByEntitySizeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by entity size of equity securities.", "label": "Equity Securities by Entity Size [Axis]", "terseLabel": "Equity Securities by Entity Size [Axis]" } } }, "localname": "EquitySecuritiesByEntitySizeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]", "terseLabel": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesByInvestmentObjectiveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by investment objective of equity securities.", "label": "Equity Securities by Investment Objective [Axis]", "terseLabel": "Equity Securities by Investment Objective [Axis]" } } }, "localname": "EquitySecuritiesByInvestmentObjectiveAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesEntitySizeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity securities segregated by entity size.", "label": "Equity Securities, Entity Size [Domain]", "terseLabel": "Equity Securities, Entity Size [Domain]" } } }, "localname": "EquitySecuritiesEntitySizeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]", "terseLabel": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesInvestmentObjectiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity securities segregated by investment objective.", "label": "Equity Securities, Investment Objective [Domain]", "terseLabel": "Equity Securities, Investment Objective [Domain]" } } }, "localname": "EquitySecuritiesInvestmentObjectiveMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r17", "r21", "r208", "r558", "r582", "r611" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error correction.", "label": "Adjustments for Error Corrections [Axis]", "terseLabel": "Adjustments for Error Corrections [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r500", "r516" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r397" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "terseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r397" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedTerseLabel": "Excess tax benefits from share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r499", "r500", "r501", "r502", "r508", "r509" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r500", "r514", "r516", "r517", "r518", "r521" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r500", "r514", "r516", "r517", "r518", "r521" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Information by level within the fair value hierarchy.", "label": "Fair Value, Hierarchy [Axis]", "terseLabel": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r507", "r509" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r500", "r510" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r500", "r514", "r516", "r517", "r518", "r521" ], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsDiscountRate": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.", "label": "Fair Value Inputs, Discount Rate", "terseLabel": "Fair Value Inputs, Discount Rate" } } }, "localname": "FairValueInputsDiscountRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r498", "r501" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Schedule of the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Table]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Table]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.", "label": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]" } } }, "localname": "FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r504", "r509" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r504", "r509" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r499", "r507" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r506" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r506" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r504" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "verboseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r499", "r507" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r120", "r511", "r515" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r229", "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r229", "r231" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r491" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r523", "r524", "r525" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r120", "r525", "r528" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by a national, local, or municipal government not within the country of domicile of the reporting entity.", "label": "Foreign Government Debt Securities [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r485", "r489" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Loss on foreign currency derivative instruments not designated as hedging instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposition of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfSecuritiesNet": { "auth_ref": [ "r567", "r602" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) realized from the sale, exchange, redemption, or retirement of securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Gain (Loss) on Sale of Securities, Net", "negatedLabel": "Loss (gain) on disposition of securities" } } }, "localname": "GainLossOnSaleOfSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r215", "r217", "r218" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, net period end", "periodStartLabel": "Goodwill, net period start", "terseLabel": "Goodwill, net", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r120", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "periodEndLabel": "Goodwill period end", "periodStartLabel": "Goodwill period start" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedPeriodEndLabel": "Accumulated impairment loss period end", "negatedPeriodStartLabel": "Accumulated impairment loss period start" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r108", "r216", "r221", "r225" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r223", "r447" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "negatedTerseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r85" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r108", "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other than Temporary Impairment Losses, Investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r120", "r237", "r242" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r126" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r417", "r423", "r425", "r440" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r446" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r437" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTerseLabel": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r120", "r405", "r406", "r424", "r425", "r444", "r612" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r113" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Increase in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "(Increase) decrease in accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "(Decrease) increase in Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Decrease in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Increase in inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "(Increase) decrease in Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Decrease in other long term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedTerseLabel": "Increase (Decrease) in Other Long Term Liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r146", "r149" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r227", "r230" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestBearingDepositsMember": { "auth_ref": [ "r546", "r554" ], "lang": { "en-US": { "role": { "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.", "label": "Interest-bearing Deposits [Member]", "terseLabel": "Interest-bearing Deposits [Member]" } } }, "localname": "InterestBearingDepositsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r529", "r532", "r568" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r104", "r113" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories [Member]" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r60" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r63", "r210" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r15", "r64", "r120", "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r62" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r61" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r88" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r9", "r41" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land and improvements" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount", "verboseLabel": "Letters of Credit Outstanding Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r555", "r592" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r500" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r23", "r552", "r581" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r552", "r588" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r23" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligations including current maturities.", "label": "Long-term Debt and Capital Lease Obligations, Including Current Maturities", "terseLabel": "Long-term Debt and Capital Lease Obligations, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.", "label": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year", "terseLabel": "Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal Remainder of Fiscal Year" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r132", "r271" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Notes Payable and Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r39" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r272" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r257", "r258", "r259" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r257", "r258", "r259" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss Contingency, Damages Paid, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r10", "r239" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and Equipment, Gross", "verboseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by major type of debt and equity security.", "label": "Major Types of Debt and Equity Securities [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain": { "auth_ref": [ "r208", "r571" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions. Equity securities are ownership interests or the right to acquire or dispose of ownership interests in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock.", "label": "Major Types of Debt and Equity Securities [Domain]", "terseLabel": "Major Types of Debt and Equity Securities [Domain]" } } }, "localname": "MajorTypesOfDebtAndEquitySecuritiesDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy": { "auth_ref": [ "r17", "r21", "r120", "r192", "r207", "r557", "r558", "r585" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.", "label": "Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]", "terseLabel": "Available-for-sale Investments" } } }, "localname": "MarketableSecuritiesAvailableForSaleSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt [Abstract]" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r608" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfErrorDomain": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the error being corrected including when and how the error arose and the fact that the error had previously been considered immaterial.", "label": "Nature of Error [Domain]", "terseLabel": "Nature of Error [Domain]" } } }, "localname": "NatureOfErrorDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r100", "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r100", "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r100", "r105", "r109" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r82", "r109", "r149", "r565", "r599" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r136", "r137", "r138" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r114", "r115", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r114", "r115", "r116" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash Purchased Marketable Securities and Investments" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Other assets and property, plant and equipment, net" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Notes payable and current maturities of long-term debt" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (Loss)", "totalLabel": "Income from operations", "verboseLabel": "Segment profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r534", "r536" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating leases, due next twelve months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r534", "r536" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "verboseLabel": "Operating leases, due in four years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r534", "r536" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating leases, due in three years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r534", "r536" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating leases, due in two years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r534", "r536" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "verboseLabel": "Operating leases, due thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r535" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating Leases, Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards, Expiration Date", "terseLabel": "Operating Loss Carryforwards, Expiration Dates" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r404", "r429", "r432" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Operating Loss Carryforward, Valuation Allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r135", "r154", "r478" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r72", "r74", "r471", "r474" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Other post-employment benefits adjustments, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r77", "r81" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67", "r527" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r78", "r79", "r81", "r278" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r471", "r472", "r474" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r75", "r443" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r69", "r74" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized holding gains on available-for-sale investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r484", "r496" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r306", "r400" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r39", "r596" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r49" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r583", "r605" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense) [Member]" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionNameDomain": { "auth_ref": [ "r114", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "The name of other significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed to enable users of the financial information to fully understand the period cash flows of the Entity in relation to the statements of financial position, income statement, and statement of changes in shareholders' equity. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Name [Domain]", "terseLabel": "Other Significant Noncash Transaction, Name [Domain]" } } }, "localname": "OtherSignificantNoncashTransactionNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis": { "auth_ref": [ "r114", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "Information by other significant noncash transactions.", "label": "Other Significant Noncash Transaction [Axis]", "terseLabel": "Other Significant Noncash Transaction [Axis]" } } }, "localname": "OtherSignificantNoncashTransactionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Significant Noncash Transactions [Line Items]", "terseLabel": "Other Significant Noncash Transactions [Line Items]" } } }, "localname": "OtherSignificantNoncashTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsTable": { "auth_ref": [ "r114", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "This table may contain information related to other significant noncash investing and financing activities that occurred during the accounting period and are not otherwise listed in the existing taxonomy. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transactions [Table]", "terseLabel": "Other Significant Noncash Transactions [Table]" } } }, "localname": "OtherSignificantNoncashTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r127", "r411", "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other Tax Expense (Benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet": { "auth_ref": [ "r204" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.", "label": "Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net", "terseLabel": "Other-than-temporary impairment losses on investments" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Bio Rad [Member]", "verboseLabel": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payment for Contingent Consideration Liability, Financing Activities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r105", "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAssetsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.", "label": "Payments to Acquire Assets, Investing Activities", "negatedTerseLabel": "Payments for acquisitions, net of cash received, and long-term investments" } } }, "localname": "PaymentsToAcquireAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments for purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures", "terseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedTerseLabel": "Payments for purchases of restricted investment" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r103" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r22", "r311", "r312", "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Liability, Defined Benefit Plan, Current" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r311", "r330", "r551", "r587" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "negatedTerseLabel": "Liability, Defined Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r24", "r311", "r312", "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Liability, Defined Benefit Plan, Noncurrent" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceGuaranteeMember": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation.", "label": "Performance Guarantee [Member]", "terseLabel": "Performance Guarantee [Member]" } } }, "localname": "PerformanceGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r333", "r351" ], "lang": { "en-US": { "role": { "documentation": "Major categories of plan assets based on the nature and risk of assets in an employer's plan(s).", "label": "Plan Asset Categories [Domain]", "terseLabel": "Plan Asset Categories [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r360", "r391" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r513", "r514" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r309", "r310", "r562", "r597" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.", "label": "Postemployment Benefits Liability", "terseLabel": "Post-Employment Benefits Liability" } } }, "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r214" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r213", "r214" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid Taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r91", "r185" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.", "label": "Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net (payments) borrowings on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r91", "r185" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r92" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r96", "r392" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash Received from Exercise of Stock Options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r266", "r267", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r264" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r241" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r239" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property, plant and equipment:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r241", "r594" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r120", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r239" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r25", "r553", "r589" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error in the financial statements.", "label": "Nature of Error [Axis]", "terseLabel": "Nature of Error [Axis]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Quantifying Misstatement in Current Year Financial Statements [Line Items]", "terseLabel": "Quantifying Misstatement in Current Year Financial Statements [Line Items]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialDataAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Data [Abstract]" } } }, "localname": "QuarterlyFinancialDataAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialData" ], "xbrltype": "textBlockItemType" }, "us-gaap_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r601", "r603" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized (gains) losses on investments", "terseLabel": "Realized Investment Gains (Losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r77", "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r166", "r168" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r166", "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r165", "r168" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r165", "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded Unconditional Purchase Obligation" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueAfterFifthYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due after Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due after Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fourth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fourth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Second Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Third Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r543" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r538", "r539", "r540", "r541", "r542" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r401", "r614" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r120", "r401" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r16", "r110", "r117", "r547", "r590" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r609", "r610" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r108", "r243", "r247", "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r244", "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r243", "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r243", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring Reserve, Current" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveNoncurrent": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Noncurrent", "terseLabel": "Restructuring Reserve, Noncurrent" } } }, "localname": "RestructuringReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r244", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r285", "r591" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanFundingStatusAxis": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Axis]", "terseLabel": "Retirement Plan Funding Status [Axis]" } } }, "localname": "RetirementPlanFundingStatusAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanFundingStatusDomain": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Domain]", "terseLabel": "Retirement Plan Funding Status [Domain]" } } }, "localname": "RetirementPlanFundingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r348", "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r348", "r350" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r307", "r308", "r347", "r348", "r356" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r307", "r308", "r347", "r348", "r356" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r119", "r120", "r121", "r298" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesRevenueNet": { "auth_ref": [ "r84" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.", "label": "Revenue, Net", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueNet", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioAdjustmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.", "label": "Scenario, Adjustment [Member]", "terseLabel": "Scenario, Adjustment [Member]" } } }, "localname": "ScenarioAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Represents the amount as previously reported before the correction of an error or other adjustment.", "label": "Scenario, Previously Reported [Member]", "terseLabel": "Scenario, Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major-Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.", "label": "Schedule of Assumptions Used [Table Text Block]", "terseLabel": "Schedule of Assumptions Used [Table Text Block]" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r192", "r196", "r201", "r202", "r203", "r205", "r571", "r575" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r449", "r450" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for income taxes [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r125", "r279", "r282", "r283", "r284", "r530", "r531", "r533", "r577" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Principal components of long-term debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant components of deferred tax assets and liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r347", "r348", "r349", "r350", "r354" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesAssumptionsForBenefitObligationsAndPeriodicBenefitCostsTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionObligationsAndFundedStatusTables", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r130", "r479", "r480", "r481", "r482", "r483", "r488", "r490", "r493", "r495" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r139", "r140", "r141" ], "lang": { "en-US": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r224", "r226" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r224", "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "U.S. and international components of income before taxes [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs [Table Text Block]" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesNetPeriodicBenefitCostTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Disclose the nature of each individual error being corrected in the correcting adjustment. This disclosure would also generally include when and how each error being corrected arose and assert that the errors were immaterial to the prior amounts reported.", "label": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]", "terseLabel": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]" } } }, "localname": "ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature and amount of prior period errors that had previously been considered immaterial and which are being corrected in the current fiscal year. This disclosure would also generally include when and how each error being corrected arose and assert that the errors were immaterial to the prior amounts reported.", "label": "Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block]", "terseLabel": "Schedule of Quantifying Prior Year Misstatements Corrected in Current Year Financial Statements [Table Text Block]" } } }, "localname": "ScheduleOfQuantifyingPriorYearMisstatementsCorrectedInCurrentYearFinancialStatementsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Data [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r245", "r246", "r250" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r245", "r246", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r84", "r171" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Net sales and assets to external customers by geographic area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r162", "r163", "r164", "r167", "r224" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r162", "r163", "r164", "r167", "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Information regarding industry segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r360", "r391" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock Options Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Resticted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r55", "r124", "r274", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r28", "r29", "r30", "r122", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock by Class [Table Text Block]" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of investments with gross unrealized losses and the associated fair value" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.", "label": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r0", "r171", "r613" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segments, Geographical Areas [Abstract]" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r87", "r209" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, general and administrative expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A16QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r107" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Purchase Price Discount from Market Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted Stock Units Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value - Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Per share weighted average intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share", "terseLabel": "Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Nonvested shares - Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted Stock Units - Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee Contribution Rate - Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Number Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price - Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options - Shares Forfeitures/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options Forfeitured/expired - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options - Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Stock Options Activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value (in millions) - Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r368", "r391" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period", "periodStartLabel": "Outstanding beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options - Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options - Shares Vested and Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r358", "r391" ], "lang": { "en-US": { "role": { "documentation": "The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Description of pertinent provisions of equity-based compensation awards that have actual or potential impact upon the company's financial statements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Options Granted Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r358", "r364" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options Exercised - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options Granted - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r120", "r360", "r365" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-based Compensation Plans" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r384", "r393" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options Exercisable Aggregate Intrinsic Value (in millions)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [ "r119", "r120", "r299", "r300", "r301" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r21", "r556", "r557", "r558", "r584" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r556", "r557", "r584", "r604" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r415" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r120", "r265" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r261", "r269", "r470", "r607" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r28", "r29", "r30", "r278" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r58", "r278" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r0", "r171", "r304", "r305", "r613" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPriorYearMisstatementsTables", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r57", "r278", "r279", "r285" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r29", "r30", "r278", "r285" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r29", "r30", "r278", "r285" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r29", "r30", "r278", "r285", "r371" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options - Shares Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r30", "r278", "r285" ], "lang": { "en-US": { "role": { "documentation": "Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r29", "r30", "r278", "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r30", "r34", "r35", "r178" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesSignificantAccountingPoliciesReclassificationCorrectionOfImmaterialErrorsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r544" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r545" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A17SubsequentEventNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r417", "r440" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Summary of income tax years currently under audit or open to examinations [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax Credit Carryforward, Limitations on Use" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r31", "r37", "r120", "r174", "r175", "r177", "r179", "r559", "r593" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.", "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r56", "r286" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r56", "r286" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r30", "r278", "r285" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r56", "r286", "r289" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r278", "r285", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r564" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsShortTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r418" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits period end", "periodStartLabel": "Unrecognized tax benefits period start" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "terseLabel": "Currency translation" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r419" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r414" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions to tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r418" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due in Twelve Months" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Four Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Four Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Two Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Two Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Three Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Three Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Unrecorded Unconditional Purchase Obligation" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due after Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due after Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r23", "r552", "r588" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r404", "r429" ], "lang": { "en-US": { "role": { "documentation": "The portion of a deferred tax asset as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income.", "label": "Valuation Allowance of Deferred Tax Assets [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves, Balance", "periodEndLabel": "Valuation Allowances and Reserves, Balance Period End", "periodStartLabel": "Valuation Allowances and Reserves, Balance Period Start" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.", "label": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense", "terseLabel": "Valuation Allowances and Reserves, Additions for Charges to Cost and Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r133" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.", "label": "Valuation Allowances and Reserves, Deductions", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "The entity's valuation, qualifying and reserve accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves [Domain]", "terseLabel": "Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "Valuation Allowances and Reserves, Period Increase (Decrease)" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, acquired in a business combination.", "label": "Valuation Allowances and Reserves, Reserves of Businesses Acquired", "terseLabel": "Other" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Information by type of valuation and reserve accounts.", "label": "Valuation Allowances and Reserves Type [Axis]", "terseLabel": "Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "A schedule of allowance and reserve accounts including their beginning and ending balances, as well as a reconciliation by type of activity during the period. Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.", "label": "Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation technique.", "label": "Valuation Technique [Axis]", "terseLabel": "Valuation Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Valuation techniques used by the entity.", "label": "Valuation Technique [Domain]", "terseLabel": "Valuation Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r147" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r147" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "c", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3098-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22644-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22658-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=64853466&loc=d3e22663-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.N)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=26874127&loc=d3e30840-122693" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1252-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1500-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=96948231&loc=d3e4984-109258" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(j)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=84173487&loc=d3e1280-108306" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8615-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8654-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8657-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8660-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8663-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8672-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e8475-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=75030427&loc=d3e22054-111558" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)-(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82895926&loc=d3e24584-111560" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82895926&loc=d3e25065-111560" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82895926&loc=d3e25351-111560" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26610-111562" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26817-111562" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82896770&loc=d3e26828-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=SL6284393-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.M)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65877573&loc=d3e87990-122713" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a,h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=64802544&loc=d3e202-110218" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=77914552&loc=d3e10037-110241" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=77914552&loc=d3e10037-110241" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=82913499&loc=d3e12803-110250" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68075638&loc=d3e60635-111653" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=68080631&loc=d3e61069-111654" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "45", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=82851458&loc=d3e221937-122793" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=96862333&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=64852052&loc=d3e1703-114919" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=64852052&loc=d3e1731-114919" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2410-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2417-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2439-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2446-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2446-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=82843861&loc=d3e2709-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=77993564&loc=d3e4179-114921" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11149-113907" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11178-113907" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11374-113907" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79981250&loc=d3e23524-113945" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75018887&loc=d3e30536-109315" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31928-109318" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=96868398&loc=d3e36027-109320" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=79507043&loc=d3e39076-109324" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84160947&loc=d3e2207-128464" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=66022390&loc=d3e923-111674" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=d3e5614-111684" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5579240-113959" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5579245-113959" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5580258-113959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41620-113959" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41638-113959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5618551-113959" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624163-113959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624171-113959" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2),(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624177-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=SL5624177-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41641-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41675-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=84234895&loc=d3e41678-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=95459573&loc=SL5629052-113961" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL7498348-110258" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19279-110258" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13217-108610" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13279-108611" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13467-108611" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13476-108611" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75027168&loc=d3e14489-108613" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30690-110894" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64836518&loc=d3e30700-110894" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r543": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r545": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=73530178&loc=d3e59706-112781" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.6(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)-(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75032840&loc=d3e61044-112788" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75032840&loc=d3e61082-112788" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "325", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=75031664&loc=d3e22529-158502" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=75027451&loc=SL29635902-196195" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S35", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488548&loc=SL6090579-123006" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r615": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r616": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e640-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=84158357&loc=d3e1436-108581" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585" } }, "version": "2.0" } ZIP 103 0000012208-18-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-18-000014-xbrl.zip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�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�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end

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